The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation by Picot, J. et al.
Health Technology Assessment 2011; Vol. 15: No. 41
ISSN 1366-5278
Health Technology Assessment
NIHR HTA programme
www.hta.ac.uk
December 2011
10.3310/hta15410
The clinical effectiveness and cost-
effectiveness of bortezomib and 
thalidomide in combination regimens 
with an alkylating agent and a 
corticosteroid for the first-line 
treatment of multiple myeloma: a 
systematic review and economic 
evaluation
J Picot, K Cooper, J Bryant and AJ Clegg
Health Technology Assessment 2011; Vol. 15: No.411
ISSN 1366-5278
Abstract
List of abbreviations
Note
Executive summary
Background
Objectives
Methods
Results
Discussion
Conclusions
Funding
Chapter 1  
Background
Description of underlying health problem
Current service provision
Description of technology under assessment
Chapter 2  
Definition of the decision problem
Decision problem
Overall aims and objectives of assessment
Chapter 3  
Methods
Search strategy
Inclusion and exclusion criteria
Inclusion and data extraction process
Critical appraisal strategy
Methods of data synthesis
Chapter 4  
Clinical effectiveness
Results of the systematic review of clinical effectiveness
SHTAC review of clinical effectiveness in manufacturers’ submissions
Ongoing studies
Summary of clinical effectiveness
Chapter 5  
Economic analysis
Introduction
Systematic review of existing cost-effectiveness evidence
Systematic review of health-related quality-of-life studies
Review of the Janssen–Cilag submission to NICE (bortezomib)
Review of the Celgene submission to NICE (thalidomide)
SHTAC independent economic assessment
Chapter 6  
Assessment of factors relevant to the NHS and other parties
Chapter 7  
Discussion
Statement of principal findings
Strengths and limitations of the assessment
Uncertainties
Chapter 8 
Conclusions
Implications for service provision
Suggested research priorities
Acknowledgements
Contributions of authors
References
Appendix 1  
Report methods for synthesis of evidence of clinical effectiveness and cost-effectiveness as 
described in the research protocol  105
Search strategy
Inclusion and exclusion criteria
Inclusion and data extraction process
Quality assessment strategy
Methods of analysis/synthesis
Report methods for economic analysis
Model structure
Clinical effectiveness data
Costs and resource estimation
Outcomes
Handling the company submission(s)
Appendix 2  
Example MEDLINE search strategies for clinical effectiveness and cost-effectiveness  109
Clinical effectiveness
Cost-effectiveness
Appendix 3  
Response criteria  111
Appendix 4  
Table of excluded studies  113
Appendix 5  
Clinical effectiveness included studies – data extraction forms  115
Appendix 6  
Karnofsky performance status and WHO performance status scores  145
Karnofsky performance status
WHO performance status scores
Appendix 7  
SHTAC data summary of manufacturers’ submissions of clinical effectiveness  147
SHTAC peer review of clinical effectiveness in Celgene’s submission for bortezomib and 
thalidomide for MM
SHTAC peer review of clinical effectiveness in Janssen–Cilag’s submission for bortezomib 
and thalidomide for MM
Appendix 8  
Table of excluded studies for systematic review of cost-effectiveness  153
Appendix 9  
Table of excluded studies for systematic review of health-related quality of life  155
Appendix 10 
Health-related quality-of-life studies – data extraction forms  157
Reference
Reference
Reference
Reference
Reference
Appendix 11  
Cost-effectiveness data extraction forms for manufacturers’ submissions  171
Reference
Reference
Appendix 12  
Critical appraisal checklist of economic evaluation  189
Appendix 13  
Methodology used for disease projection  191
Appendix 14  
Parameters included in the sensitivity analyses  195
Parameters and distributions for the deterministic and probabilistic sensitivity analyses
Appendix 15  
Additional scenario analyses  197
Scenario 1
Scenario 2
Health Technology Assessment programmeHow to obtain copies of this and other HTA programme reports
An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for 
personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). 
Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both 
public and private sector purchasers from our despatch agents.
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is 
£2 per issue and for the rest of the world £3 per issue.
How to order:
– fax (with credit card details)  
– post (with credit card details or cheque) 
– phone during office hours (credit card only).
Additionally the HTA website allows you to either print out your order or download a blank order form.
Contact details are as follows:
Synergie UK (HTA Department)
Digital House, The Loddon Centre 
Wade Road 
Basingstoke 
Hants RG24 8QW
Email: orders@hta.ac.uk
Tel: 0845 812 4000 – ask for ‘HTA Payment Services’  
(out-of-hours answer-phone service)
Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header
Payment methods
Paying by cheque 
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of 
Southampton and drawn on a bank with a UK address.
Paying by credit card 
You can order using your credit card by phone, fax or post.
Subscriptions
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for 
each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume 
(addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for 
details. Subscriptions can be purchased only for the current or forthcoming volume.
How do I get a copy of HTA on DVD?
Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free 
of charge worldwide.
The website also provides information about the HTA programme and lists the membership of the various 
 committees.
HTAThe clinical effectiveness and cost-
effectiveness of bortezomib and thalidomide 
in combination regimens with an alkylating 
agent and a corticosteroid for the first-line 
treatment of multiple myeloma: a systematic 
review and economic evaluation
J Picot,* K Cooper, J Bryant and AJ Clegg
Southampton Health Technology Assessments Centre (SHTAC), Southampton, UK
*Corresponding author
Declared competing interests of the authors: none
Published December 2011
DOI: 10.3310/hta15410
This report should be referenced as follows:
Picot J, Cooper K, Bryant J, Clegg AJ. The clinical effectiveness and cost-effectiveness of bortezomib 
and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line 
treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 
2011;15(41).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta 
Medica/EMBASE, Science Citation Index Expanded (SciSearch) and Current Contents/
Clinical Medicine.ii NIHR Health Technology Assessment programme
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was 
set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health 
technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all 
interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.
The research findings from the HTA programme directly influence decision-making bodies such as the National 
Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also 
help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National 
Knowledge Service’.
The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the 
start of projects.
First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from 
the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions 
are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then 
commissions the research by competitive tender.
Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These 
are assessed for importance to patients and the NHS, and scientific rigour.
Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions 
bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of 
specific technologies.
Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as 
little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research 
collecting new data to answer a research problem.
The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in 
the widely read journal series Health Technology Assessment.
Criteria for inclusion in the HTA journal series
Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and 
(2) they are of a sufficiently high scientific quality as assessed by the referees and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and 
synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review 
by others.
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of 
NICE as project number 08/96/01. The protocol was agreed in July 2009. The assessment report began editorial review 
in February 2010 and was accepted for publication in July 2010. The authors have been wholly responsible for all data 
collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to 
ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on 
the draft document. However, they do not accept liability for damages or losses arising from material published in 
this report.
The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the 
Department of Health.
Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Tom Marshall, Professor John Powell, 
Dr Rob Riemsma and Professor Ken Stein
Associate Editor: Dr Peter Davidson
Editorial Contact: edit@southampton.ac.uk
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
ISSN 2046-4932 (DVD)
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a 
commissioning contract issued by the Secretary of State for Health.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.
publicationethics.org/).
This journal may be freely reproduced for the purposes of private research and study and may be included in professional 
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, 
University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.
Printed on acid-free paper in the UK by the Charlesworth Group.  T© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
iii   Health Technology Assessment 2011; Vol. 15: No. 41 DOI: 10.3310/hta15410
Abstract
The clinical effectiveness and cost-effectiveness of 
bortezomib and thalidomide in combination regimens with 
an alkylating agent and a corticosteroid for the first-line 
treatment of multiple myeloma: a systematic review and 
economic evaluation
J Picot,* K Cooper, J Bryant and AJ Clegg
Southampton Health Technology Assessments Centre (SHTAC), Southampton, UK
*Corresponding author
Background: Multiple myeloma (MM) is the second most common haematological cancer 
in the UK. MM is not curable but can be treated with a combination of supportive measures 
and chemotherapy that aim to extend the duration and quality of survival. The majority of 
patients are not able to withstand intensive treatment, such as high-dose chemotherapy 
with autologous stem cell transplantation (SCT), and so they are offered single-agent or 
combination chemotherapy. Combination therapies typically include chemotherapy with an 
alkylating agent and a corticosteroid. More recently, combination therapies have 
incorporated drugs such as thalidomide (Thalidomide Celgene, Celgene) and bortezomib 
(Velcade, Janssen–Cilag).
Objective: To assess the clinical effectiveness and cost-effectiveness of bortezomib or 
thalidomide in combination chemotherapy regimens with an alkylating agent and a 
corticosteroid for the first-line treatment of MM.
Data sources: Electronic bibliographic databases, including MEDLINE, EMBASE and The 
Cochrane Library, were searched from 1999 to 2009 for English-language articles. 
Bibliographies of articles, grey literature sources and manufacturers’ submissions were also 
searched. Experts in the field were asked to identify additional published and 
unpublished references. 
Review methods: Titles and abstracts were screened for eligibility by two reviewers 
independently. The inclusion criteria specified in the protocol were applied to the full text of 
retrieved papers by one reviewer and checked independently by a second reviewer. Data 
extraction and quality assessment were undertaken by one reviewer and checked by a 
second reviewer. Differences in opinion were resolved through discussion at each stage. A 
cost–utility decision-analytic model was used to compare the cost-effectiveness estimates 
of bortezomib in combination with melphalan and prednisolone/prednisone (VMP), 
thalidomide in combination with cyclophosphamide and attenuated dexamethasone 
(CTDa), and thalidomide in combination with melphalan and prednisolone/prednisone 
(MPT) versus melphalan and prednisolone/prednisone (MP).
Results: A total of 1436 records were screened and 40 references were retrieved for the 
systematic review of clinical effectiveness. Five randomised controlled trials (RCTs) met the 
inclusion criteria for the review: one RCT evaluated VMP, three evaluated MPT and one 
evaluated CTDa. The comparator in all of the included trials was MP. The review found that 
VMP and MPT can both be considered more clinically effective than MP for the first-line iv Abstract
treatment of MM in people for whom high-dose therapy and SCT would not be appropriate. 
CTDa was more effective than MP in terms of complete response but data on survival 
outcomes did not meet the inclusion criteria. Cost-effectiveness analysis indicated that 
MPT has a greater probability of being cost-effective than either VMP or CTDa.
Limitations: For most RCTs, details needed to judge study quality were incompletely 
reported. All studies stated that the analyses followed intention-to-treat principles but none 
adequately reported data censoring. Only one RCT contributed data on VMP and the 
published peer-reviewed follow-up data were immature. For MPT, overall survival data from 
two trials were eligible for inclusion but the doses of thalidomide differed between the trials 
and the treatment period was not reflective of current UK practice so the generalisability of 
the findings was uncertain. Two RCTs had a maintenance phase with thalidomide that did 
not meet the inclusion criteria so some of these results were not eligible for the review. 
Limited evidence on health-related quality of life (HRQoL) was provided by the single trial of 
VMP versus MP.
Conclusions: Service provision is unlikely to change greatly. As uncertainties remain, 
further research is needed regarding the use of bortezomib- and thalidomide-containing 
combination regimens. Head-to-head trials of bortezomib- and thalidomide-containing 
combination regimes are required, including assessments of patient HRQoL in response 
to treatment.
Funding: The National Institute for Health Research Health Technology Assessment 
programme.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Executive summary
Background
Multiple myeloma (MM) is the second most common haematological cancer in the UK, 
characterised by unregulated plasma cell proliferation. In England and Wales there are 
approximately 3600 new diagnoses recorded annually, and in 2007 most diagnoses were 
recorded in people aged 75–79 years. Symptoms and clinical features of MM include fatigue, 
bone pain and/or fracture, anaemia, the presence of M-protein in serum and/or urine, and 
hypercalcaemia. The aetiology of MM is unknown and malignant cells display a variety of 
cytogenetic abnormalities. Myeloma is not curable, but can be treated with a combination of 
supportive measures and chemotherapy. The aim is to extend the duration and quality of survival 
by alleviating symptoms and achieving disease control while minimising the adverse effects of the 
treatment. Survival of patients from diagnosis can vary from months to over a decade. Factors 
affecting prognosis include burden of disease, type of cytogenetic abnormality present, patient-
related factors – such as age and performance status – and treatment response factors.
In England and Wales, the choice of first-line treatment depends on a combination of factors. 
The majority of patients are not able to withstand intensive treatment, such as high-dose 
chemotherapy with autologous stem cell transplantation (SCT), because of age, specific problems 
or poor performance status. These patients are therefore offered single-agent or combination 
chemotherapy (which is less intensive). Typically, combination therapies include chemotherapy 
with an alkylating agent (such as melphalan or cyclophosphamide) and a corticosteroid (such as 
prednisolone or dexamethasone). More recent treatment options may also include combination 
therapies that incorporate drugs such as thalidomide (Thalidomide Celgene, Celgene, Uxbridge, 
UK) and bortezomib (Velcade, Janssen–Cilag, High Wycombe, UK).
Objectives
To assess the clinical effectiveness and cost-effectiveness of bortezomib or thalidomide in 
combination chemotherapy regimens with an alkylating agent and a corticosteroid for the first-
line treatment of MM.
Methods
Data sources
Electronic bibliographic databases, including MEDLINE, EMBASE and The Cochrane Library, 
were searched from 1999 to 2009 for English-language articles. Bibliographies of articles, grey 
literature sources and manufacturers’ submissions (MSs) were also searched. Experts in the field 
were asked to identify additional published and unpublished references.
Study selection
Titles and, where available, abstracts were screened for eligibility by two reviewers independently. 
The inclusion criteria specified in the protocol were applied to the full text of retrieved papers 
by one reviewer and checked independently by a second reviewer. The inclusion criteria were 
as follows:x Executive summary
  ■ Interventions  Bortezomib in combination with an alkylating agent and a corticosteroid 
for first-line treatment of MM. Thalidomide in combination with an alkylating agent and a 
corticosteroid for first-line treatment of MM.
  ■ Comparators  (i) The interventions compared with each other or (ii) melphalan or 
cyclophosphamide in combination with prednisolone/prednisone or dexamethasone.
  ■ Population  People with previously untreated MM who are not candidates for high-dose 
chemotherapy with SCT.
  ■ Outcomes  Studies had to report one or more of the following outcomes – overall survival 
(OS); progression-free survival (PFS); time to progression (TTP); response rates; health-
related quality of life (HRQoL); cost-effectiveness [such as incremental cost per quality-
adjusted life-year (QALY) gained].
The study types that were eligible for inclusion in the systematic review of clinical 
effectiveness were:
  ■ randomised controlled trials (RCTs); good-quality observational studies could be considered 
if the data from available RCTs were incomplete.
And for the systematic review of cost-effectiveness, eligible study types were:
  ■ full cost-effectiveness analyses, cost–utility analyses and cost–benefit analyses.
Data extraction and quality assessment
Data extraction and quality assessment were undertaken by one reviewer and checked by a 
second reviewer. Differences in opinion were resolved through discussion at each stage.
Data synthesis
Studies were synthesised through a narrative review with full tabulation of the results of all 
included studies.
Economic modelling
A cost–utility decision-analytic model was used to compare the cost-effectiveness estimates of 
bortezomib in combination with melphalan and prednisolone/prednisone (VMP), thalidomide 
in combination with cyclophosphamide and attenuated dexamethasone (CTDa), and thalidomide 
in combination with melphalan and prednisolone/prednisone (MPT) versus melphalan and 
prednisolone/prednisone (MP). The model used a survival analysis approach to estimate 
the OS and PFS for each of the interventions for a patient with newly diagnosed MM. The 
model consisted of cycles of 6 weeks in length, to be consistent with the cycle lengths used for 
chemotherapy treatment. The model survival curves were derived using trial data for the duration 
of trial follow-up and an exponential distribution was used to extrapolate beyond the length of 
the trial. Second-line treatment costs were included. The perspective of the analysis was that of 
the NHS and Personal Social Services (PSS). The model estimated the lifetime costs and benefits 
of treatment with discount rates of 3.5%. The intervention effect in terms of improvement in OS 
and PFS was derived from the systematic review of effectiveness. The outcome of the economic 
evaluation is reported as cost per QALY gained.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Results
Number and quality of studies
A total of 1436 records were screened and 40 references were retrieved for consideration for 
the systematic review of clinical effectiveness. Five RCTs met the inclusion criteria for the 
clinical effectiveness systematic review. One RCT evaluated VMP, three evaluated MPT, and one 
evaluated CTDa. The comparator in all the included trials was MP. Study quality was uncertain 
for most RCTs because details needed to judge study quality were incompletely reported. All 
studies stated that the analyses followed intention-to-treat (ITT) principles but none adequately 
reported the amount and pattern of data censoring. Two RCTs, one of the MPT versus MP trials 
and the CTDa versus MP trial, had a maintenance phase with thalidomide that did not meet the 
inclusion criteria. This meant that some results from these trials were not eligible for inclusion in 
the systematic review.
Summary of benefits and risks
The evidence from one RCT indicated that combination chemotherapy with VMP was more 
effective than MP in terms of the primary outcome TTP, and the secondary outcomes of OS and 
the proportion of participants achieving complete response (CR), or achieving a partial response 
(PR) or better (response outcomes, not ITT). Adverse events (AEs) occurred in both trial arms. 
The use of bortezomib was associated with a statistically significant increase in grade 3 AEs.
Evidence from two RCTs indicated that MPT was more effective than MP in terms of these trials’ 
primary outcome of OS, and the secondary outcome of PFS. Three trials provided evidence 
indicating a statistically significant greater proportion of participants receiving MPT achieved 
CR. (AiC/CiC information has been removed.) AEs occurred in all MPT, CTDa and MP trial 
arms. The AEs associated with the use of thalidomide were difficult to summarise. The AE that 
was most consistently, and statistically significantly, associated with the use of thalidomide was 
peripheral neuropathy. AEs of thrombosis or embolism, somnolence, infections and constipation 
were reported as being statistically significantly increased in the thalidomide-containing arms of 
some trials but not others.
Limited evidence on HRQoL was provided by the single trial of VMP versus MP. This indicated 
that, after the onset of best response, participants treated with VMP had a higher sustained 
HRQoL improvement rate in 14 of the 15 European Organisation for Research and Treatment 
of Cancer QoL questionnaire C30 (EORTC QLQ-C30) scores than those participants receiving 
therapy with MP.
Summary of cost-effectiveness
The systematic review of published economic evaluations identified five abstracts that did 
not contain enough information for critical appraisal. The systematic review of quality-of-life 
(QoL) studies did not find any generic preference-based QoL studies that assessed QoL in the 
population of interest. However, two studies that used the EORTC QLQ-C30 questionnaire were 
identified and a mapping algorithm was available to map the EORTC QLQ-C30 to the European 
Quality of Life-5 Dimensions (EQ-5D).
Two manufacturers submitted evidence to be considered for this review:xii Executive summary
  ■ Janssen–Cilag, the manufacturer of bortezomib, constructed a survival model that estimated 
OS and PFS based on treatment effects from a mixed-treatment comparison (MTC) of 
the trials. They included second- and third-line treatment. The base-case results from the 
submission found all treatments to be cost-effective. The incremental cost-effectiveness ratio 
(ICER) for VMP versus MP is estimated to be £10,498. Furthermore, the ICERs of VMP 
versus MPT and VMP versus CTDa were estimated to be £11,907 and £10,411, respectively.
  ■ Celgene, the manufacturer of thalidomide, constructed a Markov model with health states 
for preprogression (with or without AEs), post progression and death. They assumed that 
survival after disease progression was the same irrespective of first-line treatment. Treatment 
effects for disease progression were calculated using a random effects MTC. The base-case 
results from the submission estimated an ICER of £23,381 per QALY gained for MPT versus 
MP and £303,845 per QALY for VMP versus MPT.
The Southampton Health Technology Assessments Centre (SHTAC) developed an independent 
survival model. From this independent model, the incremental cost-effectiveness figures versus 
MP for MPT, VMP and CTDa were £9135, £29,820 and £33,031 per QALY gained, respectively. 
However, MPT dominated VMP as it was cheaper and more effective.
Sensitivity analyses
The effect of a range of parameter values in the economic model were evaluated in deterministic 
and probabilistic sensitivity analyses (PSAs). The model results were robust to changes in the 
parameter values tested. The model results were most sensitive to changes in the values of 
the hazard ratios for OS. The PSA estimated the probability of each of the treatments to be 
cost-effective at the £20,000 and £30,000 willingness-to-pay thresholds. MPT has the highest 
probability of being cost-effective, with probabilities of 0.95 at both the thresholds tested.
Discussion
A systematic review and economic evaluation have been carried out independent of any vested 
interest but both are associated with some limitations. Only one RCT contributed data on VMP 
and the published peer-reviewed follow-up data are immature. For MPT, OS data from two 
trials were eligible for inclusion but the doses of thalidomide differed between the trials and the 
treatment period was not reflective of current UK practice so the generalisability of the findings 
is uncertain. No evidence on OS or PFS following treatment with CTDa met the inclusion criteria 
for the systematic review because of the use of thalidomide maintenance therapy for some 
participants in the single RCT that assessed this intervention.
No head-to-head trials were identified which compared bortezomib in combination with an 
alkylating agent and a corticosteroid with thalidomide in combination with an alkylating agent 
and a corticosteroid.
Assessment of the impact of treatment on quality of life was very limited. Data on HRQoL could 
be included from only one RCT – the study of VMP versus MP. The single RCT that assessed 
CTDa versus MP reported HRQoL outcomes but these did not meet the inclusion criteria of the 
systematic review.
An MTC was not carried out because of doubts about the validity of doing so due to potential 
differences in participant characteristics, delivery of MP treatment in the comparator arms, and 
differences in length of follow-up. Furthermore, CTDa could not have been included in such © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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an analysis because the single trial that assessed CTDa included randomisation to maintenance 
therapy for some participants.
The review of clinical effectiveness has found that VMP and MPT can both be considered more 
clinically effective than MP for the first-line treatment of MM in people for whom high-dose 
therapy and SCT would not be appropriate. CTDa is more effective than MP in terms of CR 
but data on survival outcomes did not meet the inclusion criteria of the clinical effectiveness 
systematic review.
The review of QoL found that the only HRQoL studies for the population of interest had used a 
disease-specific HRQoL measure. Therefore, EQ-5D utility estimates used in the SHTAC model 
had to be derived using a mapping algorithm. The OS outcome from the single trial of CTDa 
versus MP did not meet the inclusion criteria for the systematic review of clinical effectiveness 
(as some patients in this trial received thalidomide maintenance therapy) but CTDa was included 
in the cost-effectiveness analysis because it is a relevant comparator. (AiC/CiC information has 
been removed.) 
The results from the cost-effectiveness analyses submitted by the two manufacturers and the 
results from the SHTAC cost-effectiveness model varied considerably. These variations arise 
because of differences in the modelling approaches taken and the data used to populate each 
model. Costs vary substantially between the analyses. Key contributors to the variation in costs 
were differences in costs included for subsequent treatments, and differences in assumptions 
made about the mean number of vials of bortezomib used. Incremental QALY estimates for MPT 
versus MP also varied widely.
Cost-effectiveness analysis indicates that MPT has a greater probability of being cost-effective 
than either VMP or CTDa. Results for CTDa, however, should be treated with caution 
because this trial included maintenance therapy with thalidomide for some patients. (AiC/CiC 
information has been removed.)
Conclusions
Service provision is unlikely to change greatly; however, uncertainties remain and further 
research is needed. In particular, head-to-head trials of bortezomib- and thalidomide-containing 
combination regimens are desirable. These trials should include assessments of patient HRQoL 
in response to treatment. It is not known whether the choice of second-line treatment or the 
sequence of treatments affects patient outcomes.
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Chapter 1  
Background
Description of underlying health problem
Multiple myeloma (MM) is a type of cancer. The cancer (myeloma) tends to be located at more 
than one site where there is bone marrow, such as the pelvis, spine and ribs, which is why it is 
known as MM.1 MM occurs when a plasma cell begins to proliferate in an unregulated way. 
Plasma cells are a specialised component of the bone marrow and immune system and they 
normally produce specific antibodies to fight infection. In MM the myeloma cells produce 
large quantities of one type of abnormal antibody – monoclonal immunoglobulin protein 
(M-protein).2 As the abnormal myeloma cells build in number, the normal functions of bone 
marrow become impaired to varying degrees of severity because the abnormal myeloma cells 
may disrupt the function of normal cells, and because the space available for normal bone 
marrow may be reduced.
In the early stages of MM there may not be any symptoms or a range of symptoms may be 
present, which are not specific to MM, such as fatigue, weight loss and increased infections. 
A common presenting symptom of MM is bone pain, and/or bone fracture due to lytic bone 
lesions. Lytic bone lesions are a typical feature of MM and are caused because the malignant 
plasma cells impair normal bone repair functions. MM cells both produce and influence 
chemokines and cytokines, which causes bone resorption to become uncoupled from bone 
formation such that resorption predominates.3
The most common finding on clinical investigation is anaemia.4 This occurs because the presence 
of proliferating myeloma cells in the bone marrow negatively impacts on the ability of the bone 
marrow to produce red blood cells, leading to a reduction in red blood cells in the circulation, 
which contributes to the symptom of fatigue. Likewise, circulating numbers of other cells 
produced in the bone marrow are also reduced. The reduction in normal white blood cells and 
the antibodies these produce (hypogammaglobulinaemia) leads to an increased risk of infection, 
while the reduction in platelets contributes to easy bruising and other bleeding.
Other common findings on clinical investigation are M-protein, which is secreted by the 
myeloma cells, and an excess of calcium in the blood (hypercalcaemia), which occurs as 
a result of bone destruction.5 The presence of M-protein in serum may increase blood 
viscosity, which is associated with an increased risk of thrombosis. A high level of serum 
protein (hyperproteinaemia), M-protein and light chains may also contribute to renal failure. 
The aetiology of this is generally multifactorial, and hypercalcaemia is another common 
contributing factor.
Multiple myeloma is one of a number of lymphoproliferative diseases classified by the World 
Health Organization (WHO) International Classification of Diseases 10th edition (ICD-10) as 
malignant neoplasms of lymphoid, haematopoietic and related tissue.6 The exact aetiology of 
MM is unknown but it is clear that the malignant cells arise from a single plasma cell. Therefore, 
research has focused on gaining an understanding of the chain of events that occurs between 
haematopoietic stem cells giving rise to B lymphocytes in the bone marrow, and these B cells 
subsequently differentiating to form plasma cells.7,82 Background
Normally, plasma cells would contain a pair of each of the 22 autosomal (non-sex) chromosomes. 
Myeloma cells, however, display a variety of genetic abnormalities. Common abnormalities 
of MM cells include aneuploidy (an abnormal number of chromosomes) and translocations 
(exchange of material between two different chromosomes). When aneuploidy is present, 
monosomies (one copy of a chromosome) are more common than trisomies (three copies of a 
chromosome). One of the most common monosomies is the loss of one copy of chromosome 
13, which is associated with a shorter survival and lower response rate to treatment.9,10 Of the 
translocations t(11;14)(q13;q32) and t(4;14)(p16.3;q32) are the most common; the former 
is associated with improved survival, whereas the latter is an indication of an unfavourable 
prognosis.9,10 The genetic abnormalities underlying cases of MM can be identified by cytogenetic 
techniques, such as conventional karyotype analysis and fluorescence in situ hybridisation.
Prognosis
Myeloma is not curable, but can be treated with a combination of supportive measures and 
chemotherapy to improve survival and quality of life (QoL). A range of factors affects prognosis. 
These include factors related to burden of disease [e.g. beta2-microglobulin (β2-microglobulin)], 
characteristics of the myeloma cells’ biology (e.g. the type of cytogenetic abnormality present), 
the microenvironment surrounding the myeloma cells (e.g. bone marrow microvessel density), 
patient-related factors (e.g. age and performance status) and treatment response factors [e.g. 
whether complete response (CR) is achieved with initial therapy].5 Because of the number of 
factors that affect prognosis, survival of patients from the point of diagnosis varies from months 
to over a decade.4 In the UK and Ireland, median survival increased from around 2 years in the 
1980s and early 1990s to around 4 years in the late 1990s.11 There is evidence from some cohorts 
of patients that novel therapies can extend median survival time to 8 years.12
Epidemiology
Multiple myeloma is the second most common haematological cancer after lymphoma in the 
UK. In 2007 there were 3357 new diagnoses of MM in England,13 with the highest incidence 
among those aged 75–79 years (Table 1). In Wales, in the 3 years from 2004 to 2006, an average 
of 252 new MM diagnoses were recorded.14 MM is rare before the age of 40 years. The average 
TABLE 1  Newly diagnosed cases of MM in England in 200713
Age group (years)
Nos.a Ratesb
Males Females Males Females
20–24 2 1 0.1 0.1
25–29 3 4 0.2 0.2
30–34 9 4 0.5 0.2
35–39 11 7 0.6 0.4
40–44 26 17 1.3 0.9
45–49 47 31 2.7 1.7
50–54 96 51 6.3 3.3
55–59 158 91 10.3 5.7
60–64 214 174 15.1 11.7
65–69 239 176 22.2 15.2
70–74 300 217 32.7 20.9
75–79 324 248 44.8 26.8
80–84 256 238 53.2 32.3
85+ 173 240 50.2 31.7
a  New cases of cancer diagnosed in England, 2007, by age group and sex.
b  Rates per 100,000 population of newly diagnosed cases of cancer in England 2007, by age group and sex.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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incidence rates were higher in men than in women, and higher for both sexes in Wales compared 
with England (Table 2). There are ethnic differences in incidence rates that have been observed 
in data from the USA; in black people (African American and other black people, but not 
Hispanic people) the incidence of MM is about twice that of white people, whereas in Asian 
people the incidence is lower than that of white people.15 The statistical information team at 
Cancer Research UK has used incidence and mortality data for 2001–5 to estimate the lifetime 
risk of developing MM, which is 1 in 148 for men and 1 in 186 for women in the UK.16 There are 
currently approximately 10,000–15,000 people living with MM in the UK.17
The risk factors for developing MM are not well defined but there is evidence for involvement 
of genetic factors because the first-degree relatives of people with MM are at greater risk of 
developing MM and related conditions than the first-degree relatives of people without MM.8,18 
Epidemiological studies have looked for evidence of a causal link between a range of potential 
environmental risk factors and MM but, in general, these have not produced consistent results.4,8
Diagnosis and staging
Multiple myeloma is typically diagnosed in secondary care using a combination of tests such as 
urine tests, blood tests, bone marrow examination, imaging, plain radiograph and/or magnetic 
resonance imaging. If necessary, further tests can be conducted to find out the stage of disease.1 
There are two systems for staging MM. The Durie–Salmon19 (DS) staging system, which has 
been in use since 1975, is one of the systems but this is gradually being replaced by an updated 
system, the International Staging System (ISS).20 This new system is based on measurement of 
two serum proteins, β2-microglobulin and albumin (Table 3). A patient with stage I disease will 
not necessarily proceed linearly through disease stages. Stage III disease can be reached without 
a requirement to pass through stage II first. It is also noteworthy that staging does not have a 
significant influence on treatment. If MM is symptomatic, treatment is required irrespective of 
disease stage.
Current service provision
The aim of treatment for MM is to extend the duration and quality of survival by alleviating 
symptoms and achieving disease control while minimising the adverse effects of the treatment.21 
First-line treatment aims to achieve a period of stable disease (plateau phase) for as long as 
possible, prolonging survival and maximising QoL. In England and Wales the choice of first-line 
treatment depends on a combination of factors, including age, comorbidity, social factors and 
performance status of the patient. High-dose chemotherapy (HDT) with autologous stem-cell 
transplantation (SCT) will be offered if appropriate for the patient. However, the British Society 
for Haematology (BSH) guidelines on the diagnosis and management of MM (2005)22 state that 
(p. 428) ‘Although high-dose is recommended where possible, the majority of patients will not 
be able to receive such therapy because of age, specific problems or poor performance status’. For 
those patients who are not able to withstand such an intensive type of treatment, single-agent 
or combination chemotherapy (which is less intensive) may be offered as a first-line treatment. 
Patients eligible for HDT will get initial chemotherapy to reduce disease burden before transplant.
TABLE 2  Age-standardised incidence ratesa of MM per 100,000 of the population14
Men Women
England 6.0 3.9
Wales 6.8 4.9
a  Rate calculated as 3-year averages for 2004–6 and age standardised using the European standard population.4 Background
Typically, combination therapies include chemotherapy with an alkylating agent (such as 
melphalan or cyclophosphamide) and a corticosteroid (such as prednisolone or dexamethasone). 
The treatment recommended by the 2005 guidelines for patients who are unable to receive 
intensive treatment was either melphalan or cyclophosphamide, given either with or without 
prednisolone.22 More recent treatment options may also include drugs such as thalidomide23–25 
(Thalidomide Celgene, Celgene, Uxbridge, UK) and bortezomib26 (Velcade, Janssen–Cilag, 
High Wycombe, UK). Such drugs are being investigated in ongoing clinical trials, such as the 
Medical Research Council (MRC)-funded Myeloma IX study,27 which has compared thalidomide 
in combination with cyclophosphamide and dexamethasone (CTDa) against the standard drug 
combination of melphalan with prednisolone (MP).
The BSH guideline on the diagnosis and management of MM is being revised and updated. 
The draft of these revised guidelines28 contains a recommendation that, for older and/or less fit 
patients in whom high-dose therapy is not planned, the initial therapy should consist of either 
a thalidomide-containing regimen in combination with an alkylating agent and steroid [such 
as thalidomide in combination with MP (MPT) or CTDa] or bortezomib in combination with 
melphalan and prednisolone (VMP). The draft revised guideline indicates that the choice of first-
line therapy should take into account patient preference, comorbidities and the toxicity profile of 
the treatments.28
TABLE 3  Staging systems for MM
Stage
Criteria
DS19 ISS20
I All of the following:
  ■ Haemoglobin value > 10 g/100 ml
  ■ Serum calcium value normal (≤ 12 mg/100ml)
  ■ Normal bone structure or solitary bone plasmacytoma 
only
  ■ Low M-component production rates: (1) IgG value 
< 5 g/100 ml; (2) IgA value < 3 g/100 ml; (3) urinary 
light chain M-component (Bence-Jones protein) on 
electrophoresis < 4 g/24 hours
  ■ Serum β2-microglobulin < 3.5 mg/l
  ■ Serum albumin ≥ 3.5 g/dl
II Fitting neither stage I nor stage III Not stage I or III:
  ■ Serum β2-microglobulin < 3.5 mg/l but serum 
albumin < 3.5 g/dl
or
  ■ Serum β2-microglobulin 3.5 to < 5.5 mg/l 
irrespective of the serum albumin level
III One or more of the following:
  ■ Haemoglobin value < 8.5 g/100 ml
  ■ Serum calcium value > 12 mg/100 ml
  ■ Advanced lytic bone lesions
  ■ High M-component production rates: (1) IgG value 
> 7 g/100 ml; (2) IgA value > 5 g/100 ml; (3) urinary 
light chain M-component (Bence-Jones protein) on 
electrophoresis > 12 g/24 hours
  ■ Serum β2-microglobulin ≥ 5.5 mg/l
Subgroup for each 
stage
A – If relatively normal renal function (serum creatinine value 
< 2.0 mg/100 ml)
B – If abnormal renal function (serum creatinine value 
≥ 2.0 mg/100 ml)
Ig, immunoglobulin.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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After first-line treatment most patients will show a response. Response is usually assessed based 
on changes in serum levels of M-protein and/or urinary light chain excretion, and ranges from 
partial to complete remission, but almost all patients will eventually relapse. A minority of 
patients will have disease that proves resistant to primary treatment.
In addition to chemotherapy, patients also require concomitant supportive therapy to control 
the symptoms of the disease, including bisphosphonates to treat bone disease, erythropoietin to 
treat anaemia, antibiotics to treat infections and various types of pain medication. Prophylaxis 
against thrombosis is recommended in the thalidomide summary of product characteristics 
(SPC) for the first 5 months that patients receive thalidomide.29 In the UK this recommendation 
for prophylaxis against thrombosis is followed, but there is less agreement about whether to 
continue with prophylaxis for the entire duration of thalidomide therapy. Therefore, clinical 
practice is likely to vary. Side effects of treatment may result in discontinuation or change of 
chemotherapy treatment.
UK clinical experts have indicated that the most common combination therapy used as a 
first-line treatment for patients who are not able to withstand high-dose therapy is CTDa. The 
second most common therapy is MPT, with the ratio of patients on CTDa to those on MPT 
being approximately 2 : 1, although in some areas the ratio may be nearer 3 : 1. Intolerance to 
thalidomide limits its use in some patients, and occurrence of peripheral neuropathy limits the 
duration of treatment in some patients (clinical opinion expert advisor). VMP is not widely 
used as a first-line treatment, but may be used in the subgroup of patients who have renal 
impairment or failure at presentation. Use of MP is declining, but this is still used in patients who 
cannot tolerate thalidomide or where the use of thalidomide is contraindicated (clinical opinion 
expert advisor).
As noted above (see Description of underlying health problem) there is some evidence that 
myeloma that is characterised by a high-risk cytogenetic abnormality can demonstrate a poor 
response to conventional treatment. However, although there is interest in the use of cytogenetic 
data as a prognostic indicator, the incorporation of cytogenetic data into decisions about 
treatment choice is not currently supported in the UK.22,28
When patients relapse after first-line treatment most will receive a second-line treatment. The 
choice of second-line treatment is individualised to the patient and, in theory, a patient could 
receive the same therapy that they received as a first-line treatment, particularly if this had 
been effective and the remission had lasted a long time. However, in current UK practice many 
patients will receive bortezomib monotherapy as a second-line treatment because, as noted 
below, this has been recommended by the National Institute for Health and Clinical Excellence 
(NICE). Similarly when patients relapse after second-line treatment the treatment recommended 
by NICE for this patient group is lenalidomide.
In addition to the BSH guidelines on the diagnosis and management of MM,22 two NICE 
technology appraisals have been completed for MM. NICE (TA12930) has previously 
recommended bortezomib monotherapy for relapsed MM as a possible treatment for progressive 
MM for people:
  ■ whose MM has relapsed for the first time after having one treatment, and
  ■ who have had a SCT, or who are unsuitable to receive one.
The National Institute for Health and Clinical Excellence has also recommended lenalidomide 
(a structural derivative of thalidomide) when used in combination with dexamethasone as a 6 Background
possible treatment for MM when people have already received at least two other treatments 
(TA17131). Neither of these NICE appraisals considered first-line therapy for MM.
One technology appraisal is in development – denosumab for the treatment of bone metastases 
from solid tumours and MM – but the scope of this appraisal was not available at the time of 
writing (January 2010). A draft scope for consultation was issued in March 2010.
The National Institute for Health and Clinical Excellence has also published Guidance on Cancer 
Services – Improving Outcomes in Haematological Cancers – The Manual.32 This document covers 
all haematological cancers, including MM, and makes recommendations for service delivery and 
organisation. Some information about current service costs are included but these relate to the 
haematological cancer service as a whole.
Description of technology under assessment
Two interventions are being considered in this assessment:21 bortezomib in combination 
therapy with an alkylating agent and a corticosteroid, and thalidomide in combination therapy 
with an alkylating agent and a corticosteroid. The scope of this review allows for the inclusion 
of bortezomib or thalidomide when used in combination with any alkylating agent and any 
corticosteroid. This may therefore include drug combinations that are not covered by the licences 
for bortezomib and thalidomide, for example CTDa.
Place of the interventions in the treatment pathway
In this assessment bortezomib and thalidomide are being considered for use in combination 
therapy with an alkylating agent and a corticosteroid as a first-line treatment for MM in patients 
who are not eligible for HDT with autologous SCT.
Bortezomib
Bortezomib (Velcade, manufacturer Janssen–Cilag, High Wycombe, UK) is a proteasome 
inhibitor that is specific for the 26S proteasome of mammalian cells and it has been designed 
to inhibit the chymotrypsin-like activity of this proteasome. Inhibition of the proteasome by 
bortezomib affects cancer cells in a number of ways, resulting in cell cycle arrest and apoptosis, 
which causes a reduction in tumour growth.33
Bortezomib is administered by injection. It was initially granted a marketing authorisation in the 
European Union in 2004 as a therapy for patients with MM who had received at least two prior 
lines of treatment. Subsequently, in 2005, the indication was extended to enable treatment, earlier 
in the course of the disease, for relapsed MM in patients who have progressed after receiving at 
least one previous line of treatment.34
In 2008 the marketing authorisation for bortezomib was extended further for the following 
indication: ‘Velcade in combination with melphalan and prednisone is indicated for the treatment 
of patients with previously untreated MM who are not eligible for high-dose chemotherapy with 
bone marrow transplant’ (p. 2).34
The SPC for bortezomib33 recommends nine 6-week treatment cycles for combined therapy 
with VMP. During these treatment cycles bortezomib is administered as a 3- to 5-second bolus 
intravenous injection through a peripheral or central intravenous catheter at a dose of 1.3 mg/m2 
of body surface area, followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for 
injection. In the first four cycles of treatment, bortezomib is administered twice weekly. For cycles 
5–9, bortezomib is administered once weekly. Melphalan (9 mg/m2) and prednisone (60 mg/m2) © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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are both administered orally on days 1, 2, 3 and 4 of the first week of each cycle. The dose and 
total number of cycles may change depending on the patient’s response to treatment and on the 
occurrence of certain side effects. Because the licence for bortezomib does not cover its use in 
combination with agents other than melphalan and prednisone the SPC does not provide dosage 
information for any other alkylating agents or corticosteroids.
The net price for a 3.5-mg vial of bortezomib is £762.38.35 Full details of the estimated drug costs 
associated with the use of bortezomib as a first-line treatment for MM are described within our 
independent economic evaluation (see Chapter 5, SHTAC data sources, Estimation of costs).
Thalidomide
Thalidomide is an immunosuppressive agent with antiangiogenic and other activities that are not 
fully characterised. It is also a non-barbiturate centrally active hypnotic sedative. Although the 
precise mechanism of action is unknown and under investigation, the effects of thalidomide are 
immunomodulatory, anti-inflammatory and antineoplastic.29
Thalidomide (formerly known as Thalidomide Pharmion) is taken orally. It was granted a 
marketing authorisation in 2008 for use in combination with melphalan and prednisone as first-
line treatment for patients with untreated MM, aged ≤ 65 years or who were ineligible for HDT. 
Because thalidomide is a known human teratogen it must be prescribed and dispensed according 
to the Thalidomide Pharmion Pregnancy Prevention Programme.
The SPC for thalidomide29 recommends an oral dose of 200 mg per day, taken as a single dose 
at bedtime to reduce the impact of somnolence. However, the advisory group for this review 
has indicated that treatment usually starts with a lower dose, which is gradually increased if 
the patient can tolerate this. In the UK, most patients who are ineligible for HDT and SCT are 
likely to receive a 100-mg dose. A maximum number of 12 cycles of 6 weeks is recommended. 
Thromboprophylaxis should also be administered for at least the first 5 months of treatment, 
especially in patients with additional thrombotic risk factors. The dose and total number of cycles 
may change depending on the patient’s response to treatment and on the occurrence of certain 
side effects.
The SPC does not recommend particular doses or dosing schedule for melphalan and prednisone 
when administered in combination with thalidomide (licensed indication). Because the licence 
for thalidomide does not cover its use in combination with agents other than melphalan and 
prednisone the SPC does not provide dosage information for any other alkylating agents 
or corticosteroids.
The net price of a 50-mg × 28-capsule pack of thalidomide is £298.48.35 Full details of the 
estimated drug costs associated with the use of thalidomide as a first-line treatment for MM are 
described within our independent economic evaluation (see Chapter 5, SHTAC data sources, 
Estimation of costs).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 2  
Definition of the decision problem
T
his section states the key factors that will be addressed by this assessment, and defines the 
scope of the assessment in terms of these key factors in line with the definitions provided in 
the NICE scope.21
Decision problem
Two interventions are included within the scope of this assessment. These are (1) bortezomib in 
combination with an alkylating agent and a corticosteroid and (2) thalidomide in combination 
with an alkylating agent and a corticosteroid. In both cases the focus of this assessment is the use 
of these combination chemotherapies for the first-line treatment of MM.
The population that is being considered by this assessment is people with previously untreated 
MM, for whom HDT with SCT is not appropriate. If sufficient evidence is available consideration 
will be given to specific patient subgroups, for example patients with different prognostic 
factors such as β2-microglobulin, performance status and stage, patients whose MM has 
different cytogenetic features, and patients who have a comorbidity such as renal impairment. 
Additionally, if the evidence allows, consideration will be given to the number of treatment cycles 
and continuation rules for treatment.
The interventions will be assessed when compared with melphalan or cyclophosphamide 
in combination with prednisolone or dexamethasone. The NICE scope also allows for the 
interventions to be compared with one another. In this assessment we will include interventions 
using prednisone as well as prednisolone. Prednisone, which is not used in the UK, is converted 
into the biologically active steroid prednisolone by the liver.36 Prednisone and prednisolone are 
equally effective, they are used in the same manner, and doses are largely equivalent.
The clinical outcomes of interest include overall survival (OS), progression-free survival (PFS), 
time to progression (TTP), response rates, health-related quality of life (HRQoL), and adverse 
effects (AEs) of treatment. Other outcomes of interest, such as duration of treatment, or second-
line treatments received may also be reported. Outcomes for the cost-effectiveness assessment 
will include direct costs based on estimates of health-care resources associated with the 
interventions as well as consequences of the interventions, such as treatment of AEs.
Overall aims and objectives of assessment
The aim of this health technology assessment (HTA) is to systematically assess the evidence on 
the clinical effectiveness and cost-effectiveness of bortezomib or thalidomide in combination 
regimens with an alkylating agent and a corticosteroid for the first-line treatment of MM.21© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 3  
Methods
T
he a priori methods for systematically reviewing the evidence of clinical effectiveness and 
cost-effectiveness are described in the research protocol (Appendix 1), which was sent to 
our expert advisory group for comment. None of the comments we received identified specific 
problems with the methods of the review. The methods outlined in the protocol are briefly 
summarised below.
Search strategy
The search strategies were developed and tested by an experienced information specialist. The 
strategies were designed to identify studies reporting clinical effectiveness, cost-effectiveness, 
HRQoL, resource use and costs, epidemiology and natural history.
The following databases were searched for published studies and ongoing research from 1999 
(earliest use of thalidomide for MM37 and earliest description of bortezomib as a potential cancer 
therapy38) to December 2009: MEDLINE, MEDLINE In-Process, EMBASE, Web Of Science, 
BIOSIS, Centre for Reviews and Dissemination (CRD) Database of Abstracts of Reviews of 
Effects (DARE), HTA, NHS Economic Evaluation Database (NHS EED) and Cochrane Central 
Register of Controlled Trials (CENTRAL). Bibliographies of articles and grey literature sources 
were also searched. Reference lists within drug manufacturers’ submissions (MSs) to NICE were 
searched for any additional studies that met the inclusion criteria. Our expert advisory group 
was asked to identify additional published and unpublished references. Searches were restricted 
to English language. Further details, including an example search strategy, can be found in 
Appendix 2.
Inclusion and exclusion criteria
Study design
  ■ For the systematic review of clinical effectiveness, randomised controlled trials (RCTs) were 
eligible for inclusion. In addition, evidence from good-quality observational studies was also 
eligible for consideration if the data from available RCTs were incomplete (e.g. absence of 
data on outcomes of interest).
  ■ For the systematic review of cost-effectiveness economic evaluations (such as cost-
effectiveness studies, cost–utility studies, cost–benefit studies) were eligible for inclusion.
  ■ Abstracts or conference presentations of studies were eligible for inclusion only if sufficient 
details were presented to allow an appraisal of the methodology and the assessment of results 
to be undertaken.
  ■ Case series, case studies, narrative reviews, editorials and opinions were excluded, as were 
non-English-language studies. Systematic reviews and clinical guidelines were used only as a 
source of references.
Intervention(s)
  ■ Bortezomib in combination with an alkylating agent and a corticosteroid for first-line 
treatment of MM.12 Methods
  ■ Thalidomide in combination with an alkylating agent and a corticosteroid for first-line 
treatment of MM.
  ■ Studies of treatment with either bortezomib or thalidomide as a single agent were excluded.
Comparator(s)
  ■ Interventions described above compared with each other.
  ■ Melphalan or cyclophosphamide in combination with prednisolone/prednisone 
or dexamethasone.
  ■ Other chemotherapy regimens or SCT were excluded.
Population
  ■ People with previously untreated MM who are not candidates for HDT with SCT.
  ■ Studies of MM patients who had received previous treatment(s) were excluded.
Outcomes
Studies were included if they reported on one or more of the following outcomes:
  ■ overall survival
  ■ progression-free survival (deaths counted as events)
  ■ time to progression (deaths are excluded from the calculation of this outcome)
  ■ response rates
  ■ health-related quality of life
  ■ cost-effectiveness [such as incremental cost per quality-adjusted life-year (QALY) gained]
  ■ adverse events of treatment were reported when available within the trials that met the 
inclusion criteria.
Response definitions
  ■ Response to treatment is usually assessed based on changes in serum levels of M-protein 
and/or urinary light chain excretion. Two different systems for categorising response 
are included in this report, the European Group for Blood and Marrow Transplantation 
(EBMT) criteria39 and the Intergroupe Francophone du Myélome (IFM) criteria.23 Where 
there are differences in the two systems, in general the EBMT criteria require a slightly 
greater improvement. For example, in the definition of partial response (PR) one of the IFM 
requirements is more than a 75% reduction in 24-hour urinary light chain excretion, whereas 
one of the EBMT criteria for PR is a 90% decrease in urinary light chain excretion. The 
EBMT and IFM criteria for judging response are provided in Appendix 3.
Adverse event definitions
  ■ Two slightly different National Cancer Institute (NCI) criteria have been used to grade AEs, 
the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4, and the 
NCI Common Toxicity Criteria (CTC) version 2. The NCI CTCAE version 4 grades AEs on 
a five-point scale (1–5) and the NCI CTC version 2 grades AEs on a six-point scale, as 0 is 
included (0 = no AE or within normal limits). Events of a higher grade are more serious than 
those at a lower grade, with a grade 1 event described as ‘mild’, grade 2 ‘moderate’, a grade 3 
event would be considered ‘severe’, while a grade 4 event could be ‘life threatening’. Grade 5 is 
reserved for deaths related to an AE.
Inclusion and data extraction process
Studies were selected for inclusion in the systematic reviews of clinical effectiveness and cost-
effectiveness through a two-stage process. Literature search results (titles and abstracts) were © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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screened independently by two reviewers to identify all of the citations that might meet the 
inclusion criteria. Full manuscripts of selected citations were then retrieved and assessed by 
one reviewer against the inclusion/exclusion criteria and checked independently by a second 
reviewer. Discrepancies were resolved by discussion, with involvement of a third reviewer 
when necessary.
Data from included studies were extracted by one reviewer using a standardised data 
extraction form and each data extraction was checked for accuracy by a second reviewer. Again 
discrepancies in the extracted data were resolved by discussion, with involvement of a third 
reviewer when necessary.
Critical appraisal strategy
The quality of included clinical effectiveness studies was assessed using the CRD criteria.40 
Quality criteria were applied by one reviewer and checked by a second reviewer with any 
disagreements resolved by consensus and involvement of a third reviewer where necessary.
Methods of data synthesis
Clinical effectiveness and cost-effectiveness studies were synthesised through a narrative review 
with tabulation of results of included studies. Results of included RCTs were meta-analysed 
if appropriate (more than one trial with populations, interventions and outcomes believed to 
be sufficiently similar) and possible (adequate data reported). For time-to-event analyses (OS 
and PFS) the log-hazard ratio (HR) and its standard error (SE) for each outcome were used to 
calculate a summary HR and 95% confidence interval (CI) using the Cochrane Collaboration 
Review Manager 5.0.23 software. However, as the SEs of the log-HRs were not reported by the 
RCTs, these had to be estimated using the methods and Microsoft Excel spreadsheet of Tierney 
and colleagues.41
This report contains reference to confidential information provided as part of the NICE appraisal 
process. This information has been removed from the report and the results, discussions and 
conclusions of the report do not include the confidential information. These sections are clearly 
marked in the report.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 4  
Clinical effectiveness
Results of the systematic review of clinical effectiveness
Quantity and quality of research available
Titles and, where available, abstracts of a total of 1436 records were screened and full copies of 
40 references were retrieved. Of these, six were excluded after inspection of the full article (see 
Appendix 4). Two of these articles were excluded because they were not clinical trial reports, two 
were abstracts that were excluded because they described maintenance therapy with thalidomide, 
another abstract was excluded because it did not report on any of the outcomes of interest, and 
a sixth abstract described a systematic review with meta-analysis. Five full papers described four 
RCTs that met the inclusion criteria of the review (Figure 1 and Table 4). Each RCT was described 
by at least one full paper, with linked abstracts also being available. As the full papers provided 
the most complete data these were the primary source of information for the review.
One ongoing RCT, the Myeloma IX (MMIX) Trial, which is a UK-based MRC collaborative 
RCT with two treatment pathways, appeared to meet the inclusion criteria of the review and 
was described in conference abstracts. The search for studies of clinical effectiveness identified 
four abstracts for this RCT,42–45 with a further three abstracts identified in the MSs.46–48 
Four of the abstracts,42–44,47 were excluded because they described the intensive pathway or 
thalidomide maintenance treatment that did not meet the inclusion criteria for this review. 
Three abstracts45,46,48 described the non-intensive pathway that met the inclusion criteria. The 
final results from the 3-year median follow-up have not yet been published. However, because 
of this RCT’s potential relevance to our inclusion criteria, the Clinical Trials Research Unit 
(CTRU) at the University of Leeds, who are coordinating the RCT, provided the trial protocol,49 
additional background information50,51 and trial baseline data,52 and have also made the results 
from the non-intensive treatment pathway53–58 available to NICE and the authors of this report in 
academic confidence. As the trial protocol and results provided directly by the CTRU provided 
the most complete and up-to-date data these were used as the primary source of information for 
the review.
Four additional ongoing RCTs were described in conference abstracts but it was unclear whether 
these met the inclusion criteria for this review. These ‘unclear’ studies are briefly described later 
in this chapter (see Ongoing studies). The total number of records assessed at each stage of the 
systematic review screening process is shown in the flow chart in Figure 1.
One of the included RCTs evaluated VMP (VISTA trial),26 while three RCTs evaluated MPT 
[IFM 01/01 trial,59 IFM 99/06 trial,23 and the Gruppo Italiano Malattie Ematologiche dell’Adulto 
(GIMEMA – Italian Group for Adult Hematologic Diseases) trial24]. The fifth RCT, the MMIX 
Trial (non-intensive pathway), evaluated CTDa. The comparator in all five of the included RCTs 
was MP.
Bortezomib in combination with melphalan and prednisone (VISTA trial)
The RCT investigating VMP was a randomised (1 : 1), open-label, Phase III trial conducted in 151 
centres in 22 countries in Europe, North and South America, and Asia. The RCT enrolled 682 
participants and was funded by two industry sponsors (see Table 4).16 Clinical effectiveness
Patients received nine 6-week cycles of melphalan (at a dose of 9 mg/m2 of body surface area) and 
prednisone (at a dose of 60 mg/m2) on days 1–4, alone or in combination with bortezomib (at a 
dose of 1.3 mg/m2), by intravenous bolus on days 1, 4, 8, 11, 22, 25, 29 and 32 during cycles 1–4 
and on days 1, 8, 22 and 29 during cycles 5–9. The dose of bortezomib or melphalan was reduced 
if there was any prespecified haematological toxic effect or grade 3 or 4 non-haematological 
effect. Patients with myeloma-associated bone disease received bisphosphonates unless such 
therapy was contraindicated.
Patients were eligible if they had newly diagnosed, untreated, symptomatic, measurable myeloma 
and were not candidates for HDT plus SCT because of age (≥ 65 years) or co-existing conditions. 
Measurable disease was defined as the presence of quantifiable M-protein in serum or urine, 
or measurable soft-tissue or organ plasmacytomas. Over 80% of patients had ISS stage II or III 
disease, about one-third had a Karnofsky performance score of ≤ 70%, and over 60% had lytic 
bone lesions. Most participants were white. No exclusion criteria for study entry were stated.
Records identified through
database searching
n = 2087
Records after duplicates
removed
n = 1436
Additional records identified
through other sources
n = 85
Records screened
n = 1436
Full texts assessed for eligibility
n = 40 records
Comprising full papers n = 5,
abstracts n = 31,
other n = 4
Studies included in quantitative
synthesis (meta-analysis)
Overall survival and
progression-free outcomes n = 2
Complete response n = 3
Records excluded
n = 1396
Studies included in
qualitative synthesis
n = 5 (described by 25 records:
five full papers and
20 linked abstracts)
Four studies were described
by five full papers and
linked abstracts
The fifth study was described
in abstracts onlya
Full-text record unclearb
n = 9 records (describing
four ongoing studies)
Full-text records excluded
n = 6 (four were abstracts)
Reasons for exclusion:
  Not a clinical trial report n = 2
  Thalidomide maintenance n = 2
 Outcomes  n = 1
 Meta-analysis  n = 1
FIGURE 1  Flow diagram of reference screening processes. a, Additional information was received from the trialists 
providing details for one RCT only described in conference abstracts. The additional details allowed us to appraise the 
study methodology and make judgements about study quality. Results from this RCT could therefore be considered 
for inclusion in the systematic review of clinical effectiveness. b, Outcomes from these studies could not be included 
because of insufficient details about study methodology and insufficient details about study quality. These studies, 
which are all ongoing, are briefly summarised below (see Ongoing studies).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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During the 54-week treatment period, blood and urine samples were collected every 3 weeks. 
After completion of treatment, samples were collected every 8 weeks until disease progression. 
Patients were followed after disease progression at least every 12 weeks for survival and 
subsequent myeloma therapy.
The primary outcome measure was time to disease progression. The study was powered at 
80% for the primary outcome but no power calculations were reported for patient subgroups. 
Secondary outcomes were rate of CR, duration of response time, time to subsequent myeloma 
therapy, OS and PFS. Disease progression was defined by EBMT criteria and assessed by 
investigators. The sponsors also determined progression with the use of a computer algorithm 
that applied EBMT criteria. Data are presented in the published paper from the assessment by 
investigators and from the algorithmic analysis. TTP, time to subsequent myeloma therapy and 
OS were analysed from randomisation to the event of interest.
Thalidomide in combination with melphalan and prednisone (IFM 
and GIMEMA trials)
All three of the included RCTs investigating MPT were multicentre trials. The number of 
centres ranged from 44 to 73 and all were located in one or more European countries (France, 
Belgium, Switzerland, Italy). The IFM RCT by Facon and colleagues23 was the largest, recruiting 
447 patients; however, only 321 participants are reported on here because this trial had a third 
arm (reduced-intensity SCT), which is not relevant to this review as the intervention does not 
meet the inclusion criteria. The GIMEMA group RCT by Palumbo and colleagues24 enrolled 331 
participants, and the remaining IFM RCT, Hulin and colleagues,59 enrolled 232 participants (see 
Table 4). All of the RCTs received free thalidomide for the study from the drug manufacturers but 
other funding costs were met by grants from other sources (see Appendix 5).
The dosing schedules of the RCTs varied in terms of overall length and the drug doses used. 
Hulin and colleagues59 and Facon and colleagues,23 the two IFM RCTs, had 72-week treatment 
periods consisting of 12 six-week treatment cycles. The treatment period in the GIMEMA group 
RCT by Palumbo and colleagues24 was shorter, lasting for 24 weeks and consisting of six 4-week 
treatment cycles. The intervention in each RCT was MPT. Thalidomide was prescribed as a set 
100-mg daily dose in the RCTs by Hulin and colleagues59 and Palumbo and colleagues,24 whereas 
a 400-mg daily dose was the goal of Facon and colleagues (if this could be tolerated).23 In the 
two IFM RCTs,23,59 doses were described according to body weight. The dosing schedule of MP 
(on days 1–4 of each 6-week treatment cycle) and prednisone dose (2 mg/kg prednisone) were 
the same in both RCTs, while the melphalan doses differed slightly (Hulin and colleagues,59 
0.2 mg/kg of melphalan; Facon and colleagues,23 0.25 mg/kg of melphalan). Palumbo and 
colleagues24 described drug doses according to body surface area. Melphalan (4 mg/m2) and 
prednisone (40 mg/m2) were taken on days 1–7 of each 4-week treatment cycle. All RCTs allowed 
thalidomide dose adjustments. In each RCT the comparator was MP alone (no thalidomide 
prescribed), provided in the same manner as in the MPT arms as described (also see Table 4). 
Only one RCT, Hulin and colleagues,59 included a placebo in place of thalidomide in the 
comparator arm.
As mentioned earlier, to be included in this systematic review, RCTs had to report on treatment 
of participants with MM who were not eligible for HDT with SCT and who had not been 
previously treated. All participants in each RCT met these criteria. The two IFM RCTs differed 
in the target age range of participants: Hulin and colleagues59 focused on people aged at least 
75 years, whereas Facon and colleagues23 focused on people aged between 65 and 75 years, with 
younger patients being eligible for inclusion providing they were not eligible for HDT. Palumbo 
and colleagues24 focused on people who were older than 65 years of age without specifying any 
upper age limit, and, like Facon and colleagues,23 did include participants who were younger than 20 Clinical effectiveness
65 years, providing that they were unable to undergo SCT. All RCTs included people whose MM 
was at DS stage II or III, and the two IFM RCTs23,59 also included patients with DS stage I MM if 
they met the criteria for high-risk stage I disease. The percentage of participants in the IFM23,59 
and GIMEMA24 RCTs with a WHO performance status score of 3 or 4 ranged from 4% to 8%. 
Over three-quarters of the participants in the IFM RCTs had bone lesions but this information 
was not reported by Palumbo and colleagues24 (see Table 4). None of the RCTs reported on the 
ethnicity of the participants.
All three RCTs specified their exclusion criteria. In the two IFM RCTs23,59 these were almost 
identical, the only difference being that Hulin and colleagues59 excluded anyone with a history 
of venous thrombosis during the previous 6 months in addition to the other exclusions [anyone 
with previous neoplasms (except basocellular cutaneous or cervical epithelioma); primary or 
associated amyloidosis; a WHO performance index of 3 or higher, if unrelated to MM; substantial 
renal insufficiency with creatinine serum concentration of 50 mg/l or more; cardiac or hepatic 
dysfunction; peripheral neuropathy; HIV infection, or hepatitis B or C infections]. Palumbo and 
colleagues24 listed fewer exclusion criteria. Two were similar to those of the IFM RCTs (exclusion 
of people with another cancer or any grade 2 peripheral neuropathy) and one was novel to this 
RCT (exclusion of people with psychiatric disease). Palumbo and colleagues24 also stated that 
abnormal cardiac function, chronic respiratory disease, and abnormal liver or renal functions 
were not criteria for exclusion.
The timing of clinic visits during the RCTs varied. Palumbo and colleagues24 monitored response 
to treatment every 4 weeks, whereas visits were scheduled every 6 weeks for the RCT by Hulin 
and colleagues59 until treatment completion or study withdrawal. Facon and colleagues23 saw 
participants after inclusion at 3 months, 6 months and then every 6 months thereafter until 
withdrawal from the RCT. When scheduled clinic visits ended (after withdrawal or end of 
treatment), Palumbo and colleagues24 continued to assess participants every 2 months, and the 
two IFM RCTs23,59 continued to assess participants every 6 months.
Overall survival was the primary outcome measure for the two IFM RCTs.23,59 Both RCTs were 
powered at 80% for the primary outcome but recruitment was stopped early in both RCTs 
because interim analyses had demonstrated a clear survival advantage. The secondary outcomes 
of these RCTs were response rates,23,59 PFS,23,59 survival after progression,23 toxicity23 and safety.59 
Facon and colleagues23 report some of their outcomes for more than one follow-up period. OS, 
PFS and survival after progression analyses were reported for a data point of 8 January 2007; 
these outcomes were also reported along with all other outcomes for the earlier date point of 8 
October 2005. In contrast, the primary outcomes of the RCT by Palumbo and colleagues24 were 
stated as response rates and PFS. A power calculation was reported for the response outcome. 
The secondary outcomes of this RCT were OS, time to first evidence of response, prognostic 
factors, and frequency of any grade 3 or higher AEs.
Thalidomide in combination with cyclophosphamide and attenuated 
dexamethasone (MMIX Trial)
The MMIX RCT non-intensive pathway evaluated CTDa in comparison with MP. Participants 
were randomised in a 1 : 1 ratio to receive either CTDa or MP. Within each treatment arm, 
participants were also randomised to bisphosphonate treatment with either sodium clondronate 
or zoledronic acid. This multicentre RCT was conducted [academic-in-confidence (AiC) and/
or commercial-in-confidence (CiC) information has been removed] in the UK (AiC/CiC 
information has been removed) (see Table 4). The RCT was funded by a core grant from the 
MRC, with some other funding provided by five industry sponsors and one charitable sector 
sponsor (see Appendix 5).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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The treatment period with CTDa in the intervention arm was designed to be between 24 and 
36 weeks, equivalent to a minimum of six, or a maximum of nine, 4-week treatment cycles. 
Thalidomide was prescribed as a daily starting dose of 50 mg with the aim that this would be 
increased every 4 weeks by 50 mg to a maximum of 200 mg. During each 4-week treatment cycle 
500 mg of cyclophosphamide was taken once a week on days 1, 8, 15 and 22, and dexamethasone 
20 mg was taken daily on days 1–4 and days 15–18 of each cycle. Participants in the comparator 
arm received MP (melphalan 7 mg/m2 and prednisolone 40 mg) on days 1–4 of each 4-week cycle. 
Dose adjustments were permitted in both RCT arms.
In common with the other included RCTs, patients were eligible if they were newly diagnosed 
with symptomatic MM or non-secretory MM and had not received previous treatment for 
myeloma (other than local radiotherapy). The MMIX non-intensive pathway was designed for 
older (generally ≥ 70 years of age) or less fit patients (who could be younger than 70 years) but 
strict age restrictions were not in place to ensure that fit older patients were not excluded from 
the intensive therapy arm. (AiC and CiC information has been removed.) Exclusion criteria 
included asymptomatic MM, solitary plasmacytoma of bone and extramedullary plasmacytoma 
(without evidence of myeloma). People with acute renal failure were excluded but those with a 
history of ischaemic heart disease or psychiatric disorder could be considered for inclusion at the 
discretion of the clinician. Further details of exclusion criteria can be found in Appendix 5.
Overall survival, PFS, and response were the co-primary outcomes and power calculations were 
provided for both survival and response. Secondary outcomes were QoL, skeletal-related events, 
height loss, toxicity (thromboembolic events, renal toxicity, haematological toxicity, graft-versus-
host disease) and proportion receiving bortezomib–dexamethasone as ‘early rescue’ on induction 
chemotherapy, or at relapse.
Quality assessment of included studies
The outcome of the quality assessment of included RCTs is summarised in Table 5.
Bortezomib in combination with melphalan and prednisone
The VISTA study of VMP versus MP was an RCT, with randomisation stratified according to 
baseline levels of β2-microglobulin, serum albumin and region. However, no details are given on 
the methods used to generate random numbers or conceal allocation to treatment group, and 
therefore it is not possible to know whether the RCT is at risk of selection bias due to unbalanced 
confounding factors and failure to adequately conceal allocation. Baseline demographics and 
disease characteristics are reported to be well balanced between the two groups. The RCT is 
TABLE 5  Quality assessment of included studies
Study
Randomisation 
sequence
Allocation 
concealment
Balanced 
baseline 
characteristics Blinding
Dropout 
imbalance
More 
outcomes 
than 
reported
ITT 
analysis
Missing 
data 
accounted 
for
San Miguel et al.26,60 NR NR Yes No ? No Yes ?a
Facon et al.23 NR NR ? NR ? No Yes ?
Hulin et al.59 NR Yes Yes ? ? No Yes ?
Palumbo et al.24 Yes Yes Yes No ? No Yes ?
MMIX49,50,52 Yes Yes Yes No NR No Yes ?
?, unclear (uncertain risk of bias).
a  The MS from Janssen–Cilag provided additional information indicating that missing data were imputed using the last-observation-carried-
forward method.22 Clinical effectiveness
described as open label, which suggests that researchers and/or participants were not blinded. As 
bortezomib is administered intravenously the researchers may have felt blinding was not possible. 
However, for objective outcomes, such as OS, risk of bias is low regardless of lack of blinding. 
There is no evidence that more outcomes were measured than reported by study authors. The 
authors did not report whether there were any unexpected imbalances in dropouts between the 
groups. TTP, time to subsequent myeloma therapy, and OS from randomisation were analysed in 
the intention-to-treat (ITT) population (all randomised patients). For TTP analyses, data from 
patients for whom there was no disease progression were censored at the last assessment, or at 
the start of subsequent therapy. Although not explicitly stated it is assumed that deaths without 
disease progression were not included in the outcome of TTP. Details of censoring in terms of 
number of patients with censored data and reasons for censoring in each group are not given. 
The response analysis was not ITT as seven patients in each group could not be evaluated for 
a response: five did not receive the study drug; three patients in the VMP arm and six patients 
in the MP arm had no measurable disease at baseline on the basis of assessment by a central 
laboratory (although the patients met the eligibility criteria of measurable disease according to 
evaluation by a local laboratory).
Thalidomide in combination with melphalan and prednisone
All of the included studies were RCTs of MPT versus MP. However, one of the three RCTs, 
Facon and colleagues,23 did not report on the methods used to generate random allocations 
or how the allocations were concealed. Without this information we cannot be certain that 
the randomisation method balanced out confounding factors or that allocation bias has been 
avoided in this RCT. Hulin and colleagues59 did not report on the method used to generate the 
randomisation sequence but the central allocation of patients should have provided adequate 
allocation concealment. Palumbo and colleagues24 were the only authors to report sufficient 
information about randomisation and allocation concealment, allowing this RCT to be judged at 
low risk from unbalanced confounding factors and low risk of allocation bias.
All three MPT RCTs reported on the baseline characteristics of participants according to 
treatment group. Hulin and colleagues59 provided an indication that statistical testing had 
been used to test the similarity of the groups at baseline, and reported that the only statistically 
significant difference was for sex (more female participants in MPT group, p = 0.03). However, 
Facon and colleagues23 did not report on whether the groups had been judged to be similar at 
baseline. Palumbo and colleagues24 stated that baseline demographics and other characteristics of 
the two groups were balanced.
One of the three MPT RCTs, Palumbo and colleagues,24 was not blinded, and this was clearly 
stated by the authors. One of the RCTs, Hulin and colleagues,59 involved the use of a placebo 
in the comparator arm, which suggests blinding may have been in place although this was not 
explicitly stated. The third MPT RCT did not report whether blinding was in place or not. In each 
RCT some of the outcomes were objective (e.g. survival) and therefore the risk of bias for these 
would be low, regardless of whether blinding was in place or not.
There was no evidence in any of the MPT RCTs that more outcomes were measured than were 
reported. But for each of the three MPT RCTs it was unclear whether there were any unexpected 
imbalances in dropouts between groups because none of the RCT authors commented on 
this.23,24,59
All of the MPT RCTs stated that an ITT analysis had been conducted but the details of these 
analyses and methods used to account for missing data were unclear due to poor reporting. 
Hulin and colleagues59 stated that an ITT analysis was conducted, but in this case the ITT 
analysis appears to have excluded three randomised participants who discontinued before study © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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treatment (two in the MPT group and one in the MP group). Facon and colleagues23 stated that 
an ITT analysis was conducted and, from the numbers provided in the results for OS and PFS, 
but not response, their ITT analysis appears to have included all patients randomised, including 
those who were not treated as assigned. Palumbo and colleagues24 stated an ITT analysis had 
been conducted at 6 months (the only outcome point eligible for inclusion in this review) but at 
the time of analysis not all randomised participants had been enrolled for 6 months. Therefore, 
76 out of the 331 randomised participants (38 in each arm) were not included in the analysis of 
6-month data. As these RCTs reported time-to-event data, such as OS and PFS, it was expected 
that some data would be censored. However, only one RCT, Hulin and colleagues,59 stated when 
data on patients who were alive were censored in the survival analysis and when data on patients 
without disease progression were censored for the analysis of PFS. One of the MPT RCTs, Facon 
and colleagues,23 marked the position of censored data on the survival plots but none of the RCTs 
reported details of how many participants’ data were censored, and for what reason (e.g. censored 
due to withdrawal, censored due to death from an unrelated cause such as a car accident or 
censored as event of interest not experienced). It is not possible to determine whether the amount 
and pattern of censoring was comparable between the groups and whether this had any effect 
on outcomes.
Thalidomide in combination with cyclophosphamide and attenuated 
dexamethasone
The MMIX study of CTDa versus MP was an RCT (with randomisation) that used a 
minimisation algorithm, stratified by centre, haemoglobin, corrected serum calcium, serum 
creatinine and platelets.49,52 No details are reported on the methods used to generate random 
numbers; however, allocation to treatment groups was adequately concealed by the use of an 
automated 24-hour telephone system. The RCT is therefore at a low risk of selection bias. (AiC/
CiC information has been removed.) The RCT was not a blinded RCT, but, as already noted for 
the other included RCTs, the risk of bias is low for the objective outcomes. There is no evidence 
that more outcomes have been measured during the RCT than are reported. The authors did 
not report whether there were any unexpected imbalances in dropouts between the groups. All 
summaries and analyses were by ITT unless stated otherwise and ITT was defined as all patients 
randomised, with the exception of those misdiagnosed. For the QoL data the analysis includes all 
patients who agreed to take part in the QoL study. Patients with missing follow-up data or who 
had not experienced progression were censored on the last date they were known to be alive and 
progression free. OS was calculated from initial randomisation to death. Patients with missing 
follow-up data, or not known to have died at time of analysis, were censored on the last date they 
were known to be alive. It was not reported whether the amount and pattern of censoring was 
comparable between the groups. PFS was calculated from random assignment to progression or 
death. There was no other censoring of data.
Assessment of effectiveness
Overall survival
Overall survival was a secondary outcome in the VISTA RCT of VMP versus MP (Table 6) 
and was calculated from randomisation. A statistically significant survival benefit for VMP 
compared with MP is reported in an abstract60 after a median follow-up of 25.9 months 
(HR = 0.64, p = 0.0032). Three-year survival rates in a more recent abstract61 after a median 
follow-up of 36.7 months were 68.5% versus 54%, respectively. At the earlier median follow-up of 
16.3 months, reported in the published paper,26 median OS had not been reached. However, San 
Miguel and colleagues26,60 stated that a survival benefit was associated with bortezomib because 
45 patients (13%) in the VMP group had died in comparison with 76 patients (22%) in the 
MP group (HR 0.61, p = 0.008) (despite 43%60 of MP patients receiving subsequent bortezomib 
therapy after disease progression – see Table 21). The most recent abstract reports that median 
OS is 43.1 months in the MP group but not estimable in the VMP group.6124 Clinical effectiveness
Two23,59 of the three RCTs investigating MPT versus MP alone reported OS as their primary 
outcome. Both RCTs calculated OS from randomisation but only one of them, Hulin and 
colleagues,59 explained that data on patients who were alive at the time of analysis were censored 
in the survival analysis on the last date they were known to be alive. For the third RCT,24 OS 
was a secondary outcome and was not eligible for inclusion in this systematic review because 
participants received maintenance therapy with thalidomide after the six 4-week cycles of MPT 
were completed.
A statistically significant difference in OS in favour of the MPT group was found by both 
RCTs (see Table 6). Facon and colleagues23 reported their results after a median follow-up 
of 51.5 months. In the MPT group there were 62 events (deaths) and median survival was 
51.6 months [interquartile range (IQR) 26.6 to ‘not reached’], whereas in the MP group, where 
there were 128 events, median survival was 33.2 months (IQR 13.8–54.8). The difference in OS 
was statistically significant, with an estimated HR for median OS in favour of MPT of 0.59 (95% 
CI 0.46 to 0.81, p = 0.0006). When adjusting for prognostic factors (e.g. WHO performance 
index; β2-microglobulin, albumin, etc.) the results showed that MPT remained the superior 
treatment in terms of the specified outcome OS (HR 0.49, 95% CI 0.33 to 0.73, p = 0.0002) (see 
Appendix 5). Similarly Hulin and colleagues,59 reporting after a slightly shorter median follow-up 
of 47.5 months, found that the median survival of 44 months (95% CI 33.4 to 58.7) in the MPT 
group was statistically significantly longer than in the MP + placebo group where median survival 
TABLE 6  Overall survival
Study
Median follow-
up (months) Treatment arms HR and p-value
San Miguel et al.26 VISTA
VMP (n = 344) MP (n = 338)
OS (abstract61) 36.7 Not estimable 43.1 months 0.653; 0.0008
OS (abstract60) 25.9 NR NR 0.64; 0.0032
OS26 16.3 Median survival not reached Median survival not reached 0.61; 0.008
Deaths26 45/344 (13%) 76/338 (22%)
Three-year survival rate (abstract61): % 68.5 54.0 NR
Three-year survival rate (abstract60): % 72 59 NR
Facon et al.23 IFM 99/06
MPT (n = 125) MP (n = 196)
OS:a median (SE, IQR) 51.5
(IQR 34.4–63.2)
51.6 (4.5, 26.6 to ‘not 
reached’) months
33.2 (3.2, 13.8 to 54.8) 
months
0.59 (95% CI 0.46 to 
0.81); 0.0006
Deaths 62/125 (50%) 128/196 (65%)
Hulin et al.59 IFM 01/01
MPT (n = 113) MP + placebo (n = 116)
OS: median (95% CI) 47.5 44.0 (33.4 to 58.7) months 29.1 (26.4 to 34.9) months 0.68 (95% CI not 
reported); 0.028
Deathsb 58/113 (51%) 76/116 (65.5%) 0.03
a  At the initial analysis (median follow-up 36.8 months) no difference in OS was recorded as a function of initial thalidomide dose (≤ 200 mg per 
day vs > 200 mg per day, p = 0.93).
b  Myeloma progression was considered to be the major cause of the majority of deaths in both study arms (36/58 deaths in the MPT group, 
54/76 deaths in the MP + placebo group).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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was 29.1 months (95% CI 26.4 to 34.9). In this RCT the reported HR for median OS in favour of 
MPT was 0.68 (95% CI for the HR not reported, p = 0.028).
As noted above, neither RCT reported on the amount of censored data, or the reasons for this. It is 
therefore not possible to determine whether censored data had any impact on the outcome of OS.
The MMIX RCT49 OS outcome was not eligible for inclusion in this systematic review because 
participants were entered into a second randomisation to receive either maintenance therapy 
with thalidomide or no maintenance therapy after they had completed first-line treatment with 
either CTDa or MP.
Two MPT versus MP RCTs23,59 reported OS outcome data that met the inclusion criteria of the 
review. A fixed-effects meta-analysis was conducted and, as can be seen in Figure 2, the I2-test 
suggests there is little or no heterogeneity between the two RCTs for this outcome. The summary 
OS HR was 0.62 (95% CI 0.50 to 0.77) in favour of MPT.
The Facon study23 CIs shown in Figure 2 obtained from Review Manager are slightly different 
to those reported by the published paper and shown in Table 6. The difference arises from 
the estimating method41 used to obtain the SEs for the log-HRs needed to undertake the 
meta-analysis.
Deaths during treatment
In the VISTA RCT26 of VMP versus MP, death rates during treatment were similar for the VMP 
group and the MP group (5% and 4%, respectively) (Table 7). San Miguel and colleagues26 also 
report that treatment-related deaths were similar in the two groups, but the time at which these 
deaths occurred is not reported (treatment-related deaths VMP 1% and MP group 2%).
The two RCTs of MPT that report OS23,59 also provide some information about the deaths that 
occurred. Facon and colleagues23 provided very limited information, commenting on only toxic 
deaths (no definition is provided but the term toxic death usually refers to a treatment-related 
death) and deaths within the first 3 months of treatment (see Table 7). In the MPT group there 
were no toxic deaths and only three deaths in the first 3 months of treatment. In the MP group 
there were both more toxic deaths (four deaths all due to infection) and more early deaths (13 
deaths) but, as no statistical comparison between the arms is reported, it is not known whether 
these differences were statistically significant.
Hulin and colleagues59 reported only one toxic death in the MPT group and one in the 
MP + placebo group. Both of these toxic deaths were caused by intestinal perforation. The 
number of early deaths was also very similar between the groups. In the MPT group three 
deaths were reported after 1 month of treatment, and five deaths after 3 months of treatment. 
FIGURE 2  Melphalan, prednisolone/prednisone plus thalidomide vs MP OS.
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In the MP + placebo group, three deaths were reported after 1 month of treatment and six 
after 3 months of treatment. For both study arms it is not clear whether the number of deaths 
reported after 3 months is a cumulative value, i.e. including the deaths reported after 1 month of 
treatment, or whether these are additional deaths that have occurred in months 2 and 3.
(AiC/CiC information has been removed.)
Response to treatment
Various response to treatment rates are reported as secondary outcomes in the VISTA RCT of 
VMP (Table 8),26 although the analysis is not ITT as previously explained. The time at which 
response was assessed is not reported. Rates of PR or better (according to EBMT criteria, 
Appendix 3) were 71% in the VMP group and 35% in the MP group (p < 0.001), and the CR rates 
were 30% and 4%, respectively (p < 0.001). The rate of PR was 40% in the VMP group and 31% 
in the MP group and minimal response (MR) rates were 9% and 22%, respectively. Stable disease 
rates were 18% in the VMP group and 40% in the MP group, and progressive disease rates were 
1% and 2%, respectively.
All three RCTs investigating MPT reported on response to treatment (see Table 8).23,24,59 The 
two IFM RCTs23,59 reported the response at 12 months as a secondary outcome, and response 
was judged according to their own criteria. These criteria are very similar, but not identical, to 
the EBMT criteria that were used in the RCT by Palumbo and colleagues24 to assess response at 
TABLE 7  Deaths during treatment
Study Treatment arms p-value
San Miguel et al.26 VISTA
VMP (n = 344) MP (n = 338)
Deaths during treatment (%) 5 4 NR
Treatment-related deaths (%) 1 2 NR
Facon et al.23 IFM 99/06
MPT (n = 124) MP (n = 193)
Toxic death n = 0 n = 4 (2%), all due to infection NR
Early death – in first 3 months of 
treatment (n, %)
3/124 (2) 13/193 (7) NR
aHulin et al.59 IFM 01/01
MPT (n = 113) MP + placebo (n = 116)
Toxic death (intestinal perforation) n = 1 n = 1 NR
Early death – after 1 month of 
treatment
n = 3 n = 3 NR
Early death – after 3 months of 
treatment
n = 5 n = 6 NR
MMIX49,53,54
CTDa (AiC/CiC information has 
been removed)
MP (AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
a  Withdrawals due to death are reported in Chapter 4 (see Table 18).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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6 months, which was the primary outcome of this RCT (see Appendix 5). Facon and colleagues23 
stated that all analyses were undertaken on an ITT basis; it is therefore unclear why response 
to treatment outcomes are reported for only 60% of the MPT group (75 of the 125 participants 
enrolled to this group) and 84% of the MP group (165 of 196 enrolled). Hulin and colleagues59 
did not indicate that all analyses were ITT (only survival analyses were clearly stated to be ITT) 
but response to treatment is reported for 93% of the MPT group and 96% of the MP + placebo 
group. Palumbo and colleagues24 reported on all of those who contributed to the 6-month 
follow-up results. However, as noted earlier, not all of the randomised participants contributed 
data to this outcome because some participants had not achieved 6 months of follow-up when 
these data were analysed.
At 12 months, statistically significant differences in CR in favour of the MPT group were 
observed in both the IFM RCTs.23,59 Facon and colleagues23 reported 13% of 75 participants in 
the MPT group had achieved CR at 12 months in comparison with just 2% of 165 participants in 
the MP group (p = 0.008). Caution must be applied in interpreting these results, however, which 
appear to be based on a small proportion of the participants. The difference between the groups 
reported by Hulin and colleagues59 was less marked but still statistically significant (MPT 7% of 
107 participants CR versus 1% of 112 participants in MP + placebo group, p < 0.001). Palumbo 
and colleagues24 reported an absolute difference in CR MPT–MP at 6 months of 13% (95% CI 6.3 
to 20.5).
When response categories were combined, the percentage of participants in the IFM RCT MPT 
groups achieving at least a PR at 12 months was double the percentage achieving this level of 
response in the MP group (Facon and colleagues,23 MPT 76% vs MP 35%, p < 0.0001; Hulin and 
colleagues,59 MPT 62% vs MP + placebo 31%, p < 0.001). At 6 months in the RCT by Palumbo and 
colleagues24 there was a difference in favour of the MPT group of 28.3% (95% CI 16.5 to 39.1) for 
participants achieving either a CR or PR.
Each MPT RCT reported on a subcategory of participants with a PR. In the two IFM RCTs, 
only one subcategory of participants was reported on who were described as having a very good 
PR.23,59 These participants had more than a 90% decrease in monoclonal protein in serum and 
urine. Palumbo and colleagues24 reported on three subcategories of participants with PR.24 Those 
with a near CR had disappearance of M-protein from serum and urine but still detectable by 
immunofixation (immunofixation positive); the remaining participants with a PR were divided 
into those with a 90–99% M-protein reduction and those with a 50–89% M-protein reduction. 
Facon and colleagues23 reported at least a very good PR at 12 months in 35 out of 75 participants 
(47%), which was statistically significantly better than in the MP group where only 7% (11/165) 
of participants met the criteria (p < 0.001). Hulin and colleagues59 also reported a statistically 
significant difference in favour of the MPT group at 12 months when 21% (23/107) met the 
criteria for at least a very good PR, in comparison to 7% (8/112) in the MP group (p < 0.001). 
Palumbo and colleagues24 report greater proportions of participants in the MPT group than 
in the MP group at each subcategory of PR after 6 months of follow-up. Of the 78 participants 
(60.4%) in the MPT group with a PR most (n = 51) had experienced a 50–89% M-protein 
reduction, 11 participants had a 90–99% M-protein reduction, and 16 participants had a near CR. 
In contrast, only 57 (45.2%) of MP group participants achieved a PR with the majority (n = 45) 
having a 50–89% M-protein reduction, six participants having a 90–99% M-protein reduction, 
and six participants achieving a near CR.
Facon and colleagues23 and Hulin and colleagues59 gave no details about participants who 
achieved less than a PR at 12 months. Palumbo and colleagues,24 however, provided information 
on each of the remaining three EBMT categories – minimal response at 6 months, no response at 28 Clinical effectiveness
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6 months, and progressive disease at 6 months – as well as indicating the proportion of data that 
was not available (see Table 8). There were greater proportions of participants from the MP group 
than the MPT group in the final three categories.
The MMIX RCT49,53,54 assessed maximal response after induction chemotherapy with either 
CTDa or MP. Response was categorised using EBMT definitions (see Appendix 3). Response was 
one of the three co-primary outcomes of this RCT. (AiC/CiC information has been removed) 
(Table 8).
Risk ratios for complete response
Three MPT versus MP RCTs23,24,59 reported CR outcome data that could be meta-analysed. 
A fixed-effects meta-analysis was conducted and, as can be seen from Figure 3, the I2-test 
suggests that there is little or no heterogeneity between the three RCTs for this outcome. The 
outcome is reported as a risk ratio (RR) because a summary relative risk was required for the 
cost-effectiveness model (see Chapter 5, SHTAC data sources, Complete response). The Facon 
results were entered using the original group sizes to generate a conservative estimate of overall 
treatment effect for use in the cost-effectiveness model. The overall effect for the outcome of CR 
favours MPT (RR 5.49, 95% CI 2.55 to 11.83).
Risk ratios for the outcome of CR were also obtained for the single RCTs for the VMP versus MP 
comparison and the CTDa versus MP comparison using the data reported in Table 8 and Review 
Manager software. These RRs were needed for the cost-effectiveness model [CR VMP vs MP RR 
8.35, 95% CI 4.68 to 14.89, (AiC/CiC information has been removed)].
Other time-to-event data
The VISTA RCT26 of VMP was the only included RCT to report time to disease progression 
(TTP) and this was the primary outcome of this RCT. TTP was calculated from randomisation to 
disease progression. Data from patients in whom there was no disease progression were censored 
at the last assessment or at the start of subsequent therapy. Although not explicitly stated, it 
is assumed that this outcome does not include deaths where there was no disease progression 
(these events would be included in the outcome of the PFS section: see Progression-free survival). 
Median TTP was significantly longer in the VMP group than in the MP group (VMP group 
20.7 months vs MP group 15.0 months, HR = 0.54, p < 0.001). The median time to first response 
(partial or better) was 1.4 months in the VMP group and 4.2 months in the MP group (p < 0.001), 
and 4.2 months and 5.3 months for CR (p < 0.001), respectively (Table 9). The median duration 
of response (according to EBMT criteria) was 19.9 months in the VMP group and 13.1 months 
in the MP group; the median duration of response among patients who had a CR was 24 months 
in the VMP group and 12.8 months in the MP group. Time to subsequent myeloma therapy and 
FIGURE 3  Melphalan, prednisolone/prednisone plus thalidomide vs MP CR.
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treatment-free interval were reported in the published paper26 as 20.8 months and 9.4 months, 
respectively, in the MP group; these times were not reached for the VMP group. In the abstracts 
reporting longer follow-up,60,61 time to next therapy was 28.1 months in the VMP group 
and 19.2 months in the MP group (p < 0.000001, HR 0.53); the treatment-free intervals were 
16.6 months and 8.4 months (p < 0.00001, HR 0.54), respectively, after a median follow-up 
of 25.9 months.60 After a median follow-up of 36.7 months,61 the treatment-free interval was 
17.6 months in the VMP group and 8.4 months in the MP group (HR 0.54, p < 0.0001).
Of the MPT RCTs, only Palumbo and colleagues24 reported on the length of time it took to 
observe a PR to treatment (see Table 9). In the MPT treatment arm the median time to PR was 
1.4 months (range 22–200 days) but in the MP arm it took longer to reach the median time to PR 
of 3.1 months but responses occurred within a very similar range of 25–210 days.
The MMIX RCT49 TTP outcome was not eligible for inclusion in this systematic review because 
participants were entered into a second randomisation to either maintenance therapy with 
thalidomide or no maintenance therapy after they had completed first-line treatment with either 
CTDa or MP.
Progression-free survival
Progression-free survival in the VISTA RCT of VMP was defined by San Miguel and colleagues26 
as the time between randomisation and either disease progression or relapse from CR by 
EBMT criteria, or death due to any cause, whichever occurred first. Median PFS by investigator 
assessment based on central laboratory data and applying EBMT criteria was 21.7 months in the 
VMP group and 15.2 months in the MP group (HR 0.56, p < 0.001) – see Table 10.
The two included IFM RCTs23,59 reported on PFS and both calculated PFS from randomisation to 
either progression, or death without progression (Table 10). Hulin and colleagues59 censored data 
TABLE 9  Other time-to-event outcomes
Study Treatment arms HR and p-value
aSan Miguel et al.26 VISTA
VMP (n = 344): months MP (n = 338): months
TTP median (from computer algorithm analysis) 20.7 15.0  0.54; < 0.001
Median time to first response (PR or better) 1.4 4.2 < 0.001
Median time to CR 4.2 5.3 <0.001
Median duration of CR or PR 19.9 13.1 NR
Median duration of CR 24 12.8 NR
Median time to subsequent myeloma therapy Not reached 20.8 0.52; < 0.001
Treatment-free interval Not reached 9.4 NR
Time to next therapy from abstracts60,61 28.1 (n NR) 19.2 (n NR) 0.53; < 0.000001
Treatment-free interval from abstract60 16.6 (n NR) 8.4 (n NR) 0.54; < 0.00001
Treatment-free interval from abstract61 17.6 8.4 0.543; < 0.0001
Palumbo et al.24 GIMEMA
MPT: months MP: months
Time to PR, median (range, days) 1.4 (22–200) 3.1 (25–210) NR
a  Time-to-event data determined by computer algorithm applying EBMT criteria. TTP from trial investigators data also available (see Appendix 5).32 Clinical effectiveness
on patients who had not experienced progression to the last day that they were known to be alive 
and progression free. Facon and colleagues23 did not comment on methods for censoring data.
After a median follow-up of 51.5 months, 92 of the 125 participants in the MPT group of the 
Facon and colleagues23 RCT had either experienced disease progression or they had died. The 
median PFS of the MPT group was 27.5 months (SE 2.1). In comparison, in the MP group 171 of 
196 participants had disease progression or had died and the median PFS was 17.8 months (SE 
1.4). The difference in PFS was statistically significant (p = 0.001) with a HR for median PFS in 
favour of MPT of 0.51 (95% CI 0.39 to 0.66).
Hulin and colleagues59 also found that the difference in PFS between MPT and MP + placebo 
groups after a median follow-up of 47.5 months was statistically significant with a HR of 0.62 
(p = 0.001). In the MPT group median PFS was 24.1 months (95% CI 19.4 to 29.0) in comparison 
to 18.5 months (95% CI 14.6 to 21.3) in the MP + placebo group.
The event-free24 and progression-free49 survival outcomes reported by Palumbo and colleagues24 
and the MMIX RCT49 were not eligible for inclusion in this systematic review because 
participants received maintenance therapy with thalidomide after first-line treatment had 
been completed.
Two MPT versus MP RCTs23,59 reported PFS outcome data that was included in a fixed-effects 
meta-analysis. As can be seen in Figure 4, the I2-test suggests there is little or no heterogeneity 
between the two RCTs for this outcome. The summary PFS HR was 0.56 (95% CI 0.46 to 0.67) in 
favour of MPT.
TABLE 10  Progression-free survival
Study
Median 
follow-up 
(months) Treatment arms HR and p-value
San Miguel et al.26 VISTA
VMP (n = 344) MP (n = 338)
PFS (months): median 16.3a 21.7 15.2 0.56; < 0.001
PFS (months): median 
(reported in Janssen–Cilag 
submission to NICE)b
16.3 (AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
Facon et al.23 IFM 99/06
MPT (n = 125) MP (n = 196)
PFS (months): median (SE) 51.5 27.5 (2.1) 17.8 (1.4) 0.51 (95% CI 0.39 to 0.66); 
0.0001c
Hulin et al.59 IFM 01/01
MPT (n = 113) MP + placebo (n = 116)
PFS (months): median (95% CI) 47.5 24.1 (19.4 to 29.0) 18.5 (14.6 to 21.3) 0.62; 0.001
a  Median follow-up not explicitly stated, assumed to be the same as that for OS.
b  The Janssen–Cilag MS reported different PFS values and Janssen–Cilag informed SHTAC that the published value is incorrect although the 
reason why the published value is incorrect was not provided.
c  At the initial analysis (median follow-up 36.8 months) no difference in PFS was recorded as a function of initial, maximum or average 
thalidomide doses (p = 0.22, p = 0.75, p = 0.92, respectively).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
33   Health Technology Assessment 2011; Vol. 15: No. 41 DOI: 10.3310/hta15410
The Facon study CIs shown in Figure 4 obtained from Review Manager are slightly different 
to those reported by the published paper and shown in Table 10. The difference arises from the 
estimating method used to obtain the SEs for the log-HRs needed to undertake the meta-analysis.
Quality of life
The VISTA RCT included a QoL assessment (Table 11) that has been reported only in an 
abstract.62 The abstract states that the aim of the study was to describe the rate of patients who 
experienced a sustained HRQoL improvement after best response and the overall HRQoL 
impact of best response. A sustained HRQoL improvement was defined as a change in score of 
at least five points for at least two consecutive cycles after best response (CR, PR or MR). After 
best-response onset, patients in the VMP arm had a higher sustained HRQoL improvement rate 
than those in the MP arm in 14 of the 15 European Organisation for Research and Treatment of 
Cancer quality-of-life questionnaire C30 (EORTC QLQ-C30) scores.
The MMIX RCT49 assessed QoL but it was not possible to include data in this systematic review 
because some of the participants were entered into a second randomisation to either maintenance 
therapy with thalidomide or no maintenance therapy after they had completed first-line 
treatment with either CTDa or MP.
FIGURE 4  Melphalan, prednisolone/prednisone plus thalidomide vs MP PFS.
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TABLE 11  Quality of life
Study
Treatment arms
p-value VMP (n = 344, no. analysed NR) MP (n = 338, no. analysed NR)
Dhawan et al.62 VISTA
Sustained response in QLQ-C30 domainsa (%)
Cognitive functioning 27 28 NR
Nausea/vomiting NR NR 0.0095b
Appetite loss NR NR 0.0170
Diarrhoea NR NR 0.0082
Global health 49 40 Not statistically significant
Pain 40 32 Not statistically significant
Insomnia 32 24 Not statistically significant
a  The rate of sustained improvement was calculated in the population of patients who were followed for at least two cycles after best response 
(n = 363). The number of patients in each arm contributing data was not reported.
b  The differences for nausea and diarrhoea remained significant in the Cox models when adjusted for baseline score, score at best response, 
and type of response (CR, PR or MR).34 Clinical effectiveness
Adverse events
This section summarises AEs reported by RCTs, concentrating on the events that require active 
management and/or have the greatest impact on patient QoL. The AEs that have been omitted 
from each table are listed in the table footnotes and the complete AE data for each RCT can be 
found in the data extraction forms in Appendix 5.
Adverse events reported by San Miguel and colleagues in the VISTA RCT26 of VMP were graded 
with the use of the NCI CTCAE (version 3). Occurrence of any AE and grade 4 AE was similar 
in the two groups, although grade 3 events were more common in the VMP group (53% vs 44%, 
p = 0.02) (Table 12). Haematological toxic events were the most frequently reported AEs and were 
also similar in the two groups. Peripheral sensory neuropathy was reported more frequently in 
the VMP group but, by the data cut-off point, 74% of peripheral neuropathy events had either 
resolved (56%) or decreased by at least one toxicity grade (18%) within a median of 2 months. 
All grade 3 and grade 4 gastrointestinal events were more frequent in the VMP group than in the 
TABLE 12  Adverse events reported in the VISTA trial
Study
Treatment arms
p-value VMP (n = 340) MP (n = 337)
San Miguel et al.26,60 VISTA n (%) n (%)
Any eventa 338 (99) 326 (97) NR
Grade 3 181 (53) 148 (44) 0.02
Grade 4 96 (28) 92 (27) NR
Serious AEs 46 36 NR
Haematological eventsb
Thrombocytopenia 178 (52) 159 (47) NR
Neutropenia 165 (49) 155 (46) NR
Anaemia 147 (43) 187 (55) NR
Leucopenia 113 (33) 100 (30) NR
Lymphopenia 83 (24) 58 (17) NR
Gastrointestinal events of grade 3 and grade 4c 19 5 NR
Infections
Pneumonia 56 (16) 36 (11) NR
Herpes zoster 45 (13) 14 (4) NR
Nervous system disorders
Peripheral sensory neuropathy 151 (44) 16 (5) NR
Neuralgia 121 (36) 5 (1) NR
Dizziness 56 (16) 37 (11) NR
Other conditionsc
Fatigue 98 (29) 86 (26) NR
DVT 4 (1) 6 (2) NR
DVT, deep-vein thrombosis.
a  Listed AEs were reported in at least 15% of patients and the median-dose intensities of MP were the same in both groups. Patients could have 
more than one AE.
b  Rates of red cell transfusion were 26% in the VMP group, 35% in the MP group; rates of erythropoiesis-stimulating agents for treatment-related 
anaemia were 30% and 39%, respectively.
c  Gastrointestinal AEs detail on nausea, diarrhoea, constipation and vomiting omitted. Details of other conditions, pyrexia, anorexia, asthenia, 
cough, insomnia, peripheral oedema, rash, back pain, dyspnoea, hypocalcaemia and arthralgia, also omitted. Full details available in Appendix 5.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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MP group (19% vs 5%, no p-value given). Incidence of deep-vein thrombosis (DVT) was low and 
similar in the two groups.
The two IFM RCTs23,59 did not report which system was used to grade toxic effects and AEs to 
treatment and therefore caution must be applied when comparing the results of these two RCTs 
with each other, and with the RCT reported by Palumbo and colleagues.24 Neither IFM RCT 
describes whether all AEs that occurred have been reported, or whether only a subset of AEs 
is reported in the trial publication. Palumbo and colleagues24 used the NCI CTC (version 2) 
to grade AEs and all grade 3–4 events reported by patients or observed by investigators were 
reported. However, only AE reporting of infections from Palumbo and colleagues24 can be 
included here as the majority of AEs were reported for the whole trial period, which included 
administration of thalidomide maintenance therapy in the MPT group. AEs are summarised in 
Table 13. Facon and colleagues23 analysed safety at the October 2005 date point after 36.8 months 
of follow-up, a shorter follow-up than for the outcomes of OS, PFS and survival after progression.
Four types of haematological event (at grade 3 and 4) were reported by Facon and colleagues.23 
There were no statistically significant differences in the occurrence of anaemia (14% both 
groups, p = 0.94) or thrombocytopenia (MPT group 14%, MP group 10%, p = 0.29). A statistically 
significant difference was reported for neutropenia, which occurred in a greater proportion of 
MPT patients than MP patients (48% vs 26%, p < 0.0001). Hulin and colleagues59 also reported 
that a statistically significantly greater proportion of participants in the MPT group experienced 
neutropenia (grades 3 and 4) than in the MP group (23% vs 9%, p=0.003) but did not report on 
any other haematological events.
Both IFM RCTs23,59 reported the occurrence of grades 3 and 4 thrombosis or embolism. Facon 
and colleagues23 found that the greater proportion of patients with grades 3 and 4 thrombosis 
or embolism in the MPT group was a statistically significant difference in comparison with the 
MP group (MPT 12% vs MP 4%, p = 0.008). In contrast, there was no statistically significant 
difference in this AE in the Hulin and colleagues RCT59 (MPT 6% vs MP 3%, p = 0.33).
Peripheral neuropathy occurred statistically significantly more frequently in the MPT groups 
of both IFM RCTs but the reporting of this differed. Facon and colleagues23 reported on the 
occurrence of grades 3 and 4 peripheral neuropathy in both groups (MPT 6% vs zero events 
in the MP group, p = 0.01). Facon and colleagues23 also stated that peripheral neuropathy was 
observed in 69 (55%) patients in the MPT group, with the majority of cases (n = 62) being grade 
1 or 2, and the remainder grade 3 (n = 7), with no grade 4 events. The equivalent data for the MP 
group were not provided. In contrast, Hulin and colleagues59 reported on each grade of peripheral 
neuropathy separately for each group. The proportion of patients with peripheral neuropathy was 
reported to be statistically significantly greater in the MPT group than the MP group (p = 0.003), 
although it was not clear whether the p-value related to peripheral neuropathy in general or grade 
1 peripheral neuropathy in particular. Most cases of peripheral neuropathy were of grade 1 or 2 
(grade 1 peripheral neuropathy MPT 18%, MP 16%, grade 2 peripheral neuropathy MPT 19%, 
MP 3%). Severe peripheral neuropathy was less common with 2% of both groups experiencing 
grade 3 peripheral neuropathy, and no grade 4 events reported.
Facon and colleagues23 report what appears to be a composite outcome described as somnolence/
fatigue/dizziness (grades 3 and 4). This occurred in 8% of the MPT group, statistically 
significantly more than the MP group where no one had these symptoms at this grade 
(p < 0.0001). In contrast, Hulin and colleagues59 reported on the single outcome of somnolence 
but over a wider severity range (grades 2–4) and found no statistically significant difference 
between the groups (MPT 6% vs MP 3%, p = 0.19).36 Clinical effectiveness
The incidence of grade 3 and 4 infections was reported by two RCTs23,24 and details of the 
infections contributing to this outcome were provided. Facon and colleagues23 reported no 
statistically significant difference in the number of patients with infections of grades 3 and 4 
TABLE 13  Adverse events reported by trials investigating MPT
Study Treatment arms p-value
a,bFacon et al.23 IFM 99/06 n (%) n (%)
MPT (n = 124) MP (n = 193)
Grade 3 and 4 AEs – after 36.8 months of follow-up
Haematological:
anaemia 17 (14) 27 (14) 0.94
neutropenia 60 (48) 51 (26) < 0.0001
thrombocytopenia 17 (14) 19 (10) 0.29
thrombosis or embolism 15 (12) 8 (4) 0.008
Peripheral neuropathy 7 (6) 0 0.001
Somnolence/fatigue/dizziness 10 (8) 0 < 0.0001
Infection 16 (13) 18 (9) 0.32
Gastrointestinal:
nausea 1 (1) 2 (1)
constipation 13 (10) 0 < 0.0001
Any grade ≥ 3 non-haematological toxic effect 52 (42) 30 (16) < 0.0001
b,cHulin et al.59 IFM 01/01 n (%) n (%)
MPT (n = 113) MP + placebo (n = 116)
Peripheral neuropathy: 0.003
grade 1 20 (18) 19 (16)
grade 2 21 (19) 4 (3)
grade 3 2 (2) 2 (2)
Neutropenia grade 3 or 4 26 (23) 10 (9) 0.003
Thrombosis or embolism grade 3 or 4 7 (6) 4 (3) 0.33
Somnolence grades 2–4 7 (6) 3 (3) 0.19
Constipation grades 2–4 19 (17) 12 (10) 0.16
Nausea/vomiting grades 2–4 3 (3) 5 (4) 0.5
dPalumbo et al.24 GIMEMA n/N (%) n/N (%)
MPT  MP
Grades 3–4 infections 12/129 (10) within the first 
4 months of treatment
2/126 (2); timing of 
occurrence unknown
0.01
a  In the MPT group, 15 patients experienced 17 episodes of thrombosis or pulmonary embolism. Thalidomide was resumed in 8 of the 15 
patients with thrombosis after full anticoagulation, and without recurrence in seven patients (one patient had three episodes). In the MPT 
group, 62 patients had grade 1 or 2 peripheral neuropathy and seven patients had grade 3 peripheral neuropathy (these are the seven 
noted above).
b  For Facon et al., the AEs of severe haemorrhage, cardiac AEs, and the gastrointestinal AEs of mucositis and bleeding have been omitted. 
Details on the infections that occurred have also been omitted. For Hulin et al., AEs of depression and oedema have been omitted.
c  There is contradictory information in the text and Table 3 of this paper. For peripheral neuropathy grades 1 and 2, text states 21 (19%) grade 
1 and 20 (18%) grade 2 in MPT group but table has these the other way around (as shown here). For the MP + placebo group, table states 
17% with peripheral neuropathy (grade 1), whereas text states 16%. Text appears correct as 19/116 is 16.4%. For neutropenia (grade 3 or 4) 
text states 25 (22%) for MPT group but table has 26 (23%).
d  Full AE reporting not data extracted because period that this covered and timing of the occurrence of the events was not reported (therefore 
unable to distinguish between events occurring during the first 6 months of treatment and those occurring later during thalidomide 
maintenance). Details on the infections that occurred can be found in Appendix 5.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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(MPT n = 16 patients, 13% vs MP n = 18 patients, 9%, p = 0.32). However, it is clear, although not 
explicitly stated, that some patients must have experienced more than one grade 3 or 4 infection, 
because the reported numbers of individual infections sum to 20 (see Appendix 5). In the 
6-month period of treatment in the Palumbo and colleagues RCT24 eligible for inclusion in the 
review, there were statistically significantly more infections in the MPT group than the MP group 
(MPT 10% all within the first 4 months vs MP 2%, p = 0.01). Hulin and colleagues59 did not report 
this outcome, other than stating that the higher incidence of neutropenia in the MPT group did 
not translate into more frequent severe infections.
Gastrointestinal events of nausea and vomiting when reported were also infrequent events 
(see Table 13). Constipation was the most commonly reported gastrointestinal AE. Facon and 
colleagues23 reported that only participants in the MPT group experienced constipation at grades 
3 and 4, which was a statistically significant difference (p < 0.0001) in comparison to the MP 
group where no grade 3 and 4 constipation AEs were reported. Hulin and colleagues59 reported 
on constipation AEs of grades 2–4, and the difference between the groups was not statistically 
significant (MPT 17% vs MP 10%, p = 0.16).
Overall, Facon and colleagues23 found that non-haematological toxic effects of grade 3 or higher 
were statistically significantly more likely in the MPT group than the MP group (MPT 42% vs 
MP 16%, p < 0.0001).
The MMIX IX protocol49 does not indicate which system would be used to grade AEs. It is also 
not clear whether all AEs that occurred related to induction chemotherapy are presented in the 
results that have been made available.54 AEs are summarised in Table 14.
(AiC/CiC information has been removed.)
Discontinuation or withdrawal due to AEs
In addition to the reporting of AEs in general above (see Adverse events, Tables 12–14) some of 
the included RCTs also reported on the patients who discontinued study medication, or withdrew 
from the study as a consequence of AEs (Tables 15 and 16).
In the VISTA RCT,26 50 patients (15%) in the VMP group and 47 patients (14%) in the MP group 
discontinued treatment due to AEs (see Table 15), including 37 patients (11%) and 35 patients 
(10%), respectively, who had treatment-related events. San Miguel and colleagues26 provide no 
further details. Bortezomib alone was discontinued in an additional 63 patients (19%).
For the MPT RCTs it was not clear from the study reports how many of the AEs that led to 
discontinuation or withdrawal had already been included in the general reporting of AEs (see 
Table 13). It also seemed clear from data reported that some discontinuations and withdrawals 
were due to events not specified in the general reporting of AEs (see Table 13), for example 
discontinuation of thalidomide due to cutaneous effects,23 and withdrawals due to cardiac 
events59 and rash59 (see Table 16).
Two of the RCTs, by Hulin and colleagues59 and Palumbo and colleagues,24 reporting on 
withdrawals due to AEs/toxicity and inability to complete six cycles of treatment due to AEs, 
respectively, reported the outcome for both study groups. AEs led to more withdrawals from 
treatment in the MPT group than the MP group but the differences were not tested statistically 
(Hulin and colleagues,59 MPT 42.5% vs MP plus placebo 12.9%; Palumbo and colleagues24 MPT 
13.2% vs MP 3.2%). Palumbo and colleagues24 also report that discontinuation of thalidomide 
was required by 43 patients (33.3%) after a median of 2.1 months. It is not clear, but presumably 
these 43 patients included the 17 in the MPT group who were unable to complete the six 38 Clinical effectiveness
TABLE 14  Adverse events reported by trials investigating CTDa
Study
Treatment arms
p-value CTDa (safety population) MP (safety population)
MMIX54
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TABLE 15  Discontinuations from the VISTA trial due to AEs
Study
Treatment arms
p-value VMP (n = 340) MP (n = 337)
San Miguel et al.26 VISTA: (n, %)
Discontinued treatment due to AEs 50 (15) 47 (14) NR
Discontinued treatment due to treatment-related events 37 (11) 35 (10) NR
Discontinuations of bortezomib alone 63 (19) –
TABLE 16  Discontinuation or withdrawal due to AEs in trials of MPT
Study Treatment arms p-value
aFacon et al.23 IFM 99/06
MPT MP
Discontinuation of thalidomide because of toxic effects: 56/124 (45%) NR NR
 peripheral neuropathy n = 23 NR NR
 thrombosis n = 7 NR NR
 somnolence, dizziness or fatigue n = 8 NR NR
 cutaneous toxic effects n = 4 NR NR
 psychiatric complications n = 1 NR NR
Withdrawn because of other reasons: n = 13 NR NR
 haematological toxic effects n = 5 NR NR
 infection n = 7 NR NR
 stroke n = 1 NR NR
bHulin et al.59 IFM 01/01
MPT (n = 113)
MP + placebo 
(n = 116)
Withdrawals due to adverse events/toxicity: n = 48 (42.5%)c n = 15 (12.9%)c NR
 peripheral neuropathy n = 12 n = 3 NR
 neurological events (non-peripheral) n = 10 n = 1 NR
 thrombosis/embolism n = 7 n = 1 NR
 haematological events n = 7 n = 6 NR
 digestive events n = 4 n = 2 NR
 cardiac events n = 3 n = 1 NR
 rash n = 2 n = 0 NR
 other n = 3 n = 1 NR
Dose reduction required because of AEs n = 20 (17.7%)c n = 3 (2.6%)c NR
Palumbo et al.24 GIMEMA
MPT  MP
Unable to complete six cycles due to AEs 17/129 (13.2%)c 4/126 (3.2%)c NR
Thalidomide discontinuation required 43 (33.3%)c patients after a median of 2.1 months N/A N/A
Thalidomide dose reduction to 50 mg required 37 (28.7%)c patients after a median of 4 months N/A N/A
N/A, not applicable.
a  Outcomes reported after a median follow-up of 36.8 months.
b  There is contradictory information in text and Figure 1 of the study report. Text states that nine MPT group participants withdrew due to 
neurological events (non-peripheral), whereas Figure 1 shows 10 participants. Data provided on timing of withdrawal due to toxicity but 
appears to be for study overall, not by group: within 3 months, nine patients; within 6 months, 23 patients; within 12 months, 38 patients. Also 
unclear which patients are included, as patient numbers given with timing of withdrawals sum to 70, but only 63 patients (48 MPT and 15 
MP + placebo) withdrew due to toxicity.
c  Percentages calculated by reviewer.40 Clinical effectiveness
treatment cycles. Facon and colleagues23 report discontinuation of thalidomide in the MPT group 
among 45% of the participants who discontinued because of toxic effects, but do not report on 
discontinuations in the MP arm due to AEs.
In addition to discontinuation of thalidomide due to AEs, two RCTs reported that reductions 
in the dose of study drug were required by 17.7% of the MPT group vs 2.6% of the MP group in 
the Hulin and colleagues RCT59 and in 28.7% of the MPT group after a median of 4 months of 
treatment in the Palumbo and colleagues RCT,24 where dose reductions required in the MP arm 
were not reported.
Withdrawals from study due to any reason
A supplementary appendix to the VISTA RCT publication26 reports on the numbers of patients 
withdrawn from the study with reasons (Table 17). Numbers are similar in the two groups overall 
and for treatment-related events, death and other non-specified reasons. Withdrawal due to 
patient choice and maintenance of CR is higher in the VMP group, while withdrawal due to 
progressive disease is higher in the MP group (no p-values are given).
The IFM RCTs report on the proportion of participants withdrawn from the study, and provide 
some information on the reasons for the withdrawals. It is not clear whether withdrawal data 
in Facon and colleagues23 are reported for the initial analysis date of October 2005 (median 
follow-up 36.8 months), or the later date of 2007 (median follow-up of 51.5 months). Hulin 
and colleagues59 report withdrawals for the median follow-up of 47.5 months. The majority of 
participants from both RCTs had been withdrawn from study treatment arms at the point of data 
analysis. In Facon and colleagues’ RCT23 93 participants (75%) were withdrawn from the MPT 
arm, and 151 participants (78%) from the MP arm. Facon and colleagues23 do not report the 
reasons for these withdrawals but do indicate what proportion of withdrawn participants went 
on to receive a second-line treatment, and of those who had not received another treatment, 
how many had died and how many were still alive (Table 18). Hulin and colleagues59 had 88.5% 
of participants withdraw from the MPT arm and 93.1% withdraw from the MP + placebo arm 
of their RCT. Most withdrawals in the MPT arm were due to toxicity (48 of 100 withdrawals) 
whereas in the MP + placebo arm most withdrawals were due to disease progression (69 of 108 
withdrawals) (see Table 18). A similar pattern was reported by Palumbo and colleagues24 for the 
initial six treatment cycles (before the introduction of thalidomide maintenance therapy), where 
the most common reason for participants in the MPT group being unable to complete the six 
treatment cycles was AEs, but in the MP group progressive disease was the main reason. No 
statistical comparisons of the data are reported within any of the RCTs.
TABLE 17  Patient withdrawal from the VISTA study
Study 
Treatment arms
p-value VMP (N = 340) MP (N = 337)
San Miguel et al.26 VISTA: (n, %)
Patients still receiving assigned protocol at data cut-off point 47 (14) 33 (10) NR
Total discontinued treatment 139 (41) 166 (49) NR
Discontinued due to progressive disease 24 (7) 72 (21) NR
Discontinued due to AEsa 50 (15) 47 (14) NR
Discontinued due to patient choice 32 (9) 18 (5) NR
Discontinued due to death  14 (4) 17 (5) NR
Discontinued due to maintenance of CR 9 (3) 1 (< 1) NR
Other reasons for discontinuation 10 (3) 11 (3) NR
a  These discontinuations are also reported in Table 15.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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(AiC/CiC information has been removed.)
Withdrawals from the MMIX Trial of CTDa are shown in Table 19.
Duration and intensity of first-line treatment
San Miguel and colleagues26 reported that in the VISTA RCT26 treatment lasted for a median of 
eight cycles in the VMP arm and seven cycles in the MP arm (Table 20). This is equivalent to 
approximately 11.5 months and 10 months, respectively.
The median duration of treatment of 11 months in the MPT arm of one of the MPT RCTs, 
Facon and colleagues,23 was similar to that of the VISTA RCT. The duration of treatment was not 
reported for the MP trial arm. Facon and colleagues23 also reported on the intensity of treatment 
with thalidomide. The aim was for participants to achieve a 400-mg daily dose of thalidomide 
if it could be tolerated. Although not explicitly reported, it appears unlikely (see Table 20) that 
many participants received 400 mg for the majority of the treatment period. Approximately 29% 
(36/124 participants) received < 200mg/day for the duration of first-line treatment, and 47/124 of 
participants had their dose reduced during treatment. Only 11 participants were able to tolerate 
having their thalidomide dose increased during treatment.
TABLE 18  Withdrawals overall from trials of MPT
Study Treatment arms p-value
aFacon et al.23 IFM 99/06: (n, %)
MPT MP
Not withdrawnb 31/124 (25) 42/193 (22) NR
Withdrawn and not receiving second-line treatment 38/124 (31) 25/193 (13) NR
up to death 11/38 (29) 24/25 (96) NR
still alive 27/38 (72) 1/25 (4) NR
Withdrawn and having received second-line treatment 55/124 (44) 126/193 (65) NR
cHulin et al.59 IFM 01/01
MPT MP + placebo
Withdrawals overall: n = 100/113 (88.5%) n = 108/116 (93.1%) NR
due to disease progression n = 37 n = 69 NR
due to death n = 6 n = 16 NR
due to consent withdrawal n = 9 n = 8 NR
due to toxicity (details above) n = 48 n = 15 NR
Palumbo et al.24 GIMEMA
MPT MP
Unable to complete six cycles: 32/129 (25%) 31/126 (25%) NR
due to AEs (as noted above) 17/32 4/31 NR
due to progressive disease 9/32 16/31 NR
because withdrew consent 3/32 2/31 NR
because lost to follow-up 3/32 7/31 NR
due to protocol violations 0/32 2/31 NR
a  Outcomes reported after a median follow-up of 36.8 months.
b  Either still on first-line treatment; or first-line treatment ceased as planned and no further treatment, or alive without progression, or not 
withdrawn for another reason.
c  Percentages calculated by reviewer.42 Clinical effectiveness
TABLE 20  Median duration and intensity of first-line treatment
Study Treatment arms p-value
San Miguel et al.26 VISTA
VMP (n = 340) MP (n = 337)
Median number of treatment cycles 8 (46 weeks) 7 (39 weeks) NR
Facon et al.23 IFM 99/06
MPT MP
Median duration of treatment (IQR) 11 months (5–15) NR NR
Initial daily dosea of thalidomide 
≤ 200 mg
n = 64/124 (52%) (includes nine 
participants receiving initial dose of 
100 mg)
NR NR
Initial daily dose of thalidomide 
> 200mg
n =60/124 (48%) (includes five 
participants receiving initial dose of 
300 mg)
NR NR
No change of dose throughout first-
line treatment
n = 66/124 (36 at ≤ 200 mg/day; 30 
at > 200 mg/day)
NR NR
Dose increased during first-line 
treatment
n = 11/124 NR NR
Dose reduced during first-line 
treatment
n = 47/124 NR NR
Hulin et al.59 IFM 01/01
MPT  MP + placebo
Median duration of treatment 13.5 months 18 months NR
MMIX52,53
CTDa  MP
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has 
been removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has 
been removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
a  The initial daily dose was defined as the greatest dose used in the first 4 weeks of treatment.
TABLE 19  Withdrawals from the MMIX Trial of CTDa
Study
Treatment arms
Total CTDa MP
MMIX52
(AiC/CiC information has been removed) (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information has been removed) (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information has been removed) (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
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Hulin and colleagues59 had a treatment period of 72 weeks (about 18 months), but while the 
median duration of treatment in the MP group was 18 months, the median duration of treatment 
in the MPT group was only 13.5 months (see Table 20). The trial authors do not comment on this.
(AiC/CiC information has been removed.)
Second-line treatments received by trial participants
San Miguel and colleagues26 reported that in the MP group 57% of participants started second-
line therapy within 2 years, in comparison with 35%26 (updated to 38% in a more recent 
abstract60) in the VMP group. It is not clear what the denominator in these calculations is, the 
total number of randomised participants or the number of surviving participants. Over one-half 
of the participants in each group received either thalidomide or lenalidomide as a second-line 
therapy (Table 21).
Two of the three RCTs of MPT versus MP provided data on second-line treatment that could be 
included in the review23,59 (as participants in the RCT by Palumbo and colleagues24,25 received 
maintenance therapy with thalidomide, second-line treatment data have not been included here). 
Second-line treatment was administered to 65% of the MP group in comparison with 44% of 
the MPT group in the RCT reported by Facon and colleagues.23 Hulin and colleagues59 reported 
disease progression occurrence in 156 participants overall, with more participants with disease 
progression in the MP + placebo group than the MPT group (72% vs 64%). Second-line treatment 
was administered to a similar proportion of participants with disease progression in each arm. 
In both RCTs, thalidomide (alone or in combination) was the most commonly administered 
second-line treatment in the MP group, with about a fifth of participants in the MPT groups 
of these RCTs receiving thalidomide again as second-line therapy. The most commonly 
administered second-line treatment in the MPT group reported by Facon and colleagues23 
was a combination of vincristine, doxorubicin and dexamethasone (VAD). Only 13% of MPT 
arm participants received bortezomib. In contrast, Hulin and colleagues59 reported that 31% of 
participants in the MPT arm received bortezomib as a second-line treatment (see Table 21).
TABLE 21  Second-line therapy received by trial participants
Study Treatment arms
San Miguel et al.26 VISTA
VMP MP
Started second-line treatment within 2 years26 (%) 35 57
Outcomes from abstract61 at median follow-up of 36.7 months
n = 178 n = 233
Received subsequent therapy containing:
Bortezomib (n, %) 43 (24) 116 (50)
Thalidomide (n, %) 81 (46) 110 (47)
Lenalidomide (n, %) 57 (32)   30 (13)
Overall response rate to subsequent therapy:
Bortezomib (%) 47 59
Thalidomide (%) 41 53
Lenalidomide (%) 59 52
continued44 Clinical effectiveness
Survival time after disease progression
Median survival time after disease progression was longer by approximately 2 months in 
participants in the MPT groups than for those in the MP groups in the two RCTs that reported 
this outcome.23,59 However, in the one RCT that reported a statistical comparison this difference 
was not statistically significant (MPT 11.5 months vs MP 9.9 months, p = 0.89) (Table 22).
Subgroup analysis
Subgroup analysis in the VISTA RCT took place between VMP and MP participant subgroups 
defined by participant baseline characteristics. Results were presented only for the outcome 
of time to disease progression. These results showed that for each of the seven prespecified 
subgroups (age, sex, race, baseline β2-microglobulin level, baseline albumin level, region and 
TABLE 21  Second-line therapy received by trial participants (continued)
Study Treatment arms
Outcomes from abstract60 at median follow-up of 25.9 months
n = 129 n = 194
Required subsequent therapy (%) 38 57
Received bortezomib (%) 16 43
Received thalidomide (%) 49 44
Received lenalidomide (%) 19 6
aSubsequent therapy and number of patients who received it
CR (%) PR (%) CR (%) PR (%)
Bortezomib or bortezomib combination (n = 105) 6 33 10 45
Thalidomide combination (n = 149) 4 44 3 52
Lenalidomide combination (n = 37) 4 52 0 55
bFacon et al.23 IFM 99/06: (n, %)
MPT MP
Second-line treatment administered 55/124 (44) 126/193 (65)
Second-line treatment thalidomide alone or in combination 10/55 (18) 55/126 (44)
Second-line treatment VAD 15/55 (27) 42/126 (33)
Second-line treatment dexamethasone 7/55 (13) 12/126 (10)
Second-line treatment alkylating agent-based regimens 14/55 (25) 13/126 (10)
Bortezomib 7/55 (13) 3/126 (2)
Other 2/55 (4) 1/126 (1)
Hulin et al.59 IFM 01/01: (n, %)
MPT MP + placebo
Disease progression occurrence 72/113 (64) 84/116 (72)
Second-line treatment administeredc 61/72 (85) 70/84 (83)
Thalidomide 16/72 (22) 53/84 (63)
Bortezomib 22/72 (31) 28/84 (33)
Lenalidomide 11/72 (15) 9/84 (11)
Thalidomide and/or lenalidomide 25/72 (35) 59/70 (83)
Thalidomide and/or lenalidomide and/or bortezomib 38/72 (53) 68/81 (83)
a  Other agents were used as subsequent therapy such as dexamethasone; patient could receive multi-agent regimens.
b  Reported after a median follow-up of 36.8 months.
c  Second-line treatment administered to 156 patients (combined total both groups) presenting with disease progression.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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disease stage) and single post hoc subgroup (baseline creatinine clearance) the risk of disease 
progression in the VMP arm was lower than for participants in the equivalent subgroups in 
the MP arm (i.e. time to disease progression was shorter in the MP subgroups than the VMP 
subgroups). It is not clear whether the RCT was powered for these subgroup analyses and 
therefore caution should be applied when interpreting the results.
No subgroup analysis data were eligible for inclusion in this review from the RCTs of MPT versus 
MP. Facon and colleagues23 state in the discussion section of their paper that post hoc analyses for 
three subgroups were conducted but the results of these are not presented. No subgroup analyses 
are reported by Hulin and colleagues59 and the subgroup analyses for PFS and OS reported 
by Palumbo and colleagues24,25 are not eligible for inclusion due to the use of thalidomide 
maintenance in the MPT group of this RCT.
The MMIX Trial protocol49 states that ‘Subgroup analysis may by chance generate false negative/
positive results. Those carried out will be interpreted with caution and treated as hypothesis-
generating’ (p. 57). (AiC/CiC information has been removed.)
SHTAC review of clinical effectiveness in manufacturers’ 
submissions
Celgene Ltd (thalidomide manufacturer) and Janssen–Cilag Ltd (bortezomib manufacturer) 
submitted reports to NICE. The clinical effectiveness evidence presented in these reports 
has been briefly appraised (see Appendix 7). A discussion of the economic models and cost-
effectiveness results included in the MSs can be found in Chapter 5 (see Review of the Janssen–
Cilag submission to NICE and Review of the Celgene submission to NICE).
The manufacturers both conducted systematic reviews of the clinical effectiveness evidence; 
however, only Janssen–Cilag presented this within the main body of the MS. Celgene reported 
a systematic review only as part of the appendix, which described the meta-analysis they had 
undertaken. Both manufacturers supplied search strategies and reported on the details of the 
searches undertaken. Neither manufacturer appeared to have searched for ongoing studies 
although conference proceedings were included in their searching.
The MSs differ in the clinical effectiveness evidence that has been included, and the evidence 
in each submission also differs to that included in the SHTAC systematic review (see Results of 
the systematic review of clinical effectiveness, above). These differences can be seen in Table 23, 
which shows which studies have been included. In addition to the available published evidence, 
Janssen–Cilag included data from the clinical study reports of the bortezomib RCT.
TABLE 22  Survival time after disease progression
Study Treatment arms p-value
Facon et al.23 IFM 99/06
MPT (n = 83) MP (n = 154)
Survival time after progression: median (SE) 13.4 (2.3) months 11.4 (1.9) months
After median follow-up of 51.5 months 52 deaths/83 patients 111 deaths/154 patients
Hulin et al.59 IFM 01/01
MPT MP
Survival time after progression: median 11.5 months 9.9 months 0.8946 Clinical effectiveness
The conclusions on the clinical effectiveness of MPT and VMP of the two MSs and the SHTAC 
systematic review (based on narrative summaries of trial outcomes) are broadly similar. Owing 
to the differences in the trials included and the different methodologies employed between the 
SHTAC meta-analyses and the manufacturers’ mixed-treatment comparisons (MTCs), it has not 
been possible to draw meaningful comparisons between them.
Ongoing studies
The clinical effectiveness search for studies identified seven abstracts and two ClinicalTrials.
gov records that described four ongoing studies, each comparing MPT with MP. It is not clear 
whether these studies meet the inclusion criteria of this systematic review.
Two abstracts63,64 and a ClinicalTrials.gov record (identifier NCT00218855) describe an ongoing 
study that recruited participants in Norway, Sweden and Denmark between 2002 and 1 May 
2007. This study has not been reported on in detail because insufficient details about the 
study were provided (e.g. drug doses for MP unknown, number of participants in each study 
arm unknown), and there were also insufficient details presented to allow judgements about 
study quality to be made. Some information presented differed between the two abstracts, 
and the ClinicalTrials.gov description of the study indicates that patients receive thalidomide 
maintenance treatment, so it is therefore unclear whether this study meets the inclusion criteria 
of this review.
The second ongoing study, HOVON 49, is described in three abstracts65–67 and, again, it is unclear 
whether this study meets the inclusion criteria for this review because patients could receive 
thalidomide maintenance treatment. The study recruited participants in the Netherlands starting 
in 2002 but participant accrual was stopped early (date not reported) due to the publication of 
other RCTs showing a positive outcome for thalidomide-treated participants.
TABLE 23  Clinical effectiveness evidence included in the systematic reviews conducted by Janssen–Cilag, Celgene 
and SHTAC
Triala Janssen–Cilag Celgene SHTAC
San Miguel et al.26,60,61 (VISTA)   
Facon et al.23 (IFM 99/06)   
Hulin et al.59 (IFM 01/01)   
Palumbo et al.24 (GIMEMA)  In sensitivity analysis only Only data prior to the start of thalidomide 
maintenance therapy
bNordic myeloma study group63,64  In sensitivity analysis only × (ongoing study, designated unclear)
bHOVON 4965–67  In sensitivity analysis only × (ongoing study, designated unclear)
b,cMMIX49,52  × 
a  Reference identifiers correspond to key references used by SHTAC.
b  Reported in abstract form only at the time these systematic reviews were conducted.
c  SHTAC had access to additional information on methodology and additional results data, which was provided by the MMIX trialists at the 
request of NICE. Janssen–Cilag and Celgene had access to only the information reported in the published abstracts.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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The third ongoing study, described in a single abstract,68 compares MP with MPT but also 
includes a second randomisation at the end of induction therapy to maintenance therapy with 
either dexamethasone, or dexamethasone plus thalidomide.
If the full publications describing the three studies above report outcome data for participants at 
a time point prior to maintenance therapy then these data would be eligible for inclusion. Similar 
data have already been included in this review from the study by Palumbo and colleagues24 and 
the MMIX study,49,53,54 which both incorporated maintenance therapy.
The fourth ongoing RCT described in a conference abstract and a ClinicalTrials.gov record 
(identifier NCT00934154)69 is an RCT initiated by the Turkish Myeloma Study Group that allows 
participants from the MP arm to cross over to the MPT arm if insufficient response to MP is 
obtained, with response being evaluated at every other cycle. It is not clear whether this crossover 
RCT will meet the inclusion criteria of the review.
Summary of clinical effectiveness
  ■ Five RCTs23,24,26,49,59 met the inclusion criteria of the systematic review; four23,24,26,59 have been 
published in full papers, one has only been reported in abstracts but additional information 
has been provided by the trialists.49 One RCT26 examined the effectiveness of bortezomib in 
combination with MP, three RCTs23,24,59 examined the effectiveness of MPT, and one RCT49 
examined CTDa. The comparator in all five RCTs was MP, and the comparator of one RCT 
also included a placebo in place of thalidomide.
  ■ Four further trials, published only in abstract form,63–69 provided insufficient details to allow 
a judgement about whether they are likely to meet the inclusion criteria of this review (so 
these were excluded from the systematic review).
VMP versus MP alone
  ■ The quality of the RCT26 was difficult to determine. Risk of allocation bias and of unbalanced 
confounding factors could not be judged because details on these aspects were not reported. 
Most, but not all, analyses had followed the ITT principle but the methods used to account 
for any missing data were not described. It was not possible to determine whether the 
amount and pattern of censored data was similar between trial arms.
  ■ Time to disease progression was the primary outcome of the RCT and a statistically 
significant effect in favour of the VMP group was reported.
  ■ Overall survival was a secondary outcome. A survival advantage for the VMP arm in 
comparison with the comparator MP was reported.
  ■ Statistically significantly more participants in the VMP group achieved CR, or achieved a PR 
or better. This outcome was not analysed by ITT principles.
  ■ Median PFS was statistically significantly longer in the VMP group than in the MP group.
  ■ Limited data on HRQoL was available. This indicated that, after the onset of best response, 
participants treated with VMP had a higher sustained HRQoL improvement rate in 14 of the 
15 EORTC QLQ-C30 scores than those participants receiving therapy with MP.
  ■ Adverse events occurred in both trial arms. Although the occurrence of any AE and any 
grade 4 AE was similar in the two groups, there was a statistically significant increase in 
grade 3 AEs in the VMP group.
  ■ Subgroup analyses were conducted. The RCT may not have been powered for these analyses 
so the results, which indicate that the reported benefits of bortezomib for TTP apply to each 
of the seven subgroups of participants assessed, should be interpreted with caution.48 Clinical effectiveness
MPT versus MP alone
  ■ The quality of the three RCTs23,24,59 was variable. Risk of allocation bias could not be judged 
for one RCT, and the risk of allocation bias and of unbalanced confounding factors could 
not be judged for another RCT because the necessary details were not reported. Although 
all RCTs stated that ITT analyses had been conducted, the details of these analyses and the 
methods used to account for missing data were, in general, poorly described. It was not 
possible to determine whether the amount and pattern of censored data was similar between 
trial arms for any of the included RCTs.
  ■ Overall survival was a primary outcome in two of the RCTs.23,59 Both reported a survival 
advantage for the MPT arm in comparison with the comparator MP alone. As expected, 
meta-analysis of the OS data from two RCTs of MPT versus MP provided a HR in favour 
of MPT for the OS outcome. The third RCT of MPT included maintenance therapy with 
thalidomide and therefore OS, which was a secondary outcome of this RCT, was not eligible 
for inclusion in the review.
  ■ Response to treatment was the primary outcome of one RCT24 (at a 6-month time point) and 
a secondary outcome in two RCTs23,59 (both at a 12-month time point). At 6 months more 
participants in the MPT group achieved CR or achieved a PR or better, but a p-value for the 
comparison is not reported. At 12 months, two RCTs reported that a statistically significant 
greater proportion of participants had achieved CR or had achieved at least a PR. However, 
it was noteworthy that in one of these RCTs the numbers of participants contributing data to 
this outcome was low. Outcomes for CR from three RCTs were combined by meta-analysis, 
which confirmed that MPT was superior in comparison with MP in terms of the proportion 
of patients achieving CR.
  ■ Two RCTs23,59 reported a statistically significant advantage in the MPT group in comparison 
with the MP group for the outcome of PFS. The PFS data were combined by meta-analysis, 
which confirmed that MPT was superior in comparison with MP for this outcome.
  ■ Adverse events were reported in different ways so it was difficult to summarise the results 
across the RCTs. Because one RCT had included maintenance therapy with thalidomide, 
few AE data could be included, so the majority of the data come from just two RCTs. AEs 
with a statistically significant greater occurrence in the MPT arm that was reported by two 
RCTs included neutropenia and peripheral neuropathy. One RCT found that overall non-
haematological toxic effects were statistically significantly more likely in the MPT group. 
For the outcomes of thrombosis or embolism, somnolence, constipation and infections, the 
results were inconsistent between RCTs (no significant difference in incidence reported by 
one RCT, but statistically significantly more in the MPT arm reported by the other RCT). 
This inconsistency may be a consequence of the different methods of reporting AEs. Some 
outcomes were only reported by one RCT, such as anaemia and thrombocytopenia (no 
statistically significant differences).
CTDa versus MP
  ■ This RCT49 was judged to be at low risk from allocation bias and bias due to unbalanced 
confounding factors. Analyses had been conducted by ITT principles and some information 
was provided on the methods used to handle missing data. It was not reported whether the 
amount and pattern of censoring was comparable between the groups.
  ■ Response was one of three co-primary outcomes of this RCT. (AiC/CiC information 
has been removed.) The remaining two co-primary outcomes, OS and PFS, and also the 
HRQoL outcomes, were not eligible for inclusion because participants were randomised to 
maintenance therapy with thalidomide after induction chemotherapy and this treatment did 
not meet the inclusion criteria of the systematic review.
  ■ Adverse events occurred in both RCT arms. (AiC/CiC information has been removed.)
  ■ Subgroup analyses were conducted although numerical data were not presented. (AiC/CiC 
information has been removed.)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 5  
Economic analysis
Introduction
The aim of this section is to assess the cost-effectiveness of first-line treatments for people with 
MM, who are ineligible for HDT with SCT, compared with existing treatments. The economic 
evaluation comprises:
  ■ a systematic review of the cost-effectiveness of either bortezomib or thalidomide in 
combination with an alkylating agent and a corticosteroid (see Systematic review of existing 
cost-effectiveness evidence)
  ■ a systematic review of studies of the HRQoL of people with MM (see Systematic review of 
HRQoL studies)
  ■ a critical appraisal of the submissions from manufacturers received as part of the NICE 
appraisal process (see Review of the Janssen–Cilag submission to NICE (Bortezomib) and 
Review of the Celgene submission to NICE (Thalidomide), and
  ■ a de novo economic model and cost-effectiveness evaluation developed by SHTAC (see 
SHTAC independent economic assessment).
Systematic review of existing cost-effectiveness evidence
Methods for the systematic review of cost-effectiveness
A systematic literature search was undertaken to identify economic evaluations for first-line 
treatment with either bortezomib or thalidomide in combination with an alkylating agent and a 
corticosteroid in people with MM, who are ineligible for HDT with SCT, compared with existing 
treatments. The details of the search strategy and the methods for the systematic review of cost-
effectiveness studies are outlined in Chapter 3 and Appendix 1.
Results of the systematic review of cost-effectiveness
Searches for economic evaluations identified the titles and abstracts of 183 potentially relevant 
studies. The full text of seven papers was retrieved for further consideration, with none of 
the studies meeting the a priori inclusion criteria. A summary of the selection process and 
the reasons for exclusion are presented in Figure 5 and a list of excluded studies is presented 
in Appendix 8. Two studies were excluded as they assessed a different intervention and/or 
population group from that specified in the research protocol.70,71 Although five studies reported 
as abstracts appeared to meet the a priori inclusion criteria,72–76 they did not contain sufficient 
information on the methods used and the results to justify formal data extraction or critical 
appraisal. Given the apparent relevance of these five studies, a brief summary of the abstracts is 
presented below.
Deniz and colleagues72 estimated the lifetime health and cost consequences of MPT compared 
with MP in people in Scotland with previously untreated MM. They developed a Markov model 
for a cohort of patients receiving a course of MPT or MP, conceptualising the disease by four 
health states: preprogression without AE, preprogression with AE, progressive disease and death. 
Progression between health states as well as treatment duration, dose and AE risks were derived 50 Economic analysis
from a long-term RCT (see Chapter 4, Results of the systematic review of clinical effectiveness).23 
Patient cohorts received a maximum of 12 six-week cycles of treatment, until progression 
or treatment-limiting toxicity. The abstract indicates that health-state utilities associated 
with disease states and AEs were obtained from the literature, but no sources are provided. 
Thalidomide costs were from UK list prices and routine disease management costs reflected 
current practice in Scotland. Costs and health outcomes were discounted at 3.5% per annum. The 
model estimated improvements in health outcomes with MPT with a median TTP of 25 months 
versus 12 months with MP. Estimated median OS was 4.03 years with MPT versus 2.88 years 
with MP. These translated to a gain of 0.91 QALYs for MPT (3.24 QALYs) compared with MP 
(2.32 QALYs). There were increased costs with MPT of £25,199 per patient compared with £8935 
per patient for MP, leading to an incremental cost-effectiveness ratio (ICER) of £17,847 per 
QALY and £14,803 per life-year gained. The authors state that sensitivity analyses showed that 
these results were consistent through changes in model parameters, although no information 
is presented. The authors conclude that MPT improves PFS and OS compared with MP and 
the results are cost-effective. A similar study comparing lifetime health and cost consequences 
of MPT compared with MP was completed for untreated MM patients in Wales.74 While this 
evaluation used the same clinical outcomes for OS and PFS, it used slightly different QALY gains 
(0.9 QALYs) and lifetime costs specific to managing the disease in Wales (£16,937 per patient 
for MPT vs £1524 per patient for MP). The study produced a slightly more favourable ICER 
of £17,002 per QALY and £13,346 per life-year gained. It was reported that sensitivity analyses 
showed that findings were robust, with 95% of outcomes between £12,750 and £26,500 per QALY 
gained. Both studies were funded by the manufacturer of thalidomide.
De Abreu Lourenco and colleagues75 assessed whether MPT was cost-effective compared with 
MP for people in Australia who had been newly diagnosed with MM as part of an application 
to the Pharmaceutical Benefits Advisory Committee (PBAC). They extrapolate Kaplan–Meier 
survival curves from an unspecified Phase III study to a lifetime horizon to estimate the mean 
survival time. Costs included drugs, medical services and treatment for thalidomide-related AEs. 
These data were incorporated into a cost-effectiveness analysis adopting an Australian health-
care system perspective, with costs and benefits discounted at 5% (AUS$2008). The modelled 
analysis estimated an incremental gain in average survival of 1.47 years and 1.14 QALYs with an 
FIGURE 5  Flow chart of identification of studies for inclusion in the review of cost-effectiveness. a, The five abstracts 
provided insufficient details of methods and results to allow inclusion in a formal systematic review. However, as the 
abstracts met other inclusion criteria they are discussed for information.
Total identified
from searching
(after de-duplication)
n = 183
Titles and abstracts
inspected
References for retrieval
and screening
n = 7
Excluded
n = 176
Excluded
n = 7
(includes five
abstractsa and
two incorrect
intervention or
population) Total included studies
n = 0© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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associated average incremental cost of AUS$23,953. This results in an ICER of AUS$20,998. The 
authors concluded that the analysis had resulted in a positive recommendation from PBAC to 
fund thalidomide for the treatment of patients newly diagnosed with myeloma.
Yoong and colleagues73 estimated the cost-effectiveness of bortezomib in combination with MP 
(VMP) compared with MP and MPT in previously untreated people with MM in Canada who 
are unsuitable for SCT. Clinical outcomes originated from the VISTA study26 for VMP compared 
with MP and from an unspecified indirect comparison of VMP and MPT. The economic model 
projected OS over a 10-year horizon for VMP, MP and MPT using data from relevant studies and 
survival HRs. Resource use data included costs of drugs, outpatient cancer clinic, management of 
AEs, supportive care and subsequent lines of treatment, although sources were not specified. The 
discounted QALYs were 3.51 for VMP, 2.84 for MP and 3.29 for MPT. The total cost of treatment 
per patient was CAN$59,117 for VMP, CAN$27,026 for MP and CAN$52,226 for MPT. The 
ICER for VMP versus MP was CAN$48,294 per QALY gained, and it was CAN$31,975 per 
QALY gained for VMP versus MPT. The study states that sensitivity analyses showed that survival 
difference was the most influential factor. The authors concluded that the VMP regimen indicates 
good value for money, and it is being adopted by public cancer agencies in Canada.
Wang and colleagues76 also compared the cost-effectiveness of VMP, MPT and MP as first-line 
therapy for people with MM in the USA who were ineligible for autologous SCT. A lifetime 
(20 years) Markov model from the US payer’s perspective was developed with seven health states 
respresenting periods of treatment response (stable disease/MR, PR or CR), treatment-free 
interval, progressive disease, second-line treatment and death. Monthly transition probabilities 
were estimated from the VISTA trial data for VMP and MP,26 and from the IFM 99/06 trial for 
MPT.23 Costs included drug and medical costs, treatment-related AEs, second-line treatment 
and resource utilisation during treatment-free intervals and progressive disease. All costs were 
adjusted to 2009 and presented in US dollars. State-specific utility estimates were derived from 
patient-level European Quality of Life-5 Dimensions (EQ-5D) data from the VISTA RCT.26 
Cost and health outcomes were discounted at 3%. The discounted QALY was 2.99 for VMP, 2.09 
for MP and 2.95 for MPT. The total costs were US$110,870 for VMP, US$57,864 for MP and 
US$129,902 for MPT. The ICER of VMP versus MP was US$56,109 per QALY gained. VMP was 
dominant compared with MPT (greater benefit and lower cost). One-way sensitivity analyses 
were reported to show that the ICERs were robust, with the key drivers being the HR for VMP 
versus MP for the transition between second-line treatment and the HRs for MPT versus MP for 
treatment discontinuation. The authors concluded that VMP is cost-effective compared with MP 
in the USA.
Summary
The systematic review of cost-effectiveness showed that there were no fully published economic 
evaluations assessing the use of either bortezomib or thalidomide in combination with an 
alkylating agent and a corticosteroid as first-line treatment for people with MM who are 
ineligible for HDT. Five economic evaluations published as abstracts only were identified.72–76 
Of these evaluations, three compared MPT with MP72,74,75 and two compared VMP with MPT 
and MP.73,76 All three studies showed additional benefits from MPT compared with MP at 
additional cost, with cost per QALY gained ranging from £17,002 to £17,84772,74 in the UK 
and being AUS$20,998 in Australia.75 The two economic evaluations assessing VMP, MPT 
and MP showed that additional benefits were provided by VMP compared with MPT and by 
VMP and MPT compared with MP. The studies showed ICERs ranging from CAN$48,29473 to 
US$56,10976 per QALY gained for VMP compared with MP and CAN$31,975 per QALY gained73 
and dominance76 for VMP compared with MPT. All of the studies had the involvement of the 
manufacturer of the interventions.52 Economic analysis
Systematic review of health-related quality-of-life studies
A systematic review was undertaken to assess the HRQoL of people suffering from and/or treated 
for MM. The aim was to provide data to populate the lifetime economic model with utilities 
to calculate QALYs. Although the methods used, and the process for their application, were 
similar to those described in Chapter 3 and Appendix 1, there were some variations. The selection 
criteria used to assess the titles and abstracts of studies and the full papers of those retrieved were 
modified. Although the primary focus of the review was on people with previously untreated 
MM who were not candidates for HDT with SCT, it was thought that there would be limited 
HRQoL data available. As a consequence, the selection criteria were broadened. Studies were 
included if they assessed the HRQoL of people with previously untreated MM who were not 
candidates for HDT with SCT using either a generic preference-based utility measure (e.g. the 
EQ-5D) or the EORTC QLQ-C30 disease-specific measure. Although the EORTC QLQ-C30 is 
a disease-specific measure rather than a generic preference-based measure, it is commonly used 
to assess HRQoL in cancer and mapping studies are available to convert this measure to other 
HRQoL utility values (i.e. EQ-5D). In addition, studies were included if they assessed the HRQoL 
of people with MM irrespective of treatments received as long as a generic preference-based 
measure was used.
Generic preference-based methods generate a HRQoL score using a choice-based method, 
such as time trade-off or standard gamble, which values patients’ HRQoL on a scale between 0 
(death) and 1 (perfect health).77 These measures use a generic questionnaire that can be used 
for most health conditions or diseases. The EQ-5D is the preferred measure of HRQoL in adults 
by NICE78 and has been used and validated in many different patient populations. The EQ-5D 
consists of five dimensions of health: mobility, self-care, ability to undertake usual activities, pain 
and discomfort, and anxiety and depression. HRQoL utility values are generated for patients’ 
responses using an algorithm derived from a large UK population study.
The search strategy identified 208 papers that were potentially relevant. The titles and abstracts 
were screened with the full text of 18 papers retrieved for further inspection. After checking 
the retrieved papers, six studies met the inclusion criteria: five full papers and one abstract. A 
summary of the selection process and the reasons for exclusion are presented in Figure 6 and 
FIGURE 6  Flow chart of identification of studies for inclusion in the review of QoL studies.
Total identified
from searching
(after de-duplication)
n = 208
Titles and abstracts
inspected
References for retrieval
and screening
n = 18
Excluded
n = 190
Excluded n = 12
(includes seven
inappropriate outcome,
one inappropriate
participants and outcome,
one inappropriate participants,
outcome and design,
and three insufficient detail)
Total included
n = 6
(five full papers and
one abstract)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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a list of excluded studies in Appendix 9. The 12 studies were excluded owing to the use of an 
inappropriate measure of QoL,79–87 assessment of different population groups,80,82 or insufficient 
details due to publication as an abstract only.88–90 The six studies included in the systematic review 
are summarised in Table 24. No generic preference-based QoL studies were found for newly 
diagnosed and untreated patients who were ineligible for HDT. Three studies focused on newly 
diagnosed and untreated patients; however, they were assessed either on the EORTC QLQ-C30 
non-generic preference-based measure91,92 and/or received treatment not included in the current 
evaluation.92,93
Generic preference-based measures of HRQoL (i.e. EQ-5D) were assessed in four studies.93–96 
These four studies evaluated the EQ-5D among people with MM who were receiving either 
second-line or subsequent treatment,94,96 where treatment status was unclear95 or who had 
received or were receiving treatment not included in this evaluation.93,95,96 Two studies reported 
HRQoL for patients receiving interventions included in this evaluation,91,94 using the EORTC 
QLQ-C30 to assess patients newly diagnosed with MM receiving MP91 and patients with relapsed 
and refractory MM receiving bortezomib.94 The remainder of this section examines the six 
studies in more detail, providing an indication of the HRQoL of people with MM at different 
stages during their treatment.
Uyl-de Groot and colleagues96 investigated the HRQoL of patients with newly diagnosed MM 
who were treated in a tandem transplantation programme. All patients were scheduled for 
intensive treatment with vincristine, adriamycin and dexamethasone/vincristine, adriamycin 
and methyl prednisone (VAD/VAMP) chemotherapy followed by high-dose melphalan (HDM) 
and transplantation of whole blood stem cells and, finally, re-infusion of the previously collected 
peripheral stem cells. The EQ-5D questionnaire was completed, at several time points, by 51 
patients with a mean age of 53 years. Table 25 shows the EQ-5D utility estimates at different time 
points. The utility estimates vary between 0.38 and 0.69, with the lower utility estimates during 
treatment periods or immediately after discharge of treatment. The longer term QoL estimates 
after discharge of treatment range from 0.64 to 0.69.
Slovacek and colleagues95 analysed the effect of selected demographics, and psychosocial 
and health aspects on HRQoL in MM survivors treated with HDT (melphalan) followed by 
autologous peripheral blood progenitor cell transplantation (PBPCT). Thirty-two patients of a 
mean age of 60 years completed the EQ-5D questionnaire. The EQ-5D estimate was 0.689.
Mujica-Mota and colleagues94 mapped HRQoL measurements from EORTC QLQ-C30 estimates 
to the EQ-5D utility measure for patients with relapsed and refractory MM from the SUMMIT-1 
trial. Few details are given in this abstract. The authors stated that the utility scores appear similar 
across patient groups as defined by serological response to bortezomib, with an overall utility 
score of 0.65.
Van Agthoven and colleagues93 estimated the cost–utility of intensive chemotherapy versus 
intensive chemotherapy followed by myeloablative chemotherapy with autologous stem cell 
rescue in newly diagnosed and untreated patients with MM. There were 129 patients in the 
intensive chemotherapy arm and 132 in the myeloablative arm and all were less than 65 years 
old. Little detail was given on the methodology or results. The authors state that patients in an 
undefined state following intentionally curative primary therapy would have HRQoL 19.5% lower 
than those in the general population, i.e. 0.644.
Strasser-Weippl and colleagues92 evaluated baseline HRQoL in elderly patients recently diagnosed 
with MM who were previously untreated. Ninety-two patients (of median age 66 years) 
participated in the HRQoL substudy of an RCT of continuous or intermittent prednisolone plus 54 Economic analysis
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vincristine, melphalan, cyclophosphamide, prednisolone, interferon-α-2b (VMCP-IFN-α-2b) 
for induction therapy. They used the EORTC QLQ-C30 questionnaire for these patients and 
compared them with a reference population for the general population of same age and gender 
(see Appendix 10 for observed scores). The study found a significant impairment of physical 
and psychosocial dimensions of QoL in patients with MM at baseline compared with a healthy 
reference population. Low psychosocial QoL at baseline was associated with poor prognosis.
Gullbrandsen and colleagues91 compared HRQoL scores of MM patients at diagnosis and 
over time with the scores of a reference population. Patients from two prospective Nordic 
Myeloma Study Group trials for HDM with autologous blood stem cell support (ABSCS) and 
MP completed the EORTC QLQ-C30 questionnaire. There were 221 patients for HDM who 
were < 60 years old and 203 patients for MP who were > 60 years old. The reference population 
consisted of 3000 randomly selected adults from the Norwegian population (see Appendix 10). 
At diagnosis, the most distressing problems were pain and fatigue, reduced physical functioning, 
limitations in role functioning and reduced overall HRQoL. These differences from the reference 
population were statistically significant, and large or moderate according to the rating systems. 
After the start of treatment, small to moderate improvements in mean QoL scores were observed 
for most domains.
Summary and conclusions of the health-related quality-of-life review
The systematic review did not find any generic preference-based HRQoL studies that were 
directly related to the population of interest. The utility estimates from HRQoL studies in patients 
with MM who had intensive therapy vary between 0.38 and 0.69, with the lower utility estimates 
during treatment periods or immediately after discharge from treatment.96 The longer-term 
HRQoL estimates after discharge from treatment range from 0.64 to 0.69. This may indicate 
that HRQoL is lower during the treatment period and improves after treatment has finished. 
Furthermore, long term HRQoL may be stable over time. It is unclear whether patients with CR 
following treatment have a higher HRQoL than those with other responses.
Review of the Janssen–Cilag submission to NICE (bortezomib)
A structured data extraction form was used to guide the review of the Janssen–Cilag submission 
to NICE (see Appendix 11). The MS reports the total costs, the QALYs gained and the cost-
effectiveness associated with the interventions under consideration in the appraisal. The model 
evaluates lifetime costs and benefits for bortezomib in combination with MP (VMP), for 
previously untreated MM patients not eligible for HDT–SCT, compared with MPT, CTDa and 
MP. The perspective of the analysis is clearly stated as being that of the NHS and PSS, capturing 
direct costs and benefits only.
TABLE 25  European Quality of Life-5 Dimensions utility estimates for MM patients from Uyl-de Groot and colleagues96
QoL 
measure Baseline Discharged HDT 1 montha
Admitted 
PBSCT
Discharged 
PBSCT 6 monthsb 12 monthsb
EQ-5D value 0.52 0.55 0.66 0.66 0.38 0.64 0.69
PBSCT, peripheral blood progenitor cell transplantation.
a  Month after HDT discharge.
b  After PBSCT discharge.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Modelling approach
A decision-analytic cost–utility model, developed in Microsoft Excel, was used in this 
submission. The model uses a cohort of newly diagnosed myeloma patients treated with MP as 
the baseline treatment. Treatment effects for VMP, MPT and CTDa are then modelled over time 
by adjusting the baseline patient experience via HRs. A survival model appears to be used, which 
estimates OS and PFS curves for each of the comparators. The model also includes further lines 
of treatment (second- and third-line) to estimate the total treatment costs.
The analytic framework was based on a variant of Quality-Adjusted Analysis of Time Without 
Symptoms or Toxicity (Q-TWiST97) using partitioned survival analysis, and utilises the area 
under, and the difference between, time-to-event curves to estimate mean durations spent within 
the disease states of interest.
Survival is partitioned into three different states: (1) prior to response to treatment; (2) response 
but no progression; and (3) post progression. Death represents the final state. The time to 
response or death was estimated from life tables constructed directly from the VISTA trial 
patient-level data.26 PFS for MP was estimated from a meta-analysis of the MP arms of included 
RCTs to compute MP PFS values at 6, 12, 18 and 24 months. PFS was extrapolated beyond 
24 months, assuming an exponential survival distribution, using the hazard rate for all time 
periods beyond 24 months equal to the hazard rate calculated between months 18 and 24. OS for 
MP was estimated in a similar way to PFS, but using 48 months of summary survival data from 
the MP arms of the included RCTs.
For the comparator treatments, relative HRs were taken from the random effects results of the 
meta-analysis that used OS and PFS summary data. OS and PFS hazard rates were computed for 
each time period by multiplying the VMP–MP, MPT–MP and CTDa–MP HRs by the appropriate 
hazard rate for that time period. The computed hazard rates were then used to generate the VMP, 
MPT and CTDa OS and PFS life tables that extend out to the end of the 30-year lifetime horizon 
of the model.
The HRs were estimated using a piece-wise constant hazard model using derived survival data 
from the Kaplan–Meier curves for each of the included RCTs. HRs were estimated at 48 months 
for OS for each of the RCTs, except the VISTA Trial, which had only 36 months’ follow-up. For 
estimation of the OS hazard for thalidomide, data from five RCTs were used, which included 
RCTs that had included thalidomide maintenance. Data were synthesised using Bayesian meta-
analysis with fixed and/or random effects models. Results from the random effects model were 
used in the cost-effectiveness model. (AiC/CiC information has been removed.)
Following the first-line therapy, and upon disease progression, it was assumed that the 
second-line treatment would consist of bortezomib plus high-dose dexamethasone (HDD), 
CTDa or HDD. Most patients received CTDa after first-line VMP and bortezomib and HDD 
for all other first-line therapies. All patients received lenalidomide plus dexamethasone as 
third-line treatment.
Adverse events were included in the analysis by estimating the incidence of AEs (grades 3 and 4) 
across the RCTs for each of the comparators and combining this with the unit costs of treating the 
AEs. Unit costs were mostly based upon those used in a previous NICE report for lenalidomide 
(TA171).31 The most common AEs for MPT were non-haematological toxicity, neutropenia and 
deep venous thrombosis; for MP they were neutropenia, anaemia and thrombocytopenia; and for 
VMP they were neutropenia, oedema, leucopenia and thrombocytopenia.58 Economic analysis
Assumptions
The manufacturer’s model makes the following assumptions:
  ■ Dose of thalidomide of 150 mg per day for MPT and 167 mg per day for CTDa.
  ■ Adverse events are included in the model as the cost of treating them; the incidence of AEs 
does not influence the treatment duration, efficacy or patient utility.
  ■ Costs included for second- and third-line treatments. Most patients who received VMP as 
first-line treatment receive CTDa as second-line treatment and most who did not receive 
VMP as first-line treatment do receive it as second-line treatment.
  ■ Thalidomide RCTs that included maintenance therapy with thalidomide were included in the 
meta-analysis.
Appraisal of the manufacturer’s cost-effectiveness analysis
The Janssen–Cilag MS was appraised for methodological quality and generalisability to the UK 
NHS using a checklist adapted from the NICE reference case requirements78 and the Philips 
and colleagues checklist (see Appendix 12).98 The submission meets all of the requirements for 
methodological quality and generalisability, except that it did not provide any evidence that the 
economic model had been validated.
The evaluation provided a clear statement of the decision problem to be addressed, including the 
population, which appeared to follow the scope for the appraisal issued by NICE. The comparators 
included (VMP, CTDa, MP and MPT) were appropriate as these are being routinely used or 
considered for use within the NHS in England and Wales. The perspective for the model was the 
NHS and PSS. A survival modelling methodology was used which seemed appropriate given the 
clinical nature of MM. The lifetime horizon used in the model reflects NICE guidance. The model 
structure was clearly presented with a description and justification of the key assumptions and 
data inputs used. Measures of clinical effectiveness are from a systematic review of RCTs with 
an MTC. Benefits for the model are measured in QALYs using the EQ-5D for measuring utility. 
All benefits and costs are discounted at 3.5% as outlined in NICE guidance.78 Data on PPS were 
extrapolated from observed data using an exponential distribution. Uncertainty was assessed 
through a one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA). It 
was unclear if the model had been fully validated, as no details were provided.
Estimation of quality-adjusted life-years
Health-related quality of life utility values are assigned to each of the states: prior to response to 
treatment, response to treatment without progression, and post progression, based on a study 
evaluating chemotherapy followed by SCT in people with MM.93 For the response state, a utility 
value of 0.81 was used, based on the utility of the general public at an age (median 54 years) 
corresponding to that of the patients in the study. A utility value of 0.64 was applied to the post-
progression disease state. A utility value of 0.77 was applied to patients prior to the response to 
treatment. The submission considered this the most appropriate source of utility values because 
it is the only study that reports utility values according to response and progression status and, 
secondly, utility values were derived using the EQ-5D rather than the less methodologically 
robust indirect mapping approaches used in the other studies. However, as shown in the 
systematic review of HRQoL, there are several other more relevant HRQoL studies. In particular, 
it is unlikely that patients with MM would have the same HRQoL as the general population.
Estimation of costs
Treatment unit costs and doses were based on the British National Formulary (BNF) No. 5735 
and MIMS 2009.99 The duration of treatment was based upon the mean treatment duration 
in the trials and was assumed to incorporate discontinuation of treatment due to progression, 
death and AEs. The duration of treatment with MP was seven cycles as per the VISTA trial.26 © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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For bortezomib, (AiC/CiC information has been removed) vials were used per patient (VISTA 
trial26); the reason why the number of vials used is far fewer than the full treatment course of 
52 vials is not given. The submission used an average dose of 150 mg per day for thalidomide 
obtained from the five MPT RCTs included in the meta-analysis of the MS. Within the CTDa 
combination, a daily dose of 167 mg was used for thalidomide. This is the weighted average as per 
protocol escalating dose from the MMIX RCT prior to the maintenance phase. A mean duration 
of treatment with thalidomide of 315 days was used, based on the duration reported in the 
MPT RCTs.
The resource use cost for the management of first-line MM was assumed to be the same for 
patients receiving VMP, MPT, CTDa and MP. There was an outpatient cost of £102 per visit and 
a total of nine outpatient visits. In addition, patients receiving VMP had this outpatient cost each 
time they were administered bortezomib.
Cost-effectiveness results
Table 26 shows the base-case results from the submission. The ICER for VMP versus MP is 
estimated to be £10,498. Furthermore the ICERs of VMP versus MPT and VMP versus CTDa 
are estimated to be £11,907 and £10,411, respectively. The submission states that the incremental 
analysis shows extended dominance of MTP over CTDa. However, the assessment group has 
found an error in the calculation of third-line costs for CTDa (correct cost £24,978 instead of 
£16,652). Correction of this error resulted in an ICER of £51,552 per QALY gained for CTDa 
versus MP.
One-way sensitivity analyses were undertaken for a limited number of parameters, including 
different survival distributions for OS and PFS, alternative HRs for OS, dose and duration of 
thalidomide, utilities, time horizon and discounting rate. The results are generally robust to 
changes in the sensitivity analyses. The model is most sensitive to the following parameters: 
underlying MP survival hazard, HRs for OS, dose of thalidomide, and duration of treatment with 
thalidomide in the MPT arm.
A PSA was undertaken using Monte Carlo simulation with 10,000 iterations. All parameters 
in the model were included except medication costs. For the PSA, at the £20,000 and £30,000 
willingness to pay thresholds, VMP has the highest probability of being cost-effective: 64% and 
75%, respectively.
Two scenario analyses were conducted. Scenario A did not include the costs of subsequent 
therapy after first-line treatment. In this scenario, the cost-effectiveness results were less 
favourable for each of the treatments and the ICERs increase to £48,437, £16,956 and £21,099 per 
QALY gained for CTDa, MPT and VMP compared with MP, respectively. Scenario B assumed 
the same second-line therapies as those treated with MP in the VISTA26 RCT. The results were 
similar for this scenario to the base-case analyses.
TABLE 26  Base-case results for the Janssen–Cilag submission
Treatment Mean QALYs Mean cost (£) ICER vs MP (cost/QALY, £)
ICER (cost/QALY, £) vs next best option with 
lower cost
MP 2.86 54,434 – –
CTDa 3.07 56,668 10,905 10,905
MPT 3.41 59,322 8912 7724
VMP 4.03 66,676 10,498 11,90760 Economic analysis
Summary of general concerns
  ■ Hazard ratio used for OS for thalidomide was derived from a meta-analysis that included 
RCTs with thalidomide maintenance.
  ■ The utility estimates were from a study with the wrong population, i.e. younger patients who 
received high-dose therapy. Furthermore, patients who had responded to treatment were 
assumed to have the same utility as the general population.
  ■ There was an error in the calculation of third-line costs for CTDa.
  ■ There was no evidence provided of model validation.
Review of the Celgene submission to NICE (thalidomide)
Overview
A structured data extraction form was used to guide the review of the Celgene submission to 
NICE (see Appendix 11). The submission states that its objective is to provide an evaluation 
comparing the costs and benefits of MPT with those of VMP and MP in patients with MM who 
are older than 65 years or who are ineligible to receive HDT. The evaluation has two stages. First, 
a short unsystematic review examines the literature for any relevant cost-effectiveness models in 
general and specifically in previously untreated MM patients who are not eligible for HDT. The 
review of cost-effectiveness studies indicates that a literature search was undertaken, although 
no details of the search strategy or methods for the review are provided. Searches identified 
five publications, with only one having relevance to the scope of the appraisal. The study by 
Deniz and colleagues72 compared MPT with MP as first-line treatment for MM in Scotland and 
provided the basis for the model developed for the submission by Celgene. Second, an economic 
model has been developed using data on the clinical effectiveness of MPT23,59 and VMP26 through 
a Bayesian MTC. The perspective of the economic evaluation is stated as being that of the NHS 
and PSS, including direct costs and benefits only. The analysis takes a lifetime horizon (30 years), 
presenting costs and outcomes (i.e. years of life gained and QALYs gained) for the three 
treatment arms of MPT, MP and VMP and an incremental analysis of costs and outcomes for MP 
and VMP when compared with MPT.
Modelling approach
A Markov model was developed to compare the difference in the progression of MM and in the 
costs of treatment when managed with the three different treatment options of MPT, VMP or MP 
through a series of different health states. It was developed from a model produced by Deniz and 
colleagues,72 which compared MPT and MP as first-line treatment for MM in Scotland.
The model has four different health states that are defined by the stage of disease progression 
or the occurrence of AEs. The four states are preprogression without AEs, preprogression with 
AEs, post progression and an absorbing state of death. All patients start in the preprogression 
without AEs state and move to other states if their condition worsens or they incur an AE. As 
MM is a progressive condition, people can only move to a worse state or remain in the same state. 
The submission provides limited discussion of the rationale for the approach or of the basis for 
the transition probabilities used to determine progression between states and other approaches 
assessing the phases of treatment may reflect variations in HRQoL more closely.
The model has a cycle length of 6 weeks (42 days) with a maximum of 12 cycles for MPT and MP 
and nine cycles for VMP. The cycle length and the number of cycles correspond to those used in 
clinical RCTs.23,26,59 The time horizon used in the model equates to a lifetime horizon, although 
characteristics of the cohort used in the model are not clearly stated. The consequences of a 
shorter time horizon of 5 years were examined in the sensitivity analysis.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Treatment effects were calculated from a random effects Bayesian MTC of data originating from 
three RCTs.23,26,59 The MTC was undertaken despite differences in the dosage used in the RCTs 
comparing MP with MPT. It used measures of survival time before and after progression as the 
primary outcomes. TTP and PFS were used and assumed to be equivalent. The outcome from 
the MTC was a measure of the risk of progression, provided through the percentage of patients 
experiencing PFS at 6-month intervals up to 30 months, with extrapolation beyond this point 
using an exponential distribution. It was assumed that post-progression survival (PPS) would 
be the same irrespective of preprogression treatment, with the different arms assumed to receive 
the same alternative treatment after progression (i.e. second- and third-line treatments). PPS was 
calculated by combining the MPT, MP and MEL100 (VAD, cyclophosphamide and melphalan 
100 mg/m2) arms from the IFM 99/06 trial to create an average survival curve.23 Average survival 
at different time points was then extrapolated with an exponential distribution. Treatment 
interruptions or discontinuations were encompassed in the trial efficacy data for MP and MPT, 
with no alteration to costs in the base case. Changes in cost were encompassed in sensitivity 
analyses through a reduction in dose as they are likely to reflect clinical practice. No data were 
available for VMP on discontinuation.
Adverse events were included for people on active treatment only if they were treatment related 
and considered to be clinically significant (i.e. grade 3 or above or occurred in 2% or more of 
patients in either arm). Those associated with disease progression were not incorporated into the 
model. The treatment-related AEs were included in the model through an estimate of the risk 
of AEs per cycle based on trial data.23,26 The effects of AEs on HRQoL were also included in the 
model. A literature search revealed no HRQoL data specific to MM, and so HRQoL decrements 
were obtained for different patient populations. Costs of AEs were also included.
Assumptions
The manufacturer’s model makes the following additional assumptions:
  ■ Post-progression survival is modelled to be the same across different treatment strategies.
  ■ Patients assumed to discontinue first-line treatment upon disease progression.
  ■ Deaths can only occur at or after progression and are assumed to be due to 
disease-related deterioration.
  ■ Adverse events are included in the model as a utility decrement at the time of the event and 
the cost of treating them. They are assumed to not affect the disease progression rate or OS, 
or treatment duration, efficacy or dose.
  ■ Assumes venous thromboembolism (VTE) antithrombotic prophylaxis for 5 months for 
patients receiving MPT with no resultant risk in incidence of VTEs, and antiviral prophylaxis 
for VMP.
Appraisal of the manufacturer’s cost-effectiveness analysis
The Celgene MS was appraised for methodological quality and generalisability to the UK NHS 
using a checklist adapted from the NICE reference case requirements78 and the Philips and 
colleagues checklist (see Appendix 12).98 Although the economic evaluation lacked detail on 
some criteria, it adhered to the scope of the appraisal and followed the many aspects of the NICE 
reference case.
The evaluation provided a clear statement of the decision problem to be addressed, which 
appeared to follow the scope for the appraisal issued by NICE. Despite stating that the model 
focused on first-line therapy for people with MM who are ineligible for HDT and/or are aged 
over 65 years, insufficient details were provided of the population cohort used in the model itself. 
The comparisons of MP, MPT and VMP were appropriate as these are being routinely used or 62 Economic analysis
considered for use within the NHS in England and Wales. The setting for the evaluation was 
England and Wales and the perspective for the model was that of the NHS and PSS. A Markov 
modelling methodology was used which was developed from a previous evaluation.72 The 
methodology seemed appropriate given the progressive nature of MM through distinct stages. 
The lifetime horizon (30 years) used in the model reflects NICE guidance.
Although the model structure was presented, limited details are given linking the model structure 
to the baseline risk of the condition. The submission outlines and justifies the assumptions used 
in the model and the different benefit, resource and cost inputs and their sources. Measures 
of clinical effectiveness are from a systematic review of RCTs with an MTC. Benefits for the 
model are measured in QALYs using the EQ-5D for measuring utility. All benefits and costs 
are discounted at 3.5%, as outlined in NICE guidance.78 Data on PPS were extrapolated from 
observed data using an exponential distribution. While uncertainty has been assessed through a 
one-way deterministic sensitivity analysis, no probabilistic analysis or model validation processes 
were undertaken. As a consequence, the analysis provides only a partial assessment of the 
uncertainty in the model with the possibility of correlation between parameters and difficulty in 
summarising the implications of uncertainty.
Estimation of quality-adjusted life-years
No systematic review was undertaken to identify HRQoL values associated with the benefits of 
the treatment, but a literature search was conducted to identify utility decrements for AEs. The 
HOVON 24 study,93 an RCT of intensive chemotherapy followed by myeloblative therapy with 
autologous stem cell rescue compared with intensive chemotherapy, provided HRQoL data using 
the EQ-5D to assess the benefits of treatment for people with MM. Although not directly relevant 
in terms of the population and treatments included in the scope for the technology appraisal, it 
does provide an indication of the possible utilities for managing people with MM when specific 
assumptions are applied. The utility values used were 0.64 for people not responding to treatment 
and 0.81 for people who did respond (using general public utility for same age group). A utility 
value of 0.77 at 24 months was used for those who continue to respond to treatment with 
intensive chemotherapy and had not progressed. An assumption was made that preprogression 
patients and post-progression patients matched responders and non-responders in the HOVON 
trial.93 However, other more relevant HRQoL studies (see Systematic review of health-related 
quality-of-life studies, above) show that the utility values used in the MS are higher than would 
be experienced by people with MM, whether newly diagnosed (0.52), undergoing treatment 
(0.38–0.55) or after treatment at 6 months (0.64) and 12 months (0.69).
The literature search for utility decrements for AEs did not identify specific values for people 
with MM and so utility values from different population groups were used (e.g. breast, colon and 
rectal cancer). Average per cent reduction in utility by each AE was calculated from these values 
and applied to the cohort in the model.
Estimation of costs
Resources and costs were obtained from several sources. NHS resources were from an 
unpublished survey of UK haematologists by Celgene Ltd. Inpatient, outpatient and day-case 
hospitalisation costs were derived from NHS Reference Costs,100 including inpatient and day-care 
costs for disease-related complications and treatment-related AEs, outpatient consultations and 
disease monitoring tests and treatment care costs in primary care. Costs of medicines were from 
the BNF (No. 57)35 and costs of blood transfusions from Wilson and colleagues101 with costs 
inflated to 2008.102 When on active treatment, patients receive the mean observed treatment dose 
from the trials. Other resource use and cost data were provided for outpatient consultations, 
disease monitoring and treatment of AEs/complications. No indirect costs were included in 
the model. The costs of AEs were calculated by combining resource use data from the survey of © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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haematologists with unit costs to estimate total costs. These costs and trial data on the frequency 
of AEs23 were then used to calculate a weighted average cycle cost. The methods for deriving 
resources and costs used and the sources were clearly described.
Cost-effectiveness results
The submission reports the benefits [i.e. TTP, patients progressed, deaths, proportion of patients 
with AEs, median OS, mean survival in years of life (life-years) and total QALYs] and the total 
costs (i.e. medication, monitoring and management of AEs) separately for each treatment 
pathway in the model.
Comparison of the benefits used for the model showed considerable benefit for those receiving 
MPT or VMP over MP on median TTP, median OS, total life-years and total QALYs. In 
contrast, more people receiving MPT (43.2%) or VMP (40.9%) suffered AEs compared with 
those receiving MP (13.4%). The total costs of the different treatment strategies used within the 
model showed considerable variation between MP (£1365) and VMP (£42,616). The cost of the 
medications was the main reason for these differences.
The base-case analyses (Table 27) produced two comparisons, MPT versus MP and VMP 
versus MPT, with differing outcomes. When compared with MP, MPT had an ICER of £18,188 
per life-year gained and £23,381 per QALY gained. In contrast, the comparison of VMP with 
MPT showed that VMP produced a small benefit in additional life-years and QALYs at a large 
additional cost (£21,483). The resultant ICERs were £200,237 per life-year gained and £303,845 
per QALY gained.
The submission assessed uncertainty through one-way deterministic sensitivity analyses. No PSA 
was conducted as the manufacturer stated that the efficacy of MPT and VMP were essentially 
the same and that the cost differences would be the key driver for the model. The submission 
included a number of one-way sensitivity analyses for parameter values and model structure. 
The parameters with the greatest effect on the model results were for the changes in treatment 
efficacy with a range of £16,586–33,275 per QALY gained for MPT versus MP and a range of 
£148,873–1,000,435 per QALY gained for VMP versus MPT.
The submission concludes that MPT represents a cost-effective use of NHS resources compared 
with MP as a first-line therapy for people with MM who are not eligible for HDT and/or are aged 
over 65 years. In contrast, when comparing MPT and VMP the manufacturer stated there was 
negligible clinical benefit from VMP at an additional cost that resulted in the ICERs exceeding 
£300,000 per QALY. When these findings were assessed through sensitivity analysis, the ICERs 
were reasonably robust.
Summary of general concerns
  ■ The economic evaluation focuses on the effectiveness of first-line treatment for people with 
MM who were ineligible for HDT, reflecting the scope for the NICE technology appraisal. 
TABLE 27  Base-case results for the Celgene submission
Treatment Mean QALYs Mean cost (£) ICER vs MP (cost/QALY, £)
ICER (cost/QALY, £) vs next best option with 
lower cost
MP 2.43 1365 – –
MPT 3.28 21,133 23,381 23,381
VMP 3.35 42,616 45,024a 303,845
a  Estimated from information supplied in the Celgene submission.64 Economic analysis
Exclusion of second- or third-line treatment options may oversimplify the evaluation 
with consequences for the incremental benefits and costs that would result from different 
possible options available. Given that first-line treatment may, in part, determine subsequent 
treatment options, it would be helpful to include these in the evaluation.
  ■ All deaths are assumed to be caused by disease-related deterioration and occur only at or 
after progression. In practice, deaths may and do occur prior to progression and, as such, the 
evaluation may overestimate the benefits that are accrued.
  ■ Post-progression survival was the same irrespective of preprogression treatment, which 
would affect the incremental benefits.
  ■ No HRQoL studies relevant to the evaluation were identified by the manufacturer and 
utility values from comparisons of different MM populations using alternative management 
strategies were used.
Comparison of manufacturers’ results
The manufacturers’ economic models had similar structures but used different methodology: 
one used a survival model and the other a Markov model. Both models compared first-line 
treatment with VMP, MPT and MP. Janssen–Cilag also included CTDa as a comparator. The 
ICERs produced by the Janssen–Cilag and Celgene submissions vary considerably from £11,907 
to £303,845 per QALY gained for VMP versus MPT. These differences stem from the number of 
vials used for treatment with bortezomib, the HRs for thalidomide and the inclusion of second- 
and third-line treatments.
SHTAC independent economic assessment
Overview
We developed a new model to estimate the costs, benefits and cost-effectiveness of MPT, VMP 
and CTDa compared with MP, in newly diagnosed patients with MM ineligible for HDT–SCT. 
CTDa was included in order to compare all relevant comparators; however, there are limitations 
to the effectiveness data, as the effectiveness estimate for OS was not statistically significant 
and the MMIX RCT included a second randomisation to thalidomide maintenance for some 
patients. The model was populated with clinical effectiveness data from the included RCTs in our 
systematic review of effectiveness (Chapter 4), HRQoL data from a systematic review of HRQoL 
studies (see Systematic review of health-related quality-of-life studies) and cost data derived from 
published studies (where available) and from national and local NHS unit costs.
The economic evaluation was from the perspective of the NHS and PSS, as only these direct costs 
were included. The model estimates the lifelong costs and benefits from each of the treatments. 
The costs and benefits were discounted at 3.5%, as recommended by NICE.78 The base-price 
year for the costs was 2009. The intervention effect in terms of improvement in OS and PFS was 
derived from the systematic review of effectiveness reported in Chapter 4 (see Overall survival 
and Progression-free survival). The outcome of the economic evaluation is reported as cost per 
QALY gained.
Description of the SHTAC model
A survival model was used to compare the cost-effectiveness estimates of VMP, CTDa and MPT 
versus MP. The model uses a survival analysis approach to estimate the mean OS and PFS for 
each of the interventions for a cohort of patients with newly diagnosed MM. The model consisted 
of cycles of 6 weeks in length to be consistent with the cycle lengths used for chemotherapy 
treatment. A lifetime horizon of 30 years was modelled to capture all clinical events using 
partitioned survival analysis for OS and PFS. Two survival curves were constructed for OS and 
PFS (Figure 7b), based on the derived probability of death and progression in each model cycle, © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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respectively. The mean time spent in each state was calculated from the survival curves for OS 
and PFS (see Figure 7a).
Survival was classified into three health states, and the mean time spent in each state is as follows:
  ■ Treatment (Ttreat) is the mean duration of first-line treatment.
  ■ Post treatment (TPost_treat) is the mean time from stopping first-line treatment until 
progression, i.e. TPFS – Ttreat
  ■ Post progression (Tprog) is the time from disease progression until death, i.e. TOS – TPFS, where 
TOS is mean OS and TPFS is mean PFS.
Each health state was associated with a HRQoL utility estimate that was multiplied by the length 
of time spent in that state. The total QALYs over the lifetime of a patient were calculated by 
aggregating the estimated QALYs from each health state.
Due to lack of data on subsequent therapies, it was unclear how the subsequent therapies affected 
HRQoL and survival and therefore second-line therapy is only included in the model as a cost.
The methodology used for deriving the parameters for the survival curves for the alternative 
treatments is as follows:
1.  Construct the baseline survival curves for MP using the adjusted event probability for each 
time interval.
2.  Construct the survival curves for other treatments by using the event probability for each 
time interval; i.e. event probability for MP multiplied by HR for treatment option.
For the baseline MP treatment, OS and PFS at regular time points were derived for each of the 
included studies from our meta-analysis of the clinical RCTs. The data from the RCTs were 
combined to form baseline MP OS and PFS curves. These curves provided the probability of an 
event (death or disease progression), i.e. hazard rate, for MP in each time interval (see Baseline 
MP curves).
FIGURE 7  The survival model adopted for the cost-effectiveness model. Treatment and post-treatment health states 
refer to first-line treatment.
a) Model health states
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The treatment effects for the other interventions compared with MP (HRs) were taken from 
our systematic review of clinical effectiveness (see Assessment of effectiveness). As the HR of the 
treatments versus MP varied over time, a constant HR was not appropriate. We estimated the HR 
for each 6-monthly period for each of the treatments versus MP.
The hazard rate for death was derived for each of the treatments by multiplying the baseline 
MP probability of death by the HRs for each time interval. The hazard rate for disease 
progression was derived in a similar manner. This method provided a closer fit to the trial 
data than approximations, such as fitting distributions. Parameters used in the model and 
the data sources used to derive them are described in more detail below (see SHTAC data 
sources). The methodology used for deriving the survival curves is described in more detail in 
Appendix 13.
The costs in the model comprise drug treatment, consultation, monitoring costs, and costs for 
treating AEs. Patients remained on drug treatment unless their disease progressed or they died. 
All patients who had not died received second-line therapy and this was assumed to start at the 
mean time of disease progression for the cohort. Third-line therapy was not included as it was 
assumed that most patients would receive lenalidomide, irrespective of the initial treatment. 
Costs used in the model are described in more detail below (see Estimation of costs).
A list of the model assumptions is given below. Assumptions are applied to all treatment options 
unless explicitly stated otherwise. All assumptions were tested in sensitivity analyses.
The model includes the following assumptions:
  ■ For bortezomib, each patient receives one vial per administration.
  ■ Costs included for second-line treatments. Most patients who received VMP as first-line 
treatment receive CTDa as second-line treatment and most who did not receive bortezomib 
as first-line treatment receive it as second-line treatment.
  ■ Costs and outcomes of third-line and subsequent treatments are assumed to be the same 
between arms.
  ■ Patients discontinue first-line treatment upon disease progression.
  ■ Health-related quality of life is better for those with CR than those with less than CR and is 
assumed to improve when patients stop treatment.
  ■ AEs are not modelled explicitly in the model for patient outcomes, i.e. OS and PFS, but are 
included as additional cost for treating the AEs in the model.
In each cycle the total costs and QALYs are calculated by multiplying the individual costs and 
HRQoL by the number of people in the cohort still alive for each of the treatments. The total 
lifetime costs and QALYs are calculated by aggregating the costs and QALYs for all cycles. The 
total discounted QALY gain and cost of treatments are calculated. Thus, the cost-effectiveness of 
each of the treatments is calculated,
  [Equation 1]
Evaluation of uncertainty
The evaluation of the cost-effectiveness of treatment for MM is based on uncertain information 
about variables, such as the clinical effect, HRQoL and resource use. This uncertainty was 
evaluated using deterministic and probabilistic sensitivity analyses. One-way deterministic 
sensitivity analyses were conducted to evaluate the influence of individual parameters on 
Cost-e￿ectiveness =
Cost for treatment – Cost for MP treatment
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the model results and test the robustness of the cost-effectiveness results to variations in the 
structural assumptions and parameter inputs (see Deterministic sensitivity analysis, below).
Multiparameter uncertainty in the model was addressed using PSA (see Probabilistic sensitivity 
analysis, below).103 In the PSA, probability distributions are assigned to the point estimates 
used in the base-case analysis. The model is run for 1000 iterations, with a different set of 
parameter values for each iteration, by sampling parameter values at random from their 
probability distributions. The uncertainty surrounding the cost-effectiveness of the treatment is 
represented on a cost-effectiveness acceptability curve (CEAC) according to the probability that 
the intervention will be cost-effective at a particular willingness-to-pay threshold. Appendix 14 
reports the parameters included in the PSA, the form of distribution used for sampling each 
parameter, and the upper and lower limits assumed for each variable.
Model validation
The SHTAC model was validated by checking the model structure, calculations and data inputs 
for technical correctness. The structure was reviewed by clinical experts for appropriateness for 
the disease and its treatment. The SHTAC model was checked for internal consistency against 
the MS economic models by running the SHTAC model with the inputs used in MS models to 
ensure similar results. The robustness of the model to changes in input values was tested using 
sensitivity analyses to ensure that any changes to the input values produced changes to the results 
of the expected direction and magnitude. Finally, the model results were compared with those 
from the MSs.
SHTAC data sources
Baseline MP curves
The baseline MP OS curve was generated using the MP OS curves from the RCTs included in our 
systematic review of clinical effectiveness (see Chapter 4, Overall survival). Survival probabilities 
(at 6-month intervals) were extracted from a scanned copy of the Kaplan–Meier plots for each 
MP group using the digitising software Engauge104 (Appendix 13). A weighted average of the 
survival probabilities for each time point was calculated to provide a summary MP OS curve 
(Table 28 and Figure 8) using the number of participants in the trials as weights.
A baseline MP PFS curve was generated using the PFS curves from the trial data included in our 
systematic review of clinical effectiveness (see Chapter 4, Progression-free survival) in a similar 
way to the baseline OS curves – see Appendix 13 and Table 29. A weighted average of the PFS 
probabilities for each 6-month time point was calculated to provide a summary MP PFS curve 
(Figure 9) using of participants in the trials as weights.
FIGURE 8  Summary curve for MP OS obtained from weighted average of individual MP curves.
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The probability of an event at each time interval for the MP treatment arm (hazard OS and 
hazard PFS) is calculated from the baseline MP OS and MP PFS curves. These probabilities 
are shown in Table 30. The hazard rate for an event for MP per cycle is estimated for each time 
point, ti:
  [Equation 2]
where s(t) is the survival function over time t.
For OS, few individuals were followed up for more than 36 months, and so a constant hazard 
rate was assumed after 36 months using the hazard rate in the first 36 months. For PFS, few 
individuals were followed up for more than 24 months, and so a constant hazard rate was 
assumed after 24 months using the hazard rate in the first 24 months. The methodology used to 
derive the survival curves is described in more detail in Appendix 13.
Overall survival and progression-free survival hazard ratios for 
treatments versus MP
The relative effectiveness of the treatments versus MP for OS and PFS were represented as 
HRs. The HRs were obtained from the Kaplan–Meier plots in the trial publications (see Overall 
survival and Progression-free survival). As the HR of the treatments versus MP varied over time, 
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TABLE 29  Progression-free survival probabilities extracted from Kaplan–Meier plots using digitising software
Study MP arm No. in MP arm
Time (months)
6 12 18 24 30 36 42 48 54
Facon et al.23 196 0.77 0.63 0.49 0.34 0.22 0.14 0.08 0.06 0.05
Hulin et al.59 116 0.8 0.66 0.51 0.33 0.17 0.12 0.06 0.05 0.05
Palumbo et al.24 164 0.88 0.60 0.41 0.28 0.22 0.19 0.18 0.18
VISTA trial26 338 0.77 0.63 0.43 0.28
MP weighted averagea 0.78 0.63 0.46 0.30 0.21 0.15 0.11 0.10 0.05
a  Weighted by size of trial arm. MMIX data could not be included because a PFS curve was not available.
FIGURE 9  Summary curve for PFS obtained from weighted average of individual PFS data in MP arms of trials.
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a constant HR was not appropriate. We derived the HR for each 6-monthly period for each of the 
treatments versus MP.
The HR for each treatment j versus MP at each time point ti is,
  [Equation 3]
The HRs for the MPT trials summary were combined using simple weighted averages of the 
proportion of surviving patients in each trial arm at each time point, weighted by numbers of 
patients in the trial. The HRs were assumed to be constant after 36 months for OS and 24 months 
for PFS as there were few patients with more than this length of follow-up in the trials. HRs of OS 
and PFS are shown in Tables 31 and 32, respectively.
The event rate at each time interval for MPT, VMP and CTDa was estimated by multiplying 
the risk of death or progression by the HR for each cycle. The effects of using alternative HRs 
were evaluated in sensitivity analyses. It should be noted that the MMIX RCT included a 
second randomisation to maintenance therapy with thalidomide for some patients after first-
line therapy and there were no data available for OS and PFS for patients who did not have 
maintenance therapy.
Complete response
Complete response outcome data for each treatment option is described in Chapter 4 (see 
Response to treatment). For each treatment option, the relative risk of CR compared with MP was 
derived using Review Manager 5. The CR rate for MP was estimated using the trial data by 
simple weighted average of the MP arm using the number of trial participants as the weight. CR 
for the other treatment options was derived by multiplying the MP CR rate by the relative risk. 
Table 33 shows the CR data used in the model for MP, VMP, MPT and CTDa.
Health-related quality of life
Although our systematic review of HRQoL studies (see Systematic review of health-related quality-
of-life studies) did not find any generic preference-based HRQoL studies of people with untreated 
MM who were not eligible for HDT with SCT, it did identify two studies that assessed HRQoL 
in this group using the EORTC QLQ-C30. A targeted search was therefore conducted for studies 
that mapped data from the EORTC QLQ-C30 onto the EQ-5D to enable the estimation of health 
state values based on EORTC QLQ-C30 data. The EORTC QLQ-C30 is the most commonly used 
instrument to measure the HRQoL of cancer patients. Two studies were identified.106,107
HR
ht
ht
i
ji
mp i
= ()
()
TABLE 30  Hazard rate for MP for OS and PFS (event rate per cycle)
Months Cycles
Hazard rate
OS PFS
6 4.4 0.024 0.056
12 8.7 0.030 0.048
18 13.0 0.021 0.070
24 17.4 0.023 0.094
30 21.7 0.034 0.067
36 26.1 0.035 0.067
36+ 26+ 0.028 0.067© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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McKenzie and van der Pol107 used an ordinary least squares (OLS) regression analysis with data 
from an RCT of palliative therapies for 199 patients with inoperable oesophageal cancer, with an 
average age of 74.8 years. The regression results for the mapping are shown in Table 34.
Kontodimopoulos and colleagues106 used an OLS regression with data from 48 patients with 
gastric cancer, split into equal subgroups by age, sex and chemotherapy scheme. Three scales 
were significant predictors (p < 0.05 or better) of EQ-5D indices: physical functioning, emotional 
functioning and global health status. The regression results for the mapping are shown in 
Table 35.
TABLE 31  Hazard ratios for OS from trial publications and by derivation from publication Kaplan–Meier plots
Months Facon et al.23 MPT Hulin et al.59 MPT
SHTAC MPT trials 
summary
San Miguel et al.26 
VMP MMIX54 CTDa
0–6 0.52 0.95 0.67 1.00 (AiC/CiC information 
has been removed)
6–12 0.57 0.50 0.55 0.30 (AiC/CiC information 
has been removed)
12–18 0.49 0.91 0.71 0.60 (AiC/CiC information 
has been removed)
18–24 0.56 0.64 0.59 0.85 (AiC/CiC information 
has been removed)
24–30 0.64 0.33 0.46 0.70 (AiC/CiC information 
has been removed)
30–36 0.74 0.79 0.76 0.46 (AiC/CiC information 
has been removed)
36+ 0.59 0.64 0.62 0.62 (AiC/CiC information 
has been removed)
TABLE 32  Hazard ratios for PFS from trial publications and by derivation from publication Kaplan–Meier plots
Months Facon et al.23 MPT Hulin et al.59 MPT
SHTAC MPT trials 
summary
San Miguel et al.26 
VMP MMIX54 CTDa
0–6 0.36 0.61 0.45 0.47 (AiC/CiC information 
has been removed)
6–12 0.61 0.76 0.67 0.62 (AiC/CiC information 
has been removed)
12–18 0.49 0.70 0.57 0.74 (AiC/CiC information 
has been removed)
18–24 0.70 0.51 0.62 0.48 (AiC/CiC information 
has been removed)
24+ 0.55 0.62 0.58 0.58 (AiC/CiC information 
has been removed)
TABLE 33  Complete response for different treatment
Treatment CR (%)
MP 2.6
MPT 14.2
VMP 21.7
CTDa (AiC/CiC information has been removed)72 Economic analysis
Our systematic review of HRQoL studies found two studies in the population of interest but these 
used the EORTC QLQ-C30.91,92 For both studies, we mapped the EORTC QLQ-C30 HRQoL 
scores to the EQ-5D using each of the mapping algorithms described above (Tables 36 and 37).
Gulbrandsen and colleagues91 provide HRQoL at different time points. Based on this study, it 
appears that HRQoL is lower during the treatment period and improves after treatment has 
finished and this is consistent with HRQoL results from Uyl-de Groot and colleagues.96 Long-
term HRQoL appears to be stable over time. In addition, the utility estimates from the HRQoL 
studies in populations treated with HDT are similar to those from Gulbrandsen and colleagues.91
The accuracy of the mapping studies was assessed for the study by Uyl-de Groot and colleagues,96 
which reported EORTC QLQ-C30 and EQ-5D results. Figure 10 shows the comparison between 
the EQ-5D utility estimates using the two mapping methods compared with the EQ-5D data 
from Uyl-de Groot and colleagues. For these data, the mapping algorithm by McKenzie and van 
der Pol provides the better fit and for most time points is a good fit to the data.
We suggest that the most appropriate source of HRQoL data for the treatment period and 
post-treatment values is from Gulbrandsen and colleagues91 from the mapping by McKenzie and 
van der Pol. These utility estimates are shown in Table 37. The utility estimates for the treatment 
period are for the 1-month time point, i.e. 0.58, and for post treatment (and post progression) is 
an average of the 6- to 36-month time points, i.e. 0.68.
TABLE 34  Regression results for mapping between EORTC QLQ-C30 and EQ-5D from McKenzie and van der Pol107
Dimension Coefficient
Global QoL 0.0016
Physical functioning 0.0004
Role functioning 0.0022
Emotional functioning 0.0028
Cognitive functioning  0.0009
Social functioning 0.0002
Fatigue –0.0021
Nausea –0.0005
Pain –0.0024
Dyspnoea 0.0004
Insomnia 0.00004
Appetite loss 0.0003
Constipation 0.0001
Diarrhoea –0.0003
Financial difficulties –0.0006
Constant 0.2376
TABLE 35  Regression results for mapping between EORTC QLQ-C30 and EQ-5D from Kontodimopoulos 
and colleagues106
Dimension Coefficient
Physical functioning 0.00508
Emotional functioning 0.00313
Global health status 0.00546
Constant –0.18143© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Complete response
Health-related quality-of-life data from the MMIX RCT57 were analysed to determine whether 
patients with CR had a better HRQoL after response than those with other levels of response. 
EORTC QLQ-C30 data were available for 0, 3, 6 and 12 months after initial treatment 
commenced. We mapped the EORTC QLQ-C30 data to EQ-5D health utilities using the 
algorithm from McKenzie and van der Pol.107 For the first three periods, the EQ-5D utility 
scores were similar for both CTDa and MP groups, and similar to those from Gulbrandsen and 
colleagues.91 (AiC/CiC information has been removed.)
In the model we estimate the utility for the post-treatment health state (until disease progression) 
as a weighted average of those who had a CR (AiC/CiC information has been removed) and those 
with a lesser response (AiC/CiC information has been removed).
Estimation of costs
Drug costs
Drug unit costs and doses were based on the BNF (No. 57).35 Duration of treatment was based on 
recommendations from the SPC,29,33 expert clinical opinion and the published trials. A summary 
of the dose and duration of treatment for each of the comparators is given in Table 38.
TABLE 36  European Quality of Life-5 Dimensions utility values derived by mapping from EORTC QLQ-C30 HRQoL 
scores from Strasser-Weipl and Ludwig92
Mapping algorithm MM Reference population
McKenzie and van der Pol107 0.59 0.82
Kontodimopoulos et al.106 0.58 0.88
FIGURE 10  Comparison of results from mapping studies from EORTC QLQ-C30 to EQ-5D with EQ-5D data from Uyl-
de Groot and colleagues.96
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TABLE 37  European Quality of Life-5 Dimensions utility values derived by mapping from EORTC QLQ-C30 HRQoL 
scores from Gulbrandsen et al.91
Mapping algorithm
Reference 
population
Time (months)
0 1 6 12 24 36
McKenzie and van der Pol107 0.81 0.55 0.58 0.68 0.68 0.68 0.69
Kontodimopoulos et al.106 0.86 0.52 0.58 0.69 0.69 0.69 0.7174 Economic analysis
The duration of treatment varied between seven cycles for CTDa and nine cycles for VMP. 
We assumed that MP would be given for the same number of cycles as thalidomide and 
bortezomib when it was given in combination with them. The SPC of thalidomide states that a 
maximum number of 12 cycles of 6 weeks each should be used, as used in the trial by Facon and 
colleagues.23 However, one of our clinical experts advised that a shorter duration of eight cycles 
was more representative of clinical practice.
The dose of thalidomide was assumed to be 150 mg, based upon the dosages used in the IFM 
RCT (100 mg)59 and the MMIX RCT (200 mg).49 The dose recommended by the SPC is 200 mg 
per day, but one of our clinical experts advised that, in practice, few patients are able to tolerate 
such a high dose. Bortezomib is administered as a 3- to 5-second bolus intravenous injection. The 
cost of the 3.5-mg vial is £762.68. The cost of bortezomib administration was £153.40.100
The total cost for bortezomib depends on the wastage from the vial. In the NICE appraisal of 
bortezomib for relapsed MM,30 the appraisal committee considered the issue of vial sharing. They 
expressed a number of concerns including issues related to maintenance of best aseptic practice 
and the practical constraints of patient numbers and geographical locations of myeloma centres. 
The Committee was not convinced that vial sharing could be considered either safe or routinely 
achievable in practice across the NHS.
One of our clinical experts advised that they attempted to administer bortezomib in groups of 
three persons to minimise wastage. However, this may not be possible in smaller units. In the 
base-case analysis we assumed that only one vial would be used per patient and then varied this 
assumption in a scenario analysis.
Patients on thalidomide also received thromboprophylaxis for 5 months in the form of low-
molecular-weight heparin (dalteparin 5000 units once daily subcutaneously)28 at a total cost of 
£428.88. In addition to chemotherapy, patients also require treatment with other medication, 
such as bisphosphonates, but the cost for these was assumed to be similar across all interventions, 
and has therefore not been included in the model costs.
TABLE 38  Summary data for treatment duration, dose and unit cost
Parameter Melphalan Prednisolone Bortezomib Thalidomide Cyclophosphamide Dexamethasone Source
Drug dose 9 mg/m2  60 mg/m2 1.3 mg/m2 150 mg/day 250 mg/m2/week 20 mg/day for 
4 days every 28
BNF,35 
SPC,29,33 
VISTA,26 
MMIX49 
and 
clinical 
expert 
opinion
No. cycles 8a 8a 9 8 7 7
Cycle length 
(weeks)
6 6 6 6 6 6
Duration 10–12 months 10–12 months 54 weeks 10–12 months 6–8 months 6–8 months
Days of 
cycle
Days 1–4 Days 1–4 Cycles 1–4: 1, 4, 8, 
11, 22, 25, 29, 32
Cycles 5–9: 1, 8, 
22, 29
Daily 4 doses/cycle 30 doses/course
Unit costs Melphalan 
£11.46 for 
25-tablet pack 
(2 mg); total 
cost £126.24
Prednisolone 
£20 for 
50-tablet pack 
(25 mg); total 
cost £25.71
Bortezomib 
£762.68 per 3.5-
mg vial; total cost 
£39,643.76
£298.48 per 
28-tablet 
(50-mg) pack; 
total cost 
£10,745.80
£12.44 per 
100-tablet pack 
(50 mg); total cost 
£44.41
£13.92 per 
100-tablet pack 
(2 mg); total cost 
£58.46
BNF35
a  No. of cycles for MP in combination with bortezomib or thalidomide as for those treatments.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Second-line treatment
Following disease progression after first-line therapy, patients receive second-line treatment. 
Based on clinical advice, NICE guidance,30 trial data and assumptions used in the Janssen–Cilag 
submission, it was assumed that most individuals would receive bortezomib as second-line 
therapy unless they had already received it as first-line therapy. HDD and CTDa were also used as 
these are common second-line treatments in the UK.30 Most patients who had VMP as first-line 
treatment had CTDa as second-line treatment. The dose for HDD was 40 mg per day and the 
cost of treatment was £189.31. The assumed distribution of second-line treatments following 
first-line treatment is shown in Table 39. For all treatments, 60% of patients received second-line 
treatment, based upon the number of patients still alive at the time corresponding to mean PFS.
Consultations
Based on clinical advice, we assumed patients receive on average one consultation every 
month during their treatment period and one consultation every three months thereafter. 
The outpatient consultation cost was £121.11 (reference cost code 370: medical oncology 
follow-up consultation).100
Monitoring tests
The monitoring tests used for the management of MM, based on those used for the MMIX RCT,49 
are shown in Table 40 with their unit costs.
Adverse events
For each comparator, the incidence of AEs was estimated using evidence from the RCTs included 
in our systematic review of clinical effectiveness (see Chapter 4, Adverse events). AEs included 
in the model were treatment-related serious (grades 3 and 4) AEs and the incidence was taken 
from the VISTA trial26 for VMP, from the IFM 99/06 trial for MPT23 and from the MMIX trial 
for CTDa. The IFM 99/06 trial was used for MPT as this trial had more comprehensive reporting 
than the other MPT trials. For MP, a weighted average was calculated using data from the MP 
arm from each of these trials.
TABLE 39  Distribution of second-line treatments following first-line treatment
Second-line treatment (%)
First-line treatment
MP MPT VMP CTDa
Bortezomib + HDD 70 70 15 70
CTDa 15 15 70 15
HDD 15 15 15 15
TABLE 40  Monitoring tests completed at each outpatient appointment for MM
Test Unit cost (£) Costs source
Full blood count 3.02 Southampton University Hospital Trust 2009108
Biochemistry (calcium, creatinine, albumin and uric acid) 5.15
Protein electrophoresis 13.85
Immunoglobin (IgA, IgG, IgM) 41.55
Urinary light chain excretion 13.8576 Economic analysis
Although AE data is consistently reported across studies as percentage patients, the types of 
AEs reported differed between the studies. This summary extracts key AEs (haematological, 
gastrointestinal, infections, neuropathy and thrombosis) for use within the model (and is not 
a comprehensive analysis of all AEs). Gastrointestinal AE numbers for MMIX were calculated 
from constipation grades 3 and 4 as reported and other gastrointestinal AEs (grade not specified 
but proportion calculated for grades 3 and 4). Total infection for the VISTA study was calculated 
by totalling figures for pneumonia and herpes zoster (which assumes that there were no others). 
Infections were not specified for other studies. The definition of haematological AEs may not be 
exactly consistent across studies but gives an indication of possible rates for thrombocytopenia/
cytopenia. AE data were not available for the MMIX RCT for the incidence of neutropenia and 
anaemia and for these AEs we have assumed the same incidence for CTDa as for MPT. Where 
events of grades 3 and 4 were not reported separately, we assumed there were twice as many 
grade 3 as grade 4 events, as this was the ratio for the total numbers of grade 3 and 4 AEs.
The unit costs of treating AEs were estimated, based on those used in a NICE technology 
appraisal for lenalidomide (TA171)31 and the Celgene MS [see Review of the Celgene submission 
to NICE (Thalidomide) and Appendix 12]. The NICE technology appraisal for lenalidomide31 
collected information on the proportion of patients who would receive treatment, the location 
where treatment would be administered, and treatments administered for each specific disease-
related complication. The unit cost of inpatient and day-case treatment for the AE was calculated 
from CHKS (Caspe Healthcare Knowledge Systems) data, which contains individual patient-level 
data from most UK hospital trusts, and NHS reference cost data. This report did not include all 
relevant AE costs. The Celgene MS used a similar methodology to calculate unit costs and these 
were used for AEs of infection, dizziness or fatigue (Table 41). There was no distinction made in 
that report between the costs of grade 3 and 4 AEs and so for these AEs we have assumed equal 
costs for grades 3 and 4. We used the cost of diarrhoea for the cost of gastrointestinal AEs as this 
cost was between the costs of nausea and constipation. The unit costs for treating the AEs are 
shown in Table 42.
The total costs of treating AEs were estimated by multiplying each AE incidence by the 
appropriate unit cost for that AE.
Results of SHTAC independent economic evaluation
This section reports the cost-effectiveness results for a typical person with MM who received 
treatment with bortezomib in combination with MP or thalidomide in combination with MP 
compared with those receiving MP. Results for costs and QALYs are presented for each treatment, 
with costs and benefits discounted at 3.5%.78 The survival curves for OS from the model are 
shown in Figure 11. The results show increased survival for MPT, VMP and CTDa versus MP. The 
cost-effectiveness is presented as incremental cost per QALY compared with existing treatment 
with MP. The summary results of the non-discounted treatment effects are shown in Table 43. In 
the base-case analysis, OS varied from 4.20 years for MP to 6.66 years for MPT. Survival for MPT 
is slightly longer than for VMP. The cost-effectiveness results for CTDa should be treated with 
caution, (AiC/CiC information has been removed). The summary results of the undiscounted 
costs are shown in Table 44 for each treatment. First-line treatment costs ranged from £112 for 
MP to £43,824 for VMP. Second-line treatment costs were the same for MP, MPT and CTDa, and 
about £10,000 lower for VMP. The total costs of the treatments ranged from £23,248 for MP to 
£59,644 for VMP.
The baseline discounted cost-effectiveness results are shown in Table 45. Each of the treatments 
is more expensive than MP, with the additional cost ranging from £8,600 (CTDa) to more than 
£35,000 (VMP) over a patient lifetime. The incremental cost-effectiveness versus MP for MPT, 
VMP and CTDa figures are £9135, £29,820 and £33,031 per QALY gained, respectively.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Each comparator is presented in successive rows ordered by the number of QALYs generated. 
Each option is then compared to the next best option. In summary the incremental analysis 
suggests extended dominance of MPT over CTDa, and MPT dominates VMP as it is more 
effective and cheaper (Figure 12). The comparison of VMP versus MPT suggests that VMP and 
CTDa are unlikely to be cost-effective treatment options at the conventional willingness-to-pay 
threshold of £20,000–30,000 per QALY gained. However, there is much uncertainty around the 
results for CTDa because the OS effectiveness estimates were not statistically significant and 
the results from the MMIX RCT included those of participants who had received thalidomide 
maintenance therapy.
Sensitivity analysis
Deterministic sensitivity analysis
One-way deterministic sensitivity analyses were performed, in which model parameters were 
systematically and independently varied, using a realistic minimum and maximum value. 
TABLE 41  Incidence of AEs at grades 3 and 4 reported for different treatments
AE (%)
VISTA trial26 Facon et al.23 99/06 MMIX54
MP weighted 
average VMP MP MPT MP CTDa MP
Haematological
Thrombocytopenia 37 30 14 10 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
19
Neutropenia 40 38 48 26 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
34
Anaemia  19 28 14 14 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
23
Gastrointestinal 20 5 11 3 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
3
Nervous system
Peripheral neuropathy 14 0 6 0 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
> 1
Dizziness/fatigue 9 1 8 0 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
1
Infections 10 7 13 9 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
7
Thrombosis 1 1 12 4 (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
2
TABLE 42  Unit costs for treating AEs at grades 3 and 4
AE
Unit cost (£)
Source Grade 3 Grade 4
Thrombocytopenia 164.37 683.62 TA17131
Neutropenia 190.86 354.30 TA17131
Anaemia 384.75 551.63 TA17131
Gastrointestinal 830.84 1302.90 TA17131
Peripheral neuropathy 174.75 317.37 TA17131
Dizziness/fatigue 172.24 172.24 Celgene MS
Infection 1018.01 1018.01
DVT 347.17 1014.29 TA1713178 Economic analysis
The sensitivity analysis investigated the effect of uncertainty around the model assumptions, 
structure and parameter values on the cost-effectiveness results, in order to highlight the most 
influential parameters. The effects of uncertainty in multiple parameters were addressed using 
PSA, which is reported later in this chapter (see Probabilistic sensitivity analysis). Where possible, 
the parameters were varied according to the ranges of the CIs of these parameters, based on 
TABLE 43  Summary of the undiscounted duration in each health state for treatment with MP, MPT, VMP and CTDa
Health state
Duration (years)
MP MPT VMP CTDa
Treatment 0.92 0.92 1.04 0.81
Post treatment 0.88 2.13 2.00 1.37
Post progression 2.39 3.61 3.60 2.52
OS 4.20 6.66 6.64 (AiC/CiC information has been removed)
TABLE 44  Summary of the undiscounted costs for treatment with MP, MPT, VMP and CTDa
Cost
Costs (£)
MP MPT VMP CTDa
First-line treatment 112 10,316 43,824 8691
Second-line treatment 17,695 17,695 7786 17,695
Monitoring 5075 7248 7375 5318
AEs 365 563 658 507
Total 23,248 35,822 59,644 32,211
TABLE 45  Baseline summary of discounted cost-effectiveness results
Treatment QALY Cost (£) ICER vs MP (£/QALY) ICER (cost/QALY) vs next best option
MP 2.42 21,439 – –
CTDa 2.68 29,983 33,031 33,031
VMP 3.62 57,168 29,820 28,937
MPT 3.64 32,598 9135 Dominates VMP
FIGURE 11  Overall survival curves for MP, MPT, VMP and CTDa.
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the published estimates. Where these data were not available an alternative suitable range was 
chosen. The same ranges were used in the deterministic analyses and PSA and these are described 
in Appendix 14.
Tables 46–48 show the results of the deterministic sensitivity analyses for each of the treatments 
versus MP for the most influential parameters. Other parameters, such as AE cost, CR rate and 
utility values, were varied in the sensitivity analyses but were found to only have a negligible 
effect on the results. The cost-effectiveness results are fairly robust to changes in parameters in the 
deterministic sensitivity analysis. For each of the treatments, the model results are most sensitive 
to the HR for OS, cost and dosage of the treatment and the overall baseline survival curve used 
for MP. The deterministic sensitivity results for MPT versus MP are shown in Table 46 and varied 
between £6445 and £22,749 per QALY gained. MPT dominates VMP for all parameters, except 
the VMP treatment effectiveness for OS (HR). Using the higher CI for OS, the cost-effectiveness 
estimate of VMP versus MPT is £44,928 per QALY gained.
The deterministic sensitivity results for VMP versus MP are shown in Table 47 and varied 
between £20,440 and £87,665 per QALY gained. VMP is dominated by MPT for all parameters, 
except the MPT treatment effectiveness for OS (HR). This is also the case if the model assumes 
that vials for bortezomib can be shared, rather than assuming one vial per patient. Using the 
lower CI for OS, the cost-effectiveness estimate of VMP versus MPT is £34,015 per QALY gained.
The deterministic sensitivity results for CTDa versus MP are shown in Table 48 and varied 
between –£29,210 and £16,897 per QALY gained. (AiC/CiC information has been removed.)
Scenario analysis
In addition to the sensitivity analyses four alternative scenarios were undertaken to investigate 
the uncertainty around structural assumptions (Table 49).
Scenario A – no subsequent therapies
The base-case scenario included the cost of second-line therapy. This scenario investigates the 
cost-effectiveness of first-line therapy only without including the subsequent treatment costs. In 
this case, MPT and CTDa are slightly less cost-effective versus MP, and VMP is considerably less 
cost-effective. The cost-effectiveness estimate for VMP versus MP increases to £37,711 per QALY 
gained. MPT continues to dominate VMP.
FIGURE 12  Cost-effectiveness plane for treatments MP, CTDa, VMP and MPT.
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7080 Economic analysis
Scenario B – vial sharing
The base-case scenario assumes that it is not possible for patients to share vials of bortezomib. 
This scenario investigates the cost-effectiveness where patients do share vials of bortezomib. With 
vial sharing and no wastage, bortezomib becomes more cost-effective versus MP, with an ICER of 
£22,533 per QALY gained. MPT continues to dominate VMP.
Scenario C – inclusion of thalidomide maintenance trials
The base-case scenario uses the efficacy for MPT using only RCTs that did not include 
thalidomide maintenance. This scenario investigates the cost-effectiveness using the estimate for 
MPT efficacy from a meta-analysis that includes trials with thalidomide maintenance. Janssen–
Cilag conducted a MTC for MPT efficacy with trials that included thalidomide maintenance 
and derived a HR (AiC/CiC information has been removed) for MPT versus MP. Using this HR 
makes MPT less cost-effective with an ICER of £24,276 per QALY gained versus MP. In addition, 
MPT no longer dominates VMP, with an ICER of £32,774 for VMP versus MPT.
TABLE 47  Deterministic sensitivity analyses for VMP vs MP
Parameter Baseline Upper value Lower value
ICER (£/QALY)
Upper value Lower value Range
HR for OS 0.62 0.83 0.51 87,665 20,440 67,225
MP OS baseline 
curvea
0.028 0.039 0.02 37,791 24,778 13,013
Unit cost bortezomib 
(£)
762.38 914.86 609.90 33,779 25,862 7917
Discount rate benefits 
(%)
3.5 5 2 33,795 26,081 7714
Utility progression 0.68 0.75 0.61 27,788 32,173 4385
No. of cycles VMP 9 10 8 31,801 27,748 4052
Cost of bortezomib 
administration (£)
153.40 199.41 107.38 31,632 28,009 3623
a  Probability of death per cycle.
TABLE 46  Deterministic sensitivity analyses for MPT vs MP
Parameter Baseline Upper value Lower value
Upper value ICER 
(£/QALY)
Lower value ICER 
(£/QALY) Range
HR for OS 0.62 0.82 0.5 22,749 6445 16,304
Dosage thalidomide 
(mg/day)
150 200 100 11,765 6504 5261
MP OS baseline curvea 0.028 0.039 0.02 11,230 7779 3451
Unit cost thalidomide (£) 298.48 358.18 238.78 10,713 7557 3156
Second-line treatment, 
bortezomib MPb (%)
70 80 60 7772 10,497 2725
Second-line treatment, 
bortezomib MPTb (%)
70 80 60 10,440 7830 2610
No. of cycles, MPT 8 9 7 10,282 7976 2306
a  Probability of death per cycle.
b  First-line treatment with MP or MPT.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Scenario D – treatment effectiveness beyond the end of trial
The base-case scenario extrapolates beyond the end of the trial by assuming a constant HR for 
the treatment effectiveness compared with MP. Although this is a standard methodological 
assumption, it is unclear how the treatment effectiveness changes beyond the end of the trial. This 
scenario investigates an alternative assumption whereby there is no treatment benefit for VMP, 
MPT and CTDa over MP, i.e. the event rates for these treatments are the same as for MP after the 
end of the trial. Using this assumption has a large effect on the model results, and all treatments 
are less cost-effective compared with MP. The ICERs for each of the treatment options more than 
double to £20,605 (MPT), £71,223 (VMP) and £80,382 (CTDa) per QALY gained versus MP. 
MPT continues to dominate VMP.
There are two additional scenario analyses for treatment duration and treatment discontinuations 
in Appendix 15.
Probabilistic sensitivity analysis
In the PSA, all parameters were sampled probabilistically from an appropriate distribution using 
similar ranges as used in the deterministic sensitivity analyses. The parameters sampled were 
TABLE 48  Deterministic sensitivity analyses for CTDa vs MP
Parameter Baseline Upper value Lower value
ICER (£/QALY)
Upper value Lower value Range
HR for OS (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
–29,210 16,897 46,107
MP OS baseline 
curve a
0.028 0.039 0.02 49,240 24,621 24,619
Thalidomide dose 
(mg/day)
150 200 100 43,501 22,561 20,940
Second-line 
treatment, bortezomibb 
MP (%)
70 80 60 26,596 39,466 12,870
Second-line 
treatment, bortezomibb 
CTDa (%)
70 80 60 39,385 26,677 12,708
Unit cost 
thalidomide (£)
298.48 358.18 238.78 39,483 26,978 12,505
No. of cycles CTDa 7 8 6 39,313 26,749 12,564
a  Probability of death per cycle.
b  First-line treatment with MP or CTDa.
TABLE 49  Cost-effectiveness results for scenario analyses A–D
Scenario
ICER (cost per QALY gained, £) vs MP
MPT VMP CTDa
Base-case analysis 9135 29,820 33,031
Scenario A 9699 37,711 33,828
Scenario B 9330 22,533 33,307
Scenario C 24,276 29,820 33,031
Scenario D 20,605 71,223 80,38282 Economic analysis
discount rate, number of treatment cycles, utility values, CR rate, cost of AEs, parameters for the 
survival curves and the proportions of patients receiving bortezomib as second-line therapy. The 
distribution assigned to each variable included in the PSA and the parameters of the distributions 
are reported in Appendix 14.
One thousand simulations were run. The PSA results are presented in Table 50 and show similar 
results to the deterministic analyses (Tables 46–48). The scatter plots for cost and health outcomes 
for the treatment options for the PSA are shown in Figure 13. The CEAC is shown in Figure 14, 
and indicates that at the £20,000 and £30,000 willingness-to-pay thresholds MPT has the highest 
probability of being cost-effective of 0.95 and 0.95, respectively.
TABLE 50  Baseline PSA cost-effectiveness results vs MP
Result MP MPT VMP CTDa
Total cost (£) 21,620 33,050 57,545 30,371
Total QALY 2.44 3.68 3.66 2.70
Incremental cost vs MP (£) – 11,495 35,991 8816
Incremental QALY vs MP – 1.26 1.24 0.28
ICER vs MP (£) – 9124 29,102 31,612
FIGURE 13  Scatter plots of the costs and health benefits from PSA for MP, MPT, VMP and CTDa.
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FIGURE 14  Cost-effectiveness acceptability curve from the PSA.
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Summary of cost-effectiveness
  ■ A systematic search of the literature found five abstracts of economic evaluations of 
treatment for patients with previously undiagnosed MM, who were ineligible for HDT-SCT. 
None of the studies contained sufficient information for critical appraisal. Three of the 
abstracts compared MPT with MP in patients in Scotland, Wales and Australia. Each abstract 
concluded that MPT was a cost-effective alternative to MP. Two abstracts compared VMP, 
MPT and MP in Canadian and US patients. Both studies concluded that the VMP regimen 
was cost-effective compared with MP and MPT. The latter study stated that VMP dominated 
MPT (i.e. more effective at a lower cost). All studies were industry funded.
  ■ A systematic review of studies of QoL for patients with MM identified six studies: only two 
of these studies were for the population of interest and both studies did not include generic 
preference-based utility measures; the other four QoL studies provided utility estimates for 
patients with MM who had intensive therapy.
  ■ Two manufacturers submitted evidence to be considered for the appraisal of bortezomib 
and thalidomide treatment. Janssen–Cilag, the manufacturer of bortezomib, constructed 
a survival model that estimated OS and PFS based on treatment effects from a MTC of 
the RCTs. They included second- and third-line treatment. The base-case results from the 
submission found all treatments (VMP, MPT and CTDa) to be cost-effective. The ICER for 
VMP versus MP is estimated to be £10,498. Furthermore, the ICERs of VMP versus MPT 
and VMP versus CTDa are estimated to be £11,907 and £10,411, respectively.
  ■ Celgene, the manufacturer of thalidomide, constructed a Markov model with health states 
for preprogression (with or without AEs), post progression and death. They assumed that 
survival after disease progression was the same irrespective of first-line treatment. Treatment 
effects for disease progression were calculated from a random effects MTC. The base-case 
results from the submission estimated an ICER of £23,381 per QALY gained for MPT versus 
MP and £303,845 per QALY for VMP versus MPT.
  ■ The authors of this report developed an independent survival model. The survival model 
consisted of two survival curves which estimated the mean time to death and disease 
progression. These survival durations were used to derive the time spent in three health 
states: treatment, post treatment and progression. Utility values were applied to these 
health states to estimate total QALYs for each treatment option. Costs were included for 
medications and outpatient costs and AEs. The model base-case results showed increased 
survival for each of the treatments compared with MP at an increased cost. The OS was 
marginally longer for MPT than for VMP at a considerably lower cost. The cost-effectiveness 
estimates for MPT, VMP and CTDa versus MP were £9135, £29,820 and £33,031 per QALY 
gained, respectively. However, MPT dominated VMP as it was cheaper and more effective.
  ■ The effects of a range of parameter values in the economic model were evaluated in 
sensitivity analyses. The model results were found to be robust to changes in the parameter 
values. The model results are most sensitive to changes in the parameter values of the HRs 
for OS.
  ■ The PSA estimated the probability of each of the treatments to be cost-effective at the £20,000 
and £30,000 willingness-to-pay thresholds. MPT has the highest probability of being cost-
effective, with probabilities of 0.95 and 0.95, respectively.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 6  
Assessment of factors relevant to the NHS 
and other parties
B
ortezomib is already used as a monotherapy within the NHS for patients with relapsed MM 
and therefore oncology departments will have experience of administering this treatment. 
However, increased use of bortezomib will result in an increase in staff time to cover its 
administration. Some clinicians will also have experience of treating patients with thalidomide 
because of the UK-based MMIX RCT of CTDa versus MP. It is not clear whether there will be 
additional resource implications with increased use of thalidomide because of the requirement 
that it is prescribed and dispensed according to the Thalidomide Pharmion Pregnancy 
Prevention Programme.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
87   Health Technology Assessment 2011; Vol. 15: No. 41 DOI: 10.3310/hta15410
Chapter 7  
Discussion
Statement of principal findings
Clinical effectiveness
  ■ Five RCTs were included in the systematic review of clinical effectiveness. One examined 
the effectiveness of VMP, three examined the effectiveness of MPT, and one examined the 
effectiveness of CTDa. The comparator in all RCTs was MP. Two RCTs had a maintenance 
phase with thalidomide which followed the initial treatment phase. The maintenance phase 
did not meet the inclusion criteria. Reporting on the results of these RCTs was therefore 
limited to outcomes that had been reported at a time point prior to the start of maintenance 
therapy with thalidomide.
  ■ Judgements about aspects of study quality could not be made for some studies because of a 
lack of detailed reporting in the published papers. Consequently, there is uncertainty about 
some aspects of study quality. In particular, it was not possible to determine whether the 
amount and pattern of censoring in the RCTs was comparable between study groups.
  ■ Overall survival was increased in the intervention group in comparison to the groups 
receiving MP in both of the MPT versus MP RCTs that provided data for this outcome. 
Meta-analysis of the OS data from two RCTs of MPT versus MP confirmed the superiority of 
MPT and was in agreement with a published meta-analysis of three MPT versus MP trials.109 
OS was also increased in the single VMP versus MP RCT. Because OS data for the single 
RCT of VMP are not as mature as those for the two RCTs of MPT it was not possible to 
determine whether OS was greater with MPT or VMP.
  ■ More participants in the intervention arms of the included RCTs achieved a CR to treatment 
than in the MP comparator arms. The difference was reported to be statistically significant 
in four of the included studies, with a fifth study not reporting a p-value. It should be noted, 
however, that the proportion of participants achieving a CR to treatment was not assessed 
according to ITT principles in one RCT, which reported data for only approximately three-
quarters of the enrolled participants, and the proportions of data missing from each trial 
arm appeared to be unequal but no explanation for this was provided. The remaining four 
RCTs reported results for approximately 95% or more of the participants and the proportion 
of data missing from each arm seemed comparable. A meta-analysis of the CR outcome 
data from three MPT versus MP RCTs confirmed that MPT was superior in comparison 
with MP in terms of the proportion of patients achieving a CR. As there were only single 
trials for VMP versus MP and for CTDa versus MP no meta-analyses for these comparisons 
were undertaken.
  ■ Progression-free survival was reported to be statistically significantly longer in the 
intervention group in comparison with the groups receiving MP in both of the MPT versus 
MP RCTs that provided data on this outcome, and the single VMP versus MP RCT. Only 
the RCT of VMP versus MP reported on time to disease progression, which was the primary 
outcome of this trial. There was a statistically significant difference in median time to disease 
progression in favour of the VMP group.
  ■ Adverse events occurred with all treatments. Some AEs were statistically significantly 
increased in trial intervention arms. The combination of bortezomib and MP was associated 
with a statistically significant increase in grade 3 AEs in comparison with the MP group. AE 
outcomes for thalidomide in combination with MP varied between the RCTs, but the two 88 Discussion
trials which reported on peripheral neuropathy reported a statistically significant increase in 
this AE in the treatment groups receiving thalidomide.
Cost-effectiveness
  ■ A systematic search of the literature found five abstracts of economic evaluations of 
treatment for patients with previously undiagnosed MM, ineligible for HDT–SCT. None of 
the studies contained sufficient information for critical appraisal.
  ■ A systematic search for published studies of QoL for patients with MM identified six studies: 
only two of these studies were for the population of interest and neither study included 
generic preference-based utility measures; the other four QoL studies provided utility 
estimates for patients with MM who had intensive therapy.
  ■ Two manufacturers submitted evidence to be considered for this review for bortezomib 
and thalidomide treatment. Janssen–Cilag, the manufacturer of bortezomib, constructed 
a survival model that estimated OS and PFS based on treatment effects from a MTC of the 
trials. The base-case results from the submission found all interventions to be cost-effective, 
with ICERs of less than £11,000 per QALY gained versus MP for MPT, VMP and CTDa.
  ■ Celgene, the manufacturer of thalidomide, constructed a Markov model with health states 
for preprogression (with or without AEs), post progression and death. The base-case results 
from the submission estimated MPT to be cost-effective compared with MP, while the ICER 
for VMP versus MPT was more than £300,000 per QALY gained.
  ■ The authors of this report developed an independent survival model. From this independent 
model, the incremental cost-effectiveness versus MP for MPT, VMP and CTDa is estimated 
as £9135, £29,820 and £33,031 per QALY gained, respectively. However, MPT dominated 
VMP as it was cheaper and more effective. The model results are most sensitive to changes 
in the parameter values of the HRs for OS. The PSA showed that MPT has the higher 
probability to be cost-effective at the £20,000 and £30,000 willingness-to-pay thresholds.
Discussion of cost-effectiveness results
The results for the manufacturers’ and SHTAC’s economic analyses are shown in Table 51. The 
results of the analyses vary considerably. The costs vary substantially between the analyses; 
for example the cost of MP varies between £1365 for the Celgene submission to £54,434 for 
the Janssen–Cilag submission. The costs from the Celgene analysis were lower as they had not 
included any subsequent treatment costs, whereas the SHTAC analysis included costs for second-
line treatment and the Janssen–Cilag analysis included costs for second- and third-line treatment.
The incremental costs for MPT versus MP vary between £4888 (Janssen–Cilag) and £19,768 
(Celgene). The Celgene submission uses higher dosages of thalidomide (238 mg/day) for longer 
periods (11 cycles) than the other two analyses. The incremental costs for VMP versus MP 
vary between £12,242 (Janssen–Cilag) and £41,251 (Celgene). These differences are largely 
due to the assumptions around the number of vials of bortezomib used, with Janssen–Cilag 
assuming a mean of (AiC/CiC information has been removed) vials used per person, whereas 
the mean number of vials used is over 40 in the SHTAC and Celgene economic evaluations. The 
incremental costs for CTDa versus MP vary between £2234 (Janssen–Cilag) and £8544 (SHTAC), 
and these differences are due to an error in the cost calculation for third-line therapy for CTDa in 
the Janssen–Cilag analysis.
The total QALY estimates between the studies are reasonably similar with estimates for all 
treatment arms varying between 2.42 and 4.03 QALY. The incremental QALY estimates for 
MPT versus MP vary widely and these differences are due to the estimates chosen for the HR for 
OS compared with MP. The incremental QALY estimates for MPT versus MP range from 0.55 
(Janssen–Cilag) to 1.22 (SHTAC).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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The different assumptions and methodology described above results in a range of estimates for 
the cost-effectiveness of the treatment options. The ICER for MPT versus MP varies between 
£9135 (SHTAC) and £23,381 (Celgene) per QALY gained. The ICER for VMP versus MP varies 
between £10,498 (Janssen–Cilag) and £44,838 (Celgene) per QALY gained. The ICER for CTDa 
versus MP varies between £10,905 (Janssen–Cilag) and £33,031 (SHTAC) per QALY gained.
The results have also been estimated for VMP versus MPT. These results also vary widely for the 
reasons given above. The ICER for VMP versus MPT was estimated as £11,907 (Janssen–Cilag) 
and £303,845 (Celgene) per QALY gained. For the SHTAC economic analysis, MPT dominated 
VMP, i.e. cheaper and more effective, for the base case and most sensitivity analyses.
Strengths and limitations of the assessment
The review has the following strengths:
  ■ The systematic review and economic evaluation have both been carried out independent of 
any vested interest, and the results are presented in a consistent and transparent manner.
  ■ The project was undertaken following the established methodology and principles for 
conducting a systematic review. The methods used were set out in a research protocol (see 
Appendix 1), which drew on the NICE scope to define the research question, inclusion and 
quality assessment criteria, data extraction process and the other methods to be used during 
the evidence synthesis. The research protocol was circulated to clinical experts and agreed 
with NICE before the project started.
  ■ An advisory group reviewed and commented on drafts of the protocol and the final report.
  ■ A de novo economic model has been developed following recognised guidelines. The 
main results have been summarised and presented. The model structure and data inputs 
TABLE 51  Southampton Health Technology Assessments Centre and the manufacturers’ baseline cost-effectiveness 
results vs MP
Result Analysis MP MPT VMP CTDa
Total cost (£) SHTAC 21,439 32,598 57,168 29,983
Janssen–Cilag 54,434 59,322 66,676 56,668
Celgene 1365 21,133 42,616 –
Total QALY SHTAC 2.42 3.64 3.62 2.68
Janssen–Cilag 2.86 3.41 4.03 3.07
Celgene 2.43 3.28 3.35 –
Incremental cost vs MP (£) SHTAC – 11,159 35,729 8544
Janssen–Cilag – 4888 12,242 2234
Celgene – 19,768 41,251 –
Incremental QALY vs MP SHTAC – 1.22 1.20 0.26
Janssen–Cilag – 0.55 1.17 0.21
Celgene – 0.85 0.92 –
ICER vs MP (£ per QALY) SHTAC – 9135 29,820 33,031
Janssen–Cilag – 8912 10,498 10,905
Celgene – 23,381 45,024a –
a  The value of £45,024 was not presented in the MS but has been calculated by SHTAC to allow comparison with outputs from the SHTAC and 
Janssen–Cilag models.90 Discussion
are clearly presented in this report. This should facilitate replication and testing of our 
model assumptions.
  ■ Clinical evidence to populate the model has been extracted from reasonable quality RCTs 
included in the systematic review. The effect of treatment on OS and PFS was assessed using 
appropriate measures to model cost and outcome differences over the model time horizons.
In contrast, the review also has certain limitations:
  ■ Only two RCTs contributed data on OS following treatment with thalidomide and MP. The 
doses of thalidomide used differed between the two RCTs, as did the ages of the included 
participants, and the 72-week treatment period is not reflective of typical UK practice. It 
is therefore difficult to assess what the impact of MPT on OS would be when prescribed 
according to UK clinical practice to a typical MM patient in England and Wales.
  ■ Only one RCT contributed data on OS following treatment with bortezomib and MP and the 
published peer-reviewed follow-up data are immature. At the data-analysis cut-off date in the 
published paper not all patients had completed their assigned treatment.
  ■ No evidence on OS or PFS following treatment with CTDa met the inclusion criteria for the 
systematic review of clinical effectiveness because the only included RCT that assessed CTDa 
had a second randomisation to maintenance therapy with thalidomide for some participants 
after the completion of first-line treatment.
  ■ No head-to-head trials were identified which compared bortezomib in combination with 
an alkylating agent and a corticosteroid with thalidomide in combination with an alkylating 
agent and a corticosteroid.
  ■ Assessment of the impact of treatment on QoL was very limited. Data on HRQoL could 
only be included from one RCT, the study of VMP versus MP. Although one of the RCTs 
that assessed MPT versus MP reported on HRQoL these outcomes could not be included 
in the systematic review of clinical effectiveness because this RCT has included the use of 
thalidomide maintenance therapy in the later part of the RCT.
  ■ There were limited data available for meta-analysis. Furthermore, most studies did not 
report all the data items that were necessary to enable meta-analysis to be conducted. These 
missing data items were therefore estimated using published methods. A MTC was not 
carried out because of doubts about the validity of doing so due to potential differences in 
participant characteristics, delivery of MP treatment in the comparator arms, and length of 
follow-up. Furthermore, CTDa could not have been included in such an analysis because 
the single RCT that assessed CTDa included randomisation to maintenance therapy for 
some participants.
  ■ For pragmatic purposes in the economic model, analyses were included for CTDa, although 
the OS and PFS data included some patients who had received thalidomide maintenance 
from the MMIX RCT as no other data were available for CTDa.
  ■ Where possible, the data included in the model are in the public domain. However, some 
data for OS and PFS were extracted from an MS where these were not reported in sufficient 
detail in published sources and these are reported as AIC and CIC, as appropriate.
  ■ There were few HRQoL studies for the population of interest and these were only disease-
specific HRQoL studies, using the EORTC QLQ-C30 measure. It was necessary to derive 
EQ-5D utility estimates using a mapping algorithm.
Uncertainties
  ■ It is not clear whether participants in the European trials reflect the population of patients 
that would receive these treatments in the UK. The participants in these trials, in general, 
had a better performance status than the participants in the UK MMIX clinical trial who © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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are likely to more accurately reflect the typical UK MM patient who is ineligible for HDT 
with SCT.
  ■ It is not clear for OS and PFS outcomes how much data has been censored and for what 
reason. Therefore, it was not possible to determine whether the amount and pattern of 
censored data was comparable between the trial groups. Whether censoring had any effect on 
the reported outcomes is unknown.
  ■ Alterations in the doses of study drug were permitted in all studies and the target doses of 
thalidomide varied between the included RCTs. Although some trials provided some details 
on the duration and intensity of treatment it is not clear whether these dose alterations had a 
significant effect on the outcomes.
  ■ Duration of MPT treatment in the two IFM RCTs23,59 was longer than would be generally 
considered necessary or desirable in the UK. It is not certain what impact a shorter treatment 
period would have had on trial outcomes.
  ■ Very limited data from subgroup analyses were available for the comparisons of VMP 
versus MP, and CTDa versus MP, and no subgroup data were available from the RCTs of 
MPT versus MP. The outcomes from the available subgroup analyses should be interpreted 
with caution.
  ■ Concern was expressed by a clinical advisor that the incidence of AEs may be 
underestimated by the clinical trials. In particular, the incidence of peripheral neuropathy 
occurring with thalidomide was believed to be lower in the trials than that observed in 
UK clinical practice. Peripheral neuropathy, if it develops, can worsen quickly, and can 
be irreversible. This may be managed by dose modification or may limit the duration of 
treatment with thalidomide or with bortezomib for some patients and there can be a need for 
long-term treatment of neuropathic pain with gabapentin. Peripheral neuropathy can also 
preclude later treatment with bortezomib. Similarly the incidence of somnolence/dizziness/
fatigue that occurs with thalidomide treatment may have been underestimated.
  ■ The second-line and other subsequent treatments received by participants in the included 
RCTs were variable. They did not reflect current UK practice in which most patients in the 
UK will receive bortezomib as their second-line therapy. This is owing to NICE guidance30 
that recommends bortezomib only as a second-line therapy. The impact of second-line and 
later therapies on trial outcomes is unknown.
  ■ There is some uncertainty around the appropriate dosage for thalidomide. The daily dosages 
in the RCTs varied between 100 and 200 mg per patient. The SPC for thalidomide in the 
electronic Medicines Compendium states a daily dose of 200 mg. However, our clinical 
expert advised that, in practice, most patients will not be able to tolerate such a high 
dose and a lower dose of 100 mg is more common. In the economic analysis, we took the 
conservative assumption that the dose would be 150 mg. Lower dosages will result in more 
favourable cost-effectiveness estimates.
  ■ It is unclear what effect second-line and subsequent treatment has on patient survival and 
HRQoL. In the RCTs, there was a large number of different treatments given for second-line 
treatment. In the absence of appropriate data, we included second-line treatment as a cost 
and did not model its effect on health outcomes.
  ■ There was considerable heterogeneity in the reporting of AEs in the RCTs. For this reason, 
the cost of treating AEs was included in the model but any short-term utility decrements due 
to the AEs were not included.
  ■ The cost-effectiveness results for CTDa should be treated with caution, as the effectiveness 
estimates from the MMIX RCT include patients who received thalidomide maintenance 
therapy. (AiC/CiC information has been removed.)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 8 
Conclusions
Implications for service provision
Service provision is unlikely to change greatly, although there will be additional intravenous 
administration to cover if bortezomib use is extended.
Suggested research priorities
Head-to-head trials of combination chemotherapy regimens containing bortezomib versus 
regimens containing thalidomide are desirable. For the results of such a trial to be easily 
generalisable to UK clinical practice drug doses and treatment periods should reflect those in 
widespread use in the UK. All trials of first-line therapy for MM in patients who are ineligible for 
HDT and SCT should include assessments of patient HRQoL in response to treatment.
The patients in the RCTs included in the clinical effectiveness review received a variety of 
second-line and subsequent treatments. This does not reflect current UK practice, which is that 
most patients receive bortezomib as their second-line therapy. If research is conducted to assess 
the impact of second-line treatments on patient outcomes it would also be desirable to assess 
whether the sequence of treatment, for example first-line therapy with a thalidomide-containing 
regimen followed by second-line treatment with a bortezomib-containing regimen, or vice versa, 
has any impact on patient outcomes.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 1  
Report methods for synthesis of evidence of 
clinical effectiveness and cost-effectiveness 
as described in the research protocol
A 
systematic review of the evidence for clinical effectiveness and cost-effectiveness will be 
undertaken following the general principles outlined in Systematic reviews: CRD’s guidance 
for undertaking reviews in health care.40
Search strategy
A search strategy will be developed and tested by an experienced information specialist. The 
strategy will be designed to identify studies reporting clinical effectiveness, cost-effectiveness, 
HRQoL, resource use and costs, epidemiology and natural history.
A draft search strategy for MEDLINE will be adapted for other databases. Literature will be 
identified from several sources, including electronic databases, bibliographies of articles, and grey 
literature sources. Reference lists contained within manufacturers’ submissions to NICE will be 
searched for any additional studies that meet the inclusion criteria. Experts will be contacted to 
identify additional published and unpublished references. A comprehensive database of relevant 
published and unpublished articles will be constructed using Reference Manager software.
All databases will be searched from 1999 (earliest use of thalidomide for MM37 and earliest 
description of bortezomib as a potential cancer therapy38) to the current date. Searches will be 
restricted to English language and updated around December 2009.
Inclusion and exclusion criteria
Interventions   ■ Bortezomib in combination with an alkylating agent and a corticosteroid for first-line treatment of MM
  ■ Thalidomide in combination with an alkylating agent and a corticosteroid for first-line treatment of MM
(Studies of treatment with either bortezomib or thalidomide as a single agent will not be included)
Participants People with previously untreated MM who are not candidates for HDT with SCT
(Studies of patients with MM who have received previous treatment(s) will not be included)
Comparators Interventions described above will be compared with each other and the following comparators:
  ■ Melphalan or cyclophosphamide in combination with prednisolone or dexamethasone
(Other chemotherapy regimens or SCT will not be included)106 Appendix 1
Outcomes Studies will be included if they report on one or more of the following outcomes:
  ■ OS
  ■ PFS
  ■ TTP
  ■ Response rates
  ■ HRQoL
  ■ Cost-effectiveness (such as incremental cost per QALY gained)
Adverse effects of treatment will be reported if available within the trials that meet the inclusion criteria.
Design The following types of study will be eligible for inclusion:
  ■ Randomised controlled trials for clinical effectiveness – if no RCTs are found, or if the data from available RCTs are 
incomplete (e.g. absence of data on outcomes of interest), then evidence from good-quality observational studies may 
be considered
  ■ Economic evaluations (such as cost-effectiveness studies, cost–utility studies, cost–benefit studies)
Studies published as abstracts or conference presentations will be included only if sufficient details are presented to allow 
an appraisal of the methodology and the assessment of results to be undertaken
Systematic reviews and clinical guidelines will be used as a source of references
Case series, case studies, narrative reviews, editorials and opinions will be excluded
Non-English-language studies will be excluded
Inclusion and data extraction process
Studies will be selected for inclusion through a two-stage process. Literature search results (titles 
and abstracts) will be screened independently by two reviewers to identify all citations that may 
meet the inclusion criteria. Full manuscripts of selected citations will be retrieved and assessed 
by one reviewer against the inclusion/exclusion criteria and checked independently by a second 
reviewer. Discrepancies will be resolved by discussion, with involvement of a third reviewer 
when necessary.
Data will be extracted by one reviewer using a standardised data extraction form and will be 
checked for accuracy by a second reviewer. Discrepancies will be resolved by discussion, with 
involvement of a third reviewer when necessary.
Quality assessment strategy
The quality of included clinical effectiveness studies will be assessed using NHS CRD (University 
of York) criteria.40 Methodological quality of economic evaluations will be assessed based on 
recognised criteria for appraising economic evaluations.80,110 Quality criteria will be applied by 
one reviewer and checked by a second reviewer with any disagreements resolved by consensus 
and involvement of a third reviewer where necessary.
Methods of analysis/synthesis
Clinical effectiveness and cost-effectiveness studies will be synthesised through a narrative 
review with tabulation of results of included studies. Where appropriate the results from 
individual clinical effectiveness studies will be synthesised through meta-analysis, with causes 
of heterogeneity of results examined. The systematic review may explore the possibility of © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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conducting an indirect comparison of thalidomide and bortezomib used in combination with 
an alkylating agent and a corticosteroid versus a common comparator. The specific methods 
for meta-analysis and for the detection and investigation of heterogeneity will depend upon the 
particular outcome measure under consideration.
Report methods for economic analysis
The cost-effectiveness of bortezomib or thalidomide used in combination with an alkylating 
agent and a corticosteroid for first-line treatment of MM will be assessed through a review of 
previous cost-effectiveness studies and, if appropriate, through the development of a decision-
analytic model. The purpose of the review is to identify recent relevant evaluations, in order to 
analyse the methodological approaches undertaken, and to discern whether, and how, existing 
models can be adapted for use in the current project.
Model structure
Where necessary, a de novo decision-analytic model will be developed to assess the cost-
effectiveness of bortezomib and thalidomide. The exact structure of the model will be designed 
to reflect important clinical events over the course of the disease and will be validated through 
discussion with expert advisors. Modelling will be conducted according to accepted methodology 
for economic evaluations.78,98 The perspective will be the NHS and PSS. Costs and benefits will be 
discounted using standard rates (3.5%).78 The model will be developed using standard software 
such as Microsoft Excel and Tree-Age Pro.
The model will contain a hypothetical cohort of individuals and will estimate changes in disease 
progression, morbidity and mortality for the MM treatments under consideration. The time 
horizon for the model will be 15 years, which, for the majority of patients in the hypothetical 
cohort, is likely to be equivalent to a lifetime horizon.
Whilst de novo modelling is planned, the possibility of adapting an existing published model 
along the lines of the proposed model will be explored through contact with experts in the field.
Clinical effectiveness data
The parameters of the model will be informed primarily by the systematic review of effectiveness 
studies. Additional targeted searches will be undertaken to identify specific data to populate the 
model. These will include searches for data on the epidemiology and natural history of MM; the 
HRQoL impacts of disease stages and the adverse effects of treatment; the cost of treatment and 
health-care costs. Where these data cannot be identified through searches, estimates will be based 
on information supplied by our expert advisory group and others.
Baseline disease progression will be predicted using trial data where available or good-quality 
observational studies (such as the Mayo Clinic study, which has followed cohorts of patients 
with MM over a 13-year period111). Treatment effect will be modelled over time by adjusting the 
baseline prediction of treatment pathway and disease progression, based upon reported hazard 
ratios (HRs) in the systematic review for time to progression to more severe states, and OS.108 Appendix 1
Costs and resource estimation
The resources necessary for providing the treatments will be estimated from the systematic 
review of effectiveness, and from discussion with expert advisers. Unit costs for these resources 
will be developed based on data in published sources such as the Unit Costs of Health and Social 
Care, PSS Research Unit (PSSRU).102 Data on the cost of assessing and treating MM will be 
sought from Southampton University Hospitals Trust (SUHT), which routinely supplies SHTAC 
with cost data and clinical expertise. Information on resource use and costs will also be derived 
from sponsor submissions to NICE, as appropriate.
Outcomes
The model will provide a cost-effectiveness analysis, reporting the costs of treatments under 
consideration in the appraisal and their long-term consequences in terms of life-years saved and 
QALYs gained and additional costs. Results will be expressed in terms of ICERs (e.g. incremental 
costs per QALY gained).
Uncertainty in model parameters and structure will be investigated through one-way 
deterministic and probabilistic sensitivity analyses where appropriate and feasible. The key 
variables to be explored will include treatment effect estimates (e.g. OS and disease progression), 
baseline disease progression estimate, treatment costs and HRQoL. Cost-effectiveness 
acceptability curves (CEACs) will be generated in any probabilistic sensitivity analysis (PSA) 
to illustrate the probability of the treatment being cost-effective over a range of willingness-
to-pay values.
Handling the company submission(s)
All data submitted by the manufacturers/sponsors will be considered if received by the 
technology assessment report (TAR) team no later than 15 October 2009. Data arriving after 
this date will not be considered. If the data meet the inclusion criteria for the review they will be 
extracted and quality assessed in accordance with the procedures outlined in this protocol. Any 
economic evaluation included in the company submission, provided it complies with NICE’s 
advice on presentation, will be assessed for clinical validity, reasonableness of assumptions and 
appropriateness of the data used in the economic model.
Any ‘commercial-in-confidence’ data taken from a company submission will be underlined and 
highlighted in red in the assessment report (followed by an indication of the relevant company 
name in brackets unless it is obvious from the context). Any ‘academic-in-confidence’ data will be 
highlighted in yellow.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 2  
Example MEDLINE search strategies for 
clinical effectiveness and cost-effectiveness
Clinical effectiveness
1.  (bortezomib or velcade).mp.
2.  thalidomid*.mp.
3.  thalidomide/
4.  or/1-3
5.  exp multiple myeloma/
6.  exp Plasmacytoma/
7.  exp Paraproteinemias/
8.  (myeloma* or (multiple adj myeloma*) or plasmacytom* or plasmocytom* or MGUS or 
(monoclonal adj gammopath*)).mp.
9.  or/5-8
10.  4 and 9
11.  randomized controlled trial/
12.  randomized controlled trial.pt.
13.  controlled clinical trial/
14.  controlled clinical trial.pt.
15.  clinical trial.pt.
16.  exp Clinical Trial/
17.  random*.tw.
18.  exp Research Design/
19.  (systematic$adj2 review$).mp.
20.  (systematic$adj2 overview$).mp.
21.  (meta analy* or metaanaly*).ti,ab,pt.
22.  exp meta analysis/
23.  ((hand or manual or computer or electronic or database) adj2 search*).ti,ab.
24.  (open adj label*).tw.
25.  double-blind method/
26.  single-blind method/
27.  ((singl* or doubl* or tripl* or trebl*) adj5 (blind* or mask*)).tw.
28.  exp cohort studies/
29.  cohort*.ti,ab.
30.  or/11-29
31.  10 and 30
32.  limit 31 to (english language and humans and yr=“1999 -Current”)
33.  (editorial or comment or letter).pt.
34.  32 not 33
35.  from 34 keep 1-381110 Appendix 2
Cost-effectiveness
1.  exp economics/
2.  exp economics hospital/
3.  exp economics pharmaceutical/
4.  exp economics nursing/
5.  exp economics medical/
6.  exp “Costs and Cost Analysis”/
7.  Cost Benefit Analysis/
8.  value of life/
9.  exp models economic/
10.  exp fees/and charges/
11.  exp budgets/
12.  (value adj2 (money or monetary)).tw.
13.  (economic adj2 burden).tw.
14.  (expenditure* not energy).tw.
15.  budget*.tw.
16.  (economic* or price* or pricing or financ* or fee* or pharmacoeconomic* or pharma 
economic* or pharmaco-economic*).tw.
17.  (decision adj1 (tree* or analys* or model*)).tw.
18.  Resource Allocation/
19.  (unit cost or unit-cost or unit-costs or unit costs or drug cost or drug costs or hospital costs 
or health-care costs or health care cost or medical cost or medical costs).tw.
20.  ((value or values or valuation) adj2 (money or monetary or life or lives or costs or cost)).tw.
21.  (cost adj2 (util* or effective* or efficac* or benefit* or cosequence* or analys* or minimi* or 
saving* or breakdown* or lowering or estimate* or variable* or allocation* or control* or 
illness* or affordable* or instrument* or technolog* or fee* or charge* or charges)).tw.
22.  Markov Chains/
23.  Monte Carlo Method/
24.  exp Decision Support Techniques/
25.  (resource adj2 (use* or utili* or allocat*)).tw.
26.  or/1-25
27.  (bortezomib or velcade).mp.
28.  thalidomid*.mp.
29.  thalidomide/
30.  or/27-29
31.  exp multiple myeloma/
32.  exp Plasmacytoma/
33.  exp Paraproteinemias/
34.  (myeloma* or (multiple adj myeloma*) or plasmacytom* or plasmocytom* or MGUS or 
(monoclonal adj gammopath*)).mp.
35.  or/31-34
36.  26 and 30 and 35
37.  multiple myeloma/ec
38.  *multiple myeloma/
39.  26 and 38
40.  “multiple myeloma”.ti.
41.  26 and 40
42.  36 or 37 or 39 or 41
43.  limit 42 to (english language and humans and yr=“1999 -Current”)
44.  (editorial or comment or letter).pt.
45.  43 not 44© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 3  
Response criteria
EBMT, IBMTR and ABMTR criteriaa IFM criteriab
CR requires all of the 
following:
Absence of the original monoclonal paraprotein in serum and urine 
by immunofixation, maintained for a minimum of 6 weeks. The 
presence of oligoclonal bands consistent with oligoclonal immune 
reconstitution does not exclude CR
Absence of the original monoclonal protein 
in serum and urine by immunofixation. No 
confirmation needed
Less than 5% plasma cells in a bone marrow aspirate and also 
on trephine bone biopsy, if biopsy is performed. If absence of 
monoclonal protein is sustained for 6 weeks it is not necessary 
to repeat the bone marrow, except in patients with non-secretory 
myeloma where the marrow examination must be repeated after 
an interval of at least 6 weeks to confirm CR
Less than 5% of plasma cells in a bone 
marrow aspirate. No confirmation needed
No increase in size or number of lytic bone lesions (development of 
a compression fracture does not exclude response)
Disappearance of soft tissue plasmacytomas Disappearance of soft tissue plasmacytomas
VGPR More than a 90% decrease in monoclonal 
protein in serum and urine. No confirmation 
needed
PR requires all of the 
following:
More than 50% reduction in the level of the serum monoclonal 
paraprotein, maintained for a minimum of 6 weeks
More than a 50% reduction in the 
concentration of serum monoclonal protein. 
No confirmation needed
Reduction in 24-hour urinary light chain excretion either by > 90% 
or to < 200 mg, maintained for a minimum of 6 weeks
More than a 75% reduction in 24-hour 
urinary light chain excretion. No confirmation 
needed
For patients with non-secretory myeloma only, > 50% reduction in 
plasma cells in a bone marrow aspirate and on trephine biopsy, if 
biopsy is performed, maintained for a minimum of 6 weeks
More than 50% reduction in the size of soft tissue plasmacytomas 
(by radiography or clinical examination)
Reduction in the size of soft tissue 
plasmacytomas
No increase in size or number of lytic bone lesions (development of 
a compression fracture does not exclude response)
MR 25–49% reduction in the level of the serum monoclonal 
paraprotein maintained for a minimum of 6 weeks
50–89% reduction in 24-hour urinary light chain excretion, which 
still exceeds 200 mg/24 hours, maintained for a minimum of 
6 weeks
For patients with non-secretory myeloma only, 25–49% reduction 
in plasma cells in a bone marrow aspirate and on trephine biopsy, 
if biopsy is performed, maintained for a minimum of 6 weeks
25–49% reduction in the size of soft tissue plasmacytomas (by 
radiography or clinical examination)
No increase in the size or number of lytic bone lesions 
(development of a compression fracture does not exclude 
response)
EBTM – no change, IFM – 
stable disease
Not meeting the criteria of either MR or progressive disease Not meeting the criteria of CR, PR or 
progressive disease
Plateau Stable values (within 25% above or below value at the time 
response is assessed) maintained for at least 3 months112 Appendix 3
EBMT, IBMTR and ABMTR criteriaa IFM criteriab
Relapse from CR; requires at 
least one of the following:
Reappearance of serum or urinary paraprotein on immunofixation 
or routine electrophoresis, confirmed by at least one further 
investigation and excluding oligoclonal immune reconstitution
Greater than 5% plasma cells in a bone marrow aspirate or on 
trephine bone biopsy
Development of new lytic bone lesions or soft tissue 
plasmacytomas or definite increase in the size of residual bone 
lesions (development of a compression fracture does not exclude 
continued response and may not indicate progression)
Development of hypercalcaemia (corrected serum calcium 
> 11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause
Progressive disease (for 
patients not in CR); requires 
at least one of the following:
A greater than 25% increase in the level of the serum monoclonal 
paraprotein, which must also be an absolute increase of at least 
5 g/l and confirmed by at least one repeated investigation
A greater than 25% increase in the 
concentration of serum monoclonal protein, 
which must also be an absolute increase of 
more than 5 g/l and confirmed by at least 
one repeated assessment
A greater than 25% increase in the 24-hour urinary light chain 
excretion, which must also be an absolute increase of at least 
200 mg/24 hours and confirmed by at least one repeated 
investigation
A greater than 50% increase in the 24-hour 
urinary light chain excretion, confirmed by at 
least one repeated assessment
A greater than 25% increase in plasma cells in a bone marrow 
aspirate or on trephine biopsy, which must also be an absolute 
increase of at least 10%
Definite increase in the size of existing bone lesions or soft tissue 
plasmacytomas
A confirmed increase in the size of existing 
bone lesions or soft tissue plasmacytomas
Development of new bone lesions or soft tissue plasmacytomas 
(development of a compression fracture does not exclude 
continued response and may not indicate progression)
Development of new bone lesions or soft 
tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium 
> 11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause
Development of hypercalcaemia, not 
attributable to any cause other than MM
ABMTR, Autologus Blood & Marrow Transplant Registry; IBMTR, International Bone Marrow Transplant Registry; MR, minimal response; VGPR, 
very good partial response.
a  EBMT, IBMTR and ABMTR criteria are provided for definition of response, relapse and progression in patients with MM treated by high-dose 
therapy and SCT. However, it appears that the same criteria have been applied to the patients who are ineligible for these therapies. Patients 
in whom some, but not all, of the criteria for CR are fulfilled are classified as PR, providing the remaining criteria satisfy the requirements for 
PR. This includes patients in whom routine electrophoresis is negative but in whom immunofixation has not been performed. Patients in whom 
some, but not all, of the criteria for PR are fulfilled are classified as MR, provided that the remaining criteria satisfy the requirements for MR. 
b  The achievement of any response needed an improvement in bone pain and performance status, correction of hypercalcaemia, and no 
increase in size or number of lytic bone lesions. The best response at 12 months was defined as the highest amount of disease improvement 
achieved by a patient at any follow-up visit while on treatment, from randomisation to month 15, except if progressive disease had occurred 
during that period without response assessment at 12 months (between 9 and 15 months).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 4  
Table of excluded studies
Excluded reference Reason for exclusion
Anon. Melphalan prednisone thalidomide versus melphalan prednisone in patients aged ≥ 75 years with untreated 
multiple myeloma: preliminary results of the randomized, double-blind, placebo-controlled IFM 01–01 trial. Clin 
Lymphoma Myeloma 2007;7:455–6
Not a clinical trial report
Anon. Thalidomide added to standard therapy prolongs overall survival in newly diagnosed multiple myeloma 
patients over age 75. Oncology 2008;22:87
Not a clinical trial report
Morgan GJ, Jackson GH, Davies FE, Drayson MT, Owen RG, Gregory WM, et al. Maintenance thalidomide may 
improve progression free but not overall survival: results from the Myeloma IX Maintenance Randomisation. Blood 
2008;112:Abstract 656
Thalidomide maintenance
Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K, et al. Thalidomide combinations improve response 
rates: results from the MRC IX study. Blood 2007:110:Abstract 3593
Thalidomide maintenance
Davies FE, Child JA, Hawkins K, Bell S, Brown J, Drayson MT, et al. Newly diagnosed myeloma patients are at risk 
of venous thrombotic events – high risk patients need to be identified and receive thromboprophylaxis: the MRC 
experience. Blood 2004;104:Abstract 2395
Outcomes
Kapoor P, Rajkumar SV, Dispenzieri A, Lacy MQ, Dingli D, Kyle R, et al. Melphalan and prednisone (MP) versus 
melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant 
ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials. 51st ASH Annual Meeting 
and Exposition, New Orleans, LA, 5–8 December 2009, Abstract no. 615
Meta-analysis (insufficient 
details in abstract)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 5  
Clinical effectiveness included studies – data 
extraction forms116 Appendix 5
Data extracted by JB, extraction checked by JP.
Reference and design Intervention Participants Outcome measures
Author:
San Miguel et al.26
VISTA trial
Abstracts for follow-up 
data60,61
Year:
2008
Countries:
22 countries in Europe, 
North and South America, 
and Asia
Study design:
Multicentre
RCT
Setting:
Secondary care
No. of centres:
151 centres
Recruitment dates: 
December 2004 to 
September 2006
Funding:
Supported by Johnson & 
Johnson Pharmaceutical 
Research & Development 
and Millennium 
Pharmaceuticals
Intervention:
Nine 6-week cycles of 
melphalan (9 mg/m2) 
plus prednisone (60 mg/
m2) on days 1–4, plus 
bortezomib (1.3 mg/m2 
by intravenous bolus) 
on days 1, 4, 8, 11, 22, 
25, 29 and 32 during 
cycles 1–4 and on days 
1, 8, 22 and 29 during 
cycles 5–9
Control:
Nine 6-week cycles of 
melphalan (9 mg/m2) 
plus prednisone (60 mg/
m2) on days 1–4
Treatment discontinued 
on withdrawal of 
patient’s consent, 
disease progression 
or the occurrence of 
unacceptable toxic 
effects
Dose of melphalan or 
bortezomib reduced 
if any prespecified 
haematological toxic 
effect or grade 3/4 
non-haematological 
toxic effect; bortezomib-
associated neuropathic 
pain and peripheral 
sensory neuropathy 
managed with use 
of established dose- 
modification guidelines 
(referenced)
Other interventions 
used:
Patients with myeloma-
associated bone 
disease received 
bisphosphonates 
unless such therapy 
was contraindicated 
(referenced)
No. of participants:
682 (VMP: 344, MP: 338)
Sample attrition/dropout:
Not clearly or explicitly described – nos. provided for AE 
data but reasons for all withdrawals not given
Timing of withdrawals: NR
Sample crossovers: None
Inclusion criteria for study entry:
Newly diagnosed untreated symptomatic measurable 
myeloma patients not candidates for HDT plus SCT 
because of age (≥ 65 years) or co-existing conditions. 
Measurable disease defined as presence of quantifiable 
M-protein in serum or urine or measurable soft tissue or 
organ plasmacytomas
Exclusion criteria for study entry: None stated
Characteristics of participants:
Age (years):
Median (range): VMP 71 (57–90), MP 71 (48–91)
Age < 65: VMP 14 (4%), MP 9 (3%)
Age ≥ 75: VMP 107 (31%), MP 101 (30%)
Gender (M : F):
VMP 175 : 169 (51% : 49%), MP 166 : 172 (49% : 51%)
Ethnicity:
White VMP 304 (88%), MP 295 (87%)
Asian VMP 33 (10%), MP 36 (11%)
Black VMP 5 (1%), MP 7 (2%)
Other VMP 2 (1%), MP 0
Region:
Europe VMP 79%, MP 78%
North America VMP 9%, MP 9%
Other VMP 11%, MP 13%
Karnofsky performance status ≤ 70:
VMP 122 (35%), MP 111 (33%)
Myeloma type:
IgG VMP 64%, MP 62%
IgA VMP 24%, MP 26%
IgD VMP 1%, MP 1%
IgM VMP 1%, MP1%
Light chain VMP 8%, MP 8%
Biclonal VMP 2%, MP 2%
Lytic bone lesions, no./total no.(%):
VMP 224/343 (65%), MP 222/336 (66%)
Median plasma cells on bone marrow biopsy:
VMP 40%, MP 41%
ISS:
Stage I VMP 19%, MP 19%
Stage II VMP 47%, MP 47%
Stage III VMP 35%, MP 34%
Primary outcomes:
Time to disease progression
Secondary outcomes:
Rate of CR, duration of 
response, time to subsequent 
myeloma therapy, OS
PFS (reported in supplemental 
appendix)
Method of assessing 
outcomes:
Response to treatment and 
disease progression assessed 
using EBMT criteria and 
previously validated computer 
algorithm, on basis of 
M-protein in serum and urine
Definitions from appendix:
PFS is time between 
randomisation and either 
disease progression or relapse 
from CR or death
Blood and 24-hour urine 
samples collected every 
3 weeks during 54-week 
treatment phase and then 
every 8 weeks until disease 
progression. Other efficacy 
assessment included bone 
marrow examination and 
skeletal survey as required by 
EBMT or on basis of clinical/
biochemical measurements
Relapse from CR defined as 
reappearance of M-protein on 
immunofixation
Seven prespecified and one 
post hoc subgroups defined 
(not data extracted)
AEs:
Graded by National Cancer 
Institute’s Common 
Terminology Criteria for AEs 
(version 3.0). No further 
details given
Safety evaluated throughout 
study and until 30 days after 
administration of a study drug
Length of follow-up: 
Not specifically stated. 
Patients followed for survival 
and subsequent myeloma 
therapy at least every 
12 weeks after disease 
progression
Median follow-up at data cut-
off point not reported© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Reference and design Intervention Participants Outcome measures
Serum β2-microglobulin level (mg/l):
Median (range): VMP 4.2 (1.7–21.6), MP 4.3 (0.6–60.9)
< 2.5 VMP 12%, MP 12%
2.5–5.5 VMP 55%, MP 55%
> 5.5 VMP 33%, MP 33%
Albumin level (g/dl):
Median (range): VMP 3.3 (1.3–4.7), MP 3.3 (1.4–5.0)
< 3.5 VMP 58%, MP 62%
≥ 3.5 VMP 42%, MP 38%
Haemoglobin (g/l):
Median (range) VMP 104 (64–159), MP 106 (73–165)
Platelet count/mm3 median (range):
VMP 221,500 (68,000–515,000),
MP 221,500 (33,000–587,000)
Creatinine clearance (%):
< 30 ml/minute VMP 6%, MP 5%
30–60 ml/minute VMP 48%, MP 50%
> 60 ml/minute VMP 46%, MP 46%
History of cardiac condition:
VMP 121 (35%), MP 105 (31%)
Results
Primary outcomes  VMP (n = 344)  MP (n = 338) p-value
TTP median (from trial investigators) 24 months 16.6 months < 0.001, HR = 0.48 
TTP median (from computer algorithm analysis) 20.7 months 15.0 months < 0.001, HR = 0.54
Comments
HR in favour of VMP was 0.48 (independent of age, sex, race, baseline β2-microglobulin level, baseline albumin level, region, ISS or creatinine 
clearance)
HR using algorithmic analysis was 0.54
HR for each subgroup of patients (seven prespecified and one post hoc) was lower for VMP than MP, indicating lower risk of progression in the VMP 
group as assessed by investigators. However, the study may not have been powered to show this for subgroups
Secondary outcomes VMP (n = 337) MP (n = 331) p-value
Response rates using EBMT criteria
Rate of PR or better 238 (71%) 115 (35%) < 0.001
Rate of CR 102 (30%)  12 (4%) < 0.001
Rate of PR 136 (40%) 103 (31%) NR
MR 32 (9%) 72 (22%) NR
Stable disease 60 (18%) 113 (40%) NR
Progressive disease 3 (1%) 7 (2%) NR
Response rates using IURC (post hoc analysis)
Rate of PR or better 251 (74%) 128 (39%) < 0.001
Rate of CR 111 (33%) 13 (4%) < 0.001
Rate of VGPR 28 (8%) 13 (4%) NR
Rate of PR 112 (33%) 102 (31%) NR
Stable disease 79 (23%) 192 (58%) NR
Progressive disease 3 (1%) 7 (2%) NR118 Appendix 5
Time to eventa
Median time to first response (PR or better) 1.4 months 4.2 months < 0.001
Median time to CR 4.2 months 5.3 months < 0.001
Median duration of CR or PR 19.9 months 13.1 months NR 
Median duration of CR 24 months 12.8 months NR 
Median time to subsequent myeloma therapy Not reached (based on 344 
patients)
20.8 months (based on 338 
patients)
< 0.001, HR = 0.52 
Started second-line treatment within 2 years 35% 57% NR 
Survivalb
VMP (n = 344) MP (n = 338)
Treatment-free interval Not reached  9.4 months NR
Deaths after median follow-up of 16.3 months  45 (13%) 76 (22%) 0.008, HR = 0.61
Median OS Not reached Not reached
Median PFS 21.7 months 15.2 months < 0.001, HR = 0.56
At data cut-off point
Patients still receiving assigned protocol 47 (14%) 33 (10%)
Results from abstract61
Median OS after median follow-up of 
36.7 months
Not estimable 43.1 months NR
Three-year OS rate 68.5% 54.0% NR
Risk of death after median follow-up of 
36.7 months
Risk reduced by 35% in VMP 
group compared to MP group
0.0008, HR = 0.653
Received subsequent therapy 178 (52%) 233 (69%) NR
Median time to subsequent therapy 28.1 months 19.2 months < 0.0001, HR 0.527
Median treatment-free interval 17.6 months 8.4 months < 0.0001, HR 0.543
Median survival from start of subsequent 
therapy
30.2 months 21.9 months 0.21, HR = 0.815
Results from abstract60
Survival after median follow-up of 25.9 months NR NR 0.0032, HR = 0.64
Three-year survival rates 72% 59% NR 
Time to next therapy 28.1 months 19.2 months 0.000001, HR = 0.53
Treatment-free interval  16.6 months 8.4 months 0.00001, HR = 0.54
Required subsequent therapy 38% 57% NR
IURC, International Uniform Response Criteria.
a  Time-to-event data determined by computer algorithm using EBMT criteria.
b  Data based on 344 patients in VMP group and 338 patients in MP group.
HR after median follow-up of 16.3 months was 0.61 in favour of VMP (p = 0.008).
From abstract60
HR for survival after median follow-up of 25.9 months was 0.64 in favour of VMP (p = 0.0032).
HR for time to next therapy was 0.53 in favour of VMP (p < 0.000001).
HR for treatment-free interval was 0.54 in favour of VMP (p < 0.00001).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Results from abstract61 VMP (n = 344, no. analysed NR) MP (n = 338, no. analysed NR) p-value
Sustained response in QLQ-C30 domains
Cognitive functioning 27% 28% NR
Nausea/vomiting NR NR 0.0095
Appetite loss NR NR 0.0170
Diarrhoea NR NR 0.0082
Global health 49% 40% Not statistically 
significant
Pain 40% 32% Not statistically 
significant
Insomnia 32% 24% Not statistically 
significant
Comments
The aim of the study was to describe the rate of patients who experienced a sustained HRQoL improvement after best response and the overall 
HRQoL impact of best response. A sustained HRQoL improvement was defined as a change in score of at least five points for at least two 
consecutive cycles after best response (CR, PR or MR). The rate of sustained improvement and the time to sustained improvement were calculated 
in the population of patients who were followed for at least two cycles after best response (n = 363). All EORTC domain scores were similar at 
baseline across the study arms. Worse health was reported in all domains with VMP arm at best tumour response onset. However, after best 
response onset, patients in the VMP arm had a higher sustained HRQoL improvement rate than those in the MP arm in 14 of the 15 EORTC 
QLQ-C30 scores. The differences for nausea and diarrhoea remained significant in the Cox models when adjusted for baseline score, score at best 
response, and type of response (CR, PR or MR)
AEs VMP (n = 340) MP (n = 337) p-value
Median no. of treatment cycles 8 (46 weeks) 7 (39 weeks) NR
Death rates during treatment 5% 4% NS
Treatment-related deaths 1% 2% NS
Rate of serious AEs 46% 36% NR
Discontinued treatment due to AEs 50 (15%) 47 (14%) NR
Discontinued treatment due to treatment-
related events
37 (11%) 35 (10%) NR
Additional discontinuations (bortezomib) 63 (19%) –
NS, not significant.
AEs, no. (%)a Total Grade 3 Grade 4 Total Grade 3 Grade 4
Any event
338 (99%) 181 (53%) 96 (28%) 326 (97%) 148 (44%) 92 (27%) 0.02 for grade 3
NR for grade 4
Haematological eventsb NR
Thrombocytopenia 178 (52%) 68 (20%) 58 (17%) 159 (47%) 55 (16%) 47 (14%)
Neutropenia 165 (49%) 102 (30%) 34 (10%) 155 (46%) 79 (23%) 49 (15%)
Anaemia 147 (43) 53 (16%) 9 (3%) 187 (55%) 66 (20%) 26 (8%)
Leucopenia  113 (33%) 67 (20%) 10 (3%) 100 (30%) 55 (16%) 13 (4%)
Lymphopenia 83 (24%) 49 (14%) 18 (5%) 58 (17%) 30 (9%) 7 (2%)
Gastrointestinal events: all 19% 5% NR
Nausea 164 (48%) 14 (4%) 0 94 (28%) 1 (<1%) 0
Diarrhoea 157 (46%) 23 (7%) 2 (1%) 58 (17%) 2 (1%) 0
Constipation  125 (37%) 2 (1%) 0 54 (16%) 0 0
Vomiting 112 (33%) 14 (4%) 0 55 (16%) 2 (1%) 0120 Appendix 5
AEs, no. (%)a Total Grade 3 Grade 4 Total Grade 3 Grade 4
Infections NR
Pneumonia 56 (16%) 16 (5%) 6 (2%) 36 (11%) 13 (4%) 4 (1%)
Herpes zoster 45 (13%) 11 (3%) 0 14 (4%) 6 (2%) 0
Nervous system disorders NR
Peripheral sensory neuropathy 151 (44%) 43 (13%) 1 (<1%) 16 (5%) 0 0
Neuralgia 121 (36%) 28 (8%) 2 (1%) 5 (1%) 1 (< 1%) 0
Dizziness 56 (16%) 7 (2%) 0 37 (11%) 1 (< 1%) 0
Other conditions NR
Pyrexia 99 (29%) 8 (2%) 2(1%) 64 (19%) 6 (2%) 2 (1%)
Fatigue 98 (29%) 23 (7%) 2 (1%) 86 (26%) 7 (2%) 0
Anorexia 77 (23%) 9 (3%) 1 (< 1%) 34 (10%) 4 (1%) 0
Asthenia 73 (21%) 20 (6%) 1 (< 1%) 60 (18%) 9 (3%) 0
Cough 71 (21%) 0 0 45 (13%) 2 (1%) 0
Insomnia 69 (20%) 1 (< 1%) 0 43 (13%) 0 0
Peripheral oedema 68 (20%) 2 (1%) 0 34 (10%) 0 0
Rash 66 (19%) 2 (1%) 0 24 (7%) 1 (<1%) 0
Back pain 58 (17%) 9 (3%) 1 (<1%) 62 (18%) 11 (3%) 1 (< 1%)
Dyspnoea 50 (15%) 11 (3%) 2 (1%) 44 (13%) 5 (1%) 3 (1%)
Hypocalaemia 44 (13%) 19 (6%) 3 (1%) 25 (7%) 8 (2%) 2 (1%)
Arthalgia 36 (11%) 4 (1%) 0 50 (15%) 2 (1%) 1 (< 1%)
DVT 4 (1%) 3 (1%) 0 6 (2%) 2 (1%) 0
a  Listed AEs were reported in at least 15% of patients, grade 3/4 events in at least 5% of patients. Other events of clinical relevance (e.g. DVT) 
also listed. Patients could have more than one AE. Included are all patients who received at least one dose of study drug.
b  Rates of red cell transfusion were 26% in the VMP group, 35% in the MP group; rates of erythropoiesis-stimulating agents for treatment-
related anaemia were 30% and 39%, respectively.
Median-dose intensities for MP same in both groups.
At time of cut-off, 74% of peripheral neuropathy events had either resolved (56%) or decreased at least one toxicity grade (18%) within a median 
of 2 months.
Discontinuations VMP (n = 340)  MP (n = 337) p-value
Total discontinued treatment 139 (41%) 166 (49%) NR
Discontinued due to progressive disease 24 (7%) 72 (21%) NR
Discontinued due to AEs 50 (15%) 47 (14%) NR
Discontinued due to patient choice 32 (9%) 18 (5%) NR
Discontinued due to death  14 (4%) 17 (5%) NR
Discontinued due to maintenance of CR 9 (3%) 1 (< 1%) NR
Other reasons for discontinuation 10 (3%) 11 (3%) NR
Percentages calculated by reviewer.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Methodological comments
Allocation to treatment groups: Randomisation (1:1) was stratified according to baseline levels of β2-microglobulin (< 2.5, 2.5–5.5 or > 5.5 mg/l), 
serum albumin (< 3.5 or ≥ 3.5 g/dl) and region (North America, Europe or other region)
Blinding: Not stated but study described as open-label
Comparability of treatment groups: Baseline demographic and disease characteristics stated to be well-balanced between groups (no p-values 
given)
Method of data analysis: TTP, time to subsequent myeloma therapy and OS analyses from randomisation to event of interest. Differences between 
groups compared using stratified log-rank tests with ITT analysis (all randomised patients). Distributions estimated using Kaplan–Meier method. 
For time-to-progression analyses, data from patients in whom there was no disease progression were censored at the last assessment or at the 
start of subsequent therapy. HRs estimated using stratified Cox proportional hazards model for ITT and subgroups defined according to baseline 
characteristics (seven prespecified analyses according to age, sex, race, baseline β2-microglobulin level, baseline albumin level, region, disease 
stage and post hoc creatinine clearance). Response rates were analysed in patients who could be evaluated for a response (not ITT) and compared 
between groups using stratified Cochran–Mantel–Haenszel chi-squared test. Treatment differences tested at a two-sided alpha level of 0.05. Safety 
population was all randomised patients who received at least one dose of study drug
Sample size/power calculation: Sample size of 340 patients per group was determined to provide a power of 80% to detect a 33% improvement 
in time to progression in patients receiving VMP compared with MP. Three interim analyses planned using O’Brien–Fleming method. On basis of 
third analysis (data cut-off 15 June 2007), the data and safety monitoring committee recommended that the trial be stopped since the prespecified 
statistical boundary (an alpha level of 0.0108) for the primary end point of TTP has been crossed (HR in bortezomib group 0.54, p < 0.001). Data 
from the third analysis are presented. Not clear if study powered for subgroup analyses
Attrition/dropout: Not explicitly reported but withdrawals given in AE data. Not all reasons for discontinuations in VMP group reported
General comments
Generalisability: Patients ≥ 65 so probably generalisable in terms of population
Outcome measures: Defined and graded
Intercentre variability: Not stated
Conflict of interests: Data collected by sponsors and analysed in collaboration with senior academic authors who vouch for the completeness and 
accuracy of the data and analyses. Eleven of 21 authors report conflicts of interest
Quality criteria40
Criteria for assessment of risk of bias in RCTs Answera Notes and comments
Was the method used to generate random allocations adequate? NR
Was the allocation adequately concealed? NR
Were the groups similar at the outset of the study in terms of 
prognostic factors, e.g. severity of disease?
Yes No p-values given
Were the care providers, participants and outcome assessors blind 
to treatment allocation? If any of these people were not blinded, what 
might be the likely impact on the risk of bias (for each outcome)?
No Open label
Were there any unexpected imbalances in dropouts between groups? 
If so, were they explained or adjusted for?
Unclear
Is there any evidence to suggest that the authors measured more 
outcomes than they reported?
No
Did the analysis include an ITT analysis? If so, was this appropriate 
and were appropriate methods used to account for missing data?
Yes No details given in published paper but MS 
states that missing data were imputed using last-
observation-carried-forward method
a  Answer yes/no/NR/unclear.122 Appendix 5
Additional outcomes/comments/notes
Outcomes from abstract,61 
median follow-up of 
36.7 months VMP (n = 178)  MP (n = 233) p-value
Received subsequent therapy containing
Bortezomib 43 (24%) 116 (50%)
Thalidomide 81 (46%) 110 (47%)
Lenalidomide 57 (32%) 30 (13%)
Overall response rate to subsequent therapy
Bortezomib 47% 59%
Thalidomide 41% 53%
Lenalidomide 59% 52%
Patients could have received more than one agent, either in combination or separately, in different subsequent lines of therapy.
Outcomes from abstract60 VMP (n = 129) MP (n = 194) p-value
Received bortezomib  16% 43%
Received thalidomide 49% 44%
Received lenalidomide 19% 6%
Subsequent therapy and no. of 
patients who received ita
CR PR  CR PR
Bortezomib or bortezomib 
combination (n = 105)
6% 33% 10% 45%
Thalidomide combination (n = 149) 4% 44% 3% 52%
Lenalidomide combination (n = 37) 4% 52% 0 55%
a  Other agents were used as subsequent therapy, such as dexamethasone; patient could receive multiagent regimens.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Data extracted by JOP, extraction checked by JB.
Reference and design Intervention Participants Outcome measures
Author:
Facon et al.23
IFM 99/06
Year:
2007
Countries:
France, Belgium and 
Switzerland
Study design:
Multicentre RCT
Setting:
Not stated, appears to be 
secondary care
No. of centres:
73 IFM centres. No. in each 
country not stated
Recruitment dates:
22 May 2000 to 8 August 
2005
Funding:
Sponsored by the Centre 
Hospitalier et Universitaire 
de Lille; by a research grant 
from the French Ministry of 
Health; and by the Swiss 
Group for Clinical Cancer 
Research (SIAK). Laphal, and 
later Pharmion, supplied free 
thalidomide
MPT:
Oral thalidomide not exceeding 
400 mg daily taken throughout 
the 12 MP cycles. Thalidomide 
stopped on day 4 of the last 
MP cycle. Advice was to initiate 
thalidomide at a dose of 200 mg 
per day, increasing to 400 mg 
per day after 2–4 weeks in 
the absence of severe adverse 
effects. Initial dose defined as 
the greatest dose used in the 
first four weeks of treatment
plus
MP for 12 × 6-week cycles 
comprising melphalan 0.25 mg/
kg and prednisone 2 mg/kg on 
4 days (days 1–4) per cycle. 
Both drugs taken orally
Control, MP only:
MP for 12 × 6-week cycles 
comprising melphalan 0.25 mg/
kg and prednisone 2 mg/kg on 
4 days (days 1–4) per cycle. 
Both drugs taken orally
The trial had a third arm, 
reduced intensity stem-cell 
transplant using melphalan 
100 mg/m2, which has not been 
data extracted
Dose reductions:
Thalidomide dose modification 
allowed at discretion of local 
investigators
Thalidomide temporarily 
stopped if patients developed 
DVT or pulmonary embolism 
but treatment resumed once 
patients had undergone 
therapeutic anticoagulation
No thromboprophylaxis 
prospectively planned
Treatment stopped:
Thalidomide stopped for any 
non-haematological grade 3 or 
4 toxic effects
Other interventions used:
Clondronate orally, 1040 mg per 
day continuously to all patients
No. of participants:
447 to all three groups (one group 
NR on here)
MPT: 125 assigned (but one died 
before treatment initiation)
MP + placebo: 196 assigned (but 
three died before treatment initiation)
Sample attrition/dropout: 
Not clearly described – nos. 
withdrawn provided but reasons for 
withdrawals not provided for each 
type of event, e.g. death, progression, 
toxicity, etc.
Timing of withdrawals: NR
Sample crossovers: None
Inclusion criteria for study entry:
Generally patients aged between 
65 and 75 years of age with 
previously untreated MM at stage 
II or III (DS criteria). Prior treatment 
with minimum-dose radiotherapy 
to localised lesions for symptom 
relief allowed. Additionally, patients 
younger than 65 years were included 
if they were ineligible for high-dose 
treatment. Patients with DS stage 
I MM who met criteria of high-risk 
stage I disease also eligible (criteria 
not listed, reference provided)
Exclusion criteria for study entry:
Previous neoplasms (except 
basocellular cutaneous or cervical 
epithelioma); primary or associated 
amyloidosis; a WHO performance 
index of 3 or higher, if unrelated to 
MM; substantial renal insufficiency 
with creatinine serum concentration 
of 50 mg/l or more; cardiac or 
hepatic dysfunction; peripheral 
neuropathy; HIV infection, or hepatitis 
B or C infections
Characteristics of participants (as 
assigned, includes those who died 
before treatment):
Age ≥ 70 years: MPT 50/125 (40%); 
MP 84/196 (43%)
Gender (M : F):
MPT 63 : 62 (50% : 50%); MP 109/87 
(56% : 44%)
Ethnicity: NR
Immunoglobulin A isotype:
MPT 25/125 (20%); MP 43/196 
(22%)
DS stage II or III:
MPT 112/125 (90%); MP 177/196 
(91%)
Primary outcome: 
OS
Secondary outcomes:
Response, PFS, survival after 
progression and toxicity
Method of assessing outcomes:
Visits after inclusion at 3 months, 
6 months, and every 6 months 
thereafter until withdrawal from 
the trial. At every visit, response 
was assessed. After withdrawal 
from trial, patient treatment and 
status updated every 6 months. 
These data also requested at other 
specific points for patients still alive 
at last known status
For achievement of response there 
had to be improvement in bone pain 
and performance status, correction 
of hypercalcaemia, and no increase 
in size or no. of lytic bone lesions
Response definitions:
CR – absence of the original 
monoclonal protein in serum and 
urine by immunofixation, fewer than 
5% plasma cells in a bone marrow 
aspirate, and the disappearance of 
soft tissue plasmocytomas
Very good PR – more than 90% 
decrease in monoclonal protein in 
serum and urine
PR – reduction in the size of soft-
tissue plasmocytomas, more than a 
50% reduction in the concentration 
of serum monoclonal protein, and 
more than a 75% reduction in 24-
hour urinary light chain excretion
Progressive disease– at least one 
of a greater than 25% increase 
in serum monoclonal protein 
concentration, which must also be 
an absolute increase of more than 
5 g/l, confirmed by at least one 
repeated assessment; a greater 
than 50% increase in the 24-
hour urinary light chain excretion, 
confirmed by at least one repeated 
assessment; a confirmed increase 
in the size of existing bone lesions 
or soft tissue plasmocytomas; 
development of new bone lesions 
or soft tissue plasmocytomas or the 
development of hypercalcaemia, 
not attributable to any cause other 
than MM
Stable disease – patient not 
meeting criteria of CR, PR or 
progressive disease124 Appendix 5
Reference and design Intervention Participants Outcome measures
DS substage B:
MPT 12/125 (10%); MP 15/196 (8%)
ISS stage 1:
MPT 38/112 (34%); MP 61/182 
(34%)
ISS stage 2:
MPT 42/112 (38%); MP 67/182 
(37%)
ISS stage 3:
MPT 32/112 (29%); MP 54/182 
(30%)
WHO performance index 3–4:
MPT 10/125 (8%); MP 13/196 (7%)
Bone lesions:
MPT 90/125 (76%); MP 154/196 
(79%)
β2-microglobulin ≥ 3.5 mg/l:
MPT 69/112 (62%); MP 110/182 
(60%)
Albumin < 35 g/l: MPT 24/125 
(19%); MP 45/194 (23%)
Creatinine ≥ 20 mg/l:
MPT 11/124 (9%); MP 13/196 (7%)
Calcium ≥ 105 mg/l:
MPT 17/125 (14%); MP 40/196 
(20%)
C-reactive protein ≥ 6 mg/l:
MPT 50/114 (44%); MP 85/173 
(49%)
Lactate dehydrogenase ≥ 300 U/l:
MPT 65/107 (61%); MP 116/175 
(66%)
Chromosome 13 deletion:
MPT 49/101 (49%); MP 72/147 
(52%)
Translocation (11;14):
MPT 11/58 (19%); MP 11/95 (12%)
Translocation (4;14):
MPT 10/57 (18%); MP 7/95 (7%)
The best response at 12 months 
was defined as the highest amount 
of disease improvement achieved 
by a patient at any follow-up 
visit while on treatment, from 
randomisation to month 15, except 
if progressive disease had occurred 
during that period without response 
assessment at 12 months (between 
9 and 15 months)
AEs:
Method of monitoring or assessing 
NR. Reported for the safety 
population (all those randomised 
but excluding those who died before 
receiving treatment)
Length of follow-up:
Not clearly stated but a 2-year 
follow-up appears to have been 
planned. Outcomes reported 
for two date points with median 
follow-ups of 36.8 months 
(IQR 20.8–51.2 months) in 
October 2005, and 51.5 months 
(IQR 34.4–63.2 months) in 
January 2007© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Results
Primary outcomes  MPT MP p-value
OS, median (SE, IQR) 51.6 months (4.5, 26.6 to ‘not 
reached’)
33.2 months (3.2, 13.8–54.8) 0.0006
No. of deaths/no. of patients after 
median follow-up of 51.5 months 
(IQR 34.4–63.2)
62/125 (50%)a 128/196 (65%)a
Toxic death n = 0 n = 4 (2%), all due to infection
Early death – in first 3 months of 
treatment
3/124 (2%) 13/193 (7%)
a  Percentages calculated by reviewer.
Comments
HR for median OS in favour of MPT = 0.59 (95% CI 0.46 to 0.81). When adjusting for prognostic factors (e.g. WHO performance index; β2-
microglobulin, albumin, etc.) the results showed that MPT remained the superior treatment (HR 0.49, 95% CI 0.33 to 0.73, p = 0.0002). At the initial 
analysis (median follow-up 36.8 months) no difference in OS was recorded as a function of initial thalidomide dose (≤ 200 mg per day vs > 200 mg 
per day, p = 0.93).
Secondary outcomes MPT MP p-value
PFS, median (SE, no. of events/
no. of patients) after median 
follow-up of 51.5 months
27.5 months (2.1, 92/125) 17.8 months (1.4, 171/196) 0.0001
Survival time after progression, 
median (SE, no. of events/no. of 
patients) after median follow-up 
of 51.5 months
13.4 months (2.3, 52/83) 11.4 months (1.9, 111/154)
At least PR at 12 months 57/75 (76%) 57/165 (35%) < 0.0001
At least very good PR at 
12 months
35/75 (47%) 11/165 (7%) < 0.0001
CR at 12 months 10/75 (13%) 4/165 (2%) 0.0008
Not withdrawn (still on first-line 
treatment; first-line treatment 
ceased as planned and no 
further treatment, alive without 
progression, not withdrawn for 
other reason)
31/124 (25%) 42/193 (22%)
Withdrawn and not receiving 
second-line treatment
38/124 (31%) 25/193 (13%)
- up to death 11/38 (29%) 24/25 (96%)
- still alive 27/38 (72%) 1/25 (4%)
Withdrawn and having received 
second-line treatment
55/124 (44%) 126/193 (65%)
Comments
HR for median PFS in favour of MPT = 0.51 (95% CI 0.39 to 0.66) after median follow-up of 51.5 months. At the initial analysis (median follow-up 
36.8 months), no difference in PFS was recorded as a function of initial, maximum or average thalidomide doses (p = 0.22, p = 0.75 and p = 0.92, 
respectively)
Details of second-line treatments given are presented in the table following the Quality criteria table below
AEs and safety MPT MP p-value
Discontinuation of thalidomide 
because of toxic effects
56/124 (45%)
Peripheral neuropathy n = 23
Thrombosis n = 7
Somnolence, dizziness or 
fatigue
n = 8
Cutaneous toxic effects n = 4
Psychiatric complications n = 1126 Appendix 5
Withdrawn because of other 
reasons
n = 13
 Haematological toxic effects n = 5
 Infection n = 7
 Stroke n = 1
Grade 3 and 4 AEs, nos. of 
patients (%) MPT (n = 124) MP (n = 193) p-value
Haematological
Anaemia 17 (14%) 27 (14%) 0.94
Neutropenia 60 (48%) 51 (26%) < 0.0001
Thrombocytopenia 17 (14%) 19 (10%) 0.29
Severe haemorrhage 0 3 (1.5%) Too few events to be clinically 
meaningful
Thrombosis or embolism 15 (12%) 8 (4%) 0.008
Peripheral neuropathy 7 (6%) 0 0.001
Somnolence/fatigue dizziness 10 (8%) 0 < 0.0001
Infection 16 (13%) 18 (9%) 0.32
Fever of unknown origin 1 (1%) 2 (1%)
Pneumonia 9 (7%) 5 (2.5%)
Septicaemia 4 (3%) 6 (3%)
Meningitis 2 (2%) 0
Other 1 (1%) 6 (3%)
Herpes zoster 3 (2.5%) 6 (3%)
Cardiac 2 (2%) 1 (0.5%) Too few events to be clinically 
meaningful
Arrhythmia 2 (2%) 0
Myocardial infarction/angina 0 0
Cardiac failure 0 1 (0.5%)
Hypertension 0 0
Gastrointestinal
Nausea 1 (1%) 2 (1%) Too few events to be clinically 
meaningful
Constipation 13 (10%) 0 < 0.0001
Mucositis 0 1 (0.5%) Too few events to be clinically 
meaningful Bleeding 0 2 (1%)
Any grade ≥ 3 non-
haematological toxic effect
52 (42%) 30 (16%) < 0.0001
Comments
Note that Facon et al. analysed safety at the October 2005 date point after 36.8 months of follow-up, a shorter follow-up than for the outcomes 
of OS, PFS and survival after progression analyses. In the MPT group 15 patients experienced 17 episodes of thrombosis or pulmonary embolism. 
Thalidomide was resumed in 8 of the 15 patients with thrombosis after full anticoagulation, and without recurrence in seven patients (one patient 
had three episodes). In the MPT group 69 (55%) of patients experienced peripheral neuropathy. Of these the majority, 62 patients, had grade 1 or 2 
peripheral neuropathy and seven patients had grade 3 peripheral neuropathy (these are the seven noted above), and none had grade 4
Median duration of treatment 
(IQR)
11 months (5–15)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Methodological comments
Allocation to treatment groups: States randomly assigned in a 3 : 2 : 2 ratio (MP : MPT : Mel100; Mel100 arm not included here). No further details
Blinding: No details provided
Comparability of treatment groups: Not described and no evidence presented to indicate whether similarity of groups had been statistically tested 
(although methods describe how this would be done). Visual inspection of the data suggests groups similar for most baseline characteristics 
reported on
Method of data analysis: Parameters generally described by number and percentage of patients. Distributions of parameters assessed at inclusion 
compared between treatment groups using chi-squared tests for categoric variables and Kruskal–Wallis rank test for continuous variables (although 
no evidence from such tests presented as noted above). Best response rates at 12 months compared using the chi-squared test or Fisher’s exact 
test when necessary. Curves for OS, PFS and survival after progression calculated from randomisation and from progression (for survival after 
progression) using the Kaplan–Meier method. Time-to-event data expressed as median (SE and IQR). Comparison between treatment groups and 
HRs for death, progression or death without progression, or death after progression were estimated through the unstratified proportional hazards 
model, with 95% CI. AE rates compared through chi-squared test or Fisher’s exact test when necessary. Comparisons of OS between groups were 
adjusted on prognostic factors using a stepwise multivariate proportional hazards model, by forward selection with likelihood ratio test. All analyses 
carried out on an ITT population (not defined but numbers presented in tables indicate true ITT). AEs were analysed on the safety population (all 
those who received treatment, i.e. not including those who died before start of treatment). Confirmatory analysis on the primary end point was done 
on the per-protocol population at the first follow-up but data NR. Authors of this study do not report if it was necessary to censor any data and if so 
how this was done
Sample size/power calculation: Sample size was estimated to be 500 patients (for the three arms of the trial) to guarantee, in a two-sided test, a 
power of 80% to detect an increase in the median survival time of 18 months (with an accrual time of 3 years and additional follow-up of 2 years). 
Power calculation assumed a median survival time of 30 months in the control group and used the Bonferroni correction for a global type I error 
rate of 5%. Slightly fewer than 500 patients were recruited (447 overall) because recruitment was stopped earlier than planned (although this is not 
explicitly stated) in August 2005 when a clear survival advantage for MPT was found. The authors do not comment on any possible implications of 
the recruitment shortfall
Attrition/dropout: Withdrawals reported (see outcomes above)
General comments
The ITT analysis included patients not treated per protocol: MP – six protocol violations at inclusion; three protocol violations during follow-up; MPT 
– 0 protocol violations at inclusion; two protocol violations during follow-up
Generalisability: This trial focuses on patients 65–75 years and the results may therefore only be applicable to patients in this age bracket
Outcome measures: Methods for grading of AEs not described
Intercentre variability: No comments made regarding possible intercentre variability
Conflict of interests: States that the study sponsor had no role in study design, data collection, data analysis, data interpretation or writing of the 
report. Three authors had received scientific adviser board and lecture fees from Pharmion, Celgene and Janssen–Cilag. The remaining authors had 
no conflict of interest to declare
Quality criteria40
Criteria for assessment of risk of bias in RCTs Answera Notes and comments
Was the method used to generate random allocations adequate? NR
Was the allocation adequately concealed? NR
Were the groups similar at the outset of the study in terms of 
prognostic factors, e.g. severity of disease?
Unclear Baseline characteristics provided but no p-values and 
no statement indicating whether groups were similar
Were the care providers, participants and outcome assessors blind 
to treatment allocation? If any of these people were not blinded, what 
might be the likely impact on the risk of bias (for each outcome)?
NR
Were there any unexpected imbalances in dropouts between groups? 
If so, were they explained or adjusted for?
Unclear No comments made by authors of paper on this
Is there any evidence to suggest that the authors measured more 
outcomes than they reported?
No
Did the analysis include an ITT analysis? If so, was this appropriate 
and were appropriate methods used to account for missing data?
Unclear ITT analysis was conducted but no indication of 
whether missing data had to be accounted for and, if 
so, how this was done
a  Answer yes/no/NR/unclear.128 Appendix 5
Additional outcomes/comments/notes
Outcomes  MPT MP p-value
Initial daily dose of T 200 mg or less n = 64/124 (52%)
Initial daily dose of T 200 mg or more n = 60/124 (48%)
Initial daily dose of T 100 mg n = 9
Initial daily dose of T 300 mg n = 5
No change of dose throughout first-line 
treatment
n = 66/124 (36 at ≤ 200 mg/day; 30 at 
> 200 mg/day)
Dose increased during first-line treatment n = 11/124
Dose reduced during first-line treatment n = 47/124
Second-line treatment administered 55/124 (44%) 126/193 (65%)
Second-line treatment thalidomide alone or 
in combination
10/55 (18%) 55/126 (44%)
Second-line treatment VAD 15/55 (27%) 42/126 (33%)
Second-line treatment dexamethasone 7/55 (13%) 12/126 (10%)
Second line treatment alkylating agent-
based regimens
14/55 (25%) 13/126 (10%)
Second-line treatment bortezomib 7/55 (13%) 3/126 (2%)
Second-line treatment other 2/55 (4%) 1/126 (1%)
T, thalidomide.
Comments
Less than one-half of the patients at first progression on MP received rescue with thalidomide alone or in combination. Only 12 patients given MP or 
MPT underwent a transplant. These outcomes reported for the shorter median follow-up of 36.8 months© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Data extracted by JOP, extraction checked by JB.
Reference and design Intervention Participants Outcome measures
Author:
Hulin et al.59
IFM 01/01
Year:
2009
Countries:
France and Belgium
Study design:
Multicentre RCT
Setting:
Not stated; appears to be 
secondary care
No. of centres:
44 IFM centres (39 in France, 5 
in Belgium)
Recruitment dates:
10 April 2002 to 22 December 
2006
Funding:
Sponsored by the Centre 
Hospitalier Universitaire de 
Nancy; by a research grant from 
the French Ministry of Health; 
by Laphal; by Pharmion; and 
by Celgene, which supplied 
free experimental treatment 
(thalidomide or placebo) for the 
study
MP + T:
Oral thalidomide 100 mg daily 
dose at bedtime for 72 weeks
plus
MP for 12 × 6-week cycles 
comprising melphalan 0.2 mg/kg 
on days 1–4; prednisone 2 mg/
kg on days 1–4.
Control – MP+placebo:
Oral placebo at bedtime for 
72 weeks
plus
MP for 12 × 6-week cycles 
comprising melphalan 0.2 mg/kg 
on days 1–4; prednisone 2 mg/
kg on days 1–4.
Dose reductions:
Dose reduction to 50 mg per 
day of thalidomide or placebo 
allowed at investigator discretion 
in event of patient intolerance 
to 100 mg/day dose, especially 
in case of mild or moderate 
peripheral neuropathy (grade 
1 or 2)
No other dose reductions 
allowed
Treatment stopped:
Thalidomide stopped for 
symptomatic peripheral 
neuropathy (grade 3 or 4) 
confirmed by electromyogram
Experimental treatment stopped 
and unblinded in the event of 
any non-haematological grade 3 
or 4 AEs or disease progression 
before 72 weeks
Other interventions used:
Clondronate orally, 1040 mg per 
day continuously to all patients.
No thromboprophylaxis 
prospectively planned
Transfusions of red blood 
cells and platelets, and the 
administration of neutrophil 
growth factors or erythropoiesis-
stimulating agents permitted as 
required
Plasmapheresis at initial 
treatment and radiotherapy 
to localised lesions to relieve 
symptoms during the treatment 
phase permitted
No. of participants: 
232 (229 received treatment)
MP + T: 115 (113 received 
treatment)
MP + placebo: 117 (116 received 
treatment)
Sample attrition/dropout: 
Three discontinued before 
treatment (failed inclusion criteria); 
208 withdrawn (MP + T n = 100; 
MP + placebo n = 108) from study 
for other reasons (details in results)
Timing of withdrawals: NR
Sample crossovers: None
Inclusion criteria for study entry:
At least 75 years of age with newly 
diagnosed MM at stage II or III (DS 
criteria). Patients with DS stage I MM 
who met criteria of high-risk stage 
I disease also eligible (criteria not 
listed; reference provided). Patients 
with non-secretory or oligosecretory 
MM allowed
Exclusion criteria for study entry:
Previous neoplasms (except 
basocellular cutaneous or cervical 
epithelioma); primary or associated 
amyloidosis; a WHO performance 
index of 3 or higher, if unrelated to 
MM; substantial renal insufficiency 
with creatinine serum concentration 
of 50 mg/l or more; clinically 
significant cardiac or hepatic 
dysfunction; clinically significant 
peripheral neuropathy; history 
of venous thrombosis during the 
previous 6 months; HIV infection, or 
hepatitis B or C infections
Characteristics of participants 
(only for participants who received 
treatment):
Age ≥ 80 years:
MP + T 43/113 (38%)
MP + placebo 40/116 (34%)
Gender (M : F):
MP + T 43 : 70 (38% : 62%);
MP + placebo 61/55 (53% : 47%)
Ethnicity: NR
Immunoglobulin A subtype: 
MP + T 31/113 (28%)
MP + placebo 34/116 (30%)
DS stage II or III:
MP + T 100/113 (89%)
MP + placebo 107/116 (93%)
Primary outcomes: 
OS
Secondary outcomes: Safety, 
response rates, PFS.
Method of assessing outcomes:
Visits every 6 weeks until 
treatment completion or study 
withdrawal
Response assessed at 3, 6, 12 and 
18 months
After end of treatment or 
withdrawal from trial, patient status 
assessed every 6 months
All clinical responses required 
documentation of improvement 
from baseline in bone pain and 
performance status, correction of 
hypercalcaemia, and no increase in 
size or number of lytic bone lesions
Response definitions:
CR – absence of the original 
monoclonal protein in serum 
and urine by immunofixation, 
fewer than 5% plasma cells in 
a bone marrow aspirate, and 
the disappearance of soft tissue 
plasmocytomas
Very good PR – more than 90% 
decrease in monoclonal protein in 
serum and urine
PR – reduction in the size of soft-
tissue plasmocytomas, a more than 
50% reduction in the concentration 
of serum monoclonal protein, and 
a more than 75% reduction in 24-
hour urinary light chain excretion
Progressive disease – at least one 
of a higher than 25% increase 
in serum monoclonal protein 
concentration constituting an 
absolute increase of more than 
5 g/l, confirmed by at least one 
repeated assessment; a higher 
than 50% increase in the 24-
hour urinary light chain excretion, 
confirmed by at least one repeated 
assessment; a confirmed increase 
in the size of existing bone lesions 
or soft-tissue plasmocytomas; 
development of new bone lesions 
or soft-tissue plasmocytomas; 
or the development of 
hypercalcaemia, not attributable to 
any cause other than MM
Stable disease – patient not 
meeting criteria of CR, PR or 
progressive disease130 Appendix 5
Reference and design Intervention Participants Outcome measures
DS substage B:
MP + T 8/113 (7%)
MP + placebo 14/116 (12%)
ISS stage 1:
MP + T 25/98 (25%)
MP + placebo 26/104 (25%)
ISS stage 2:
MP + T 39/98 (40%)
MP + placebo 47/104 (45%)
ISS stage 3:
MP + T 34/98 (35%);
MP + placebo 31/104 (30%)
WHO performance index 3–4:
MP + T 9/113 (8%);
MP + placebo 7/116 (6%)
Bone lesions:
MP + T 87/113 (78%);
MP + placebo 93/116 (82%)
β2-microglobulin ≥ 3.5 g/dl:
MP + T 70/101 (69%);
MP + placebo 73/107 (68%)
Albumin < 3.5 g/dl:
MP + T 27/110 (25%)
MP + placebo 34/113 (30%)
Clearance creatinine ≤ 30 ml/minute:
MP + T 11/105 (11%)
MP + placebo 16/105 (15%)
Significant comorbidity:
MP + T 70/113 (62%)
MP + placebo 69/116 (60%)
Electromyogram abnormal:
MP + T 17/54 (31%);
MP + placebo 22/58 (38%)
The best response at 12 months 
was defined as the best 
improvement achieved by a patient 
at any time on treatment, from 
random assignment to month 15
AEs:
Safety issues related to thalidomide 
closely monitored at every visit. 
Explanation of grading of AEs NR
Length of follow-up:
Not explicitly stated. Median follow-
up 47.5 months at time of data 
analysis in October 2008© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Results
Primary outcomes  MP + T MP + placebo p-value
OS, median (95% CI) 44.0 months (33.4 to 58.7) 29.1 months (26.4 to 34.9) 0.028
Overall deaths 58/113 (51%) 76/116 (65.5%) 0.03
Death – myeloma progression 
considered major cause
n = 36 n = 54
Toxic death (intestinal perforation) n = 1 n = 1
Early death – after 1 month of treatment n = 3 n=3
Early death – after 3 months of treatment n = 5 n = 6
Comments
HR for median OS in favour of MP+T = 0.68
Secondary outcomes MP + T MP + placebo p-value
PFS, median (95% CI) 24.1 months (19.4 to 29.0) 18.5 months (14.6 to 21.3) 0.001
At least PR 66/107 (62%) 35/112 (31%) < 0.001
At least very good PR 23/107 (21%) 8/112 (7%) < 0.001
CR 7/107 (7%) 1/112 (1%) < 0.001
Disease progression occurrence 72/113 (64%) 84/116 (72%)
Comments
HR for median PFS in favour of MP+T = 0.62
AEs and safety MP + T MP + placebo p-value
Peripheral neuropathy grade 1 20/113 (18%) 19/116 (16%) 0.003 reported. Although aligned 
in table with grade 1, appears 
more likely that this relates to all 
peripheral neuropathy
Peripheral neuropathy grade 2 21/113 (19%) 4/116 (3%)
Peripheral neuropathy grade 3 2/113 (2%) 2/116 (2%)
Neutropenia grade 3 or 4 26/113 (23%) 10/116 (9%) 0.003
Thrombosis or embolism grade 3 or 4 7/113 (6%) 4/116 (3%) 0.33
Somnolence grades 2–4 7/113 (6%) 3/116 (3%) 0.19
Depression grades 2–4 8/113 (7%) 3/116 (3%) 0.11
Constipation grades 2–4 19/113 (17%) 12/116 (10%) 0.16
Nausea/vomiting grades 2–4 3/113 (3%) 5/116 (4%) 0.5
Oedema grades 2–4 15/113 (13%) 8/116 (7%) 0.11
Comments
There is contradictory information in text and Table 3 of this paper. For peripheral neuropathy grades 1 and 2 text states 21 (19%) grade 1 and 
20 (18%) grade 2 in MP + T group but table has these the other way around (as shown here). For the MP + placebo group table states 17% with 
peripheral neuropathy grade 1, whereas text states 16%. Text appears correct as 19/116 is 16.4%. For neutropenia (grades 3 or 4) text states 25 
(22%) for MP + T group but table has 26 (23%). There were no peripheral neuropathy events reported at grade 4
Withdrawals MP + T (n = 113) MP + placebo (n = 116) p-value
Withdrawals due to AEs/toxicity n = 48 (42.5%)a n = 15 (12.9%)a
Peripheral neuropathy n = 12 n = 3
Neurological events (non-peripheral) n = 10 n = 1
Thrombosis/embolism n = 7 n = 1
Haematological events n = 7 n = 6
Digestive events n = 4 n = 2
Cardiac events n = 3 n = 1
Rash n = 2 n = 0
Other n = 3 n = 1132 Appendix 5
Dose reduction required because of AEs n = 20 (17.7%)a n = 3 (2.6%)a
Median duration of treatment 13.5 months 18 months
a  Percentages calculated by reviewer.
Comments
There is contradictory information in text and Figure 1. Text states that nine MP + T group participants withdrew due to neurological events (non-
peripheral), whereas Figure 1 shows 10 participants. Data provided on timing of withdrawal due to toxicity but appear to be for study overall, not 
by group: within 3 months, nine patients; within 6 months, 23 patients; within 12 months, 38 patients. Also unclear which patients are included, as 
patient numbers given alongside timing of withdrawals sum to 70, but only 63 patients (48 MP + T and 15 MP + placebo) withdrew due to toxicity.
Withdrawals overall n = 100 (88.5%)a n = 108 (93.1%)a
Due to disease progression n = 37 n = 69
Due to death n = 6 n = 16
Due to consent withdrawal n = 9 n = 8
Due to toxicity (details above) n = 48 n = 15
a  Percentages calculated by reviewer.
Methodological comments
Allocation to treatment groups: Described as random in a 1 : 1 ratio with assignments provided centrally. No further details
Blinding: Not explicitly described but assume this is a blinded study due to use of a placebo and statement that, if experimental treatment stopped 
due to grade 3–4 AEs or disease progression, unblinding occurred. Issue of patients taking thalidomide needing to comply with a risk-management 
programme (which would mean patients not blind to study drug) is not discussed. All patients may have been subject to the same protocol
Comparability of treatment groups: Groups described as well balanced except for sex as there were more female participants in the MP + T group 
(p = 0.03)
Method of data analysis: Parameters described by number and percentage of patients. Distributions of parameters assessed at inclusion compared 
between treatment groups using chi-squared tests for categoric variables and Kruskal–Wallis rank test for continuous variables. Best response rates 
at 12 months compared using the chi-squared test. OS calculated from random assignment to death from any cause. Data on patients alive at the 
time of analysis were censored in the survival analysis on the last date they were known to be alive. PFS calculated from random assignment to 
progression or death. Patients who had not experienced progression were censored on the last date they were known to be alive and progression 
free. Survival estimated with Kaplan–Meier product limit method and curves were compared with the stratified log-rank test on an ITT basis. HRs 
estimated by stratified Cox proportional hazards model for the ITT population. AEs compared between groups using the chi-squared test. ITT not 
defined
Sample size/power calculation: Sample size was estimated to be 280 patients to guarantee, in a two-sided test, a power of 80% to detect an 
increase in the median survival time of 6 months. Power calculation assumed a median survival time of 22 months in the control group and a 
global type I error rate of 5%. Fewer than 280 patients were recruited, presumably because recruitment was stopped earlier than planned (although 
this is not explicitly stated) in December 2006 when a clear survival advantage for MPT was found in the IFM 99/06 trial and because the French 
Autorisation Temporaire d’Utilisation had made MPT available for newly diagnosed myeloma patients ineligible for high-dose therapy. The authors do 
not comment on any possible implications of the recruitment shortfall
Attrition/dropout: Reasons for withdrawals reported (see outcomes above). After loss from the trial of those with disease progression, due to deaths, 
and withdrawals due to toxicity very few participants remained (MPT n = 8; MP + placebo n = 13)
General comments
Substantial renal insufficiency with creatinine serum concentration of 50 mg/l or more was an exclusion criterion. At baseline 13% of patient had 
severe renal failure (creatinine clearance < 30 ml/minute)
Generalisability: This trial focuses on patients 75 years and older and the results may therefore only be applicable to patients in this age range. 
Authors state doses of melphalan and thalidomide were lower than had been used in similar trials with patients 65–75 years of age
Outcome measures: Methods for grading of AEs not described
Intercentre variability: No comments made regarding possible intercentre variability
Conflict of interests: Two authors had consultant or advisory roles with Pharmion, Celgene and Janssen–Cilag for which they had been 
compensated. Three authors had received honoraria from Pharmion, Celgene and Janssen–Cilag© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Quality criteria40
Criteria for assessment of risk of bias in RCTs Answera Notes and comments
Was the method used to generate random allocations adequate? NR
Was the allocation adequately concealed? Yes Participants assigned centrally
Were the groups similar at the outset of the study in terms of 
prognostic factors, e.g. severity of disease?
Yes Only difference was in proportion of women
Were the care providers, participants and outcome assessors blind 
to treatment allocation? If any of these people were not blinded, what 
might be the likely impact on the risk of bias (for each outcome)?
Unclear Not explicitly stated but use of placebo suggests 
blinding in place. Plus text states that treatment was 
unblinded on participant withdrawal. However, those 
on thalidomide may have had to comply with a risk 
management programme but this is not discussed. 
Most outcomes were objective therefore risk of bias low
Were there any unexpected imbalances in dropouts between groups? 
If so, were they explained or adjusted for?
Unclear Overall withdrawals similar – but greater withdrawals 
due to toxicity of thalidomide in MP + T group. Authors 
describe toxicity as acceptable
Is there any evidence to suggest that the authors measured more 
outcomes than they reported?
No
Did the analysis include an ITT analysis? If so, was this appropriate 
and were appropriate methods used to account for missing data?
Unclear Analysis described as ITT, although ITT was not defined
a  Answer yes/no/NR/unclear.
Additional outcomes/comments/notes
Outcomes MPT MP + placebo p-value
Rescue treatment administered 131 (84%) of 156 patients presenting with disease progression. Rate similar in the two 
groups (as in row below)
Prescription of any type of novel 
agent as rescue treatment after 
progression
61/72 (85%) 70/84 (83%)
Thalidomide 16/72 (22%) 53/84 (63%)
Bortezomib 22/72 (31%) 28/84 (33%)
Lenalidomide 11/72 (15%) 9/84 (11%)
Thalidomide and/or 
lenalidomide
25/72 (35%) 59/70 (83%)
Thalidomide and/or 
lenalidomide and/or bortezomib
38/72 (53%) 68/81 (83%)
Survival time after progression, 
median
11.5 months 9.9 months 0.89
Comments
Inevitably most patients (84% as noted above) in the study who had disease progression went on to have further treatment. The possible effects of 
the different rescue treatment on the outcomes of OS and survival after progression are not commented on by the authors of this paper. Survival 
after progression was described as ‘similar in the two groups’ by the authors who state that this strongly suggests the first-line treatment is of major 
importance in this population of elderly patients. The impact of the initial treatment on treatment decisions at progression are not commented on134 Appendix 5
Data extracted by JOP, extraction checked by JB.
Reference and design Intervention Participants Outcome measures
Author: 
Palumbo et al.24
Year:
2006
Linked to later publication:
Palumbo et al.25 2008
Country:
Italy
Study design:
Multicentre RCT
Setting:
Not stated, appears to be 
secondary care
No. of centres:
54
Recruitment dates:
January 2002 to May 2005
Funding:
Supported by Associazione 
Italiana Ricerca Cancro, Milan; 
Associazione Italiana Leucemie, 
Rome; Compagnia di S. Paolo, 
Turin; Fondazione Neoplasie 
Sangue Onlus, Turin; Ministero 
Università Ricerca Scientifica e 
Tecnologica, Rome; Consiglio 
Nazionale delle Ricerche, 
Rome. Pharmion supplied free 
thalidomide for the study
MPT:
Thalidomide 100 mg daily 
dose administered continually 
during the six MPT cycles
plus
MP six cycles, each cycle 
repeated every 4 weeks: oral 
melphalan 4 mg/m2 on days 
1–7; oral prednisone 40 mg/
m2 on days 1–7
Note: After 6 × 4-week cycles 
of MPT, thalidomide was 
continued at 100 mg per day 
as maintenance therapy. This 
does not meet the inclusion 
criteria of the review, therefore 
only outcomes to 24 weeks 
are data extracted here
Control, MP:
Six cycles, each cycle 
repeated every 4 weeks: oral 
melphalan 4 mg/m2 on days 
1–7; oral prednisone 40 mg/
m2 on days 1–7
Note: In the control group 
there was no planned 
maintenance therapy
Dose reductions:
Dose reduced by 50% on 
the occurrence of any non-
haematological grade 2 toxic 
effect
Treatment stopped:
Thalidomide stopped for any 
non-haematological grade 3 
toxic effects
Other interventions used:
No anticoagulation prophylaxis 
was given initially but the 
protocol was amended 
December 2003 and 
enoxaparin at 40 mg per day 
was delivered subcutaneously 
during the first four cycles of 
therapy
No. of participants: 
331 overall (MPT : 167; MP: 164). 
However, only 255 had been 
followed up for 6 months or more 
at time of the initial analysis 
included here (no thalidomide 
maintenance)
MPT : 129
MP : 126
Sample attrition/dropout: 
Of the 331 overall, 76 follow-
up less than 6 months (MPT 
n = 38; MP n = 38). Of the 255 
followed up for 6 months 63 had 
not completed six cycles (MPT 
n = 32; MP n = 31) (details in 
results)
Timing of withdrawals: NR
Sample crossovers: 
In the MP (control) group patients 
with progressive disease or 
relapse were permitted to cross 
over to receive thalidomide as 
salvage treatment
Inclusion criteria for study entry:
Older than 65 years of age, or 
younger but unable to undergo 
transplantation, with previously 
untreated stage II or III (DS 
criteria) MM and measurable 
disease (not defined)
Exclusion criteria for study entry:
Another cancer; psychiatric 
disease; any grade 2 peripheral 
neuropathy
Abnormal cardiac function, 
chronic respiratory disease, and 
abnormal liver or renal functions 
were not criteria for exclusion
Characteristics of participants (for 
those included in initial analysis):
Median age, years:
MPT 72; MP 72
Age < 65 years: 4/129 (3%); MP 
3/126 (2%)
Age 65–70 years: 49/129 (38%); 
MP 51/126 (41%)
Age 71–75 years: 44/129 (34%); 
MP 37/126 (29%)
Age 76–80 years: 26/129 (20%); 
MP 28/126 (22%)
Age > 80 years: MPT 6/129 
(5%); MP 7/126 (6%)
Gender (M : F): NR
Ethnicity: NR
Primary outcomes: 
Response rates and PFS
Secondary outcomes: 
OS, time to first evidence of response, 
prognostic factors, frequency of any 
grade 3 or higher AEs
Method of assessing outcomes:
Visits every 4 weeks during 
chemotherapy regimens to 
monitor response to treatment by 
measurement of protein in serum and 
urine. Assessments every 2 months 
thereafter. Response rate assessed at 
6 months and confirmed after a further 
6 weeks. Bone marrow plasmacytosis 
and skeletal disease were included in 
response evaluation
Response definitions used criteria of 
the EGBMT/IBMTR:
CR – disappearance of myeloma 
protein in serum and urine and 
negative immunofixation
PR – at least 50% reduction of 
myeloma protein in serum and a 90% 
decrease in urine.
Near CR (subcategory of PR) – 
disappearance of myeloma protein 
in serum and urine and positive 
immunofixation
MR – serum myeloma protein reduction 
of 25–49% and in urine of 50–89%.
No response – reduction in myeloma 
protein of 24% or less
Progressive disease – an increase of 
25% or greater in myeloma protein
AEs:
Assessed at each visit and graded 
according to the National Cancer 
Institute Common Toxicity Criteria 
(version 2). Causes of death 
were recorded as attributable 
to myeloma, study drugs, other 
causes or a combination of these. 
Thromboembolism was assessed 
by clinically objective evidence of 
thrombosis and use of ultrasound 
echography
Length of follow-up:
Data analysed after median 
follow-up of 38.4 months (range 
0.23–69.45 months; SD 16.5 months) 
in the MPT group and 37.7 months 
(range 0–72.34 months; SD 
17.1 months) in the MP group. Due 
to use of thalidomide as maintenance 
therapy only 6-month data eligible for 
inclusion in review© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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M-protein IgG class: MPT 83/129 
(64%); MP 73/126 (58%)
M-protein IgA class: MPT 31/129 
(24%); MP 37/126 (29%)
Bence-Jones protein: MPT 
15/129 (12%); MP 16/126 (13%)
DS stage IIA: MPT 50/129 (39%); 
MP 49/126 (39%)
DS stage IIB: MPT 4/129 (3%); 
MP 3/126 (2%)
DS stage IIIA: MPT 64/129 
(50%); MP 62/126 (49%)
DS stage IIIB: MPT 11/129 (8%); 
MP 12/126 (10%)
WHO performance index ≥ 3: 
MPT 9/129 (7%); MP 6/126 (4%)
Bone marrow plasmacytosis %, 
median (range): MPT 45 (5–95); 
MP 46 (5–95)
Serum β2-microglobulin mg/l, 
median (range): MPT 116 
patients, 3.7 (0.36–40); MP 110 
patients, 3.7 (0.2–37.5)
β2-microglobulin ≤ 3.5 mg/l: MPT 
53/129 (41%); MP 53/126 (42%)
β2-microglobulin > 3.5 mg/l: MPT 
63/129 (49%); MP 57/126 (45%)
β2-microglobulin data missing: 
MPT 13/129 (10%); MP 16/126 
(13%)
Plasma C-reactive protein 
mg/l, median (range): MPT 105 
patients, 2.53 (0.005–157); MP 
100 patients, 2.0 (0.001–128)
Haemoglobin g/l, median 
(range): MPT 125 patients, 106 
(73–147); MP 122 patients, 102 
(67–155)
Serum creatinine mg/l, median 
(range): MPT 129 patients, 8 
(5.6–102); MP 125 patients, 8 
(6–68)
Calcium mmol/l, median (range): 
MPT 115 patients, 2.25 (1.22–
3.17); MP 118 patients, 2.27 
(1.09–2.72)136 Appendix 5
Results
Primary outcomes  MPT MP Absolute difference: MPT – MP (95% CI)
Complete or PR at 6 months 98/129 (76.0%) 60/126 (47.6%) 28.3% (16.5 to 39.1)
Complete response 20/129 (15.5%) 3/126 (2.4%) 13.1% (6.3 to 20.5)
PR 78/129 (60.4%) 57/126 (45.2%) 15.2% (3.0 to 26.9)
Near CR 16/129 (12.4%) 6/126 (4.8%)
90–99% myeloma protein 
reduction
11/129 (8.5%) 6/126 (4.8%)
50–89% myeloma protein 
reduction
51/129 (39.5%) 45/126 (35.7%)
MR 7/129 (5.4%) 21/126 (16.7%) –11.2% (–19.2 to –3.6)
No response 7/129 (5.4%) 19/126 (15.1%) –9.7% (–17.4 to –2.2)
Progressive disease 10/129 (7.8%) 21/126 (16.7%) –8.9% (–17.2 to –0.8)
Not available 7/129 (5.4%) 5/126 (4.0%)
Secondary outcomes MPT MP p-value
Time to PR, median (range) 1.4 months (22–200 days) 3.1 months (25–210 days)
AEs and safety MPT MP p-value
Grade 3–4 infections 12/129 (10%) within the first 
4 months of treatment:
2/126 (2%), timing of 
occurrence unknown:
0.01
Pneumonia 6 (5%) patients  2 (2%) patients
Upper respiratory tract 2 (2%) patients  0 patients
Herpes zoster 1 (1%) patient
Fever of unknown origin 3 (2%) patients 
Comments
Full AE reporting not data extracted because period that this covered and timing of the occurrence of the events was NR (therefore unable to 
distinguish between events occurring during the first 6 months of treatment and those occurring later during thalidomide maintenance)
Withdrawals MPT MP p-value
Unable to complete six cycles 
owing to:
32/129 (25%) 31/126 (25%)
AEs 17/32 (13.2%)a 4/31 (3.2%)a
progressive diseases 9/32 16/31
withdrew consent 3/32 2/31
Lost to follow-up 3/32 7/31
Protocol violations 0/32 2/31
Thalidomide discontinuation 
required
43 (33.3%)a patients after a 
median of 2.1 months
Thalidomide dose reduction to 
50 mg required
37 (28.7%)a patients after a 
median of 4 months
a  Percentages calculated by reviewer.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Methodological comments
Allocation to treatment groups: A simple randomisation sequence was generated by a centralised computer. Registration to the trial was via the 
internet to centralised database. An automated assignment procedure concealed from the investigators randomly allocated patients to treatments
Blinding: Study described as unblinded
Comparability of treatment groups: For patients included in the 6-month follow-up states baseline demographics and other characteristics of the two 
groups were balanced but results of any statistical tests to confirm this not presented. Comparability of patient groups in final analysis NR
Method of data analysis: For the analysis of the 6-month follow-up data times of observation were censored on 15 June 2005. Analysis was 
undertaken on an ITT basis (this is not defined). The absolute difference (with 95% CI) of the proportion of patients in each response category 
between the two groups was calculated with ci analysis, version 2.1.1. Methods for analysis of data NR here also described. The incidence of any AE 
was compared by the chi-squared test or Fisher’s exact test when cell counts were lower than five. The analyses were performed with sas (version 
8.2)
Sample size/power calculation: Sample size was estimated to be 380 patients (190 per arm) to detect a 10% increase in CR in the MPT arm (from 
5% to 15%), with an α error of 0.05 and a β error of 0.10. Fewer than 380 patients were recruited because at the second interim analysis (timing 
of this not stated) there were statistically significant improvements for the MPT group in response rate and prolongation of event-free survival 
compared with the MP group. In addition enrolment was falling. The steering committee therefore decided to stop the trial in May 2005 when 331 
patients had been randomised (87% of planned sample size). The authors do not comment on any possible implications of the recruitment shortfall
Attrition/dropout: Reasons for withdrawals, but not timing of withdrawal, reported (see outcomes above)
General comments
Generalisability: This trial focuses on patients 65 years and older and the results may therefore be applicable only to patients in this age range
Outcome measures: Due to the use of thalidomide as a maintenance therapy only the first 6 months of data are eligible for inclusion. It is not 
clear whether the observed results would have been maintained longer term. Only some of the AEs were reported with an indication of when they 
occurred. It was not possible to extract all AE data and thus AEs are likely to be underrepresented in the data extraction
Intercentre variability: No comments made regarding possible intercentre variability
Conflict of interests: Two authors had received scientific adviser board and lecture fees from Pharmion and Celgene. However, their association with 
Celgene involved lenalidomide only, and not thalidomide. The other authors declared they had no conflict of interest
Quality criteria40
Criteria for assessment of risk of bias in RCTs Answera Notes and comments
Was the method used to generate random allocations adequate? Yes Generated by computer
Was the allocation adequately concealed? Yes Participants assigned centrally
Were the groups similar at the outset of the study in terms of 
prognostic factors, e.g. severity of disease?
Yes Although no statistical evidence of similarity 
presented authors state groups were comparable and 
this appears to be the case
Were the care providers, participants and outcome assessors blind 
to treatment allocation? If any of these people were not blinded, what 
might be the likely impact on the risk of bias (for each outcome)?
No States study is unblinded
Were there any unexpected imbalances in dropouts between groups? 
If so, were they explained or adjusted for?
Unclear Overall withdrawals similar – but greater withdrawals 
due to toxicity of thalidomide in MPT group and 
greater withdrawals due to progression in MP group
Is there any evidence to suggest that the authors measured more 
outcomes than they reported?
No
Did the analysis include an ITT analysis? If so, was this appropriate 
and were appropriate methods used to account for missing data?
Unclear Analysis described as ITT, although ITT was not 
defined.
a  Answer yes/no/NR/unclear.
Additional outcomes/comments/notes
Nothing to add.138 Appendix 5
Data extracted by JOP, extraction checked by JB.
Reference and design Intervention Participants Outcome measures
Author:
MMIX Trial (from 
investigators),49,50,52–54 Davies et 
al.,42 MRC myeloma info guide,27 
Owen et al.48
Year:
2009
Country:
UK
Study design:
Multicentre RCT
Setting:
Hospitals
(AiC/CiC information has been 
removed)
Recruitment dates: 
June 2003 to November 2007
Funding:
Core grant from the MRC. 
Unrestricted educational grants 
provided by Pharmion, Novartis, 
Bayer-Schering, Chugai and Ortho 
Biotech. Leukaemia Research 
Fund supported some of the 
biological studies
CTDa (cyclophosphamide, 
thalidomide, attenuated 
dexamethasone):
Cyclophosphamide: Once a week, 
500 mg orally (on days 1, 8, 15 
and 22)
Dexamethasone: Days 1–4 and 
15–18 of each cycle, 20 mg daily 
(orally)
Thalidomide: Daily, 50 mg daily 
for 4 weeks, increasing every 
4 weeks by 50-mg increments to 
200 mg daily
Cycle length 4 weeks, to maximal 
response, but with a minimum–
maximum no. of cycles of 6–9
Control, MP: 
Daily once a day by mouth for 
days 1–4 of a 4-week cycle. No. 
of cycles 6–9
Melphalan: 7 mg/m2
Prednisolone: dose 40 mg
Note: After completion of induction 
chemotherapy, eligible patients 
entered a second randomisation 
to thalidomide maintenance 
or no maintenance. The initial 
randomisation to chemotherapy 
was not maintained, although 
initial chemotherapy was 
a stratification factor. As 
maintenance therapy does not 
meet the inclusion criteria of the 
review only outcomes from the 
induction chemotherapy are data 
extracted here
Dose modification:
MP:
Treatment delay indicated by 
neutrophil and platelet counts. 
Melphalan reduced to 5 mg/m2 if 
serum creatinine >200 µmol/l
CTDa:
Treatment-related cytopenias led 
to omission of cyclophosphamide 
for one course, then dose 
reduction, e.g. to 400 mg or 
300 mg. Cyclophosphamide 
omitted if serum creatinine is 
>300 µmol/l despite vigorous 
hydration
Thalidomide stopped if a 
thromoboembolic event occurred. 
Under good anticoagulant control 
thalidomide could be started 
again at 50 mg, with escalation 
to 100 mg
(AiC/CiC information has been 
removed)
Timing of withdrawals: NR
Sample crossovers: None
Inclusion criteria for study entry:
At least 18 years of age with 
newly diagnosed symptomatic 
MM or non-secretory MM (criteria 
provided). Provided written 
informed consent. Prepared to use 
contraception. Negative pregnancy 
test
Exclusion criteria for study entry:
Asymptomatic MM. Solitary 
plasmacytoma of bone. 
Extramedullary plasmacytoma 
(without evidence of myeloma). 
Previous or concurrent active 
malignancies, except surgically 
removed basal cell carcinoma 
of the skin or other in situ 
carcinomas. Previous treatment 
for myeloma except local 
radiotherapy to relieve bone pain 
or spinal cord compression; prior 
bisphosphonate treatment; low-
dose corticosteroids, up to four 
single doses of corticosteroids 
(total dose 1 g methylprednisolone, 
200 mg dexamethasone or 
1.25 g prednisolone). Past history 
of ischaemic heart disease or 
psychiatric disorders – exclusion 
at discretion of clinician. Acute 
renal failure (unresponsive to 
72 hours rehydration, creatinine 
> 500 µmol/l or urine output 
< 400 ml/day or requirement for 
dialysis)
(AiC/CiC information has been 
removed)
Primary outcomes:
OS
PFS
Response
Secondary outcomes:
QoL
Skeletally related events
Height loss
Toxicity (thromboembolic events; 
renal toxicity; haematological 
toxicity; graft-versus-host disease)
Proportion receiving bortezomib–
dexamethasone as ‘early rescue’ 
on induction chemotherapy, or at 
relapse
Method of assessing outcomes:
Response was assessed at the 
end of randomised induction 
chemotherapy
Patients were followed up locally 
4-weekly during chemotherapy, 
then 3-monthly thereafter. Central 
follow-up was 3-monthly until 
disease progression then annually 
thereafter
QoL was assessed with the 
EORTC QLQ-C30, QLQ-MY24 and 
the EQ-5D at:
Pre-initial randomisation (when 
patient unaware of treatment 
allocation); at 3, 6 and 12 months 
post initial randomisation 
and annually thereafter until 
maintenance randomisation or 
5 years post initial randomisation
A diary card was also used daily 
from initial randomisation for 
3 months
Indicators of skeletally related 
events collected at 3-monthly 
intervals
Response definitions:
Response assessments were 
according to the modified EBMT/
IBMTR definitions (i.e. EMBT 
criteria plus the categories of 
very good PR, and early death). 
Reference provided
Survival time calculated from 
randomisation to date of death 
from any cause. If patient still 
alive or lost to follow up they will 
be censored at date last known 
to be alive© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Thalidomide stopped for a cycle 
then reintroduced at 50 mg if 
grade 3–4 toxicity occurred
In rare instance of intolerance to 
low-dose dexamethasone dose 
reduction or omission of one of 
the 4-day pulses per cycle was 
permitted
Treatment stopped:
CTDa: Pregnancy or suspected 
pregnancy (including in male 
patient’s partner) also led to 
stopping of thalidomide
Other interventions used:
In addition to the randomisation 
to CTDa or MP, participants were 
also randomised to either sodium 
clodronate 1600 mg daily or 
zoledronic acid 4 mg by infusion 
every 3–4 weeks. Treatment 
continued indefinitely, or at least 
until disease progression
Thromboprophylaxis:
Physicians were advised to 
consider full anticoagulation with 
warfarin or low-molecular-weight 
heparin for all patients at high risk 
of VTE42
Provision of thalidomide had to 
meet the approved process for 
thalidomide risk management and 
pregnancy prevention
PFS – from randomisation to date 
of disease progression or death.
Disease progression – relapse 
from CR (if patient had achieved 
this) or progressive disease (EBMT 
criteria) if not in CR
AEs:
SAEs, Hickman line infection, 
renal toxicity, sensory neuropathy, 
motor neuropathy, constipation, 
somnolence, infection, rash, 
elevated alkaline phosphatase, 
hypothyroidism, postural 
hypotension, thromboembolic 
events, osteonecrosis of the 
jaw, haematological toxicity, and 
pregnancy/suspected pregnancy 
summarised by trial arm/
treatment group
Length of follow-up (AiC/CiC 
information has been removed):
The cut-off date for final analysis 
was 5 October 2009
Results
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)
(AiC/CiC information has been 
removed)140 Appendix 5
Comments
Outcomes of OS, PFS and survival after progression: TTP not data extracted because after first-line chemotherapy participants meeting eligibility 
criteria were entered into a second randomisation to thalidomide maintenance therapy, which does not meet the inclusion criteria for this review
(AiC/CiC information has been removed)
Secondary outcomes CTDa MP p-value
QoL
Comments
(AiC/CiC information has been removed)
(AiC/CiC information has been 
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Comments
(AiC/CiC information has been removed). No other withdrawals appear to be reported
Methodological comments
Allocation to treatment groups: Conducted by a central trials office using an automated 24-hour telephone system. Random assignment in a 1 : 1 
ratio to CTDa or MP and bisphosphonate (sodium clodronate or zoledronic acid). Allocations concealed until interventions assigned. Randomisation 
used a minimisation algorithm and was stratified by centre, haemoglobin, corrected serum calcium, serum creatinine, platelets
Blinding: Not blinded
Comparability of treatment groups: (AiC/CiC information has been removed)
Method of data analysis: All summaries and analyses by ITT unless otherwise stated. The per-protocol population may also be used if deemed 
appropriate. ITT defined as all patients randomised, with the exception of those misdiagnosed. Only patients who withdraw consent for the study, 
or for whom no written informed consent was received are not included in the ITT population. The QoL population includes all randomised patients 
agreeing to take part in the QoL study. All hypothesis tests are two-sided and at the 5% significance level; p-values < 0.05 considered statistically 
significant. Primary end points will be ranked according to clinical relevance, i.e. survival and PFS have equal ranking and response a lower 
ranking. OS calculated from initial randomisation to death. Patients with missing follow-up data, or not known to have died at time of analysis will 
be censored on the last date they were known to be alive. PFS calculated from random assignment to progression or death. Patients with missing 
follow-up data or who had not experienced progression were censored on the last date they were known to be alive and progression free. There 
was no other censoring of data. Cox’s proportional hazards models used to compare chemotherapy groups while adjusting for bisphosphonate 
treatment group and the minimisation factors. Models will be constructed for OS and PFS. The proportional hazards assumptions will be assessed by 
plotting hazards over time for each treatment arm. Kaplan–Meier and adjusted curves will be constructed for each chemotherapy group. Response 
outcomes centrally reviewed and only responses from the central review will be reported. Subgroup analyses will be conducted (six subgroups 
defined)
Sample size/power calculation: Sample size was based on testing the hypothesis that CTDa is superior to MP in terms of OS and PFS. It was 
anticipated that 850 patients (425 per group) would be randomised to induction chemotherapy in the non-intensive pathway. 204 patients (102 per 
group) would provide 80% power at a 5% significance level to detect a 15% absolute difference in 5-year survival (two-tailed test). This was based 
on the assumption of 15% 5-year survival in the MP group. 152 events would be required for these analyses. Sample size reached. For response, if 
182 patients (91 per group) were entered the trial would be powered to detect an increase in the number of patients achieving a CR from 20% with 
MP as induction chemotherapy to 40% with CTDa (with 80% power at a 5% level of significance). The anticipated number per group (425) would 
provide more than 80% power to detect this difference. No power calculation was made for subgroups
Attrition/dropout: Not reported on (apart from some data on participants withdrawing consent during induction chemotherapy)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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General comments
The results of this study have not yet been fully published. The assessment team has had early access to data but these have not been peer 
reviewed. It is possible that some data, particularly those on QoL may alter as analyses are finalised
Generalisability: Likely to be generalisable as the study took place in the UK
Outcome measures: Methods for grading of AEs not described
Intercentre variability: Not discussed
Conflict of interests: States none
Quality criteria40
Criteria for assessment of risk of bias in RCTs Answera Notes and comments
Was the method used to generate random allocations adequate? Yes An automated 24-hour telephone system was used 
but no further information
Was the allocation adequately concealed? Yes Participants assigned centrally
Were the groups similar at the outset of the study in terms of 
prognostic factors, e.g. severity of disease?
Yes Not specifically stated but appear to be from baseline 
characteristics provided
Were the care providers, participants and outcome assessors blind 
to treatment allocation? If any of these people were not blinded, what 
might be the likely impact on the risk of bias (for each outcome)?
No
Were there any unexpected imbalances in dropouts between groups? 
If so, were they explained or adjusted for?
NR
Is there any evidence to suggest that the authors measured more 
outcomes than they reported?
No
Did the analysis include an ITT analysis? If so, was this appropriate 
and were appropriate methods used to account for missing data?
Unclear Analysis was ITT, with ITT defined. Unclear how 
missing data was accounted for
a  Answer yes/no/NR/unclear.
Additional outcomes/comments/notes
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Appendix 6  
Karnofsky performance status and WHO 
performance status scores
Karnofsky performance status
  ■ 100% – normal, no complaints, no signs of disease
  ■ 90% – capable of normal activity, few symptoms or signs of disease
  ■ 80% – normal activity with some difficulty, some symptoms or signs
  ■ 70% – caring for self, not capable of normal activity or work
  ■ 60% – requiring some help, can take care of most personal requirements
  ■ 50% – requires help often, requires frequent medical care
  ■ 40% – disabled, requires special care and help
  ■ 30% – severely disabled, hospital admission indicated but no risk of death
  ■ 20% – very ill, urgently requiring admission, requires supportive measures or treatment
  ■ 10% – moribund, rapidly progressive fatal disease processes
  ■ 0% – death.
WHO performance status scores
  ■ 0 –Asymptomatic (fully active, able to carry on all pre-disease activities without restriction).
  ■ 1 – Symptomatic but completely ambulatory (restricted in physically strenuous activity 
but ambulatory and able to carry out work of a light or sedentary nature; for example, light 
housework, office work).
  ■ 2 – Symptomatic, < 50% in bed during the day (ambulatory and capable of all self-care but 
unable to carry out any work activities; up and about more than 50% of waking hours).
  ■ 3 – Symptomatic, > 50% in bed, but not bedbound (capable of only limited self-care, confined 
to bed or chair 50% or more of waking hours).
  ■ 4 – Bedbound (completely disabled, cannot carry on any self-care, totally confined to bed 
or chair).
  ■ 5 – Death.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 7  
SHTAC data summary of manufacturers’ 
submissions of clinical effectiveness
SHTAC peer review of clinical effectiveness in Celgene’s 
submission for bortezomib and thalidomide for MM
Comprehensiveness of ascertainment of published studies
Clinical effectiveness
  ■ The MS contains a narrative summary of trials, with the methods and results of each trial 
presented separately. Tabulation of details on study design and methodology, baseline 
characteristic of participants, efficacy outcomes, subgroups, second-line therapy, and AEs is 
presented in Appendix 2 of the MS (pp. 134–9).
  ■ There is no formal systematic review of clinical effectiveness evidence in the main body 
of the MS. However, a systematic review was conducted to identify clinical effectiveness 
evidence for the Bayesian meta-analysis that is reported in Appendix 4 of the MS, which was 
presented as a separate document.
  – Were databases and dates of searches specified?
  – Appendix 4 of the MS clearly reports search dates, search strategies and 
databases searched.
  – Were search strategies supplied?
  – Yes.
  – Was enough detail provided to be reproducible?
  – Sufficient detail was provided in Appendix 4 of the MS for the searches to 
be reproducible.
  – Did they search/report on ongoing studies?
  – No searches for ongoing studies are reported.
  – Did they search for conference proceedings?
  – Conference proceedings were included in the searching.
  – How much of the data is CIC/AIC?
  – The submission contains little CIC information and no AIC information. CIC 
information is located only on p. 54 and pp. 84–6 of the submission and all relates to 
the same clinical study report (CSR).
Cost-effectiveness
The MS economic evaluation section states that a literature search was conducted to identify 
cost-effectiveness models, but no search strategy is presented. There does not appear to have been 
a search for QoL data.
Searches identified
  ■ XXX clinical trials (details)
The systematic review conducted as part of the MTC and reported in Appendix 4 included the 
following RCTs (the references are as cited in Celgene’s submission116):
  ■ IFM 99/06 (Facon 2007 and Facon 2004 abstract); IFM 01/01 (Hulin 2009, three Hulin 2007 
abstracts); GIMEMA (Palumbo 2008, Palumbo 2006, and Palumbo abstracts of 2004–8); 148 Appendix 7
Nordic study (Gulbransen 2008 abstract, Waage 2007 abstract, and Nordic Myeloma Study 
Group PowerPoint slide presentation 2009); HOVON 49 (two Wijermans 2008 abstracts, 
Wijermans 2008 ASH PowerPoint presentation ‘Final analysis. The HOVON 49 study’); 
VISTA (San Miguel 2008, San Miguel 2008 abstracts, San Miguel 2007 abstract; Palumbo 
2008 abstract; Harousseau 2008 abstract). The studies identified in the systematic review are 
the same as those reported on in the main submission document. The submission document 
also recognises the Myeloma IX study is ongoing but the study was not included as complete 
data were not available.
  ■ What study types (X RCTs, X cohort studies, etc.)?
  – The included studies were RCTs.
  ■ Did any meet our inclusion criteria that we have not already included?
  – The identified studies published as full papers (IFM 99/06, IFM 01/01, GIMEMA and 
VISTA) are included in the SHTAC systematic review. As the GIMEMA study included 
maintenance therapy with thalidomide, the SHTAC review only includes outcomes 
reported for the period prior to the start of maintenance therapy. SHTAC also identified 
abstracts reporting on the Nordic myeloma group study, and the HOVON 49 study but 
the powerpoint presentations had not been identified. Owing to the limited reporting 
of methodological details and outcome data these studies were not included in the 
SHTAC systematic review but have been briefly mentioned as ongoing studies.
Clinical analysis
  ■ Any major differences in evidence reported?
  – The MS includes a narrative summary for individual trials, with tabulation of the studies’ 
characteristics and results located in MS Appendix 2. There was no quality assessment of 
the trials. AEs are also presented separately for each trial.
  ■ Are their conclusions are similar to ours?
  – Although the Celgene MS (but not the MTC) included the OS outcome from Palumbo 
and colleagues,24 which SHTAC excluded due to the use of thalidomide maintenance 
treatment in the MPT arm, the conclusions (based on narrative summary) on the clinical 
effectiveness of MPT and VMP are broadly similar. MPT and VMP treatments both 
show better OS and PFS than MP. The conclusions from the MS MTC were the same. A 
summary statement on response outcomes from the included trials is not provided. The 
MS presents an indirect comparison (as noted below), which suggests that MPT provides 
better PFS outcomes than VMP at 6, 12 and 18 months but the credibility intervals cross 1. 
The MS finds subgroup data variable and insufficient, so no conclusions have been drawn.
  ■ Any indirect comparisons?
  – The MS included an indirect comparison to enable comparison of MPT and VMP as 
there are no head-to-head trials for this comparison. Not all of the studies identified by 
the systematic review were included in the meta-analysis and indirect comparison. The 
base case excluded the GIMEMA trial (on the basis of a different regimen of thalidomide 
not consistent with the label, and due to cross over to thalidomide in the MP arm after 
disease progression), and the Nordic and HOVON 49 trials (insufficient information in 
abstracts for meta-analysis). These three studies were included in a sensitivity analysis 
(using information from slide presentations for Nordic and HOVON 49 trials).
  ■ Any differences in outcome measures?
  – The MS reports on the same outcome measures as the SHTAC review. Outcome data 
were not reported from the studies included in the systematic review presented in MS 
Appendix 4.
  ■ Any extra AE info?
  – Adverse event information was restricted to that reported in trial publications.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Interpretation
  ■ Does their interpretation of the clinical data match their analyses?
  – Limited analyses in main MS document (mainly just narrative summary) but where 
analyses are presented, for example MTC, the interpretation of the clinical data broadly 
matches these.
Questions
  ■ Any areas of uncertainty/discrepancy compared with the SHTAC review?
  – The MS presents a narrative summary of the Palumbo and colleagues24 study as well as 
the Nordic and HOVON 49 trials (as cited in Celgene’s submission116), which have been 
reported only in abstract form. However, these three studies were not included in the 
base-case MTC, and therefore the data in the base-case MTC more closely match the 
data included in the SHTAC review.
  – The SHTAC excluded most of the data from Palumbo and colleagues24 because 
participants in the MPT group received thalidomide maintenance therapy. In contrast, 
this study was excluded from the MS MTC because the thalidomide regimen was 
inconsistent with the label and because participants could cross over to thalidomide 
at disease progression. SHTAC do not believe that on this latter point the study differs 
substantially from the IFM trials,23,59 where participants received treatment after 
disease progression that could include thalidomide, and where a greater proportion 
of participants in the MP groups received thalidomide at this point than in the 
MPT group.
SHTAC peer review of clinical effectiveness in Janssen–Cilag’s 
submission for bortezomib and thalidomide for MM
Comprehensiveness of ascertainment of published studies
Clinical effectiveness
The MS contains a systematic review of clinical effectiveness evidence in the main body of the 
report. Summary details on trial size, interventions, inclusion criteria, efficacy end points, and 
duration of treatment are tabulated. Trials were critically appraised. Results from the included 
studies were tabulated.
  ■ Were databases and dates of searches specified?
  – The MS briefly summarises the searches and clearly reports search dates, search 
strategies and databases searched in Appendix 1. Searches were conducted in two phases, 
before and after the finalisation of the scope of the appraisal.
  ■ Were search strategies supplied?
  – Yes.
  ■ Was enough detail provided to be reproducible?
  – Sufficient detail was provided for the searches to be reproduced.
  ■ Did they search/report on ongoing studies?
  – No searches for ongoing studies are reported.
  ■ Did they search for conference proceedings?
  – Conference proceedings were included in the searching.
  ■ How much of the data is CIC/AIC?
  – The submission contains both CIC and AIC information. CIC data appears on the 
following pages: 32–4; 60; 61; 67; 70; Appendix 4 (from VISTA); References: all three 
clinical study reports (J&J, Velcade CSR 1, CSR 2, CSR 3). AIC data appears on pages 2; 
3; 33–6; 40–41; 43–47; 59–60; 66; Appendices 7, 8 and 11.150 Appendix 7
Cost-effectiveness
A review of economic evaluations was conducted, reported in detail in Appendix 9. The review 
sought to identify any economic evaluations and resource use studies assessing the first-line 
therapy of patients with MM with regimens included in the NICE scope, as well as others, for 
example VAD that did not form part of the final scope. The review included studies assessing 
first-line chemotherapy regimens but also included induction/mobilisation regimens prior to 
transplantation. Appendix 9 reports on 30 studies, but the MS states that none of these cost-
effectiveness studies included bortezomib-based regimens in the patient group of interest. There 
does not appear to have been a search for QoL data.
Searches identified
  ■ XXX clinical trials (details)
The systematic review included the following RCTs:
  ■ VMP versus MP  VISTA (Dimopoulos et al. 2008;112 Harousseau et al. 2008;113 San Miguel et 
al. 2008;60 San Miguel et al. 2008;114 San Miguel et al. 200826).
  ■ MPT versus MP  IFM 99/06 (Facon et al. 200723); GIMEMA [Palumbo et al. 2006 (not in 
MS reference list, presume24) and 200825]; IFM 01/01 (Hulin et al. 200959); HOVON 49 
(Wijermans et al. 200864); Gulbrandsen et al. 2008 (Gulbrandsen et al. 200866)].
  ■ MP versus CTDa (maintenance treatment: thalidomide only)  MRC Myeloma IX study (non-
intensive arm) (Owen 2009; Morgan 2009, not in MS reference list).
  ■ What study types (X RCTs, X cohort studies, etc.)?
  – The included studies were RCTs.
  ■ Did any meet our inclusion criteria which we have not already included?
  – The identified studies published as full papers (IFM 99/06, IFM 01/01, GIMEMA, and 
VISTA) are included in the SHTAC systematic review. As the GIMEMA study included 
maintenance therapy with thalidomide the SHTAC review only includes outcomes 
reported for the period prior to the start of maintenance therapy. SHTAC also identified 
abstracts reporting on the Nordic myeloma group study (Gulbrandsen), and the 
HOVON 49 study. Due to the limited reporting of methodological details and outcome 
data these studies were not included in the SHTAC systematic review but have been 
briefly mentioned as ongoing studies. Abstracts for the MRC Myeloma IX study were 
identified, but not the two cited by the MS, the second of which is not referenced in 
the MS.
Clinical analysis
  ■ Any major differences in evidence reported?
  – The MS includes a narrative summary and tabulation of the studies’ characteristics. The 
main efficacy results are very briefly summarised and tabulated. Trials were subject to 
critical appraisal using a modification of the CONSORT Assessment Framework. The 
VISTA study is additionally presented in more detail including some data that is not 
in the public domain. A small amount of non-RCT evidence from Phase I/II trials of 
bortezomib is presented.
  ■ Are their conclusions are similar to ours?
  – Although the Janssen–Cilag MS systematic review included more studies than SHTAC, 
the conclusions (based on narrative summary) on the clinical effectiveness of MPT and 
VMP are broadly similar. The results from meta-analysis and indirect comparison are 
more difficult to compare with the SHTAC results because of additional data used in the 
MS and the different methodology (MS winbugs MTC, SHTAC pairwise meta-analysis). 
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effect is the same, although the magnitude differs. It appears that the MS MTC indicates 
a greater difference in effect in favour of MPV over MPT than the SHTAC pairwise 
estimates suggest.
  ■ Any indirect comparisons?
  – The MS included an indirect comparison to enable comparison of MPT and VMP 
as there are no head-to-head trials for this comparison. The studies identified by the 
systematic review were included and, in addition, unpublished updated survival data 
from the VISTA trial were also included in the meta-analysis and indirect comparison.
  ■ Any differences in outcome measures?
  – The MS reports on the same outcome measures as the SHTAC review.
  ■ Any extra AE info?
  – Adverse event information was restricted to that reported in trial publications.
Interpretation
  ■ Does their interpretation of the clinical data match their analyses?
  – The interpretation of clinical data appears to match the analyses that have 
been undertaken.
Questions
  ■ Any areas of uncertainty/discrepancy compared with the SHTAC review?
  – The MS has included final data from the Palumbo and colleagues24 study, which SHTAC 
did not include, as well as the Nordic and HOVON 49 trials, which have only been 
reported in abstract form and were therefore not included by SHTAC (with the HOVON 
49 trial designated ‘unclear’ because of the use of thalidomide maintenance therapy). 
The impact of including these studies within the MTC presented by the MS is uncertain 
and SHTAC cannot determine what the outcomes would have been had these data been 
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Appendix 8  
Table of excluded studies for systematic 
review of cost-effectiveness
Excluded reference Reason for exclusion
Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment 
of advanced multiple myeloma. Br J Haematol 2001;113:1015–19
Participants and 
intervention
Deniz B, Facon T, Singer I, Micallef-Eynaud P, Joseph I, Shearer A, et al. Economic evaluation of thalidomide combined 
with melphalan and prednisone in previously untreated multiple myeloma in Scotland. Blood 2008;112:835
Abstract
Cecchi M, Caccese E, Messori A, Orsi C, Tendi E. Cost-effectiveness of bortezomib in multiple myeloma. Pharm World 
Sci 2007;29:485–6
Participants
Yoong K, Attard C, Jivraj F, Shustik C, Reece D. Cost effectiveness analysis of bortezomib in previously untreated 
multiple myeloma patients in Canada. Value Health 2009;12:A272
Abstract
Joseph I, Facon T, Lewis P, Deniz HB, Caro JJ. Cost effectiveness of thalidomide combined with melphalan and 
prednisone in previously untreated multiple myeloma in Wales. Value Health 2009;12:A271
Abstract
De Abreu Lourenco R, Colman S, Lee C. Thalidomide plus melphalan and prednisone for Australian patients newly 
diagnosed with multiple myeloma is cost effective when compared with melphalan and prednisone alone. Value Health 
2009;12:A381
Abstract
Wang S, Huang H, Shi H, Duh M, Chen K. The cost effectiveness of bortezomib for the initial treatment of 
multiple myeloma in the United States. #1379. 51st ASH Annual Meeting and Exposition, New Orleans, LA, 
5–8 December 2009
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Appendix 9  
Table of excluded studies for systematic 
review of health-related quality of life
Excluded reference
Reason for 
exclusion
Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among 
multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow 
Transplant 2009;15:12–20
Outcome
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. Bortezomib is associated with better 
health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the 
APEX study. Br J Haematol 2008;143:511–19
Participants and 
outcome
Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial adjustment and quality of life among multiple myeloma 
patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 2004;33:955–62
Outcome
Gulbrandsen N, Wisloff F, Brinch L, Carlson K, Dahl IM, Gimsing P, et al. Health-related quality of life in multiple myeloma 
patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65–77
Participants and 
outcome
Multiple myeloma: QALY gains from optimal therapy. Drugs Ther Perspect 2000;16:12–16 Outcome
Ellis K, Smith AG. An evaluation of quality of life (QOL) in patients after treatment for multiple myeloma (MM). Br J Haematol 
2005;129:192
Outcome
Thomas ML. Quality of life in persons with multiple myeloma: a descriptive study. Blood 2001;98:4971 Outcome
Deniz B, Morgan G, Schey S, Ishak J, Dale P, Shearer A et al. Economic evaluation of lenalidomide combined with 
dexamethasone for the treatment of multiple myeloma in the UK. Blood 2008;112:836–7
Outcome
Belch A, Reece DE, Bahlis NJ, White D, Teixeira B, Camacho F, et al. Bortezomib [VELCADE (TM)], pegylated liposomal 
doxorubicin [DOXIL/CAELYX (R)] and dexamethasone in the treatment of previously untreated multiple myeloma patients: 
impact on quality-of-life. Blood 2007;110:A1058–9
Outcome
Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi D, et al. Costs and quality of life of multiple myeloma (MM) 
in Italy: the Co. Mim Study. Value Health 2009;12:A265
Abstract
Meunier J, Regnault A, Robinson D, Rosa K, Miguel JFS, van de Velde H, et al. Impact of tumor response on health-related 
quality of life (HRQOL) in newly diagnosed multiple myeloma patients treated with velcade/melphalan/prednisone (V-MP): 
results from the Vista Trial. Value Health 2009;12:A284
Abstract
Dhawan R, Meunier J, Regnault A, Robinson D, Rosa K, Cakana A, et al. Impact of complete response on quality of life in 
newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma 2009;9:S58
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Appendix 10 
Health-related quality-of-life studies – data 
extraction forms
Reference
  ■ Gulbrandsen and colleagues (2004).91
  ■ Data extracted by KC; extraction checked by AC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?
To compare QoL scores of MM patients at diagnosis and over time with the scores of a 
reference population.
  ■ Describe the type of study and study design.
Two prospective studies using a QoL questionnaire with comparison to a reference population 
through regression.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Patients from two prospective Nordic Myeloma Study Group trials: high-dose melphalan (HDM), 
and melphalan and prednisone (MP)
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age < 60 years old for HDM; > 60 years old treated with MP
Sex NR
Race (if appropriate) NR
Indication/disease Newly diagnosed MM
Other characteristics (sample size) 221 patients for HDM and 203 patients for MP. QoL was also estimated for reference 
Norwegian population, consisting of 3000 randomly selected adult individuals (18–93 years)
QoL instrument  EORTC QLQ-C30 at baseline and at 1, 6, 12, 24 and 36 months
Utility values (Y/N) N
Treatment effect (if reported) NR
Country/setting
  ■ What is the country and setting for the evaluation?
Denmark, Sweden and Norway.158 Appendix 10
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion?
Two trials.
Results
Results reported as mean difference between scores of all newly diagnosed MM patients and age- 
and gender-adjusted reference population.
Mean score difference 95% CI for the difference p-value
Functioning scales
Global QoL –24.3 –21.7 to –26.9 < 0.001
Physical functioning –34.3 –31.8 to –36.7 < 0.001
Role functioning –48.4 –45.4 to –51.3 < 0.001
Social functioning –21.0 –18.1 to –23.9 < 0.001
Emotional functioning –14.0 –11.7 to –16.4 < 0.001
Cognitive functioning –5.8 –3.5 to –8.1 < 0.001
Symptom scales
Nausea/vomiting 5.6 4.1 to 7.1 < 0.001
Pain 26.7 23.4 to 29.9 < 0.001
Fatigue 19.1 16.3 to 21.9 < 0.001
Single items
Sleep disturbance 6.1 2.8 to 9.3 < 0.001
Appetite loss 15.4 13.1 to 17.7 < 0.001
Diarrhoea –1.1 –3.5 to 1.2 0.349
Constipation 10.4 7.7 to 13.1 < 0.001
Dyspnoea 6.9 4.2 to 9.6 < 0.001
Financial impact 5.3 2.7 to 8.0 < 0.001
Change in most important functioning and symptom scales during the first 3 years for patients 
who received MP (values estimated from graphs).
Reference 
group 0 months 1 month 6 months 12 months 24 months 36 months
Global QoL 70 46 52 60 60 60 60
Physical functioning 78 46 51 60 60 60 63
Role functioning 85 43 45 58 59 61 66
Social functioning 81 70 70 76 76 75 72
Fatigue 30 51 48 38 41 40 42
Pain 27 52 38 30 33 33 33
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes. The EORTC QoL questionnaire was used.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Not applicable.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
At diagnosis, the most distressing problems were pain and fatigue, reduced physical functioning, 
limitations in role functioning and reduced overall QoL. These differences from the reference 
population were statistically significant, and large or moderate, according to the rating systems. 
After the start of treatment, small to moderate improvement in mean QoL scores was observed 
for most domains.
  ■ What are the implications of the study for the model?
This study indicates that QoL is worse initially at diagnosis but improves after end of treatment. 
Long-term QoL appears stable but is lower than for the reference population.
Reference
  ■ Mujica-Mota and colleagues (2004).94
  ■ Data extracted by KC; extraction checked by AC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?
To map HRQoL measurements into generic utility measures (EQ-5D).
  ■ Describe the type of study and study design.
Utility mapping study; limited details of statistical mapping process provided.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Patients with relapsed and refractory MM.
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age NR
Sex NR
Race (if appropriate) NR
Indication/disease Patients with relapsed and refractory MM
Other characteristics (sample size) Sample size of SUMMIT-1 trial (n = 202) identified but not all of the sample used for mapping 
study
QoL instrument  EORTC QLQ-C30 and MY24, FACT Fatigue and GOG-Ntx mapped to EQ-5D
Utility values (Y/N) Y
Treatment effect (if reported) NR160 Appendix 10
Country/setting
  ■ What is the country and setting for the evaluation? 
Although the setting is not stated, the SUMMIT-1 trial was undertaken in the USA.
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion? 
Phase II trial.
Results
Utility scores appear similar across patient groups as defined by serological response to Velcade, 
with an overall utility score of 0.65.
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Limited details of the methods or results are reported in the abstract.
Questions relevant to the EQ-5D were identified from EORTC and FACT, and five summary 
measures of severity, corresponding to the five EQ-5D dimensions, were obtained. The summary 
measures were transformed into the corresponding EQ-5D scale for each dimension.
Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Not applicable.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis
Method used to derive utility scores from reported HRQoL outcomes is a feasible and sensitive 
option for providing valid estimates of patient well-being for terminal conditions. 
  ■ What are the implications of the study for the model?
Study provides a post-treatment utility measure for relapsed or refractory MM patients post 
treatment with Velcade. This is not the patient group or intervention for the evaluation.
Reference
  ■ Slovacek and colleagues (2008).95
  ■ Data extracted by KC; extraction checked by AC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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To analyse an effect of selected demographics, psychosocial and health aspects on QoL in MM 
survivors treated with high-dose chemotherapy followed by autologous PBPCT.
  ■ Describe the type of study and study design.
Observational study. Mailed QoL questionnaire.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Patients with MM scheduled to be treated with high-dose chemotherapy (single dose of 
melphalan) followed by PBPCT.
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age Mean 60 years (53–67 years)
Sex 18 M, 14 F
Race (if appropriate) NR
Indication/disease MM treated with HDT followed by autologus PBPCT
Other characteristics (sample size) Total n = 32
QoL instrument  EQ-5D and EQ-5D VAS
Utility values (Y/N) Y
Treatment effect (if reported) Not applicable
Country/setting
  ■ What is the country and setting for the evaluation? 
University Hospital, Hradec Kralove, Czech Republic. All patients scheduled for intensive 
treatment of MM.
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion?
Single observational study.
Results
  ■ Summarise the results.
The global QoL in respondents with MM treated with HDT followed by autologous PBPCT was 
0.689 for EQ-5D and 0.666 for EQ-5D VAS.
For individual dimensions, 59% had trouble with mobility, 19% had trouble with self-care, 81% 
had difficulty with their normal activity, 69% had medium to serous pain, and 59% had medium 
to serious anxiety/depression.
The study also presented QoL results by age.162 Appendix 10
QoL measure
Age (years)
40–49 50–59 60–69 70–79
EQ-5D score 0.815 0.742 0.642 0.615
EQ-5D VAS 0.775 0.673 0.604 0.712
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes, the Czech version of the EuroQol EQ-5D questionnaire was used in the study (Slovacek 
2005 reference no. 2). The EQ-5D questionnaire was mailed to respondents with a covering letter. 
The QoL was analysed for the effect of age, sex, level of education, marital status, number of 
associated diseases, smoking, abuse, religion and time lapse from PBPCT.
Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Not applicable.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
Global QoL was at a low level for all studied patients and reduces with increasing age. Smokers 
and former smokers have lower QoL than non-smokers.
  ■ What are the implications of the study for the model?
The study assesses a different population group and intervention than assessed in the 
NICE appraisal.
Reference
  ■ Strasser-Weippl and Ludwig (2008).92
  ■ Data extracted by AC; extraction checked by KC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?
To evaluate the prognostic importance of baseline QoL and whether QoL at onset of therapy 
is a truly independent prognostic factor. To identify which dimensions of QoL are important 
predictors for outcome in patients with MM.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Describe the type of study and study design.
Substudy within an RCT of continuous or intermittent prednisolone plus vincristine, melphalan, 
cyclophosphamide, prednisolone, interferon-α-2b (VMCP-IFN-α-2b) for induction therapy. 
Maintenance therapy of IFN-α-2b with or without prednisolone twice weekly.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Elderly patients recently diagnosed with MM who were previously untreated (ECOG 
performance status of ≤ 3, adequate organ function) (n = 92).
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age (years) Median (range): 66 (43–84)
Sex M/F: 51 : 41
Race (if appropriate) NR
Indication/disease MM – DS stage: I – 5 (5.4%); II – 26 (28.3%); III – 61 (66.3%)
Other characteristics (sample size) n = 92
QoL instrument  EORTC QLQ-C30
Utility values (Y/N) N
Treatment effect (if reported) RCT showed similarity between two treatment arms with respect to response rate, PFS and OS. 
No data are presented
Country/setting
  ■ What is the country and setting for the evaluation? 
Vienna, Austria.
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion?
A substudy within an RCT.
Results
Observed, age/gender equivalent expected mean scores and deviations for myeloma patients 
at baseline.
Observed Expected Observed – expected p-value
Global QoLa 47.28 70.63 –22.3 1.60 × 1015
Physicala 58.74 80.75 –22.01 2.26 × 1010
Rolea 58.4 87.04 –28.64 3.82 × 1015
Emotionala 66.67 83.61 –16.94 1.30 × 107
continued164 Appendix 10
Observed Expected Observed – expected p-value
Cognitivea 78.44 82.89 –4.45 0.04
Sociala 71.2 82.34 –11.14 0.001
Fatigueb 49.14 30.17 18.97 6.0 × 109
Painb 47.64 25.92 21.72 8.5 × 108
Nausea/vomitingb 13.04 4.18 8.86 0.001
Dyspnoeab 32.25 19.41 12.84 4.1 × 105
Insomniab 32.61 25.79 6.82 0.035
Appetite lossb 28.99 7.30 21.69 1.9 × 108
Constipationb 22.71 15.30 7.41 0.024
Diarrhoeab 8.79 9.62 –0.83 0.64
Financial difficultiesb 12.59 10.66 1.93 0.22
a  Higher score indicates better function.
b  Higher score indicates more symptoms.
Observed are mean scores in myeloma patients; Expected are mean scores one would get in the general population if the age and gender 
distributions were the same as in the myeloma patients.
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes.
Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Regression techniques were used to evaluate QoL as a prognostic indicator in relation to 
outcomes such as survival.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
Study showed low levels of functional QoL scores and increased symptom scores in patients with 
active disease at start of first-line therapy, supporting previous reports of severe and significant 
impairment of QoL in MM patients. Although independent of age and gender, they did reflect 
parameters of disease activity that were thought to be linked to individual psychological factors. 
It was felt that physical measures of QoL, such as pain, fatigue, physical functioning and global 
QoL, were particularly important.
There is a significant impairment of physical and psychosocial dimensions of QoL in patients 
with MM at baseline compared with a healthy reference population. Low psychosocial QoL at 
baseline is associated with poor prognosis. 
  ■ What are the implications of the study for the model?
The study provides baseline measures of QoL on the EORTC QLQ-C30 for patients recently 
diagnosed with MM who have not undergone treatment. If these can be mapped to utility 
measures it may provide a source for the model.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
165   Health Technology Assessment 2011; Vol. 15: No. 41 DOI: 10.3310/hta15410
Reference
  ■ Uyl-de Groot and colleagues (2005).96
  ■ Data extracted by AC; extraction checked by KC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?
To investigate the subjective well-being of patients with newly diagnosed MM who were treated 
in a tandem transplantation programme.
All patients were scheduled for the following treatment protocol: two courses of VAD or 
VAMP chemotherapy, HDM and transplantation of whole blood stem cells, collection of r-met 
HuG-CSF mobilised peripheral blood progenitor cells by leucopheresis and, finally, HDT 
(busulfan/cyclophosphamide) followed by reinfusion of the previously collected peripheral stem 
cells (PSCT).
  ■ Describe the type of study and study design.
Prospective, longitudinal questionnaire study.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Patients with MM irrespective of previous treatment regimes who were scheduled for intensive 
treatment between March 1997 and December 1998, whether at the start of the treatment 
protocol or who were undergoing treatment and had not passed the last two measurement points 
for QoL (started between March 1995 and September 1996).
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age (years) All patients (n = 51): mean (SD) 53 (7.2); median (minimum/maximum) 54 (31/65)
Patients in analysis (n = 25): mean (SD) 53 (8.2); median (minimum/maximum) 55 (31/65)
Sex All patients (n = 51): male 31 (61%); female 20 (39%)
Patients in analysis (n = 25): male 16 (64%); female 9 (36%)
Race (if appropriate) NR
Indication/disease MM
DS stage [n (%)]
All patients (n = 51): Ia 12 (24); IIa 4 (8); IIIa 32 (63); IIIb 3 (6)
Patients in analysis (n = 25): Ia 8 (32); IIa 1 (4); IIIa 15 (60); IIIb 1 (4)
Other characteristics (sample size) n = 51; 35 from the start of the treatment protocol and 16 partially completed treatment
QoL instrument EORTC QLQ-C30, EQ-5D
Data collected at baseline (2 weeks post induction therapy); day of hospital discharge after HDM (T2); 
1 month after discharge after HDM (T3); day of hospital admission for PSCT (T4); day of discharge 
following PSCT (T5); 6 months post discharge following PSCT (T6); 12 months post discharge following 
PSCT (T7)
Utility values (Y/N) Y
Treatment effect (if reported) NR166 Appendix 10
Country/setting
  ■ What is the country and setting for the evaluation? 
Local referring hospitals and the academic hospital at the VU University Medical Centre, 
Amsterdam, the Netherlands. 
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion? 
A single observational study.
Results
Mean absolute scores (SD) at baseline after VAD/VAMP (baseline) 
and mean change scores from baseline
Baseline 
(n = 25) T2 (n = 22) T3 (n = 24) T4 (n = 15) T5 (n = 14) T6 (n = 15) T7 (n = 12)
EORTC QLQ-C30 functioning scales
Physical 50 (28) –2 13b 13a –19a 13a 20a
Role 41 (29) 2 18b 14 –26b 19a 20
Emotional 72 (22) 3 10a 6 0 0 1
Cognitive 76 (25) –11 8 1 –6 3 3
Social 59 (30) 5 12 6 –23a 10 13a
Global QoL 58 (23) –11a 3 10a –17b 7 4
EORTC QLQ-C30 symptoms
Fatigue 55 (29) 7 –15a –13 10 –13 –6
Nausea/
vomiting
11 (25) 26b 2 –1 27a –1 4
Pain 37 (29) –7 –8 –10 4 –9 –11
Appetite loss 22 (31) 40b 2 –4 43b –4 –3
Diarrhoea 18 (31) 25b –1 0 36b –2 3
Disease/treatment-related symptoms
Pain in back 43 (37) –6 –14a –7 –21a –7 –11
Soreness of 
mouth
9 (20) 26b 1 –11 36b –2 –6
Change in taste 20 (32) 23a 6 –9 21 –4 –8
Diminished 
sexual interest
52 (40) 11 –1 –27a –12 –20 –22
Pain in bones 35 (35) –20a –4 –7 –21a –9 –6
EuroQol utility 0.52 (0.33) 0.03 0.14a 0.14 –0.14 0.12 0.17
a  p < 0.05.
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Mean absolute scores (SD) at baseline and at 12 months’ follow-up 
for the patients who proceeded to PSCT 12 months’ follow-up
Baseline: patients who 
proceeded to 12 months’ 
follow-up (n = 12)
12 months’ follow-up
Patients with baseline (n = 12) All patients (n = 26)
EORTC QLQ-C30 functioning scales
Physical 65 (28) 85 (15) 78 (19)
Role 53 (32) 72 (18) 71 (21)
Emotional 74 (19) 74 (20) 78 (19)
Cognitive 79 (21) 82 (21) 85 (17)
Social 69 (27) 82 (25) 82 (25)
Global QoL 66 (23) 70 (16) 69 (19)
EORTC QLQ-C30 symptoms
Fatigue 42 (30) 35 (27) 30 (26)
Nausea/vomiting 1 (5) 6 (13) 3 (9)
Pain 28 (30) 17 (17) 15 (16)
Appetite loss 6 (13) 3 (10) 1 (7)
Diarrhoea 0 (0) 3 (10) 1 (7)
Disease/treatment-related symptoms
Pain in back 31 (39) 19 (17) 22 (19)
Soreness of mouth 11 (22) 6 (13) 4 (11)
Change in taste 14 (22) 6 (13) 7 (22)
Diminished sexual interest 56 (38) 33 (40) 40 (38)
Pain in bones 19 (30) 14 (17) 17 (7)
EuroQol utility 0.60 (0.33) 0.77 (0.13) 0.79 (0.18)
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes. The EORTC QLQ-C30 and the EQ-5D are outlined as are the methods for their application.
Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Not applicable.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
The authors found an improvement in subjective well-being on the EORTC QLQ-C30 and the 
EQ-5D for patients who were able to complete the treatment programme. There was a trend 
towards improved functioning and reduced symptoms. There were declines associated with the 
provision of treatment; however, improvements did occur with time.168 Appendix 10
  ■ What are the implications of the study for the model
Although the study provides utility outcomes for MM patients, these are related to a different 
patient group and to different treatment regimens.
This study indicates that QoL is worse initially at diagnosis and treatment but improves after end 
of treatment. Long-term QoL appears stable but is lower than for the reference population.
Reference
Van Agthoven and colleagues (2004).93
Data extracted by KC; extraction checked by AC.
Study characteristics
Research question
  ■ What are the stated objectives of the study?
Estimate the cost–utility of intensive chemotherapy versus intensive chemotherapy followed 
by myeloablative chemotherapy with autologous stem cell rescue in newly diagnosed patients 
with MM.
  ■ Describe the type of study and study design.
Cost–utility study based on a RCT in patients ≤65 years old with previously untreated MM. 
Trial of intensive chemotherapy versus intensive chemotherapy followed by myeloablative 
chemotherapy with autologous stem cell rescue.
  ■ Phase I VAD remission–induction therapy (three to four cycles at 28-day intervals), 
Phase II cyclophosphamide and autologous stem cell collection, Phase III intensive 
melphalan (two cycles at 8-week intervals), Phase IV peripheral blood SCT for patients in 
myeloablative group (cyclophosphamide/total body irradiation), Phase V maintenance with 
interferon-α-2a.
  ■ Was the sample from (1) the general population, (2) patients with the disease of interest, (3) 
individuals with knowledge of the disease, (4) other?
Patients with undiagnosed and untreated MM. 
  ■ What are the characteristics of the baseline cohort for the evaluation?
Age (years) Mean (range): intensive chemotherapy 55 (38–65); myeloablative 55 (32–65)
Sex Intensive chemotherapy 74 M, 55 F; myeloablative therapy 81 M, 51 F
Race (if appropriate) NR
Indication/disease Newly diagnosed MM and stage II or II A/B disease; in intensive arm 32/129 stage IIA; 89/129 
stage IIIA; 8/129 stage IIIB; myeloblative arm 26/132 stage IIA; 92/132 stage IIIA; 11/132 
stage IIIB
Other characteristics (sample size) 129 in intensive chemotherapy arm and 132 in myeloablative treatment arm
QoL instrument  EQ-5D assessed up to 24 months and then assumed to be stable until 36 months
Utility values (Y/N) Y
Treatment effect (if reported) Median OS in myeloablative treatment group 47 months vs 50 months in intensive 
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Country/setting
  ■ What is the country and setting for the evaluation?
Holland and Belgium.
Data sources
Effectiveness
  ■ Were the QoL data derived from: a single (observational) study, a review/synthesis or 
combination of previous studies, expert opinion?
Single study.
Results
Authors state that patients in an undefined state following intentionally curative primary therapy 
would have a QoL 19.5% lower than those in the general population (0.8), i.e. QoL is 0.644 
[0.8 – (0.195 × 0.8)].
Utility values for the different treatment groups
Time from randomisation (months) Intensive chemotherapy Myeloablative treatment
6 0.81 0.65
12 0.80 0.62
18 0.81 0.69
24 0.77 0.75
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Limited detail given on methodology or results in present study. Reference given for more detail: 
Segeren CM. Intensive therapy in MM. Thesis. Rotterdam: Erasmus University; 2002.
Mapping
  ■ If a model was used, describe the type of model (e.g. regression) or other 
conversion algorithm.
Not applicable.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
Cost-effectiveness of myeloma therapy after 3 years of follow-up seems not to be favoured by 
myeloablative treatment with autologous stem cell rescue. Cost per QALY at 3 years: intensive 
€37,328; myeloablative €51,357.
  ■ What are the implications of the study for the model?
Although the study assessed the QoL in newly diagnosed and untreated people with MM, it 
focused on interventions not included in the current evaluation. It provides an indication of the 
QoL following curative treatment and over 2-year period of treatment.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
171   Health Technology Assessment 2011; Vol. 15: No. 41 DOI: 10.3310/hta15410
Appendix 11  
Cost-effectiveness data extraction forms for 
manufacturers’ submissions
Reference
Janssen–Cilag (2009).115
Research question
  ■ What are the stated objectives of the evaluation?
To provide a cost-effectiveness analysis, reporting the total costs associated with the interventions 
under consideration in the appraisal and the QALYs gained (p. 49).
Funding source
  ■ Janssen–Cilag.
Study population
  ■ What definition was used for [condition]?
The patient population is newly diagnosed patients ineligible for HDT–SCT in line with the scope 
of the appraisal.
  ■ What are the characteristics of the baseline cohort for the evaluation?
The characteristics of the baseline cohort are not specified but the authors report that they are 
reflective of the UK population and the trial evidence.
Interventions and comparators
  ■ What interventions/strategies were included?
Bortezomib in combination therapy with an alkylating agent and a corticosteroid. Thalidomide in 
combination therapy with an alkylating agent and a corticosteroid 
  ■ Was a no treatment/supportive care strategy included?
Compared with melphalan + prednisone (MP)
  ■ Describe interventions/strategies.
Bortezomib + melphalan + prednisone (VMP). Thalidomide + melphalan + prednisone (MPT). 
Thalidomide + cyclophosphamide + dexamethasone (CTDa)
Analytical perspective
  ■ What is the perspective adopted for the evaluation [health service, health and PSS, third 
party payer, societal (i.e. including costs borne by individuals and lost productivity]?172 Appendix 11
UK NHS and PSS.
Study type
  ■ Cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility.
Institutional setting
Where is/are the intervention(s) being evaluated usually provided?
NHS inpatient care.
Country/currency
  ■ Has a country setting been provided for the evaluation? What currency are costs expressed in 
and does the publication give the base year to which those costs relate?
UK, pounds sterling, 2008–9 costs.
Effectiveness
  ■ Were the effectiveness data derived from: a single study, a review/synthesis of previous 
studies or expert opinion?
A meta-analysis was conducted to estimate the treatment effects.
  ■ Give the definition of treatment effect used in the evaluation.
The treatment effects for VMP, MPT and CTDa were estimated using constant HRs for PFS and 
OS relative to MP. 
  ■ Give the size of the treatment effect used in the evaluation.
(AiC/CiC information has been removed)
Intervention costs
  ■ Were the cost data derived from: a single (observational) study, a review/synthesis of 
previous studies or expert opinion?
Treatment unit costs are based on the BNF No. 5735 and MIMS 2009.99
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes.
  ■ List the direct intervention costs used in the evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well as sources for unit costs used.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Summary of costs
Dose Duration of treatment Unit cost
Bortezomib  1 × 3.5-mg vial Mean no. of vials used in the VISTA 
trial: (AiC/CiC information has been 
removed) (J&J, Velcade CSR 1)
£762
Thalidomide CTDa arm: 167 mg per day
MPT arm: 150 mg per day
315 days £298 per 28 tablets
Enoxaparin as 
thromboprophylaxis
40 mg per day 6 months (four cycles of 
thalidomide)
40 mg/0.4 ml: 10 syringes = £40.36
Melphalan 9 mg/m2
Four doses/cycle; 28 doses/course
Seven cyclesa £11.46 for 25 tablets of 2 mg
Prednisone 60 mg/m2
Four doses/cycle; 28 doses/course
Seven cyclesb £20 for 56 tablets of 25 mg; £0.98 
for 28 tablets of 5mg
Cyclophosphamide 500 mg
Four doses/cycle; 30 doses/course
Seven and a half cyclesb US$12.44 for 100 tables of 50 mg
a  Median no. of MP cycles administered in VISTA = 7.
b  Midpoint between the minimum (n = 6) and maximum (n = 9) no. of courses in the MMIX Trial protocol.
Indicate the source for individual cost values (if appropriate).
Other direct costs (costs incurred directly in treating patients)
  ■ Were the cost data derived from: a single (observational) study, a review/synthesis of 
previous studies expert opinion?
Costs for subsequent treatment and AEs were from previous studies. Incidence of the included 
AEs was from the RCTs.
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes.
  ■ List the costs used in the evaluation – if quantities of resource use are reported separately 
from cost values, show sources for the resource estimates as well as sources for unit 
costs used.
Upon disease progression, patients have second-line treatment. Costs for second- and third-line 
treatment are shown in Table 28 of the MS.
The unit costs of treating AEs (Table 25) were applied to the incidence of AEs (Table 24) to 
obtain the total cost of treating AEs (Table 26). Unit costs of AEs are mainly from NICE TA17131 
for lenalidomide.174 Appendix 11
Unit costs of AEs
AE Cost (£) Care setting
Anaemia 430.53 Day case
Deep venous thrombosis 199.00 Outpatient
Haematological 455.00 Day case
Infection 685.00 Day case
Leukopenia 470.00 Day case
Lymphopenia 470.00 Day case
Neurological 580.00 Day case
Neutropenia 470.00 Day case
Non-haematological toxicity (≥ grade 3) 97.00 Outpatient
Oedema (peripheral) 0.85 Outpatient
Peripheral neuropathy 97.00 Outpatient
Thrombocytopenia 547.89 Day case
Indicate the source for individual cost values (if appropriate).
Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
  ■ Were indirect costs included?
None.
  ■ Describe how indirect costs were estimated (e.g. how days of lost productivity were estimated 
and how those days were valued).
Not applicable (indicate the source for individual cost values if appropriate).
Health-state valuations/utilities (if study uses QoL adjustments to 
outcomes)
  ■ Were the utility data derived from: a single (observational) study, a review/synthesis of 
previous studies or expert opinion? Were the methods for deriving these data adequately 
described (give sources if using data from other published studies)?
Single study (Van Agthoven et al. 2004).
  ■ List the utility values used in the evaluation:
Utilities
For prior to response to 
treatment state For response state For post-progression state
EQ-5D (UK weights) – (Van Agthoven et 
al. 2004)
0.77 0.81 0.64© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Modelling
  ■ If a model was used, describe the type of model used (e.g. Markov state transition model, 
discrete event simulation). Was this a newly developed model or was it adapted from a 
previously reported model? If an adaptation, give the source of the original.
A cost–utility decision-analytic model was used in this economic evaluation. The model, 
developed using Excel, considers a cohort of newly diagnosed myeloma patients and defines 
a baseline response, disease progression and survival based on treatment with MP. Treatment 
effects for VMP, MPT and CTDa are then modelled over time by adjusting this baseline 
patient experience via HRs. Further lines of treatment (second- and third-line) are taken into 
consideration to estimate the total treatment costs.
The analytic framework was based on a variant of Quality-Adjusted Analysis of Time Without 
Symptoms or Toxicity (Q-TWiST97) using partitioned survival analysis, and utilises the area 
under and the difference between time-to-event curves to estimate mean durations spent within 
the disease states of interest.
  ■ What was the purpose of the model (i.e. why was a model required in this evaluation)?
Not reported. However, model needed to extrapolate trial data over patient lifetime.
  ■ What are the main components of the model (e.g. health states within a Markov model)? Are 
sources for assumptions over model structure (e.g. allowable transitions) reported? List them 
if reported.
Survival is partitioned into three different states: (1) prior to response to treatment; (2) response 
but no progression; and (3) post-progression. Death represents the final state. The steps to 
estimate the mean periods in these states are described below and the approach is presented 
schematically in Figure 15:
  ■ Step 1  Estimate mean OS (µOS) from start of treatment until death.
  ■ Step 2  Estimate mean PFS (µPFS) from start of treatment until progression or death.
  ■ Step 3  Estimate mean survival after progression (µPROG) as µOS – µPFS.
  ■ Step 4  Estimate mean time until response (µPreRESP) from start of treatment until response, 
progression, or death (include all patients, such that non-responders will either have event 
time as that of progression or death, or will be censored if they drop out).
  ■ Step 5  Estimate mean time from response to progression or death (µDOR) as µPROG – µPreRESP.
To determine QALYs over the life of a patient, utilities for the following health states 
were assigned:
  ■ from start of treatment until response (uPRE)
  ■ from response to progression (ur)
  ■ from progression to death (uPROG).
Responded, progressed, died or censored TTRPD
Progressed, died or censored PFS
Died or censored OS
FIGURE 15  Partitioned survival framework. TTRPD, time to response or disease progression.176 Appendix 11
QALY = (uPRE × µPreRESP) + (ur × µDOR) + (uPROG × µPROG)  [Equation 4]
  ■ Extract transition probabilities for [natural history/disease progression] model and show 
sources (or refer to table in text).
None stated.
  ■ What is the model time horizon?
30-year time horizon.
  ■ What, if any, discount rates have been applied in the model? Same rate for costs 
and outcomes?
3.5%.
Results/analysis
  ■ What measure(s) of benefit were reported in the evaluation?
Cost per QALY gained.
  ■ Provide a summary of the clinical outcome/benefits estimated for each intervention/strategy 
assessed in the evaluation:
CTDa MPT MP VMP
QALYs (discounted) 3.07  3.41  2.86  4.03 
  ■ Provide a summary of the costs estimated for each intervention/strategy assessed in 
the evaluation:
CTDa MPT MP VMP
Costs (discounted) (£) 56,668 59,322 54,434 66,676
  ■ Synthesis of costs and benefits – are the costs and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of the results.
The ICER for VMP versus MP is estimated to be £10,498. Furthermore, the ICERs of VMP versus 
MPT and VMP versus CTDa are estimated to be £11,907 and £10,411, respectively.
Base-case results
VMP vs MP VMP vs MPT VMP vs CTDa MPT vs MP MPT vs CTDa CTDa vs MP
Incremental QALYs 1.17 0.62 0.96 0.55 0.34 0.20
Incremental cost (£) 12,241 7353 10,007 4888 2654 2234
Incremental ICER (£) 10,498 11,907 10,411 8912 7724 10,905© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Give results of any statistical analysis of the results of the evaluation.
Survival curves are presented for PFS and OS.
  ■ Was any sensitivity analysis performed – if yes, what type(s) [i.e. deterministic (one-way, 
two-way, etc.) or probabilistic]?
One-way sensitivity analyses and PSAs have been undertaken. Two alternative scenario analyses 
have also been undertaken.
  ■ What scenarios were tested in the sensitivity analysis? How do these relate to structural 
uncertainty (testing assumptions over model structure such as relationships between health 
states), methodological uncertainty (such as choices of discount rate or inclusion of indirect 
costs) or parameter uncertainty (assumptions over values of parameters in the model, such as 
costs, QoL or disease progression rates)?
One-way sensitivity analyses have been undertaken for a limited number of analyses, including 
different survival distributions for OS and PFS, alternative HRs for OS, dose and duration of 
thalidomide, utilities, time horizon and discounting rate.
A PSA was undertaken using Monte Carlo simulation with 10,000 iterations. All parameters in 
the model were included except medication costs.
  ■ Give a summary of the results of the sensitivity analysis: did they differ substantially from the 
base-case analysis? If so, what were the suggested causes?
The results are generally robust to changes in the sensitivity analyses. The model is most sensitive 
to the following parameters: underlying MP survival hazard, HRs for OS, dose of thalidomide, 
and duration of treatment with thalidomide in the MPT arm.
For the PSA, at the £20,000 and £30,000 willingness-to-pay thresholds, VMP has the highest 
probability of being cost-effective: 64% and 75%, respectively.
Two scenarios were conducted:
Scenario A assumes there is no subsequent therapy after first-line treatment:
Mean QALYs Mean cost (£) ICER vs MP (£)
MP 2.86 13,888 –
CTDa 3.07 23,810 48,437
MPT 3.41 23,188 16,956
VMP 4.03 38,574 21,099a
a  Erroneously reported as £15,360 in MS.
Scenario B assumes that the same second-line therapies as those treated with MP in the VISTA 
trial. The results were similar for this scenario to the base-case analyses.178 Appendix 11
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
Base-case results from the model demonstrated that VMP is more costly, but more effective than 
comparator treatments.
  ■ What are the implications of the evaluation for practice?
None stated.
Reference
Celgene (2009).116
Research question
  ■ What are the stated objectives of the evaluation?
To compare the costs and benefits of adding thalidomide (T) to the combination melphalan and 
prednisolone (MP) with those of MP alone and bortezomib in combination with melphalan and 
prednisolone (VMP) in patients with MM older than 65 years or who are ineligible for HDT.
Funding source
Celgene Ltd.
Study population
  ■ What definition was used for [condition]?
Patients with untreated MM aged 65 years and over or who are ineligible for HDT.
  ■ What are the characteristics of the baseline cohort for the evaluation?
The characteristics of the baseline cohort are not discussed.
Interventions and comparators
  ■ What interventions/strategies were included?
MPT compared with MP alone and with VMP.
  ■ Was a no treatment/supportive care strategy included?
No. Comparisons as defined above.
  ■ Describe interventions/strategies
Comparisons defined above.
Analytical perspective
  ■ What is the perspective adopted for the evaluation [health service, health and PSS, third-
party payer, societal (i.e. including costs borne by individuals and lost productivity)]?
NHS and PSS.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Study type
  ■ Cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility analysis.
Institutional setting
  ■ Where is/are the intervention(s) being evaluated usually provided?
Patients were treated in several settings. Although the majority of care was provided as day-case 
and outpatient care, there was some provision of care within inpatient and primary care. The 
effect of the setting is taken into account in resources and costs.
Country/currency
  ■ Has a country setting been provided for the evaluation? What currency are costs expressed in 
and does the publication give the base year to which those costs relate?
The evaluation is for England and Wales, with costs expressed as pounds sterling. The base year 
for costs appears to be 2008, although some costs are for 2007–9 and 2009.
Effectiveness
  ■ Were the effectiveness data derived from: a single study, a review/synthesis of previous 
studies or expert opinion? Give the definition of treatment effect used in the evaluation.
Treatment effects were calculated from a Bayesian MTC of data originating from three trials,23,26,59 
using survival time before and after progression as the primary outcomes. PFS was assumed to be 
equivalent to TTP. The percentage of patients at 6-month intervals was used with extrapolation 
using an exponential distribution. Treatment interruptions/reductions were included in 
sensitivity analysis for MPT through reduction in average dose. AEs were included through data 
from two trials.23,26 PPS was reported as if patients had changed treatments from their original 
treatment to a similar but different treatment. PPS was calculated by combining the MPT, 
MP and MEL100 arms from the IFM 99/06 trial to create an average survival curve.23 Average 
survival at different time points was then extrapolated through an exponential distribution. 
Treatment interruptions/discontinuations were encompassed in the trial efficacy data, with no 
alteration to costs in the base case. Differences in costs were assessed.
  ■ Give the size of the treatment effect used in the evaluation.
Meta-analysed odds ratios of PFS for MPT compared with MP and VMP – random effects:
Comparison Point estimate 95% CI
MPT vs MP – 6 months 2.63 1.03 to 7.01
MPT vs VMP – 6 months 1.08 0.23 to 5.21
MPT vs MP – 12 months 2.15 0.92 to 5.1
MPT vs VMP – 12 months 1.07 0.25 to 4.47
MPT vs MP – 18 months 2.10 0.83 to 5.24
MPT vs VMP – 18 months 1.02 0.22 to 4.81
MPT vs MP – 24 months 2.19 0.9 to 5.07
MPT vs VMP – 24 months 0.85 0.2 to 3.52
MPT vs MP – 30 months 2.70 1.1 to 6.55180 Appendix 11
Meta-analysed odds ratios of PPS for MPT compared with MP – random effects:
Comparison Point estimate 95% CI
MPT vs MP – 6 months 1.04 0.37 to 2.81
MPT vs MP – 12 months 1.05 0.41 to 2.66
MPT vs MP – 18 months 1.15 0.47 to 3.03
MPT vs MP – 24 months 0.99 0.38 to 2.68
MPT vs MP – 30 months 1.15 0.43 to 3.06
Intervention costs
  ■ Were the cost data derived from: a single (observational) study, a review/synthesis of 
previous studies or expert opinion?
Resources and costs were obtained from several sources. NHS resources were obtained from an 
unpublished survey of UK Haematologists by Celegene Ltd.117 Inpatient, outpatient and day-case 
hospitalisation costs were derived from NHS reference costs.100 Costs of medicines were from the 
BNF No. 5735 and costs of blood transfusions from Wilson et al.101 with costs inflated to 2008.102
  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes.
  ■ List the direct intervention costs used in the evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well as sources for unit costs used.
Medication and preparation costs used in model base case:
Medication Drug acquisition cost (£) Cost per mg (£) Dosing (mg/day)a
Drug acquisition 
cost per cycle (£)
Preparation costs 
(£)
Bortezomib 762.40 for 1 × 3.5-mg vial 217.83 1 vial 6099.04 (cycles 
1–4), 3049.52 
(cycles 5–9)
159.93 per dose
Melphalan 11.46 for 25 × 2 mg 0.229 0.25 16.23 0
Prednisone 1.95 for 28 × 5 mg 0.014 2 7.87 0
Thalidomide 298.48 for 28 × 50 mg 0.213 238.1 2132.04 13.64 per cycle
a  Dose source p. 114; CSR 1 using IFM 99/06;23 drug costs from BNF No. 57.35
Indicate the source for individual cost values (if appropriate).
Other direct costs (costs incurred directly in treating patients)
  ■ Were the cost data derived from: a single (observational) study, a review/synthesis of 
previous studies or expert opinion?
Other resource use and cost data were provided for outpatient consultations, disease 
monitoring and treatment of AEs/complications. Resources and costs used and their sources are 
outlined below.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Were the methods for deriving these data adequately described (give sources if using data 
from other published studies)?
Yes. The costs of AEs were calculated by combining resource use data from the survey of 
haematologists with unit costs to estimate total costs. These costs and trial data on the frequency 
of AEs23 were then used to calculate a weighted average cycle cost. AE management costs were 
calculated for the entire time horizon for each AE through addition of the average medication 
and treatment cost (weighted for setting of care). This was then multiplied by the proportion of 
occurrence of AEs over the total number of AEs in the treatment arm. The costs per specific AE 
are then summed to provide an average cost per AE, which is applied at the time of the AE.
  ■ List the costs used in the evaluation – if quantities of resource use are reported separately 
from cost values, show sources for the resource estimates as well as sources for unit 
costs used.
Unit costs and mean number of regular outpatient consultations and disease monitoring tests:
Cost (£) Source
Frequency (mean no. of assessments per year)
Preprogression
Post progression Active treatment
Off active 
treatment
Outpatient 82 OP 12 6 12
Tests to monitor therapy response and disease status
Routine blood counts (FBC) 2.99 H 10.7 7.1 20.1
Clotting 2.99 H 1.1 0.4 3.9
INR monitoring 2.99 H 2.9 0.4 2.6
Biochemistry (U&Es) 1.34 P 9.7 6.6 17.3
Liver function tests 1.34 P 7.6 5.1 14.6
Erythrocyte sedimentation rate 2.99 H 1.4 0.9 2.6
Plasma viscosity 1.34 P 0.3 0.3 1.6
Uric acid (urate) 1.34 P 1.4 0.9 2.7
Immunoglobulin 1.34 P 6.4 4.9 9.7
Paraprotein measurements 1.34 P 7.6 6.1 11.1
Protein electrophoresis 1.34 P 6.7 5.1 9.6
Serum β2-microglobulin 1.34 P 3.0 2.0 5.0
Serum erythropoietin level 1.34 P 0.1 0.1 0.5
Immunofixation 1.34 P 3.4 2.9 4.8
Creatinine clearance 1.34 P 0.7 0.4 2.3
Glomerular filtration rate 1.34 P 3.3 2.7 7.1
Serum-free light chains 1.34 P 2.9 1.7 4.1
Routine urinalysis 1.34 P 1.7 1.0 4.4
24-hour urine measurement 1.34 P 1.3 1.0 3.0
24-hour urine for creatinine 1.34 P 0.6 0.1 1.4
Total urine protein (24 hour) 1.34 P 1.4 0.4 3.2
Urine protein electrophoresis/light 
chains
1.34 P 2.7 2.1 4.9
Urine immunofixation 61.70 Assumption 1.0 1.0 2.1
Skeletal survey by X-ray 18.56 Assumption 0.1 0.0 1.6
Skeletal survey by X-ray individual 
sites
18.56 Assumption 0.1 0.1 1.6182 Appendix 11
Cost (£) Source
Frequency (mean no. of assessments per year)
Preprogression
Post progression Active treatment
Off active 
treatment
Bone marrow aspirate 1.34 P 0.2 0.1 2.1
Bone marrow trephine biopsy 1.34 P 0.2 0.1 2.0
Bacterial investigation 7.52 P 0.4 0.3 1.6
Calcium 1.34 P 6.0 1.0 20
Albumin 1.34 P 6.0 1.0 20
FBC, full blood count; INR; international normalised ratio; U&E, urea and electrolytes.
Sources:
H, Department of Health. NHS Reference Costs 2007–8 –TPATH – Specialty: Haematology [Excluding Anti-Coagulant Services] – Specialty Code: 
DAP823. accessed September 2008.
OP, NHS Reference Costs 2007–8 – Outpatient Adult Follow Up Attendance (TOPS FUA) – Specialty: Clinical Haematology – Specialty Code: 303. 
– accessed September 2009.
P, Department of Health. NHS Reference Costs 2007–8 – Pathology Services Test Data (TPATH) – Specialty: Biochemistry – Specialty Code: 
DAP841]; URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945 – accessed September 
2009.
Unit costs used in the model analyses:
Average unit cost (£)a
Anaemia – grade 3/4 358.07
Thrombocytopenia – grade 3/4 379.71
Neutropenia – grade 3/4 772.13
Leucopenia – grade 3/4 573.62
Lymphopenia – grade 3/4 1480.55
Peripheral neuropathy – grade 3 856.99
Thrombosis or embolism – grade 3/4 661.59
Somnolence/fatigue/dizziness – grade 3/4 147.94
Fever of unknown origin – grade 3/4 1,195.37
Pneumonia – grade 3/4 12,734.34
Septicaemia – grade 3/4 2740.69
Meningitis – grade 3/4 857.98
Herpes zoster – grade 3/4 383.82
Constipation – grade 3/4 1277.13
Lung disorder – grade 5 971.46
Septic shock – grade 5 784.53
a  Weighted average of unit costs.
Source: Unpublished survey of UK Haematologists by Celgene.117
Indicate the source for individual cost values (if appropriate).
Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
  ■ Were indirect costs included?
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  ■ Describe how indirect costs were estimated (e.g. how days of lost productivity were estimated 
and how those days were valued).
Not applicable.
Indicate the source for individual cost values (if appropriate).
Health-state valuations/utilities (if study uses QoL adjustments to 
outcomes)
  ■ Were the utility data derived from: a single (observational) study, a review/synthesis of 
previous studies expert opinion. Were the methods for deriving these data adequately 
described (give sources if using data from other published studies)?
The HOVON study,93 a RCT of intensive chemotherapy followed by myeloblative therapy with 
autologous stem cell rescue compared with intensive chemotherapy, provided QoL data using the 
EQ-5D. A literature search was conducted for utility decrements for AEs, with utility values from 
different population groups used (e.g. breast, colon and rectal cancer). Average per cent reduction 
in utility by each AE was calculated from these values. 
  ■ List the utility values used in the evaluation.
Utility values were 0.64 for people not responding to treatment and 0.81 for people who did 
respond (using general public utility for same age group). A utility value of 0.77 at 24 months 
was presented for those who continue to respond to treatment with intensive chemotherapy. 
An assumption was made that preprogression patients and post-progression patients matched 
responders and non-responders in the HOVON trial.93 A 0.77 utility score was used for those 
who had not progressed at the end of 2 years.
Indicate the source for individual cost values (if appropriate).
Modelling
  ■ If a model was used, describe the type of model used (e.g. Markov state transition model, 
discrete event simulation). Was this a newly developed model or was it adapted from a 
previously reported model? If an adaptation, give the source of the original.
A lifetime Markov model developed from the evaluation presented by Deniz and colleagues,72 
which compared MPT to MP in first-line treatment for MM in Scotland. The model was updated 
to include comparison with VMP.
  ■ What was the purpose of the model (i.e. why was a model required in this evaluation)?
Not stated.
  ■ What are the main components of the model (e.g. health states within a Markov model)? Are 
sources for assumptions over model structure (e.g. allowable transitions) reported – list them 
if reported.184 Appendix 11
Model structure
The model tracks the progress of patients with MM as managed with MPT, VMP or MP through 
four Markov states, specifically (1) preprogression without AE, (2) preprogression with AE, (3) 
post progression and (4) death. Patients start in the preprogression without AE health state and 
may move to a worse state or remain in the same state. Patients receive first-line treatment with 
MPT or MP for up to 12 six-week cycles or VMP for up to nine cycles. If the patients experience 
a serious treatment-related AE, they enter preprogression with AE state with no risk of additional 
AE. History of AEs does not determine progression. Death can only occur at progression or after 
progression and is assumed to be disease-related deterioration. Cycle length 6 weeks (42 days), 
equivalent to dosing cycle in trials.23,26,59
Resources and costs
  ■ Dose reductions, treatment interruptions and discontinuations are modelled as a reduction 
in costs.
  ■ When on active treatment, patients receive the mean observed treatment dose from the trials.
  ■ Routine management resources were estimated by UK haematologists by progression status 
and costed using publicly available data and applied to relevant cohorts until the end of the 
time horizon.
Adverse events
Only costs of treatment-related serious (grade 3 and above) AEs or AEs that occurred in ≥ 2% 
in treatment arms are included for those on active treatment. Rates are taken from the trials.23,26 
Risk of AE was estimated from the mean time alive per patient from Kaplan–Meier survival 
curves, with average patients alive during a 6-month period calculated and average duration on 
treatment calculated. Progression is the point of stopping treatment. (AiC/CiC information has 
been removed.) The magnitude and duration of the risk reductions were used to calculate the 
relative reduction in utility value over the complete time horizon of the AE in cycles. These values 
were weighted according to relative frequency and summed to produce the average total relative 
disutility per AE which was applied to the cohort experiencing AEs.
Assumptions
  ■ Only patients on active treatment at risk of AEs.
  ■ Costs of managing AE considered separately.
  ■ AE disutility applied at time of the event.
  ■ No discontinuation through AEs, implicitly included in dosing, duration and efficacy 
of treatment.
  ■ Deaths from AEs are through OS.
Average treatment duration applied in the base-case model was 12 months for MP and MPT, 
despite treatment interruptions/discontinuations meaning median treatment duration was less 
(AiC/CiC information has been removed). This assumption increases costs not efficacy. No data 
on discontinuation for VMP were available.
Progression
  ■ Post-progression survival is modelled to be the same across treatment strategies.
  ■ Patients assumed to discontinue active treatment upon disease progression.
  ■ Adverse events assumed not to affect progression rate.
Concurrent medication
Assumes VTE antithrombotic prophylaxis for patients receiving MPT with no resultant risk in 
incidence of VTEs and antiviral prophylaxis for VMP. © Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Extract transition probabilities for [natural history/disease progression] model and show 
sources (or refer to table in text).
None stated.
  ■ What is the model time horizon?
Lifetime horizon.
  ■ What, if any, discount rates have been applied in the model? Same rate for costs 
and outcomes?
Costs and benefits were discounted at 3.5%.
Results/analysis
  ■ What measure(s) of benefit were reported in the evaluation?
Cost per life-year gained and cost per QALY.
  ■ Provide a summary of the clinical outcome/benefits estimated for each intervention/strategy 
assessed in the evaluation:
MPT MP VMP
Summary of clinical outcomes (discounted model)
Median time to progression 
(months)
26.3 13.8 27.6
Patients progressed (%) 100 100 100
Deaths (%) 100 100 100
Proportion of patients with AE (%) 43.2 13.4 40.9
Median OS (months) 51.1 37.3 52.5
Total life-years 4.49 3.4 4.60
Total QALYs 3.28 2.43 3.35
  ■ Provide a summary of the costs estimated for each intervention/strategy assessed in 
the evaluation:
MPT MP VMP
Cost outcomes (overall population) (discounted model) (£)
Medication 18,937 192 41,019
Monitoring 1126 1034 1117
AE management 439 139 404
Total cost  21,133 1365 42,616
  ■ Synthesis of costs and benefits – are the costs and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of the results.186 Appendix 11
Base-case results calculated by model (discounted):
MPT vs MP MPT vs VMP
Incremental life-years 1.09 0.11
Incremental QALYs 0.85 0.07
Incremental costs (£) 19,768 21,483
Incremental cost per life-year gained (£) 18,188 200,237
Incremental cost per QALY gained (£) 23,381 303,845
  ■ Give results of any statistical analysis of the results of the evaluation.
None.
  ■ Was any sensitivity analysis performed? If yes, what type(s) [i.e. deterministic (one-way, 
two-way, etc.) or probabilistic].
Yes.
  ■ What scenarios were tested in the sensitivity analysis? How do these relate to structural 
uncertainty (testing assumptions over model structure such as relationships between health 
states), methodological uncertainty (such as choices of discount rate or inclusion of indirect 
costs) or parameter uncertainty (assumptions over values of parameters in the model, such as 
costs, QoL or disease progression rates)?
One-way deterministic sensitivity analysis examined time horizon (5 years), risk progression 
(2.5% and 97.5% CIs from MTC), resource use and costs (monitoring, AE and all costs varied by 
± 100%), AE rates and utility (scores varied by ± 10%), PFS and OS (expanded MTC).
  ■ Give a summary of the results of the sensitivity analysis. Did they differ substantially from 
the base-case analysis? If so, what were the suggested causes?
One-way deterministic sensitivity analysis (discounted):
MPT vs MP MPT vs VMP
Incremental cost/LYG (£) Incremental cost/QALY (£) Incremental cost/LYG (£) Incremental cost/QALY (£)
Base case 18,188 23,381 200,201 303,790
No discounting 14,892 19,355 153,339 226,033
Time horizon (5 years) 41,703 49,134 613,900 1,241,139
Efficacy
2.5% CI MTC 25,836 33,275 482,097 1,000,435
97.5% CI MTC 12,916 16,586 106,683 148,873
Monitoring costs and AE costs
+100% 18,538 23,831 199,749 303,103
–100% 18,005 23,145 200,427 304,133
Utility scores
+10% increase 18,188 22,961 200,201 305,666
–10% decrease 18,188 23,816 200,201 302,045
LYG, life-years gained.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Single trial analyses (discounted):
MPT vs MP MPT vs VMP
Incremental cost/LYG (£) Incremental cost/QALY (£) Incremental cost/LYG (£) Incremental cost/QALY (£)
IFM 99/06 16,603 21,285 MPT dominates MPT dominates
IFM 01/01 9404 12,067 1,430,625 7,234,876
GIMEMA 23,648 30,882 314,357 462,088
LYG, life-years gained.
Conclusions/implications
  ■ Give a brief summary of the author’s conclusions from their analysis.
The analyses indicate that MPT represents a cost-effective use of NHS resources when compared 
with MP in England and Wales for managing previously untreated MM patients aged ≥ 65 years 
or ineligible for HDT.
  ■ What are the implications of the evaluation for practice?
The authors estimate that the eligible incident and prevalent population will increase from 3196 
in 2010 to 15,929 in 2014. With the assumption that MPT currently has no market share and 
that its market share will grow from 60% in 2010 to 70% by 2014, the authors estimate that the 
incremental budget impact of using thalidomide (based on the proposed total annual costs with 
MPT and MP minus the total annual costs of managing patients with MP alone) will rise from 
£32M in 2010 to £44.8M in 2014. As MPT is estimated to have a market share of 54% currently, 
the incremental budget impact of increasing the market share to 60% in 2010 and 70% by 2014 
will result in an incremental total annual cost of £3.2M in 2010 rising to £10.2M in 2014.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 12  
Critical appraisal checklist of economic 
evaluation
T
he quality of the cost-effectiveness studies was assessed using a critical appraisal checklist 
based on that by Drummond and Jefferson,118 Philips and colleagues,98 and the NICE 
reference case.
Item Celgene116 Janssen–Cilag115
1 Is there a clear statement of the decision problem? Y Y
2 Is the comparator routinely used in UK NHS? Y Y
3 Is the patient group in the study similar to those of interest in UK NHS? ? Y
4 Is the health-care system or setting comparable to UK? Y Y
5 Is the perspective of the model clearly stated? Y Y
6 Is the study type and modelling methodology reasonable? Y Y
7 Is the model structure described and does it reflect the disease process? ? Y
8 Are assumptions about model structure listed and justified? Y Y
9 Are the data inputs for the model described and justified? Y Y
10 Is the effectiveness of the intervention established based on a systematic review? Y Y
11 Are health benefits measured in QALYs? Y Y
12 Are health benefits measured using a standardised and validated generic instrument? Y Y
13 Are the resource costs described and justified? Y Y
14 Have the costs and outcomes been discounted? Y Y
15 Has uncertainty been assessed?  Y Y
16 Has the model been validated?  N N
Y, yes; N, no; ?, unclear/incomplete.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 13  
Methodology used for disease projection
T
he methodology used for estimating survival curves for the alternative treatments is 
as follows:
  ■ Derive a baseline survival curve for MP. This curve is derived by calculating the event 
probability for each time interval, by calculating a weighted average of the trial MP arms 
using number of participants in the trial as a weight.
  ■ Derive HRs for each of the treatments versus MP at different time points for each trial. 
Combine HRs for treatments with more than one trial.
  ■ Construct the baseline survival curves for MP using the event probability for each 
time interval.
  ■ Construct the survival curves for other treatments by using the event probability for each 
time interval, i.e. event probability for MP multiplied by HR.
For MP treatment, OS and PFS at regular time points were estimated for each of the included 
studies from our meta-analysis of the clinical trials. The data from the trials were combined to 
form baseline MP, OS and PFS curves through a weighted average, using number of patients 
in the trials as the weight. We estimated the hazard rate for MP for each 6-monthly period 
(Table 52). The hazard rate for death for MP per cycle is estimated for each time point ti:
  [Equation 5]
where s(t) is the survival function over time t.
The treatment effects for the other interventions compared with MP were taken from our clinical 
review (see Chapter 4, Assessment of effectiveness). As the HR of the treatments versus MP varied 
over time, a constant HR was not appropriate. A similar methodology was used for estimating OS 
and PFS; however, only OS is described in this appendix.
We derived the HR for each 6-monthly period for each of the treatments versus MP.
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TABLE 52  Baseline MP OS curve and derived death rate
Months Cycles Survival OS Hazard OS
6 4.35 0.90 0.024
12 8.69 0.79 0.030
18 13.04 0.72 0.021
24 17.38 0.65 0.023
30 21.73 0.56 0.034
36 26.07 0.48 0.035
36+ 26+ 0.028192 Appendix 13
The hazard rate for death for each of the treatments per cycle is estimated for each time point ti:
  [Equation 6]
where s(t) is the survival function over time t.
The HR (HR) for each intervention j versus MP at each time point ti is:
  [Equation 7]
The HR was assumed to be constant after 36 months for OS as there were few patients with more 
than this length of follow-up in the trials. This HR was estimated for each of the treatments 
versus MP at 36 months’ follow-up for OS.
The hazard rate for death for each of the treatments per cycle was also assumed to be constant 
after 36 months and is given by:
h(t) =1 – s(t)1/t  [Equation 8]
where s(t) is the survival function and t is 36 months (26.1 cycles).
The methodology is illustrated for OS for VMP with data from the VISTA trial. Table 53 shows 
the hazards and the HRs derived from the VISTA trial for OS.
To generate the survival curves for each of the treatments the baseline death rate in each 
time period for MP was multiplied by the HR to give the new death rate for the alternative 
treatment. This method provided a closer fit to the trial data than approximations, such as 
fitting distributions.
The survival curves were constructed by multiplying the survival in the previous time point by 
the proportion who survived in the current time interval, using the estimated hazards for MP and 
the HR for the other interventions.
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TABLE 53  Hazards and HR for VMP vs MP for OS from the VISTA trial
Months Cycles
Survival s (t ) Hazard h (t )
HR MP VMP MP VMP
0 0 1.00 1.00
6 4.35 0.92 0.92 0.019 0.019 1.00
12 8.69 0.82 0.89 0.026 0.008 0.30
18 13.04 0.76 0.85 0.017 0.010 0.60
24 17.38 0.69 0.78 0.022 0.019 0.85
30 21.73 0.64 0.74 0.018 0.013 0.70
36 26.07 0.54 0.69 0.036 0.017 0.46
36+ 26+ 0.54 0.69 0.023 0.014 0.62© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Thus the survival function s(t) is given by:
MP: s(ti) = s(ti – 1) × (1 – h(ti))  [Equation 9]
Other interventions: s(ti) = s(ti – 1) × (1 – h(ti) × HRi)  [Equation 10]
To demonstrate the fit from this method we derive the VMP survival curves using the trial MP 
curves and compare with the original trial curves. Figure 16 shows the MP and VMP survival 
curves derived for the model against the trial data from the VISTA trial. As can be seen in 
the figure, the derived survival curves in the model closely match both treatments during the 
trial period.
In the model, instead of using the MP trial data, the MP baseline data are used with the same 
method as described above. Figure 17 shows the MP and VMP survival curves derived for the 
model using the baseline combined MP curves.
FIGURE 16  MP and VMP survival curves derived for the model against trial data from the VISTA trial.
FIGURE 17   Melphalan + prednisolone/prednisone (MP) and VMP survival curves for the model using combined 
baseline MP curves.
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Appendix 14  
Parameters included in the sensitivity 
analyses
T
he ranges used for the deterministic analyses and PSAs are reported in this appendix. 
Where appropriate, parameters were assigned a distribution in the PSA. Distributions 
were chosen according to the methodology suggested by Briggs and colleagues.103 They suggest 
that the normal distribution is a ‘candidate distribution for representing the uncertainty in any 
parameter in the model’. Further, they suggest the beta distribution for binomial outcomes, 
where parameters can vary between zero and one, for example probabilities, and the gamma 
distribution for costs where parameters are non-negative.
  ■ Discount rates were varied between 2% and 5% for costs and benefits in the deterministic 
sensitivity analyses.
  ■ The number of cycles for each of the treatments varied between seven and nine. For each of 
the interventions, we assumed a range between one fewer than the mean to one more than 
the mean. The number of cycles was assumed to follow a normal distribution.
  ■ Second-line treatment was varied according to the proportion who had bortezomib and 
HDD. For MP, MPT and CTDa, the proportion varied between 60% and 80% and for VMP, 
the proportion varied between 5% and 25%.
  ■ The range for the utility values was assumed to be ± 10% of the mean utility values, based 
on the uncertainty in the utility values from the MMIX Trial. We analysed the HRQoL data 
from the MMIX Trial. (AiC and/or CiC information has been removed.) Utility values were 
sampled from a beta distribution.
  ■ The CR data were obtained from the trials and SEs were derived. Values were sampled from a 
beta distribution.
  ■ The costs for AEs, bortezomib administration and consultation were assumed to vary within 
the range ± 30% of the mean and were sampled from a gamma distribution.
  ■ The ranges for the HRs and event rates for the MP survival curves were taken from the trial 
data. Values were sampled from a log-normal distribution.
  ■ The costs for AEs, bortezomib administration and consultation were varied within ± 30% of 
the mean for the deterministic sensitivity analysis.
Parameters and distributions for the deterministic and 
probabilistic sensitivity analyses
Name Mean
CI
SE Distribution Higher Lower
Discount rate
Discount rate costs (%) 3.5 5.0 2.0 NA
Discount rate benefits (%) 3.5 5.0 2.0 NA
Cycles of treatment
cycle_MP 8 9 7 0.5102 Log normal
cycle_MPT 8 9 7 0.5102 Log normal196 Appendix 14
Name Mean
CI
SE Distribution Higher Lower
cycle_VMP 9 10 8 0.5102 Log normal
cycle_CTDa 7 8 6 0.5102 Log normal
Subsequent treatment, Bort.
Sub_treat_Bort_MP 70 80 60 5.1020 Log normal
Sub_treat_Bort_MPT 70 80 60 5.1020 Log normal
Sub_treat_Bort_VMP 15 25 5 5.1020 Log normal
Sub_treat_Bort_CTDa 70 80 60 5.1020 Log normal
Utility values
u_treatment 0.58 0.639 0.522 0.030 Beta
u_response (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
Beta
u_progression 0.68 0.748 0.612 0.035 Beta
CR
CR_MP 0.026 0.035 0.017 0.005 Beta
CR_MPT 0.142 0.307 0.066 0.084 Beta
CR_VMP 0.217 0.386 0.121 0.087 Beta
CR_CTDa (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
Beta
AEs (£ per cycle)
cAE_MP 45.63 59.32 31.94 6.98 Gamma
cAE_MPT 70.40 91.52 49.28 10.78 Gamma
cAE_VMP 73.16 95.11 51.21 11.20 Gamma
cAE_CTDa 72.45 94.19 50.72 11.09 Gamma
Other
Cost of bortezomib 
administration (£)
153.40 199.42 107.38 23.4796 Gamma
Outpatient appointment 
medical oncology (£)
121.11 157.44 84.78 18.5372 Gamma
Survival curve parameters
Multipliers
MP OS baseline curve 0.028 0.039 0.020 0.0041 Log normal
MP PFS baseline curve 0.067 0.070 0.060 0.0036 Log normal
HR OS MPT 0.62 0.82 0.50 0.0714 Log normal
HR OS VMP 0.62 0.83 0.51 0.0714 Log normal
HR OS CTDa (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
Log normal
HR PFS MPT 0.58 0.77 0.49 0.0612 Log normal
HR PFS VMP 0.58 0.76 0.48 0.0612 Log normal
HR PFS CTDa (AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
(AiC/CiC information 
has been removed)
Log normal
Cost of treatments
Unit cost bortezomib (£) 762.38 914.86 609.90 77.7939 NA
Unit cost thalidomide (£) 298.48 358.18 238.78 30.4571 NA
Dosage thalidomide (mg/day) 150 200 100 25.5102 Log normal
NA, not applicable.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 15  
Additional scenario analyses
Scenario 1
The base-case analysis uses the number of cycles of treatment with bortezomib as per the 
protocol for the VISTA study, i.e. nine cycles. After discontinuation of treatment for some 
patients due to death or disease progression, this equates to about 48 vials per individuals. This 
scenario investigates the cost-effectiveness through treatment for a shorter number of treatment 
cycles, i.e. four cycles, with no loss of efficacy. A reduced number of treatment cycles equates to 
about 31 vials. In this scenario, bortezomib becomes more cost-effective, with an ICER of £19,039 
per QALY gained versus MP and £332,546 per QALY gained versus MPT.
VMP vs MP VMP vs MPT
Base case Scenario Base case Scenario
Incremental QALY 1.20 1.26 –0.02 0.04
Incremental cost (£) 35,749 24,002 24,542 12,592
ICER (£/QALY) 29,820 19,039 –1 million 322,546
Scenario 2
The base-case analysis uses the number of cycles of treatment with thalidomide as suggested 
by clinical experts, i.e. eight cycles. This scenario investigates the cost-effectiveness through 
treatment for a longer number of treatment cycles as used in the MPT IFM trials, i.e. 12 cycles. 
In this scenario, MPT becomes slightly less cost-effective compared with MP, with an ICER of 
£13,619 per QALY gained (base case £9135).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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